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A B S T R A C T
Background
Rotavirus results in more diarrhoea-related deaths in children under five years than any other single agent in countries with high
childhood mortality. It is also a common cause of diarrhoea-related hospital admissions in countries with low childhood mortality.
Rotavirus vaccines that have been prequalified by theWorldHealth Organization (WHO) include a monovalent vaccine (RV1; Rotarix,
GlaxoSmithKline), a pentavalent vaccine (RV5; RotaTeq, Merck), and, more recently, another monovalent vaccine (Rotavac, Bharat
Biotech).
Objectives
To evaluate rotavirus vaccines prequalified by the WHO (RV1, RV5, and Rotavac) for their efficacy and safety in children.
Search methods
On 4 April 2018 we searched MEDLINE (via PubMed), the Cochrane Infectious Diseases Group Specialized Register, CENTRAL
(published in the Cochrane Library), Embase, LILACS, and BIOSIS. We also searched the WHO ICTRP, ClinicalTrials.gov, clinical
trial reports from manufacturers’ websites, and reference lists of included studies and relevant systematic reviews.
Selection criteria
We selected randomized controlled trials (RCTs) in children comparing rotavirus vaccines prequalified for use by the WHO versus
placebo or no intervention.
Data collection and analysis
Two review authors independently assessed trial eligibility and assessed risks of bias. One review author extracted data and a second
author cross-checked them. We combined dichotomous data using the risk ratio (RR) and 95% confidence interval (CI). We stratified
the analysis by country mortality rate and used GRADE to evaluate evidence certainty.
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Main results
Fifty-five trials met the inclusion criteria and enrolled a total of 216,480 participants. Thirty-six trials (119,114 participants) assessed
RV1, 15 trials (88,934 participants) RV5, and four trials (8432 participants) Rotavac.
RV1
Children vaccinated and followed up the first year of life
In low-mortality countries, RV1 prevents 84% of severe rotavirus diarrhoea cases (RR 0.16, 95% CI 0.09 to 0.26; 43,779 participants,
7 trials; high-certainty evidence), and probably prevents 41% of cases of severe all-cause diarrhoea (RR 0.59, 95% CI 0.47 to 0.74;
28,051 participants, 3 trials; moderate-certainty evidence). In high-mortality countries, RV1 prevents 63% of severe rotavirus diarrhoea
cases (RR 0.37, 95% CI 0.23 to 0.60; 6114 participants, 3 trials; high-certainty evidence), and 27% of severe all-cause diarrhoea cases
(RR 0.73, 95% CI 0.56 to 0.95; 5639 participants, 2 trials; high-certainty evidence).
Children vaccinated and followed up for two years
In low-mortality countries, RV1 prevents 82% of severe rotavirus diarrhoea cases (RR 0.18, 95% CI 0.14 to 0.23; 36,002 participants,
9 trials; high-certainty evidence), and probably prevents 37% of severe all-cause diarrhoea episodes (rate ratio 0.63, 95% CI 0.56 to
0.71; 39,091 participants, 2 trials; moderate-certainty evidence). In high-mortality countries RV1 probably prevents 35% of severe
rotavirus diarrhoea cases (RR 0.65, 95% CI 0.51 to 0.83; 13,768 participants, 2 trials; high-certainty evidence), and 17% of severe all-
cause diarrhoea cases (RR 0.83, 95% CI 0.72 to 0.96; 2764 participants, 1 trial; moderate-certainty evidence).
No increased risk of serious adverse events (SAE) was detected (RR 0.88 95% CI 0.83 to 0.93; high-certainty evidence). There were
30 cases of intussusception reported in 53,032 children after RV1 vaccination and 28 cases in 44,214 children after placebo or no
intervention (RR 0.70, 95% CI 0.46 to 1.05; low-certainty evidence).
RV5
Children vaccinated and followed up the first year of life
In low-mortality countries, RV5 probably prevents 92% of severe rotavirus diarrhoea cases (RR 0.08, 95% CI 0.03 to 0.22; 4132
participants, 5 trials; moderate-certainty evidence). We did not identify studies reporting on severe all-cause diarrhoea in low-mortality
countries. In high-mortality countries, RV5 prevents 57% of severe rotavirus diarrhoea (RR 0.43, 95% CI 0.29 to 0.62; 5916 partic-
ipants, 2 trials; high-certainty evidence), but there is probably little or no difference between vaccine and placebo for severe all-cause
diarrhoea (RR 0.80, 95% CI 0.58 to 1.11; 1 trial, 4085 participants; moderate-certainty evidence).
Children vaccinated and followed up for two years
In low-mortality countries, RV5 prevents 82% of severe rotavirus diarrhoea cases (RR 0.18, 95% CI 0.08 to 0.39; 7318 participants, 4
trials; moderate-certainty evidence). We did not identify studies reporting on severe all-cause diarrhoea in low-mortality countries. In
high-mortality countries, RV5 prevents 41% of severe rotavirus diarrhoea cases (RR 0.59, 95% CI 0.43 to 0.82; 5885 participants, 2
trials; high-certainty evidence), and 15% of severe all-cause diarrhoea cases (RR 0.85, 95% CI 0.75 to 0.98; 5977 participants, 2 trials;
high-certainty evidence).
No increased risk of serious adverse events (SAE) was detected (RR 0.93 95% CI 0.86 to 1.01; moderate to high-certainty evidence).
There were 16 cases of intussusception in 43,629 children after RV5 vaccination and 20 cases in 41,866 children after placebo (RR
0.77, 95% CI 0.41 to 1.45; low-certainty evidence).
Rotavac
Children vaccinated and followed up the first year of life
Rotavac has not been assessed in any RCT in countries with low child mortality. In India, a high-mortality country, Rotavac probably
prevents 57% of severe rotavirus diarrhoea cases (RR 0.43, 95% CI 0.30 to 0.60; 6799 participants, moderate-certainty evidence); the
trial did not report on severe all-cause diarrhoea at one-year follow-up.
Children vaccinated and followed up for two years
Rotavac probably prevents 54% of severe rotavirus diarrhoea cases in India (RR 0.46, 95% CI 0.35 to 0.60; 6541 participants, 1 trial;
moderate-certainty evidence), and 16% of severe all-cause diarrhoea cases (RR 0.84, 95% CI 0.71 to 0.98; 6799 participants, 1 trial;
moderate-certainty evidence).
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No increased risk of serious adverse events (SAE) was detected (RR 0.93 95% CI 0.85 to 1.02; moderate-certainty evidence). There
were eight cases of intussusception in 5764 children after Rotavac vaccination and three cases in 2818 children after placebo (RR 1.33,
95% CI 0.35 to 5.02; very low-certainty evidence).
There was insufficient evidence of an effect on mortality from any rotavirus vaccine (198,381 participants, 44 trials; low- to very low-
certainty evidence), as the trials were not powered to detect an effect at this endpoint.
Authors’ conclusions
RV1, RV5, and Rotavac prevent episodes of rotavirus diarrhoea. Whilst the relative effect estimate is smaller in high-mortality than in
low-mortality countries, there is a greater number of episodes prevented in these settings as the baseline risk is much higher. We found
no increased risk of serious adverse events.
P L A I N L A N G U A G E S U M M A R Y
Vaccines for preventing rotavirus diarrhoea: vaccines in use
What is the aim of this review?
The aim of this Cochrane Review was to find out if rotavirus vaccines are effective in preventing diarrhoea and deaths in infants and
young children. We also aimed to find out if the rotavirus vaccines are safe. We collected and analyzed all relevant studies to answer
these questions, and found 55 studies.
Key messages
RV1, RV5, and Rotavac prevent episodes of rotavirus diarrhoea (moderate- to high-certainty evidence). We found no increased risk of
serious adverse events (moderate- to high-certainty evidence) including intussusception (where the bowel telescopes on itself, and can
cause obstruction) (very low to low-certainty evidence).
What was studied in the review?
Rotavirus infection is a common cause of diarrhoea in infants and young children, and can cause mild illness, hospitalization, and death.
Since 2009, the World Health Organization (WHO) has recommended that a rotavirus vaccine be included in all national infant and
child immunization programmes, and 95 countries have so far followed this recommendation. In the years before infants and children
started receiving rotavirus vaccine, rotavirus infection resulted in about half a million deaths a year in children aged under five years,
mainly in low- and middle-income countries.
In this review we included randomized controlled trials in infants and young children that evaluated a monovalent rotavirus vaccine
(RV1; Rotarix, GlaxoSmithKline) or a pentavalent rotavirus vaccine (RV5; RotaTeq, Merck). These vaccines have been evaluated in
several large trials and are approved for use in many countries. We also included trials that evaluated another monovalent rotavirus
vaccine (Rotavac; Bharat Biotech), which is used in India only. The rotavirus vaccines were compared with placebo or with no vaccine.
The included studies did not allow comparisons between the vaccines.
What are the main results of the review?
We found 55 relevant studies with 216,480 participants. The trials took place in several locations worldwide. These studies compared
a rotavirus vaccine versus placebo or versus no vaccine for infants and young children. The vaccines tested were RV1 (36 trials with
119,114 participants), RV5 (15 trials with 88,934 participants), and Rotavac (four trials with 8432 participants). Fifty-one studies
were funded or co-funded by vaccine manufacturers, while four were independent of manufacturer funding.
In the first two years of life, RV1:
prevents more than 80% of severe cases of rotavirus diarrhoea in countries with low death rates (high-certainty evidence)
prevents 35% to 63% of severe rotavirus diarrhoea in countries with high death rates (high-certainty evidence)
probably prevents 37% to 41% of severe cases of diarrhoea from all causes (such as any viral infection, bacterial infection, or parasitic
infection) in countries with low death rates (moderate-certainty evidence)
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probably prevents 18% to 27% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-
certainty evidence).
In the first two years of life, RV5:
probably prevents 82% to 92% of severe cases of rotavirus diarrhoea in countries with low death rates (moderate-certainty evidence)
prevents 41% to 57% of severe cases of rotavirus diarrhoea in countries with high death rates (high-certainty evidence)
probably prevents 15% of severe cases of diarrhoea from all causes in countries with high death rates (moderate- to high-certainty
evidence); we did not identify any studies that reported on diarrhoea from all causes in countries with low death rates.
In the first two years of life, Rotavac:
probably prevents more than 50% of severe cases of rotavirus diarrhoea in India, a country with high death rates (moderate-certainty
evidence)
probably prevents 18% of severe cases of diarrhoea from all causes in India (moderate-certainty evidence). Rotavac has not been
evaluated in a randomized controlled trial in a country with low death rates.
We found little or no difference in the number of serious adverse events (moderate- to high-certainty evidence), or intussusception
cases (low- to very low-certainty evidence), between those receiving RV1, RV5, or Rotavac compared with placebo or no intervention.
How up-to-date is this review?
We searched for studies that had been published up to 4 April 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: children
Setting: low-mortality countries (WHO strata A and B)
Intervention: RV1
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV1
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 1 year
13 per 1000 2 per 1000
(1 to 3)
RR 0.16
(0.09 to 0.26)
43,779
(7 studies)
⊕⊕⊕⊕
higha
RV1 reduces severe ro-
tavirus diarrhoea com-
pared to placebo at up
to one year follow-up
One study (RV1
Vesikari 2007a-EU) re-
ported higher ef f icacy
compared to the pooled
data. When we ex-
cluded this study f rom
the analysis, there was
no heterogeneity ob-
served in the pooled
data
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 2 years
24 per 1000 4 per 1000
(3 to 5)
RR 0.18
(0.14 to 0.23)
36,002
(9 studies)
⊕⊕⊕⊕
high
RV1 reduces severe ro-
tavirus diarrhoea com-
pared to placebo at up
to two years follow-up
Severe cases of all-
cause diarrhoea
Follow-up: up to 1 year
41 per 1000 24 per 1000
(19 to 30)
RR 0.59
(0.47 to 0.74)
28,051
(3 studies)
⊕⊕⊕©
moderateb
due to reporting bias
RV1 probably reduces
severe all-cause di-
arrhoea compared to
placebo at up to one
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year follow-up
Severe episodes of all-
cause diarrhoea
Follow-up: up to 2 years
39 per 1000 24 per 1000
(22 to 28)
Rate Ratio 0.63
(0.56 to 0.71)
39,091
(2 studies)
⊕⊕⊕©
moderatec
due to reporting bias
RV1 probably reduces
severe all-cause di-
arrhoea compared to
placebo at up to two
years follow-up
Three addit ional stud-
ies reported on cases
of children with severe
all-cause diarrhoea (RR
0.60, 95% CI 0.36 to 1.
02; 9417 part icipants);
these data could not be
pooled with the studies
report ing on number of
episodes
All- cause death
Follow-up: 2 months to
2 years
1 per 1000 2 per 1000
(1 to 2)
RR 1.22
(0.87 to 1.71)
97,597
(22 studies)
⊕⊕©©
lowd
due to imprecision
RV1 may make lit t le
or no dif ference to all-
cause death compared
to placebo
All serious adverse
events
Follow-up: 2 months to
2 years
45 per 1000 40 per 1000
(37 to 42)
RR 0.88
(0.83 to 0.93)
96,233
(24 studies)
⊕⊕⊕⊕
high
RV1 slight ly reduces se-
rious adverse events
compared to placebo
Serious
adverse events: intus-
susception
Follow-up: 2 months to
2 years
1 per 1000 1 per 1000
(0 to 1)
RR 0.69
(0.45 to 1.04)
96,513
(17 studies)
⊕⊕©©
lowe
due to imprecision
RV1 may make lit t le or
no dif ference to intus-
suscept ion compared
to placebo
* The basis for the assumed risk is the control group risk across studies included in the meta-analysis. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io
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GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
aWe observed heterogeneity (I2 stat ist ic = 61%) in the pooled data, but given the strength of the evidence, and that est imates
were all in the same direct ion, we did not downgrade the outcome.
bDowngraded by one for risk of select ive report ing bias. Only three of the seven studies report ing on severe rotavirus diarrhoea
provided data for this outcome.
cDowngraded by one for risk of select ive report ing bias. Only f ive of the nine studies report ing on severe rotavirus diarrhoea
provided data for this outcome.
dDowngraded by two for imprecision. These trials were not powered to detect an ef fect on mortality.
eDowngraded by two for imprecision. There was a 1:10,000 to 1:32,000 increased risk of intussuscept ion with a previous
rotavirus vaccine (Bines 2005), so these trials were not powered to detect an associat ion between RV1 and intussuscept ion.
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B A C K G R O U N D
Description of the condition
The global impact of rotavirus infection
Rotavirus is the leading known cause of severe gastroenteritis in
infants and young children worldwide (Parashar 2006a; Vesikari
1997; WHO 2013). While nearly every child experiences at least
one rotavirus infection in early childhood regardless of setting,
the vast majority of rotavirus-associated deaths occur in children
in low- and middle-income countries, particularly in sub-Saharan
Africa and in the Indian subcontinent. Prior to the rollout of
rotavirus vaccination, rotavirus caused 37% of diarrhoeal deaths
(~ 450,000 deaths worldwide in 2008) in children younger than
five years. Five countries accounted formore than half of all deaths,
and 22% of deaths attributable to rotavirus infection occurred in
India (Tate 2012). In high-income countries, where deaths due to
rotavirus are rare, rotavirus accounted for 40% to 50% of hospital
admissions due to diarrhoeal disease in the pre-rotavirus vaccine
period (Linhares 2008; Parashar 2006a; Tate 2012).
Epidemiology of rotavirus infection
Rotavirus is transmitted primarily via the faecal-oral route, with
symptoms typically developing one to two days following infec-
tion. Rotavirus infection occurs throughout life, and successive ro-
tavirus infections occur during infancy and early childhood. The
first rotavirus infection typically results in the most severe dis-
ease outcome; subsequent rotavirus infections are associated with
milder disease or may be asymptomatic. However, differences in
the age of first infection and number of infections required to ac-
quire protection from symptomatic disease vary from one pop-
ulation to another. Rotavirus diarrhoea is particularly associated
with severe outcomes between the ages of three and 35 months
(Parashar 2006b), with a peak incidence of all episodes occurring
between six and 24 months (CDC-ASIP 1999; Linhares 2008).
The peak incidence of severe rotavirus disease occurs earlier in
high-mortality countries than in low-mortality countries; an esti-
mated 43% of all rotavirus hospitalizations in children aged under
five occur by eight months of age in Africa compared with 27%
in Europe (Crawford 2017; Sanderson 2011). Typically, infants
in low-income countries experience a greater number of symp-
tomatic episodes (Gladstone 2011; Velázquez 1996). In temperate
countries rotavirus infections display marked seasonality, with dis-
tinct peaks during the winter months and few infections identified
outside this period, whereas rotavirus infections occur year-round
in most tropical countries.
Rotavirus classification
Rotaviruses are double-stranded (ds) RNA viruses: genus Ro-
tavirus, family Reoviridae. Each of the 11 dsRNA segments, con-
tained within the core of a triple-layered viral particle, encodes one
or more viral proteins. Rotavirus A,which causes most human dis-
ease, is genetically diverse in each of its 11 genome segments (called
genotypes), and a nucleotide sequence-based, complete genome
classification system is used. Because of their importance in pro-
tective immunity, the outer capsid proteins VP7 and VP4 have
been most extensively investigated. Species A rotaviruses are clas-
sified into G and P genotypes, based on the sequence diversity
of the RNA segments encoding VP7 and VP4, respectively; 32
G genotypes and 47 P genotypes have been described (Crawford
2017) (see Figure 1 for details). Rotavirus vaccines are designed to
protect against disease caused by the most prevalent strain types;
globally, G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12 in
combination with P[6] or P[8] account for over 90% of the geno-
types that infect humans (Bányai 2012).
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Figure 1. A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn, Wikipedia (public
domain image)): Rotaviruses are segmented, double-stranded RNA viruses. The mature, triple-layered virus
particle comprises a core (which contains the viral genome), a middle layer (comprised of viral protein (VP)6,
and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines rotavirus group, and most
rotaviruses that infect humans are of group A. The two outer capsid proteins independently induce
neutralizing antibodies: VP7, a glycoprotein, defines G-serotype; and the protease-sensitive VP4 protein
defines P-serotype. G-serotype determined by serological methods correlates precisely with G-genotype
obtained through molecular assays, whereas there is an imperfect correlation of P-serotype and P-genotype;
P-genotype is thus included in square brackets.
Description of the intervention
Vaccines approved for use
This review evaluates three vaccines, including a monovalent ro-
tavirus vaccine (RV1; Rotarix, GlaxoSmithKline Biologicals) and a
pentavalent rotavirus vaccine (RV5; RotaTeq, Merck&Co., Inc.),
which have been evaluated in several large trials and are in routine
use inmany countries; and a furthermonovalent vaccine (Rotavac,
Bharat Biotech Ltd.), which is currently licensed in India only.
All three vaccines are listed as prequalified vaccines by the WHO
(Dellepiane 2015; WHO 2018). As of April 2018, 95 countries
have introduced rotavirus vaccines into their immunization pro-
grammes (ROTA council 2018).
RV1 is an oral, live-attenuated, human rotavirus vaccine derived
from the most common circulating wild-type strain G1P[8]. RV1
is based on a rotavirus of entirely human origin and is adminis-
tered to infants in two oral doses with an interval of at least four
weeks between doses. The manufacturer states that the “vaccina-
tion course should preferably be given before 16 weeks of age, but
must be completed by the age of 24 weeks” (EMA 2011). As of
May 2016, RV1 had been introduced in national immunization
programmes in 63 countries around the world (PATH 2016).
RV5 is an oral, live, human-bovine, reassortant, multivalent ro-
tavirus vaccine developed from an original Wistar calf 3 (WC3)
strain of bovine rotavirus. The vaccine contains five live, human-
bovine reassortant rotavirus strains. Four reassortant rotavirus
strains each express one of the common human VP7 (G) types
including G1, G2, G3, and G4, and the fifth reassortant expresses
the common human VP4 (P) type P[8]. The three-dose liquid
vaccine is intended for infants aged between six and 32 weeks,
with the first dose given at six to 12 weeks and subsequent doses
administered at four- to 10-week intervals; however, the third dose
should not be given after 32 weeks of age (Merck 2008). As of
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May 2016, RV5 had been introduced in national immunization
programmes in 22 countries around the world (PATH 2016).
Rotavac is a live-attenuated, monovalent vaccine derived from
a naturally-occurring reassortant G9P[11] strain [116E] isolated
from a newborn child in India (Yen 2014). This oral vaccine was
developed by Bharat Biotech Ltd. in India and was licensed in
India in 2014 (VAC Chandola 2017-IND). Three doses are rec-
ommended, to be administered at 6, 10, and 14 weeks of age.
There are a further three rotavirus vaccines that have been licensed
and approved for use in individual countries, but are not yet pre-
qualified by the WHO. Lanzhou lamb rotavirus vaccine (LLR;
Lanzhou Institute of Biomedical Products) which is licensed and
used in China; a bovine rotavirus pentavalent vaccine (BRV-PV,
Rotasiil, Serum Institute of India Ltd.) which is licensed and used
in India; and a monovalent vaccine (Rotavin-M1, POLYVAC)
which is licensed and used in Vietnam.
Vaccines no longer in use
Several vaccines, including the first licensed rotavirus vaccine
(RRV-TV; RotaShield, Wyeth Laboratories) were developed,
tested in trials, and later abandoned or withdrawn from use. These
vaccines are covered in a separate Cochrane Review (Soares-Weiser
2004). RRV-TV, a tetravalent rhesus-human reassortant vaccine,
was withdrawn from use in 1999 following reports of intussuscep-
tion (bowel obstruction which occurs when one segment of bowel
becomes enfoldedwithin another segment). Evaluations have since
suggested that the risk of intussusception was age-related, with
80% of intussusception cases occurring in infants who were more
than 90 days old when the first vaccine dose was administered
(Simonsen 2005). Although it is still currently licensed, this vac-
cine is no longer in clinical use (Dennehy 2008).
How the intervention might work
Recommendations for rotavirus vaccine use
Vaccination with RV1 and RV5was first recommended in 2006 in
Europe and the Americas, where clinical trials had demonstrated
vaccine efficacy of 85% to 100% (RV1 Ruiz-Palac 06-LA/EU;
RV5 Vesikari 2006b-INT). In April 2009, following clinical trials
of RV1 and RV5 in low- and middle-income countries in Africa
and Asia, the WHO Strategic Advisory Group of Experts (SAGE)
on Immunization recommended “the inclusion of rotavirus vac-
cination of infants into all national immunization programmes”,
with a stronger recommendation for countries where “diarrhoeal
deaths account for ≥10% of mortality among children aged <5
years” (SAGE 2009). Due to an age-related risk of intussusception
identified with RRV-TV (Murphy 2001), SAGE recommended
administering the first dose of RV1 or RV5 to infants of six to 15
weeks of age, with the last dose administered before 32 weeks of
age (SAGE 2009). In April 2012, SAGE relaxed the age restricted
recommendation and advised to vaccinate “as soon as possible af-
ter the age of six weeks” because “the current age restrictions for
the first dose (< 15 weeks) and last dose (< 32 weeks) are prevent-
ing vaccination of many vulnerable children” (Patel 2012; SAGE
2012).
Performance of oral rotavirus vaccines by setting
Many oral vaccines, including rotavirus vaccines, have demon-
strated lower immunogenicity and efficacy in low- and middle-
income countries in Africa and Asia compared to high-income
countries in North America, South America, and Europe (Levine
2010). A systematic review demonstrated a correlation between
lower vaccine efficacy against severe rotavirus diarrhoea and high
child mortality rates (Fischer Walker 2011). The reasons for re-
duced oral vaccine efficacy in countries with higher childmortality
rates are unknown; factors may include interference by maternal
antibody, co-administration with oral poliovirus vaccine, histo-
blood group antigen, diverse rotavirus strain types, micronutrient
deficiencies, endemic infections such as malaria, tuberculosis, or
HIV, concomitant enteric infections, gut inflammation, and al-
tered gut microbiota (Czerkinsky 2015).
Outcomes of interest
The safety and efficacy of the licensed vaccines for the prevention
of rotavirus gastroenteritis in infants have been assessed in several
randomized controlled trials (RCTs) worldwide. The goal of this
review is to systematically assess these trials and evaluate vaccine
efficacy against rotavirus diarrhoea, all-cause diarrhoea, and di-
arrhoea-related medical visits and hospitalization. We also exam-
ine the occurrence of deaths and serious adverse events, including
intussusception, to provide decision-makers, clinicians, and care-
givers with the relevant information to aid decisions about vaccine
use.
Why it is important to do this review
Development of Cochrane systematic rotavirus
vaccine reviews
The originalCochraneReviewof rotavirus vaccines (Soares-Weiser
2004) examined vaccines in use andother vaccines, including those
that were no longer in use or were in development. Soares-Weiser
2004 concluded that more trials were needed before routine vac-
cine use could be recommended. An update in 2009 included
a new search, revised inclusion criteria (only vaccines in use in
children), updated review methods and new authors. The review
was updated again in 2010 with nine new studies (Soares-Weiser
2010). The 2010 version of the review concluded that RV1 and
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RV5 are both effective vaccines for the prevention of rotavirus di-
arrhoea. Another update in February 2012 added a further nine
new studies, GRADE ‘Summary of findings’ tables and, again,
new authors joined the team (Soares-Weiser 2012a). The Novem-
ber 2012 update included a new search, major restructuring of
analyses, including re-evaluating primary outcomes in consulta-
tion with the WHO to reflect the observation that vaccine ef-
ficacy profiles are different in countries with different mortality
rates (Soares-Weiser 2012b). This current update adds a further
10 RV1 and RV5 studies to the review and four studies of a new
vaccine, Rotavac, that has been prequalified by the WHO since
the previous version of the review.
O B J E C T I V E S
To evaluate rotavirus vaccines prequalified by the WHO (RV1,
RV5, and Rotavac) for their efficacy and safety in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
Children (age as defined in the trials).
Types of interventions
Intervention
Rotavirus vaccines approvedby theWHOvaccine prequalification
programme (Dellepiane 2015; WHO 2018).
Control
Placebo, no vaccination, or other vaccine.
Types of outcome measures
Primary
We selected our primary outcome measures in consultation with
theWHO, and stratified them according to high- or low-mortality
rate, based on WHO mortality strata (WHO 1999), and up to
one and up to two years follow-up.
• Rotavirus diarrhoea: severe (as defined in trial report)
• All-cause diarrhoea: severe
• All-cause death
• Serious adverse events (that are fatal, life-threatening, or
result in hospitalization); e.g. Kawasaki disease
• Intussusception
Secondary
• Rotavirus diarrhoea: of any severity
• All-cause diarrhoea (as defined in trial report)
• Rotavirus diarrhoea: requiring hospitalization
• All-cause diarrhoea: requiring hospitalization
• Emergency department visit
• Hospital admission: all-cause
• Reactogenicity (capacity to produce an adverse reaction,
such as fever, diarrhoea, and vomiting)
• Adverse events that require discontinuation of vaccination
schedule
Other
• Immunogenicity
◦ Vaccine virus shedding in stool
◦ Seroconversion: conversion from seronegative to
seropositive for anti-rotavirus IgA antibodies
• Dropouts
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and on-
going).
For this review update, Dr Vittoria Lutje (Information Special-
ist, Cochrane Infectious Diseases Group) searched the follow-
ing databases using the search terms and strategy described in
Appendix 1.
• Cochrane Infectious Diseases Group Specialized Register (4
April 2018)
• Cochrane Central Register of Controlled Trials
(CENTRAL), published in the Cochrane Library (2018, Issue 4)
• MEDLINE (via PubMed; 1966 to April 2018)
• Embase (1974 to 4 April 2018)
• LILACS (1982 to 4 April 2018)
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• BIOSIS (1926 to 4 April 2018)
We also searched the WHO International Clinical Trials Registry
Platform (ICTRP) and Clinicaltrials.gov Clinical Study Register
( www.clinicaltrials.gov) on 4 April 2018, using ‘rotavirus’ as the
search term.
We searched manufacturers’ websites for clinical trial reports. We
also checked the reference lists of relevant systematic reviews and
included studies.
Data collection and analysis
Selection of studies
For this review update, we uploaded and screened references in
DistillerSR online. Two review authors independently screened
each title and abstract identified in the search. We retrieved full
texts for potentially relevant references and two review authors
again screened them independently, resolving disagreements by
recourse to a third review author.We tabulated the excluded studies
along with the reason for excluding them in the Characteristics of
excluded studies tables. We ensured that data from each trial were
entered only once in our review. In previous versions of this review
we had screened references in an EndNote database.
Data extraction and management
For this review update, we extracted data in DistillerSR online.
We created forms for data collection, which were piloted and then
revised after the review author team’s discussion. For previous ver-
sions of this review we had used Microsoft Word or Excel data
collection forms.
One review author extracted data and another review author cross-
checked them. All outcomes were dichotomous, and we extracted
the total number of participants and the number of participants
who experienced the event. We cross-checked the extracted data
to identify errors, resolving disagreements by referring to the trial
report or by consulting a third review author. One review author
entered data into ReviewManager 5 (RevMan 5) (RevMan 2014).
Assessment of risk of bias in included studies
Two review authors independently assessed the risks of bias of
each trial, using the Cochrane ‘Risk of bias’ tool (Higgins 2017).
Based on the guidance of the Cochrane ‘Risk of bias’ tool (Higgins
2017), we created a form to make judgements on the risk of bias
for the rotavirus diarrhoea outcome measure in six domains: se-
quence generation; allocation concealment; blinding (of partic-
ipants, personnel, and outcome assessors); incomplete outcome
data; selective outcome reporting; and other potential sources of
bias. We categorized these judgements as ‘low’, ‘high’, or ‘unclear’
risk of bias. We resolved disagreements through discussion with a
third review author.
For the 2012 published version of this review, we asked for help
from Dr Ana Maria Restrepo at the WHO Initiative for Vac-
cine Research, who contacted the vaccine manufacturers Glaxo-
SmithKline (RV1) and Merck (RV5), who were involved in de-
signing and fundingmost of the included trials.We provided them
with an Excel spreadsheet with specific details of each trial that
would impact on the assessment of risk of bias. We received details
fromMerck (RV5), (see Characteristics of included studies for de-
tails). For this review update, we matched most of the previously-
included RV1 studies to the full clinical trial reports available on
the manufacturer’s website ( www.gsk-clinicalstudyregister.com).
More details were available in these trial reports than in the pub-
lished studies, that were helpful in assessing the risks of bias for
these studies.
Measures of treatment effect
We analyzed dichotomous data of cases by calculating the risk ratio
(RR) for each trial (expressed using blue squares in forest plots)
with the uncertainty in each result expressed using 95%confidence
intervals (CIs). For dichotomous data of events that could occur
more than once in one participant, we calculated the rate ratio
(expressed using red squares in forest plots) on the logarithmic
scale using the generic inverse variance method (see Data synthesis
for more details). For outcomes that included cluster-RCTs we
calculated risk ratios (expressed using red squares in forest plots)
using the generic inverse variance method (see Unit of analysis
issues for more details).
Unit of analysis issues
When trials had multiple treatment arms and we considered it
suitable, we grouped the trial arms. We excluded irrelevant trial
arms.
We pooled cluster-RCT data that had been adjusted for clustering
with data from trials that randomly assigned individuals (individ-
ual-RCTs). For outcomes that included cluster-RCTs, we pooled
risk ratios on the logarithmic scale with their standard errors using
the generic inverse variance method (16.3.3. in Higgins 2011).
When the results of a cluster-RCT had not been adjusted for clus-
tering, we imputed the clustering effect (intracluster correlation
coefficient (ICC)) from another study, and performed sensitivity
analyses excluding these studies.
Dealing with missing data
Weundertook a complete-case analysis (the number analyzed) and
an intention-to-treat analysis when data were available.
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Assessment of heterogeneity
We initially assessed heterogeneity in the results of the trials by
inspecting the graphical presentations and by calculating the Chi
2 test of heterogeneity. However, we were aware of the fact that
the Chi2 test has a poor ability to detect statistically significant
heterogeneity among studies. We therefore also quantified the im-
pact of heterogeneity in the meta-analysis using a measure of the
degree of inconsistency in the studies’ results (Higgins 2003). This
measure (the I2 statistic) describes the percentage of total variation
across studies that are due to heterogeneity rather than to the play
of chance (Higgins 2003). The I2 statistic values lie between 0%
and 100%, and a simplified categorization of heterogeneity could
be low, moderate, and high for I2 statistic values of 25%, 50%,
and 75% respectively (Higgins 2003).
Assessment of reporting biases
If 10 or more studies were included in an outcome, we examined a
funnel plot for the primary outcome (severe rotavirus diarrhoea),
estimating the precision of trials (plotting the RR against the stan-
dard error (SE) of the log of RR) to estimate potential asymmetry.
Data synthesis
We stratified all analyses by the type of vaccine, RV1, RV5 or Ro-
tavac. Subsequently, we grouped all outcomes in themeta-analyses
according to the time point when the outcome was measured or
the number of rotavirus seasons, or both, as follows: less than two
months; up to one year (one rotavirus season); up to two years (up
to two rotavirus seasons); and up to three years (three rotavirus
seasons). If data were available for more than one time point, we
used the number of completers for each time point in the trial.
For the current update, we stratified each primary outcome (ro-
tavirus diarrhoea, all-cause diarrhoea, all-cause death, all serious
adverse events, and intussusception) and selected secondary out-
comes (rotavirus diarrhoea and all-cause diarrhoea of any severity,
and all-cause hospitalization) by country mortality rate according
to WHO mortality strata (WHO 1999), as follows:
• Low-mortality: countries in WHO strata A and B (very
low/low child mortality and low adult mortality)
• High-mortality: countries in WHO strata D and E (high
child mortality and high/very high adult mortality)
We used a fixed-effect model, unless we found statistically signifi-
cant heterogeneity (P < 0.10) for a specific outcome, in which case
we used the random-effects model.
We included separate analyses for cases of diarrhoea (e.g. a child
who has diarrhoea regardless of the number of episodes) and
episodes (i.e. one child can experience more than one episode),
where data permitted. We combined episodes using the rate ratio
in the logarithmic scale and SE, with the uncertainty in each result
being expressed using a 95% CI (9.4.8. in Higgins 2011).
Certainty of the evidence
We interpreted the findings of this review using the GRADE
approach (Schünemann 2017), and we used GRADE profiler
(GRADE 2004) to import data from RevMan 5 (RevMan 2014)
to create ‘Summary of findings’ tables. These tables provide out-
come-specific information concerning the overall certainty of evi-
dence from each included study in the comparison, themagnitude
of effect of the interventions examined, and the sum of available
data on all outcomes we rated as important to patient care and de-
cision-making, and is reflected as follows: high certainty (“vaccine
prevents....”); moderate certainty (“vaccine probably prevents...”);
low certainty (“vaccine may prevent....”); and very low certainty
(“we do not know whether or not the vaccine prevents....”).
We selected primary outcomes, all stratified by vaccine and high or
low country mortality, for inclusion in the ‘Summary of findings’
tables: severe rotavirus diarrhoea; severe all-cause diarrhoea; all-
cause death; serious adverse events; and intussusception.
Subgroup analysis and investigation of heterogeneity
In addition to stratifying the results by country-based high-mor-
tality and low-mortality rates usingWHOmortality country strata
(WHO 1999), we planned to perform subgroup analyses to as-
sess the impact of the following possible sources of heterogene-
ity for any of the included vaccines: vaccine protection against
specific rotavirus G types; and vaccination of special groups, in-
cluding immunocompromised (including HIV-infected) children
and children with malnutrition. In previous versions of this re-
view (Soares-Weiser 2010; Soares-Weiser 2012a), we also analyzed
vaccine effect according to each study’s country income, use of
other childhood vaccines, number of doses administered, source
of funding, and whether infants were born prematurely or were
breast- or formula-fed. These subgroup analyses did not show any
differences, and are not presented in this updated version; they
can be found in Soares-Weiser 2010 and Soares-Weiser 2012a.
Sensitivity analysis
We also planned to conduct sensitivity analyses for the primary
outcomes according to allocation concealment (high, low, and
unclear risk of bias) for outcomes in which data could not be
pooled because of significant heterogeneity (I2 statistic > 75%).
R E S U L T S
Description of studies
Results of the search
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The update search in 2017 identified 1247 records and the up-
date search in 2018 identified a further 488 records. After de-
duplication, we screened 1614 records and considered 1500 to
be irrelevant. We reviewed the full texts of 114 records. In the
previously published version of this review there were 41 in-
cluded studies. The review now includes 55 independent trials
(see Characteristics of included studies), 14 of which are new to
this update (RV1Colgate 2016-BGD;RV1Kim2012-KOR; RV1
Li 2013a-CHN; RV1 Li 2013b-CHN; RV1 Li 2014-CHN; RV1
NCT00158756-RUS; RV1 Zaman 2017-BGD; RV5 Dhingra
2014-IND; RV5 Levin 2017-AF; RV5 Mo 2017-CHN; VAC
Bhandari 2006-IND; VAC Bhandari 2009-IND; VAC Bhandari
2014-IND; VAC Chandola 2017-IND) and we also added an-
other 23 new companion papers to previously included trials with
this update. The review also includes 15 ongoing studies (see
Characteristics of ongoing studies).We excluded 78 studies for the
reasons given in the Characteristics of excluded studies section.
Included studies
The 55 included trials enrolled about 216,480 participants (ap-
proximate number, as some trials provided only the number evalu-
able), and each trial compared a rotavirus vaccine with a placebo.
The vaccines tested were RV1 (36 trials reported in 171 publica-
tions or reports; 119,114 participants), RV5 (15 trials reported in
60 publications or reports; 88,934 participants), and Rotavac (4
trials reported in 13 publications or reports; 8432 participants).
The trials were conducted in Africa, Asia, Europe, and the
Americas, and the location can be identified in the study ref-
erence: AF, Africa; AS, Asia; EU, Europe; INT, several inter-
national locations; LA, Latin America; NA, North America;
or country three-letter acronym according to ISO 3166-1 Al-
pha-3 (e.g. BGD for Bangladesh) from www.all-acronyms.com/
special/countries acronyms and abbreviations, if the study was
conducted in a single country.
1. RV1
The 36 RV1 trials were published between 1998 and 2017. Five of
the trials are unpublished and were located on the GlaxoSmithK-
line website through clinicalstudyresults.org or clinicaltrials.gov.
One trial (RV1 Madhi 2010-AF) provided country-specific data
for efficacy outcomes but not for safety outcomes, and was con-
sequently split into RV1 Madhi 2010-MWI and RV1 Madhi
2010-ZAF for theMalawi- andSouthAfrica-specific data. Twenty-
five trials enrolled around 500 participants or fewer, three tri-
als enrolled around 1000 participants, seven trials enrolled be-
tween 2155 and 12,318 participants, and one large trial enrolled
63,225 participants. Most children were aged between one and
three months at the time of the first vaccination.
Population
Most trials included healthy infants. Two trials included HIV-
infected or -exposed infants (RV1 Madhi 2010-AF; RV1 Steele
2010a-ZAF), one trial included premature infants (RV1Omenaca
2012-EU), and one trial included children aged two to six years
(RV1 Li 2013a-CHN).
Outcome measures
Each trial reported on one or more of the outcome measures spec-
ified for this review (see Appendix 2). We included data on partic-
ipants requiring medical visits, as this was reported in some trials
and is a similar outcome measure to participants requiring hospi-
talization.
Twenty-three trialswere safety studies, reportingmainly safety out-
comes (e.g. serious adverse events and reactogenicity), immuno-
genicity outcomes, or both. Eleven of these trials also reported
efficacy outcomes with a follow-up of up to two months. Eleven
trials reported one or more efficacy outcomes (e.g. rotavirus di-
arrhoea) in addition to safety outcomes; most reported one or
more immunogenicity outcomes. Two trials reported on efficacy
or effectiveness but not safety or immunogenicity (RV1 Colgate
2016-BGD; RV1 Zaman 2017-BGD). The trials varied in the
length of follow-up, but in general the trials that specified efficacy
outcome measures had longer follow-up times (Appendix 2).
As shown in Appendix 3, rotavirus diarrhoea (of any severity) was
the most common efficacy outcome reported (by 23 trials); 14
trials reported on severe rotavirus diarrhoea, and 10 reported on
rotavirus diarrhoea requiring hospitalization. Data on all-cause
diarrhoea were provided by 17 trials, and severe all-cause diarrhoea
by nine trials. Most reported all-cause death and dropouts, but
other efficacy outcomes were reported by few trials.
For safety outcomes (Appendix 4), 29 trials reported on reacto-
genicity, all but four trials reported on serious adverse events, and
24 reported on adverse events leading to discontinuation of the
intervention.
Most trials reported on one or more immunogenicity outcomes;
see Appendix 4.
Location
Early trials were conducted in North America and Europe, but
since 2005 trials have also been conducted in Asia (Bangladesh,
China, India, Japan, Philippines, South Korea, Singapore, Thai-
land, Vietnam; 17 trials), Latin America (Argentina, Brazil, Chile,
Colombia, Dominican Republic, Honduras, Mexico, Nicaragua,
Panama, Peru, Venezuela; six trials), and Africa (South Africa,
Malawi; four trials); see Appendix 5.Most trials hadmultiple sites,
often in several countries; RV1 Vesikari 2007a-EU included 98
sites in six European countries.
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Country mortality rate
Most trials were conducted in countries with low mortality rates,
corresponding toWHOmortality strata A and B. Eight trials were
conducted in countries with high mortality rates (RV1 Colgate
2016-BGD; RV1 Madhi 2010-AF; RV1 Narang 2009-IND;
RV1 Steele 2008-ZAF; RV1 Steele 2010a-ZAF; RV1 Steele
2010b-ZAF; RV1 Zaman 2009-BGD; RV1 Zaman 2017-BGD),
corresponding toWHOmortality strata D and E; see Appendix 5.
For RV1Madhi 2010-AF, available data were split between coun-
tries into RV1 Madhi 2010-MWI and RV1 Madhi 2010-ZAF.
Two trials were conducted in several countries with both low
and high mortality: RV1 GSK[033] 2007-LA was conducted in
four study centres in a high-mortality country (Peru), but also
in three study centres in two low-mortality countries (Colombia
and Mexico), and was placed in the high-mortality group; and
RV1 Ruiz-Palac 06-LA/EU was conducted mainly in low-mor-
tality countries in Latin America and in Finland, but also in two
high-mortality countries (Nicaragua and Peru), and was placed in
the low-mortality group.
Vaccine schedule
The trials varied in the vaccine dose and schedule (see Appendix
6). Most trials gave two doses of the vaccine with virus concen-
tration of more than 106 plaque-forming units (PFUs). Older tri-
als, conducted between 1998 and 2005, tended to include slightly
lower PFUs or a range of PFUs for comparison.
RV1 was given as two doses in all but five trials: one trial con-
ducted inpartnershipwithGlaxoSmithKline andPATHRotavirus
Vaccine Program tested two and three doses of the vaccine (RV1
Madhi 2010-AF); another trial conducted by GlaxoSmithKline in
which the poliovirus vaccine was co-administeredwith RV1, tested
two or three vaccine doses to investigate differences in immune re-
sponse (RV1 Steele 2010b-ZAF); a third study tested three vaccine
doses in HIV-positive infants (RV1 Steele 2010a-ZAF); a fourth
study tested three vaccine doses in healthy infants (RV1GSK[021]
2007-PAN); a fifth study that included children aged two to six
years administered one dose only (RV1 Li 2013a-CHN).
Some trials compared more than one arm: different PFU virus
concentrations (RV1 Vesikari 2004a-FIN; RV1 Dennehy 2005-
NA; RV1 Phua 2005-SGP; RV1 Salinas 2005-LA; RV1 Ward
2006-USA); different formulations (RV1 GSK[021] 2007-PAN;
RV1 GSK[033] 2007-LA; RV1 GSK[101555] 2008-PHL; RV1
Kerdpanich 2010-THA; RV1 Vesikari 2011-FIN); co-adminis-
tration of other vaccine (RV1 Steele 2008-ZAF; RV1 Zaman
2009-BGD; RV1 NCT00158756-RUS; RV1 Li 2014-CHN);
and different intervals between doses (RV1 Anh 2011-PHL; RV1
Anh 2011-VNM).
Infant vaccination status
All but four trial reports referred to vaccination with other infant
vaccines (see Appendix 6). Most trials co-administered other rou-
tine infant vaccines, such as diphtheria-tetanus-acellular pertussis,
Haemophilus influenzae type b (HiB), inactivated polio vaccine,
and hepatitis B vaccine (HBV). Some trials also co-administered
oral polio vaccine. Other trials imposed a two-week separation
between other infant vaccines and rotavirus vaccine or placebo, or
specified other vaccines as not allowed.
Methods for collecting adverse event data
Fifteen of the 36 trials did not provide details of how adverse event
data were collected. Out of the trials that did report the method
of collecting adverse event data, 13 trials used passive methods
(e.g. diary cards), two used an active method (“active surveillance
system”), and five used both passive and active methods (e.g. diary
card plus regular telephone calls to parents); see Appendix 7.
Source of funding
Most trials were supported by GlaxoSmithKline Biologicals, three
of which were in partnership with PATH Rotavirus Vaccine Pro-
gram (RV1 Li 2014-CHN; RV1 Madhi 2010-AF; RV1 Zaman
2009-BGD), and another two in partnership with RAPID trials
and the WHO (RV1 Steele 2008-ZAF; RV1 Steele 2010a-ZAF).
One trial was funded by The Bill and Melinda Gates Founda-
tion (RV1 Colgate 2016-BGD) and one by GAVI and PATH
(RV1 Zaman 2017-BGD). Three trials were sponsored by Avant
Immunotherapeutics (formerly Virus Research Institute, Inc.)
(RV1Bernstein 1998-USA; RV1Bernstein 1999-USA; RV1Ward
2006-USA).
2. RV5
We identified 15 trials of RV5 vaccine. The earliest was reported
in 2003 and the most recent in 2017. One of the trials is un-
published and was accessed via clinicalstudyresults.org. Two tri-
als (RV5 Armah 2010-AF and RV5 Zaman 2010-AS) provided
country-specific data for some outcomes but not for all outcomes,
and were consequently split into RV5 Armah 2010-GHA; RV5
Armah 2010-KEN; and RV5 Armah 2010-MLI for the Ghana-,
Kenya, and Mali-specific data, and RV5 Zaman 2010-BGD and
RV5 Zaman 2010-VNM for the Bangladesh- and Vietnam-spe-
cific data. Overall, 88,934 participants were included in the tri-
als; the largest trial included 70,301 participants (RV5 Vesikari
2006b-INT) and the smallest included 48 participants (RV5
Lawrence 2012-CHN). For the 2012 update of this review, we
received new information from Merck (Merck 2012) for some of
the trials on the outcomes serious adverse events, intussusception,
and deaths. We have incorporated the new information into the
analyses and have indicated this in the Characteristics of included
studies section.
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Population
Most trials included healthy infants. One trial included both
healthy and HIV-infected infants (RV5 Armah 2010-KEN), an-
other trial included HIV-exposed but uninfected and HIV-in-
fected infants (RV5Levin 2017-AF), andone trial includedprema-
turely-born infants as well as those born at normal gestation (RV5
Vesikari 2006b-INT). All but two trials enrolled children aged be-
tween one month and three months; the children in RV5 Vesikari
2006a-FIN were aged between three months and six months, and
there was a child cohort (2- to 6-year-old children) in addition to
an infant cohort in RV5 Lawrence 2012-CHN.
Outcome measures
Six trials were safety studies (Appendix 2), reporting safety out-
comes (e.g. serious adverse events and reactogenicity) and gener-
ally immunogenicity outcomes as well. The other nine trials re-
ported one or more efficacy and safety outcomes, and seven out
of those nine also reported immunogenicity outcomes (Appendix
2). The trials varied in the length of follow-up (Appendix 2), but
in general the trials that specified efficacy outcome measures had
longer follow-up times (up to three years). Similar to the RV1 tri-
als, we included data on participants requiring medical visits, as
this was reported in some trials and is a similar outcome measure
to participants requiring hospitalization.
As shown inAppendix 3, rotavirus diarrhoea, severe cases and cases
of any severity, were themost common efficacy outcomes reported
(by eight trials); only one of these reported rotavirus diarrhoea
requiring hospitalization. Three trials provided data on severe cases
of all-cause diarrhoea; two also presented data on cases with any
severity. Eleven trials reported all-cause death, and 13 of the 15
trials reported dropouts.
For safety outcomes, all trials reported on serious adverse events
and reactogenicity, and 13 trials reported on adverse events leading
to discontinuation of the intervention; see Appendix 4.
Twelve trials reported on an immunogenicity outcome (Appendix
4).
Location
Half of the trials were conducted in low-mortality countries in
North America and Europe. Six trials, including the smallest and
the largest trials, were conducted in other regions: RV5 Armah
2010-AF was conducted in Ghana, Kenya and Mali; RV5 Levin
2017-AF was conducted in Botswana, Tanzania, Zambia and
Zimbabwe, RV5 Dhingra 2014-IND was conducted in India,
RV5 Kim 2008-KOR was conducted in South Korea; RV5 Iwata
2013-JPN was conducted in Japan; RV5 Lawrence 2012-CHN
and RV5Mo 2017-CHNwere conducted in China; RV5 Vesikari
2006b-INTwas conducted in 12 countries in Asia, theCaribbean,
Europe, LatinAmerica,North America; andRV5Zaman 2010-AS
was conducted in Bangladesh and Vietnam. Each trial had mul-
tiple sites, ranging from three (RV5 Vesikari 2006a-FIN) to 356
sites (RV5 Vesikari 2006b-INT); see Appendix 5.
Country mortality rate
Most trials were conducted in countries with low mortality
rates, corresponding to WHO mortality strata A and B; see
Appendix 5. One trial was conducted in high-mortality India
(RV5 Dhingra 2014-IND). Four trials were conducted in sev-
eral low- and high-mortality countries. RV5 Armah 2010-AF was
conducted in three high-mortality countries, Ghana, Kenya, and
Mali, and when available the data were split into RV5 Armah
2010-GHA, RV5 Armah 2010-KEN and RV5 Armah 2010-MLI.
RV5 Levin 2017-AF was conducted in four high-mortality coun-
tries (Botswana, Tanzania, Zambia and Zimbabwe). RV5 Vesikari
2006b-INT was conducted mainly in European and Latin Amer-
ican low-mortality countries, but also in Guatemala, a high-mor-
tality country, and was placed in the low-mortality group. RV5
Zaman 2010-AS was conducted in one high-mortality country
(Bangladesh) with 1136 participants, and in one low-mortality
country (Vietnam) with 900 participants, and was placed in the
high-mortality group, except when data could be split into RV5
Zaman 2010-BGD and RV5 Zaman 2010-VNM.
Vaccine schedule
Each trial used three doses of RV5 vaccine, with intervals between
doses of four and 10 weeks (see Appendix 6). All but two trials
had one vaccine and one placebo arm; RV5 Vesikari 2006a-FIN
included three vaccine arms in which there were different RV5
components (G1-4, P1A, G1-4, and P1A), and RV5 Dhingra
2014-IND included a RV5 arm, a placebo arm, and three arms
with different concentrations of BRV-TV vaccine.
Infant vaccination status
Most trials did not restrict the use of other childhood vaccines (see
Appendix 6). Two trials co-administered hepatitis B, diphtheria-
tetanus-pertussis, poliovirus, andH influenzae type b vaccines with
RV5 (RV5 Ciarlet 2009-EU; RV5Dhingra 2014-IND). One trial
randomized participants to either concomitant or staggered ad-
ministration of other childhood vaccines (OPV, DTaP) with RV5
or placebo (RV5 Mo 2017-CHN). Three trials allowed the use
of oral polio vaccine, in addition to other licensed childhood vac-
cines (RV5 Armah 2010-AF; RV5 Mo 2017-CHN; RV5 Zaman
2010-AS). Three trials did not allow the use of other vaccines
(RV5 Clark 2003-USA; RV5 Clark 2004-USA; RV5 Lawrence
2012-CHN), and one trial did not mention their use (RV5 Iwata
2013-JPN).
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Methods for collecting adverse event data
As shown in Appendix 7, seven trials used a combination of passive
methods (e.g. diary cards for parents) and active methods (directly
contacting parents) to collect adverse event data. The other trials
used passive methods only (diary cards, three trials), active meth-
ods only (“active surveillance”, three trials), or the information was
not provided (two trials).
Source of funding
All but one trial was funded by Merck & Co., Inc. Two of those
trials also received funding and were run by PATH (GAVI Alliance
grant) (RV5 Armah 2010-AF; RV5 Zaman 2010-AS), and one
trial also received funding from the International Maternal, Pedi-
atric, and Adolescent AIDS Clinical Trial Network (IMPAACT)
through the National Institute of Health (RV5 Levin 2017-AF).
One trial was funded by Shantha Biotechnics Ltd (RV5 Dhingra
2014-IND).
3. Rotavac
We identified four trials of Rotavac vaccine. The earliest was re-
ported in 2006 and themost recent in 2017. Overall, 8432 partic-
ipants were included in the trials; the largest trial included 6799
participants (VACBhandari 2014-IND) and the smallest included
90 participants (VAC Bhandari 2006-IND).
Population
All trials included healthy infants. Trials enrolled infants aged be-
tween six weeks and nine weeks.
Outcome measures
Three trials were safety studies (Appendix 2) reporting safety out-
comes and immunogenicity outcomes. They reported on follow-
up results for one to 12 months after the last vaccine dose. The
other trial (VACBhandari 2014-IND) reported on efficacy, safety,
and immunogenicity outcomes until the infants were two years of
age.
As shown in Appendix 3, VAC Bhandari 2014-IND reported on
rotavirus diarrhoea (severe cases, cases of any severity, and cases
requiring medical attention). The same trial also provided data
on severe cases of all-cause diarrhoea. Two trials reported all-cause
death, and three of the four trials reported dropouts.
For safety outcomes, all trials reported on serious adverse events
and two reported on reactogenicity. All trials reported on an im-
munogenicity outcome (Appendix 4).
Location
All trials were conducted in India, one at three sites in the cities
of Delhi, Pune, and Vellore (VAC Bhandari 2014-IND), and the
remaining three studies at one site in Delhi.
Country mortality rate
All trials were conducted in India, a high-mortality country
(WHO mortality stratum D).
Vaccine schedule
Most trials used three doses of Rotavac vaccine, with intervals
between doses of four to eight weeks (see Appendix 6). One trial
(VAC Bhandari 2006-IND) administered one dose. One trial had
one vaccine and one placebo arm (VAC Bhandari 2014-IND).
VAC Bhandari 2006-IND included an additional vaccine arm
for a rotavirus vaccine candidate (I321) that we did not include
for analysis in this review. VAC Bhandari 2009-IND randomized
participants to high- (1 x 105 ffu) and low-dose (1 x 104 ffu)
vaccine arms which we combined in this review. VAC Chandola
2017-IND randomized participants to three vaccine production
lots as well as to placebo. We combined the different production
lot arms in our analyses.
Infant vaccination status
Two trials separated the use of other routine childhood vaccines
fromRotavac administration by at least two weeks (VACBhandari
2006-IND; VAC Bhandari 2009-IND). Two trials co-adminis-
tered other routine childhood vaccines (OPV, DPT, Hep B and
Hib) with Rotavac (VAC Bhandari 2014-IND; VAC Chandola
2017-IND).
Methods for collecting adverse event data
As shown in Appendix 7, three trials used a combination of passive
methods (e.g. diary cards for parents) and active methods (directly
contacting parents) to collect adverse event data. The other trial
(VAC Chandola 2017-IND) used active methods only (directly
contacting parents).
Source of funding
One trial was funded by Bharat Biotech (VAC Bhandari 2006-
IND), one trial was co-funded by Bharat Biotech (VAC Bhandari
2009-IND) and the other two trials were funded by PATH, the
Government of India, and other not-for-profit organizations (VAC
Bhandari 2014-IND; VAC Chandola 2017-IND).
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Ongoing studies
We identified 15 ongoing trials, three of RV1, one of RV5 and
11 others (RV1 together with RV5; RV3-BB; Rotasiil; Rotavac;
BRV-TV; Trivalent P2VP8; Bio Farma’s rotavirus vaccine) (see
Characteristics of ongoing studies). As shown in Appendix 8, the
RV1 trials are being conducted in South Africa and Bangladesh.
The ongoing RV5 trial is in Bangladesh, and the studies testing
other vaccines are located in Australia, Bangladesh, China, India,
Indonesia, Malawi, Mexico, South Africa, and the USA.
Excluded studies
There are 78 excluded studies with 100 references (Figure 2).
We excluded most studies because they were not RCTs (34 stud-
ies). We excluded 27 studies because they reported on compar-
isons not relevant to this review, three studies because they did
not report on RV vaccines, three because they included adult
populations, 10 because they reported on unlicensed vaccines
in development (OTHER Bines 2015; OTHER Bines 2018;
OTHER Cowley 2017; OTHER Groome 2017) or licensed vac-
cines that have not been prequalified by the WHO (OTHER
CTRI/2009/091/000821;OTHERDang 2012;OTHERIsanaka
2017-NER;OTHERKulkarni 2017; OTHERZade 2014a-IND;
OTHER Zade 2014b-IND), and one because it reported on a
withdrawn vaccine (OTHER Armah 2013).
Figure 2. PRISMA diagram.
Risk of bias in included studies
We prepared a ‘Risk of bias’ assessment for each trial, with a focus
on the rotavirus diarrhoea outcome measure. Of the 55 RCTs an-
alyzed in this review, 48 (87%) reported an adequate generation
of allocation sequence, while the method of assignment was un-
clear in the remaining studies. We considered the methods used
to conceal allocation to be adequate in 46 trials (84%), and un-
clear in the remaining studies. Information about blinding of par-
ticipants, care providers, or outcome assessors was provided and
18Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
we considered it to be adequate in 42 studies (76%), unclear
for nine studies, and at high risk of bias for four studies (RV1
Colgate 2016-BGD; RV1 Kerdpanich 2010-THA; RV1 Zaman
2017-BGD; RV5Dhingra 2014-IND). Incomplete outcome data
were adequately addressed in 46 studies (84%), unclear in eight
studies, and was not addressed adequately in one study. Thirty-
eight (69%) trials were free from selective reporting bias, nine were
not, and the remaining eight trials were unclear. No other bias was
apparent for 31 trials (56%). An overall pictorial summary of the
‘Risk of bias’ assessment is shown in Figure 3 and Figure 4.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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RV1
Since the previous update of this review, detailed clinical study
reports of most of the GlaxoSmithKline-sponsored studies ( an-
other five, totaling 27 of the 36 trials) have been published online
( gsk-clinicalstudyregister.com). Full details of blinding, partici-
pant selection, and attrition are available from these reports, and
we could subsequently update risks of bias for these studies, where
previously there was no information available. We rated five trials
as at high risk of bias for at least one domain; three trials for blind-
ing (RV1Colgate 2016-BGD; RV1 Kerdpanich 2010-THA; RV1
Zaman 2017-BGD), and three trials for selective reporting bias
(RV1 Ruiz-Palac 06-LA/EU; RV1 Salinas 2005-LA; RV1 Zaman
2017-BGD).
RV5
Based on unpublished information provided by Merck, many of
the trials’ risks of bias were upgraded for the previous 2012 ver-
sion of this review. Details of the new information are indicated in
the ‘Risk of bias’ tables in the Characteristics of included studies
section. We judged 10 of the 15 RV5 trials as having a low risk of
bias for sequence generation, allocation concealment, and blind-
ing, and varying risks of bias for attrition, selective reporting and
other bias. We rated two of these trials (RV5 Armah 2010-AF;
RV5 Zaman 2010-AS) at an overall low risk of bias. Seven of the
15 RV5 trials had a high risk of bias for one or more domains,
most commonly a high risk of selective reporting.
Rotavac
Peer-reviewed articles for most Rotavac studies reported clearly
on how the trials were conducted. Full details about blinding,
participant selection, attrition, and outcome reporting could be
obtained frommost of these reports.We rated only one of the trials
at unclear risk of performance and detection bias, since no details
about blinding were provided and unclear risk of attrition bias
since not all outcomes were assessed with the full study population
and the reason for this was not clear (VAC Bhandari 2009-IND).
Effects of interventions
See: Summary of findings for the main comparison RV1
compared to placebo for preventing rotavirus diarrhoea in low-
mortality countries; Summary of findings 2 RV1 compared
to placebo for preventing rotavirus diarrhoea in high-mortality
countries; Summary of findings 3 RV5 compared to placebo
for preventing rotavirus diarrhoea in low-mortality countries;
Summary of findings 4 RV5 compared to placebo for preventing
rotavirus diarrhoea in high-mortality countries; Summary of
findings 5 Rotavac compared to placebo for preventing rotavirus
diarrhoea in high-mortality countries
1. RV1
1.1. Primary outcomes
1.1.1. Rotavirus diarrhoea: severe
Eleven trials provided data on the efficacy of RV1 to prevent severe
rotavirus diarrhoea in children; see Analysis 1.1 for up to one-
year follow-up and Analysis 1.2 for two years follow-up. Trials
were performed in low-mortality countries (RV1 Bernstein 1999-
USA; RV1 Kawamura 2011-JPN; RV1 Li 2014-CHN; RV1 Phua
2005-SGP; RV1 Phua 2009-AS; RV1 Ruiz-Palac 06-LA/EU; RV1
Salinas 2005-LA; RV1 Tregnaghi 2011-LA; RV1 Vesikari 2004b-
FIN; RV1 Vesikari 2007a-EU), and high-mortality countries (
RV1 Colgate 2016-BGD; RV1 Madhi 2010-MWI; RV1 Madhi
2010-ZAF; RV1 Steele 2010b-ZAF; RV1 Zaman 2017-BGD).
Data below are grouped accordingly.
Low-mortality countries (WHO strata A and B)
RV1 reduced severe rotavirus diarrhoea cases by 84% after one
year (RR 0.16, 95% CI 0.09 to 0.26; 43,779 participants, 7 tri-
als) and by 82% after two years (RR 0.18, 95% CI 0.14 to 0.23;
36,002 participants, 9 trials; Analysis 1.2). After three years there
was no statistically significant difference betweenRV1 and placebo
(RR 0.10, 95% CI 0.01 to 1.52; 12,109 participants, two tri-
als (RV1 Phua 2009-AS and RV1 Vesikari 2007a-EU; data not
shown)). Pooled results showed statistical heterogeneity at one-
year (I2 statistic = 61%, Analysis 1.1) and three years (I2 statistic
= 69%, data not shown) follow-up.
High-mortality countries (WHO strata D and E)
RV1 reduced severe rotavirus diarrhoea cases by 63% during the
first year of follow-up (RR 0.37, 95% CI 0.23 to 0.60; 6114 par-
ticipants, 4 comparisons from 3 trials) and by 35% after two years
(RR 0.65, 95% CI 0.51 to 0.83; 7113 participants, 3 compar-
isons from 2 trials; Analysis 1.2). Pooled results showed statistical
heterogeneity at one-year follow-up (I2 statistic = 57%, Analysis
1.1).
We noted a funnel plot asymmetry for trials reporting results up
to one year (Figure 5).
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Figure 5. Funnel plot of comparison: 1 RV1 versus placebo, outcome: 1.1 Rotavirus diarrhoea: severe (up to
1 year follow-up).
1.1.2. All-cause diarrhoea: severe
Severe all-cause diarrhoea was reported as cases in six trials (RV1
Colgate 2016-BGD; RV1 Li 2014-CHN; RV1 Madhi 2010-AF;
RV1 Phua 2005-SGP; RV1 Ruiz-Palac 06-LA/EU; RV1 Vesikari
2007a-EU) and as episodes in two trials (RV1 Phua 2009-AS; RV1
Ruiz-Palac 06-LA/EU). We have reported these data separately.
Trials were performed in low-mortality countries (RV1 Li 2014-
CHN; RV1 Phua 2005-SGP; RV1 Phua 2009-AS; RV1 Ruiz-
Palac 06-LA/EU; RV1 Vesikari 2007a-EU), and in high-mortality
countries (RV1 Colgate 2016-BGD; RV1 Madhi 2010-MWI;
RV1 Madhi 2010-ZAF).
Low-mortality countries (WHO strata A and B)
RV1 reduced the number of severe cases of all-cause diarrhoea by
41% at one year (RR 0.59, 95% CI 0.47 to 0.74; 28,051 partici-
pants, 3 trials; Analysis 1.3), and by 40% at two years (RR 0.60,
95% CI 0.36 to 1.02; 9417 participants, 3 trials; Analysis 1.4).
Pooled results showed statistical heterogeneity at both one year (I2
statistic = 63%) and two years follow-up (I2 statistic = 90%). RV1
reduced the rate of severe episodes of all-cause diarrhoea by 40%
at one year (rate ratio 0.60, 95% CI 0.50 to 0.72; 17,867 partic-
ipants, 1 trial; Analysis 1.5), and by 37% at two years (rate ratio
0.63, 95% CI 0.56 to 0.71; 39,091 participants, 2 trials; Analysis
1.6). One trial reported on severe all-cause diarrhoea after three
years follow-up (RV1 Phua 2009-AS); RV1 reduced the number
of severe cases by 27% (RR 0.73, 95% CI 0.61 to 0.88; 10,519
participants; data not shown).
High-mortality countries (WHO strata D and E)
RV1 reduced the number of severe cases of all-cause diarrhoea by
27% at one year follow-up (RR 0.73, 95% CI 0.56 to 0.95; 5639
participants, 3 comparisons from 2 trials; Analysis 1.3), and by
17% at two years follow-up (RR 0.83, 95%CI 0.72 to 0.96; 2764
participants, 2 comparisons from 1 trial; Analysis 1.4). Pooled
results showed statistical heterogeneity at one-year follow-up (I2
statistic = 75%).
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1.1.3. All-cause death
Thirty trials reported on all-cause death, either as the number of
deaths (RV1 Bernstein 1999-USA; RV1 Kim 2012-KOR; RV1 Li
2013b-CHN; RV1 Li 2014-CHN; RV1 Madhi 2010-AF; RV1
NCT00158756-RUS; RV1Phua 2005-SGP; RV1Phua 2009-AS;
RV1 Steele 2010a-ZAF; RV1 Vesikari 2007a-EU) or as the num-
ber of fatal serious adverse events (RV1 Anh 2011-PHL; RV1
Anh 2011-VNM; RV1 GSK[021] 2007-PAN; RV1 GSK[033]
2007-LA; RV1GSK[041] 2007-KOR; RV1GSK[101555] 2008-
PHL; RV1 Kawamura 2011-JPN; RV1 Kerdpanich 2010-THA;
RV1 Narang 2009-IND; RV1 Omenaca 2012-EU; RV1 Rivera
2011-DOM; RV1 Ruiz-Palac 06-LA/EU; RV1 Salinas 2005-LA;
RV1 Steele 2008-ZAF; RV1 Steele 2010b-ZAF; RV1 Tregnaghi
2011-LA; RV1 Vesikari 2004b-FIN; RV1 Vesikari 2011-FIN;
RV1 Zaman 2009-BGD). We pooled the number of deaths and
fatal serious adverse events; see Analysis 1.7. We present details of
causes of death for each trial in Appendix 9. Most trials were per-
formed in low-mortality countries, with eight trials in high-mor-
tality countries (RV1 Colgate 2016-BGD; RV1 GSK[033] 2007-
LA; RV1 Madhi 2010-AF; RV1 Narang 2009-IND; RV1 Steele
2008-ZAF; RV1 Steele 2010a-ZAF; RV1 Steele 2010b-ZAF; RV1
Zaman 2009-BGD).
Low-mortality countries (WHO strata A and B)
There was no statistically significant difference in all-cause death
between the two arms (RR 1.22, 95% CI 0.87 to 1.71; 97,597
participants, 22 trials).
High-mortality countries (WHO strata D and E)
There was no statistically significant difference in all-cause death
between the two arms (RR 0.88, 95% CI 0.64 to 1.22; 8181
participants, 8 trials).
1.1.4. All serious adverse events
The total number of serious adverse events was reported in 31
trials, performed in low-mortality countries (RV1 Anh 2011-
PHL; RV1 Anh 2011-VNM; RV1 Bernstein 1998-USA; RV1
Dennehy 2005-NA; RV1 GSK[021] 2007-PAN; RV1 GSK[041]
2007-KOR; RV1 GSK[101555] 2008-PHL; RV1 Kawamura
2011-JPN; RV1 Kerdpanich 2010-THA; RV1 Kim 2012-KOR;
RV1 Li 2013a-CHN; RV1 Li 2014-CHN; RV1 NCT00158756-
RUS; RV1 Omenaca 2012-EU; RV1 Phua 2005-SGP; RV1 Phua
2009-AS; RV1 Rivera 2011-DOM; RV1 Ruiz-Palac 06-LA/EU;
RV1 Salinas 2005-LA; RV1 Tregnaghi 2011-LA; RV1 Vesikari
2004a-FIN; RV1 Vesikari 2004b-FIN; RV1 Vesikari 2007a-EU;
RV1 Vesikari 2011-FIN), and in high-mortality countries (RV1
GSK[033] 2007-LA; RV1 Madhi 2010-AF; RV1 Narang 2009-
IND; RV1 Steele 2008-ZAF; RV1 Steele 2010a-ZAF; RV1 Steele
2010b-ZAF; RV1 Zaman 2009-BGD); see Analysis 1.8.
Low-mortality countries (WHO strata A and B)
Fewer children allocated to RV1 had serious adverse events com-
pared with placebo (RR 0.88, 95% CI 0.83 to 0.93; 96,233 par-
ticipants, 24 trials). In addition, in one trial (RV1 Li 2013a-CHN)
that vaccinated 25 older children (aged two to six years) with one-
dose RV1 there were no serious adverse events reported.
High-mortality countries (WHO strata D and E)
There was no statistically significant difference in the number of
serious adverse events between the two arms (RR 0.89, 95% CI
0.76 to 1.04; 7481 participants, 7 trials).
1.1.5. Serious adverse events: intussusception
Twenty-one trials reported on intussusception, and 11 of these
reported that no cases of intussuception had occurred. Trials were
performed in low-mortality countries (RV1 Dennehy 2005-NA;
RV1 GSK[041] 2007-KOR; RV1 Kawamura 2011-JPN; RV1
Kim 2012-KOR; RV1 Phua 2005-SGP; RV1 Phua 2009-AS;
RV1Rivera 2011-DOM;RV1Ruiz-Palac 06-LA/EU; RV1Salinas
2005-LA; RV1 Tregnaghi 2011-LA; RV1 Vesikari 2004b-FIN;
RV1 Vesikari 2007a-EU; RV1 Vesikari 2011-FIN), and in high-
mortality countries (RV1Madhi 2010-AF; RV1 Steele 2008-ZAF;
RV1 Steele 2010b-ZAF; RV1 Zaman 2017-BGD); see Analysis
1.9.
Low-mortality countries (WHO strata A and B)
Twenty-nine cases of intussusception were reported in a total of
49,355 children in the RV1 arm compared with 28 cases of intus-
susception in 42,477 children of the placebo arm. Pooled results
showed no increased risk for intussusception in children receiving
RV1 when compared to placebo (RR 0.69, 95% CI 0.45 to 1.04;
96,513 participants, 17 trials).
High-mortality countries (WHO stratum E)
One case of intussusception was reported in a total of 3677 chil-
dren in the RV1 arm compared with no cases of intussusception
in 1737 children in the placebo or no-intervention arm. Pooled
results showed no increased risk for intussusception in children
receiving RV1 when compared to placebo (RR 1.49, 95% CI 0.06
to 36.63; 10,460 participants, 4 trials).
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1.2. Secondary outcomes
1.2.1 Serious adverse events: Kawasaki disease
Three trials reported four cases of Kawasaki disease among 7701
children allocated to RV1 compared to no cases in 5416 children
allocated to placebo (RV1 Phua 2005-SGP; RV1 Phua 2009-AS;
RV1 Salinas 2005-LA). We did not observe a statistically signifi-
cant difference between the intervention and placebo groups (RR
1.79, 95%CI 0.30 to 10.61; 13,117 participants, 3 trials; Analysis
1.10).
1.2.2. Serious adverse events requiring hospitalization
Two trials reported serious adverse events requiring hospitalization
(RV1 Ruiz-Palac 06-LA/EU; RV1 Steele 2008-ZAF) and found
fewer events in the RV1 group than the placebo group (RR 0.88,
95% CI 0.81 to 0.96; 63,675 participants, 2 trials; Analysis 1.11).
1.2.3 Rotavirus diarrhoea of any severity
Eighteen trials provided data for the efficacy of RV1 to pre-
vent rotavirus diarrhoea in children; see Analysis 1.12 for two-
months safety trial follow-up, Analysis 1.13 for one-year follow-
up and Analysis 1.14 for two-year follow-up. Trials were per-
formed in low-mortality countries (RV1 Anh 2011-PHL; RV1
Anh 2011-VNM; RV1 Bernstein 1999-USA; RV1 GSK[041]
2007-KOR; RV1 GSK[101555] 2008-PHL; RV1 Kerdpanich
2010-THA;RV1Omenaca 2012-EU; RV1 Phua 2005-SGP; RV1
Rivera 2011-DOM; RV1 Salinas 2005-LA; RV1 Vesikari 2004b-
FIN; RV1 Vesikari 2007a-EU; RV1 Vesikari 2011-FIN), and in
high-mortality countries (RV1 Madhi 2010-MWI; RV1 Madhi
2010-ZAF;RV1Narang 2009-IND;RV1Steele2010a-ZAF;RV1
Steele 2010b-ZAF; RV1 Zaman 2009-BGD). Data below are
grouped accordingly.
Low-mortality countries (WHO strata A and B)
Safety trials (up to two months follow-up): RV1 was not supe-
rior to placebo in the prevention of rotavirus diarrhoea in the trials
assessing outcomes up to two months after vaccination (RR 1.28,
95% CI 0.66 to 2.50; 3537 participants, 9 trials). These trials,
although reporting cases of rotavirus diarrhoea, were not designed
to measure efficacy.
Efficacy trials (one to three years follow-up): RV1 reduced ro-
tavirus diarrhoea by 78% at up to one year (RR 0.22, 95%CI 0.13
to 0.40; 9083 participants, 4 trials) and 65% at the second year of
follow-up (RR 0.35, 95% CI 0.25 to 0.48; 10,441 participants, 6
trials). Pooled results, however, showed statistical heterogeneity at
one year (I2 statistic = 80%, Analysis 1.13) and two years (I2 statis-
tic = 55%, Analysis 1.14) of follow-up. At the third year of follow-
up, there were very few reported cases of rotavirus diarrhoea of
any severity. Based on a single trial (RV1Vesikari 2007a-EU, 1590
participants), there was no difference between RV1 and placebo
groups (data not shown).
High-mortality countries (WHO strata D and E)
Safety trials (up to twomonths follow-up):Three trials foundno
difference in the RV1 group compared to placebo when outcomes
were assessed up to two months after vaccination (RR 1.00, 95%
CI 0.41 to 2.41; 757 participants, 3 trials).
Efficacy trials (one to two years follow-up): RV1 reduced ro-
tavirus diarrhoea by 51% during the first year of follow-up (RR
0.49, 95% CI 0.35 to 0.68; 6114 participants, 4 comparisons
from 3 trials), and by 59% during the second year (RR 0.41, 95%
CI 0.28 to 0.62; 1251 participants, 1 trial). Pooled results showed
statistical heterogeneity at one-year follow-up (I2 statistic = 76%,
Analysis 1.13).
1.2.4. All-cause diarrhoea: of any severity
This outcome was reported as cases in 11 trials from low-mor-
tality countries (RV1 Anh 2011-PHL; RV1 Anh 2011-VNM;
RV1 Kerdpanich 2010-THA; RV1 Kim 2012-KOR; RV1 Li
2014-CHN; RV1 Omenaca 2012-EU; RV1 Phua 2005-SGP;
RV1 Rivera 2011-DOM; RV1 Salinas 2005-LA; RV1 Vesikari
2004b-FIN; RV1 Vesikari 2011-FIN), in two trials from high-
mortality countries (RV1 Colgate 2016-BGD; RV1 Steele 2010a-
ZAF), and as episodes in three trials from low-mortality countries
(RV1 Rivera 2011-DOM; RV1 Salinas 2005-LA; RV1 Vesikari
2004b-FIN). We have reported these data separately.
Low-mortality countries (WHO strata A and B)
Safety trials (up to two months follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diarrhoea
at two months (RR 0.86, 95% CI 0.67 to 1.09; 3032 participants,
6 trials; Analysis 1.15).
Efficacy trials (one to two years follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diarrhoea
at one year follow-up (RR 0.92, 95% CI 0.82 to 1.03; 2204 par-
ticipants, 2 trials, Analysis 1.16), or after two years (RR 0.93, 95%
CI 0.87 to 1.00; 5937 participants, 3 trials; Analysis 1.17).Two
trials reported the number of episodes, with no statistically sig-
nificant benefit with RV1 when compared to placebo at one year
(Rate Ratio 0.98, 95%CI 0.88 to 1.10; 2204 participants, 2 trials;
Analysis 1.18) or at two years (Rate Ratio 1.02, 95% CI 0.78 to
1.33; 736 participants, 1 trial; Analysis 1.19).
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High-mortality countries (WHO stratum E)
Safety trials (up to two months follow-up): RV1 was not better
than placebo in reducing the number of cases of all-cause diarrhoea
at two months (RR 1.04, 95% CI 0.69 to 1.58; 100 participants,
1 trial; Analysis 1.15).
Efficacy trials (one-year follow-up): RV1 was not better than
no intervention in reducing the number of cases of all-cause diar-
rhoea at one-year follow-up (RR 0.99, 95% CI 0.93 to 1.05; 700
participants, 1 trial; Analysis 1.16)
1.2.5. All-cause hospitalizations
Two trials (RV1 Phua 2005-SGP; RV1 Ruiz-Palac 06-LA/EU)
provided data for the efficacy of RV1 to prevent all-cause hospi-
talizations.
Low-mortality countries (WHO stratum A)
RV1 was not better than placebo in reducing the number of hos-
pitalizations at up to two years of follow-up (RR 0.63, 95% CI
0.27 to 1.47; 65,646 participants, 2 trials; Analysis 1.20).
1.2.6. Rotavirus diarrhoea: requiring hospitalization or
medical attention
Rotavirus-related hospitalizations were reduced by 82% after one
year (RR 0.18, 95% CI 0.09 to 0.33; 48,718 participants, 8 tri-
als), 85% at two years (RR 0.15, 95% CI 0.11 to 0.22; 35,331
participants, 7 trials), and 95% at three years (RR 0.05, 95% CI
0.02 to 0.16; 10,519 participants, 1 trial (RV1 Phua 2009-AS,
data not shown)); pooled results showed statistical heterogeneity
at one year of follow-up (I2 statistic = 55%); see Analysis 1.21.
RV1 reduced rotavirus-related medical visits by 92% at one year
(RR 0.08, 95% CI 0.04 to 0.16; 3874 participants, 1 trial) and
78% at two years (RR 0.22, 95% CI 0.16 to 0.31; 7017 partici-
pants, 3 trials); see Analysis 1.22.
1.2.7. All-cause diarrhoea: requiring hospitalization
There was no significant difference between RV1 and placebo in
cases of hospitalization for all-cause diarrhoea at one-year follow-
up (RR 0.43, 95% CI 0.17 to 1.11; 14,393 participants, 2 tri-
als; Analysis 1.23). At two years follow-up, RV1 reduced cases by
48% (RR 0.52, 95% CI 0.27 to 0.99; 14,367 participants, 2 tri-
als; Analysis 1.23). RV1 Phua 2009-AS reported that for hospi-
talizations due to all-cause diarrhoea at three years of follow-up,
RV1 reduced hospitalizations by 28% (RR 0.72, 95% CI 0.59 to
0.86; 10,519 participants, data not shown). Pooled results showed
statistical heterogeneity at one year (I2 statistic = 83%) and at two
years follow-up (I2 statistic = 77%).
RV1 Ruiz-Palac 06-LA/EU presented data on the number of
episodes (Analysis 1.24); RV1 reduced hospitalizations by 42% at
one year (rate ratio 0.58, 95% CI 0.47 to 0.71; 17,867 partici-
pants, 1 trial) and 47% at two years (rate ratio 0.53, 95% CI 0.46
to 0.61; 14,286 participants, 1 trial).
1.2.8. Reactogenicity
The occurrence of fever (Analysis 1.25), diarrhoea (Analysis 1.26),
and vomiting (Analysis 1.27) were evaluated at several time points:
after the first dose, after the second dose, after the third dose, and
at the end of the follow-up period. Most trials contributed data to
these outcomes. There were similar results for RV1 and placebo
for each outcome and time point.
1.2.9. Adverse events that require discontinuation of
vaccination schedule
There was no statistically significant difference between RV1 and
placebo in the number of adverse events leading to discontinua-
tion of the vaccination schedule (RR 1.03, 95% CI 0.83 to 1.26;
94,980 participants, 26 trials; Analysis 1.28).
1.3. Immunogenicity
Data on immunogenicity was not stratified by WHO strata. RV1
was more immunogenic than placebo when measured by vaccine
virus shedding after the final vaccine dose (RR10.94, 95%CI 4.90
to 24.43; 2638 participants, 16 trials), although the results showed
statistical heterogeneity (I2 statistic = 76%, Analysis 1.29). RV1
was also more immunogenic when measured by seroconversion at
all time points (Analysis 1.30); although the pooled data showed
statistical heterogeneity after one dose (I2 statistic = 57%), after
two doses (I2 statistic = 79%), and after three doses (I2 statistic =
51%).
1.4. Dropouts before the end of trial
Twenty-eight trials reported on the number of participants who
dropped out of the trial before it ended. Overall, there was no
statistically significant difference between the RV1 and placebo or
no-intervention groups (RR 0.95, 95% CI 0.90 to 1.00; 93,106
participants, 28 trials; Analysis 1.31).
1.5. Subgroup analyses
1.5.1. G type
Rotavirus diarrhoea: of any severity
Six trials reported on rotavirus diarrhoea of any severity by differ-
ent G types. There were significantly fewer episodes of rotavirus
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diarrhoea of any severity in the group receiving RV1 when com-
pared to placebo, regardless of G type (G1, G2, G3, G4, or G9);
however, the pooled data for G1 (I2 statistic = 81%) and G9 (I2
statistic = 63%) types showed statistical heterogeneity, see Analysis
1.32.
Rotavirus diarrhoea: severe
There were significantly fewer severe episodes of rotavirus diar-
rhoea in the RV1 groups compared with placebo in episodes at-
tributed to the G1, G2, G3, G9, and G12 types; see Analysis 1.33.
Results were not statistically significant for G4 and G8 types. The
pooled data for G8 types showed statistical heterogeneity (I2 statis-
tic = 63%).
1.5.2. Malnourished children
Rotavirus diarrhoea: of any severity
One trial provided data separately as the number of cases of ro-
tavirus diarrhoea of any severity in a subgroup of malnourished
children (RV1Salinas 2005-LA). RV1was significantly better than
placebo in preventing rotavirus diarrhoea for this subgroup at one
year of follow-up (RR 0.39, 95% CI 0.19 to 0.79; 287 partici-
pants, 1 trial, Analysis 1.34).
1.5.3. Children infected with HIV
Rotavirus diarrhoea: of any severity
One safety trial included only confirmed HIV-positive, asymp-
tomatic ormildly symptomatic children (RV1 Steele 2010a-ZAF).
At one-month follow-up, no statistically significant difference be-
tween the RV1 and placebo arms for rotavirus diarrhoea was re-
ported (RR 1.00, 95% CI 0.26 to 3.78; 100 participants, 1 trial;
Analysis 1.35).
One efficacy trial included children who were infected with HIV
or children that had been exposed to HIV, as long as they were not
clinically immunosuppressed (e.g. AIDS) at the age of vaccination
(six weeks) (RV1 Madhi 2010-AF). HIV tests were performed on
approximately 46% of children fromMalawi and 23% of children
from South Africa. We did not conduct a specific analysis for this
population, but the authors stated that demographic characteris-
tics and the proportion of children who were infected with HIV
were similar across the study groups.
1.6 Sensitivity analysis
1.6.1 Primary outcomes with high heterogeneity according
to allocation concealment
To investigate heterogeneity for primary outcomes with pooled
results where I2 statistic > 75%, we planned to pool data only
from studies with low risk of bias for allocation concealment in
a sensitivity analysis. We rated all trials at low risk of bias for
allocation concealment for the two outcomes where heterogeneity
was high (I2 statistic > 75%); see Analysis 1.3 (I2 statistic = 75%)
and Analysis 1.4 (I2 statistic = 90%).
1.6.2 Cluster-randomised trials
Two outcomes (serious adverse events: intussusception, and ro-
tavirus severe diarrhoea at two years) included one cluster-ran-
domised trial carried out in a high-mortality country (RV1Zaman
2017-BGD). When we excluded data from this trial there was a
small but non-significant change to the effect estimate and 95%
CI for Rotavirus diarrhoea: severe (up to 2 years follow-up) (RR
0.58, 95% CI 0.42 to 0.79, 2764 participants, 1 trial; analysis not
shown), and there were no changes to effect estimates or 95% CIs
for serious adverse events: intussusception.
‘Summary of findings’
Summary of findings of primary outcomes according to country
mortality rate (WHO strata A to E) are presented in Summary of
findings for the main comparison (RV1, low-mortality countries),
and in Summary of findings 2 (RV1, high-mortality countries).
2. RV5
2.1. Primary outcomes
2.1.1. Rotavirus diarrhoea: severe
Seven trials provided data for the efficacy of RV5 to prevent se-
vere rotavirus diarrhoea in children; see Analysis 2.1 for one-year
follow-up and Analysis 2.2 for two years follow-up. Trials were
performed in low-mortality countries (RV5 Clark 2004-USA;
RV5 Vesikari 2006a-FIN; RV5 Vesikari 2006b-INT; RV5 Block
2007-EU/USA; RV5 Iwata 2013-JPN; RV5Mo 2017-CHN), one
trial was split between low-mortality Vietnam in stratum B (RV5
Zaman 2010-VNM) and high-mortality Bangladesh in stratum
D (RV5 Zaman 2010-BGD), and another between high-mortal-
ity Ghana and Mali in stratum D (RV5 Armah 2010-GHA; RV5
Armah 2010-MLI) and high-mortality Kenya in stratum E (RV5
Armah 2010-KEN). Data below are grouped accordingly.
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Low-mortality countries (WHO strata A and B)
RV5 reduced the number of severe rotavirus diarrhoea cases by
92% at one year (RR 0.08, 95% CI 0.03 to 0.22; 4132 partic-
ipants, 5 trials) and 82% by two years (RR 0.18, 95% CI 0.08
to 0.39; 7318 participants, 4 trials). Pooled results showed statis-
tical heterogeneity at two-year follow-up (I2 statistic = 44%); see
Analysis 2.2.
High-mortality countries (WHO strata D and E)
RV5 reduced the number of severe rotavirus diarrhoea cases by
57% at one year (RR 0.43, 95% CI 0.29 to 0.62; 5916 partici-
pants, 4 comparisons from2 trials) and 41%at two years (RR0.59,
95% CI 0.43 to 0.82; 5885 participants, 4 comparisons from 2
trials). Pooled results showed statistical heterogeneity at two-year
follow-up (I2 statistic = 43%); see Analysis 2.2.
2.1.2. All-cause diarrhoea: severe
Only two trials provided data for the efficacy of RV5 to prevent
severe all-cause diarrhoea in children; see Analysis 2.3 for one-
year follow-up and Analysis 2.4 for two-year follow-up. Trials were
performed in high-mortality countries (RV5 Armah 2010-GHA;
RV5 Armah 2010-KEN; RV5 Armah 2010-MLI; RV5 Zaman
2010-AS). We did not identify any trial that reported on this
outcome that was performed in a low-mortality country.
High-mortality countries (WHO strata D and E)
There was no statistically significant difference between RV5 and
placebo for all-cause severe diarrhoea at one-year follow-up (RR
0.80, 95%CI 0.58 to 1.11; 4085 participants, 3 comparisons from
1 trial). At two-year follow-up, RV5 reduced severe cases by 15%
(RR 0.85, 95%CI 0.75 to 0.98; 5977 participants, 4 comparisons
from 2 trials). Pooled results showed statistical heterogeneity at
one-year follow-up (I2 statistic = 46%); see Analysis 2.3.
2.1.3. All-cause death
Eleven trials reported on all-cause death, in most trials as the num-
ber of deaths (RV5 Armah 2010-AF; RV5 Iwata 2013-JPN; RV5
Lawrence 2012-CHN; RV5 Levin 2017-AF; RV5 Merck[009]
2005-USA; RV5Mo 2017-CHN; RV5 Vesikari 2006a-FIN; RV5
Vesikari 2006b-INT; RV5 Zaman 2010-AS), and in two trials
as fatal serious adverse events (RV5 Block 2007-EU/USA; RV5
Ciarlet 2009-EU). We pooled the number of deaths and fatal se-
rious adverse events; see Analysis 2.5. We present details of causes
of death for each trial in Appendix 9. Most trials were performed
in low-mortality countries, with one trial split between low-mor-
tality Vietnam in stratum B (RV5 Zaman 2010-VNM) and high-
mortality Bangladesh in stratum D (RV5 Zaman 2010-BGD),
and another between high-mortality Ghana and Mali in stratum
D (RV5 Armah 2010-GHA; RV5 Armah 2010-MLI) and high-
mortality Kenya in stratum E (RV5 Armah 2010-KEN).
Low-mortality countries (WHO strata A and B)
There was no statistically significant difference in all-cause death
between RV5 and placebo arm (RR 1.13, 95% CI 0.65 to 1.96;
77,642 participants, 9 trials; Analysis 2.5).
High-mortality countries (WHO strata D and E)
There was no statistically significant difference in all-cause death
between the two arms (RR 0.92, 95% CI 0.68 to 1.24; 6806
participants, 5 comparisons from 3 trials; Analysis 2.5).
2.1.4. All serious adverse events
Serious adverse events were reported in 11 trials, in trials in
low-mortality countries (RV5 Block 2007-EU/USA; RV5 Ciarlet
2009-EU; RV5 Iwata 2013-JPN; RV5 Kim 2008-KOR; RV5
Lawrence 2012-CHN; RV5 Mo 2017-CHN; RV5 Vesikari
2006b-INT; RV5 Zaman 2010-VNM), and in high-mortality
countries (RV5 Armah 2010-GHA; RV5 Armah 2010-KEN;
RV5 Armah 2010-MLI; RV5 Dhingra 2014-IND; RV5 Levin
2017-AF; RV5 Zaman 2010-BGD); see Analysis 2.6.
Low-mortality countries (WHO strata A and B)
Pooled results showed no statistically significant difference in the
number of serious adverse events in the RV5 group compared
with the placebo group (RR 0.93, 95% CI 0.86 to 1.02; 75,672
participants, 8 trials; Analysis 2.6). In addition, in a separate cohort
of RV5 Lawrence 2012-CHN that vaccinated 24 older children
(aged two to six years) with one-dose RV5 there were no serious
adverse events reported.
High-mortality countries (WHO strata D and E)
Pooled results showed no statistically significant difference in the
number of serious adverse events in the RV5 group compared
with the placebo group (RR 0.92, 95% CI 0.66 to 1.28; 6830
participants, 6 comparisons from 4 trials; Analysis 2.6).
2.1.5. Serious adverse events: intussusception
Thirteen trials reported cases of intussusception. Trials were per-
formed in low-mortality countries (RV5 Block 2007-EU/USA;
RV5 Ciarlet 2009-EU; RV5 Clark 2003-USA; RV5 Clark 2004-
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USA; RV5 Iwata 2013-JPN; RV5Kim2008-KOR;RV5Lawrence
2012-CHN; RV5Merck[009] 2005-USA; RV5 Mo 2017-CHN;
RV5 Vesikari 2006a-FIN; RV5 Vesikari 2006b-INT; RV5 Zaman
2010-VNM), and in high-mortality countries (RV5 Armah 2010-
GHA; RV5 Armah 2010-KEN; RV5 Armah 2010-MLI; RV5
Zaman 2010-BGD); see Analysis 2.7.
Low-mortality countries (WHO strata A and B)
Fourteen cases of intussusceptionwere reported in a total of 38,321
children in theRV5armcomparedwith 20 cases of intussusception
in 36,553 children in the placebo arm. Pooled results showed no
increased risk of intussusception in children receiving RV5 when
compared to placebo (RR 0.77, 95% CI 0.41 to 1.45; 78,907
participants, 12 trials; Analysis 2.7).
High-mortality countries (WHO strata D and E)
There were no reported cases of intussusception in a total of 3294
children in the RV5 arm and 3294 children in the placebo arm (4
comparisons from 2 trials).
2.2. Secondary outcomes
2.2.1. Rotavirus diarrhoea: of any severity
Nine trials provided data for the efficacy of RV5 to prevent ro-
tavirus diarrhoea of any severity in children; see Analysis 2.8
for one-year follow-up and Analysis 2.9 for two-year follow-up.
Trials were performed in low-mortality countries (RV5 Block
2007-EU/USA; RV5 Clark 2003-USA; RV5 Clark 2004-USA;
RV5 Iwata 2013-JPN; RV5Mo 2017-CHN; RV5Vesikari 2006a-
FIN; RV5 Vesikari 2006b-INT), and in high-mortality countries
(RV5 Armah 2010-GHA; RV5 Armah 2010-KEN; RV5 Armah
2010-MLI; RV5 Zaman 2010-AS). Data below are grouped ac-
cordingly.
Low-mortality countries (WHO strata A and B)
RV5 reduced the number of cases of rotavirus diarrhoea by 70%
at one year (RR 0.30, 95% CI 0.25 to 0.37; 8644 participants, 5
trials; Analysis 2.8) and by 66% during the second year (RR 0.34,
95% CI 0.26 to 0.43; 6144 participants, 3 trials; Analysis 2.9).
High-mortality countries (WHO strata D and E)
RV5 reduced the number of cases of rotavirus diarrhoea by 48%
at one year (RR 0.52, 95% CI 0.28 to 0.94; 4806 participants,
3 comparisons from 1 trial; Analysis 2.8) and by 39% during the
second year (RR 0.61, 95% CI 0.45 to 0.83; 6744 participants,
4 comparisons from 2 trials; Analysis 2.9). Pooled results were
significantly heterogenous at one-year (I2 statistic = 67%; see
Analysis 2.8) and at two-year (I2 statistic = 69%; see Analysis 2.9)
follow-up.
2.2.2. All-cause diarrhoea: of any severity
One trial performed in high-mortality Kenya (RV5 Armah
2010-KEN) provided data for the efficacy of RV5 to prevent all-
cause diarrhoea of any severity; see Analysis 2.10 for one-year and
Analysis 2.11 for two-year follow-up.
High-mortality countries (WHO stratum E)
There was no statistically significant difference between RV5 and
placebo for any severity all-cause diarrhoea at one year (RR 0.82,
95% CI 0.61 to 1.11; 1059 participants, 1 trial; Analysis 2.10)
or at two-year follow-up (RR 0.89, 95% CI 0.68 to 1.16; 1059
participants, 1 trial; Analysis 2.11).
All-cause hospitalization
Data on all-cause hospitalization were provided from one trial
carried out in Botswana, Tanzania, Zambia, and Zimbabwe (RV5
Levin 2017-AF).
There was no statistically significant difference between RV5 and
placebo for all-cause hospitalization at two-year follow-up (RR
1.21, 95% CI 0.42 to 3.49; 202 participants, 1 trial; Analysis
2.12).
2.2.3. Rotavirus diarrhoea: requiring hospitalization or
medical attention
RV5 reduced hospitalizations due to rotavirus diarrhoea episodes
by 96% at one year of follow-up (RR 0.04, 95% CI 0.02 to 0.10;
57,134 participants, 1 trial; Analysis 2.13).
RV5 reduced the number of children requiring medical attention
at one year of follow-up by 93% compared to placebo (RR 0.07,
95% CI 0.04 to 0.12; 57,134 participants, 1 trial; Analysis 2.14).
Data for medical attention and hospitalization rates due to all-
cause diarrhoea were not estimable.
2.2.4. Reactogenicity
The incidence of fever (Analysis 2.15), diarrhoea (Analysis 2.16),
and vomiting (Analysis 2.17) were evaluated after the first dose,
seconddose, and third dose, and at the endof the follow-up period.
We found no statistically significant differences between the RV5
and placebo groups for any of the reactogenicity outcomes and
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time points. We noted significant heterogeneity for the pooled
post-first dose data on fever (I2 statistic = 61%).
2.2.5. Adverse events that require discontinuation of
vaccination schedule
Ten trials reported the number of adverse events leading to dis-
continuation of the vaccination schedule, with no statistically sig-
nificant difference between RV5 and placebo (RR 0.89, 95% CI
0.57 to 1.39; 15,471 participants, 10 trials; Analysis 2.18).
2.3. Immunogenicity
RV5 immunogenicity was measured by rotavirus vaccine virus
shedding (5 trials, Analysis 2.19) and seroconversion (10 trials,
Analysis 2.20) after the third vaccine dose. We decided not to pool
the data, however, because of significant heterogeneity (I2 statistic
= 80% and 87%, respectively).
2.4. Dropouts before the end of trial
Similar numbers of children taking RV5 and placebo dropped out
from trials before they ended (RR 0.98, 95% CI 0.90 to 1.08;
85,855 participants, 13 trials; Analysis 2.21).
2.5. Subgroup analyses
2.5.1. G type
Rotavirus diarrhoea: of any severity
When the analyses were stratified by the G type (Analysis 2.22),
there were fewer episodes of rotavirus diarrhoea in the RV5 group
compared to the placebo group for the G1 type (RR 0.26, 95%CI
0.21 to 0.32; 11,022 participants, 4 trials), the G2 type (RR 0.35,
95% CI 0.16 to 0.78; 9907 participants, 3 trials), and the G9 type
(RR 0.33, 95% CI 0.20 to 0.54; 9537 participants, 2 trials). The
results were not statistically significant for G3 (RR 0.40, 95% CI
0.08 to 2.02; 11,022 participants, 4 trials) or for G4 (RR 0.41,
95% CI 0.13 to 1.33; 9907 participants, 3 trials).
Rotavirus diarrhoea: severe
There were significantly fewer severe episodes of rotavirus diar-
rhoea in the RV5 groups for G4 (RR 0.12, 95% CI 0.03 to 0.46;
76,606 participants, 3 trials) and G9 (RR 0.13, 95% CI 0.05 to
0.34; 76,606 participants, 3 trials). Pooled results were not signif-
icant for G1 (RR 0.23, 95% CI 0.03 to 1.74; 76,606 participants,
3 trials), G2 (RR 0.41, 95% CI 0.13 to 1.37; 76,606 participants,
3 trials), and for G3 (RR 0.38, 95% CI 0.05 to 2.74; 76,606 par-
ticipants, 3 trials). The pooled data for G1 (I2 statistic = 97%) and
G3 (I2 statistic = 64%) types showed statistical heterogeneity.
2.5.2. HIV-infected children
One trial (RV5 Armah 2010-AF) performed HIV tests for 89%
of participants and reported outcomes for HIV-infected children
(38/1158); another trial (RV5 Levin 2017-AF) included and re-
ported outcomes for HIV-exposed but uninfected and HIV-in-
fected children. We included only HIV-infected children from
this study in this subgroup analysis (Analysis 2.24).
Rotavirus diarrhoea: severe (up to two years of follow-up)
1/21 children in the vaccine arm, and 0/17 children in the placebo
arm had severe rotavirus diarrhoea at two-year follow-up; there
was no statistically significant difference detected between the two
treatment arms (1 trial).
All-cause diarrhoea: severe (up to two years of follow-up)
5/21 children in the vaccine arm, and 1/17 children in the placebo
arm had severe all-cause diarrhoea at two-year follow-up; there
was no statistically significant difference detected between the two
treatment arms (1 trial).
All-cause death
9/58 children in the vaccine arm, and 6/56 children in the placebo
arm died; there was no statistically significant difference between
the two arms (2 trials).
Serious adverse events (1 - 14 days after any dose)
10/58 children in the vaccine arm, and6/55 children in the placebo
armhad a serious adverse event; therewas no statistically significant
difference between the two arms (2 trials).
2.6 Sensitivity analysis
2.6.1 Primary outcomes with high heterogeneity according
to allocation concealment
There were no primary outcomes with high heterogeneity (I2
statistic > 75%).
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‘Summary of findings’
Summary of findings of primary outcomes according to country
mortality rate (WHO strata A to E) are presented in Summary
of findings 3 (RV5, low-mortality countries), and in Summary of
findings 4 (RV5, high-mortality countries).
3. Rotavac
3.1. Primary outcomes
3.1.1. Rotavirus diarrhoea: severe
High-mortality countries (WHO stratum D)
One trial conducted in India provided data for the efficacy of
Rotavac to prevent severe rotavirus diarrhoea in children. Rotavac
reduced severe rotavirus diarrhoea cases by 57% at one year (RR
0.43, 95% CI 0.30 to 0.60; 6799 participants, 1 trial; Analysis
3.1) and by 54% by two years (RR 0.46, 95% CI 0.35 to 0.60;
6541 participants, 1 trial; Analysis 3.2).
3.1.2. All-cause diarrhoea: severe
High-mortality countries (WHO stratum D)
One trial conducted in India provided data for the efficacy of
Rotavac to prevent severe all-cause diarrhoea in children. The trial
showed a reduction in the number of severe cases of diarrhoea with
Rotavac compared to placebo at one year by 16% (RR 0.84, 95%
CI 0.71 to 0.98; 6799 participants, 1 trial; Analysis 3.3).
3.1.3. All-cause death
High-mortality countries (WHO stratum D)
Two trials conducted in India reported on all-cause death. There
was no statistically significant difference in all-cause death between
Rotavac and placebo (RR 0.92, 95% CI 0.52 to 1.62; 8155 par-
ticipants Analysis 3.4). We present details of causes of death for
each trial in Appendix 9.
3.1.4. All serious adverse events
High-mortality countries (WHO stratum D)
Serious adverse events were reported in three trials conducted in
India. Pooled results showed no statistically significant difference
in the number of serious adverse events in the Rotavac group
compared with the placebo group (RR 0.93, 95%CI 0.85 to 1.02;
8210 participants, 3 trials; Analysis 3.5).
3.1.5. Serious adverse events: intussusception
High-mortality countries (WHO stratum D)
Four trials conducted in India reported on cases of intussuscep-
tion. Eight cases of intussusception were reported in a total of
5764 children in the Rotavac arm compared with three cases of in-
tussusception in 2818 children in the placebo arm. Pooled results
showed no increased risk of intussusception in children receiving
Rotavac when compared to placebo (RR 1.33, 95% CI 0.35 to
5.02; 8582 participants, 4 trials; Analysis 3.6).
3.2. Secondary outcomes
3.2.1. Rotavirus diarrhoea: of any severity
One trial provided data for the efficacy of Rotavac to prevent
rotavirus diarrhoea of any severity in children. Rotavac reduced the
number of cases of rotavirus diarrhoea of any severity by 34% at
both one-year (RR 0.66, 95% CI 0.56 to 0.78; 6799 participants,
1 trial; Analysis 3.7) and two-year follow-up (RR 0.66, 95% CI
0.57 to 0.76; 6541 participants, 1 trial; Analysis 3.8).
3.2.2. Rotavirus diarrhoea: requiring medical attention
Rotavac reduced the number of children requiring medical atten-
tion due to rotavirus diarrhoea at one year of follow-up by 31%
compared to placebo (RR 0.69, 95% CI 0.58 to 0.81; 6799 par-
ticipants, 1 trial; Analysis 3.9).
3.2.3. Reactogenicity
The incidences of fever (Analysis 3.10), diarrhoea (Analysis 3.11),
and vomiting (Analysis 3.12) were evaluated after the first dose in
two trials, second dose in one trial, and third dose in one trial. We
found no statistically significant differences between the Rotavac
and placebo groups for most of the reactogenicity outcomes and
time points, except for diarrhoea, which demonstrated an increase
with Rotavac compared to placebo after the second dose (RR 1.55,
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95% CI 1.00 to 2.41; 356 participants) and third dose (RR 4.09,
95% CI 2.11 to 7.92; 358 participants).
3.2.4. Immunogenicity
Rotavac was more immunogenic than placebo when measured by
vaccine virus shedding at the end of follow-up (RR 9.86, 95% CI
2.58 to 37.63; 427 participants, 2 trials, Analysis 3.13). It was also
more immunogenic when measured by seroconversion at all time
points (Analysis 3.14): after the first dose (RR 3.58, 95% CI 2.03
to 6.29; 121 participants, 1 trial), after the second dose (RR 2.97,
95% CI 1.78 to 4.98; 117 participants, 1 trial), and after the third
dose (RR 2.82, 95% CI 2.26 to 3.51; 1699 participants, 3 trials).
3.2.5. Dropouts before the end of trial
Similar numbers of children taking Rotavac or placebo dropped
out from trials before they ended (RR 0.81, 95% CI 0.62 to 1.06;
8215 participants, 3 trials; Analysis 3.15).
3.3. Subgroup analyses
3.3.1. G type
Rotavirus diarrhoea: severe
One trial reported severe cases of rotavirus diarrhoea by G and P
type (VAC Bhandari 2014-IND).
At one-year follow-up (Analysis 3.16) there were significantly
fewer severe episodes of rotavirus diarrhoea in the Rotavac groups
forG2P[4] (RR0.39, 95%CI0.22 to 0.69; 6541 participants) and
G12P[6] (RR 0.31, 95% CI 0.13 to 0.74; 6541 participants); re-
sults were not significantly different between Rotavac and placebo
for G1P[8] (RR 0.66, 95% CI 0.36 to 1.20; 6541 participants)
and G12P[8] (RR 0.30, 95% CI 0.07 to 1.26; 6541 participants).
At two-year follow-up (Analysis 3.17) there were significantly
fewer severe episodes of rotavirus diarrhoea in the Rotavac groups
for G1P[8] (RR 0.59, 95% CI 0.38 to 0.93; 6541 participants),
G2P[4] (RR 0.37, 95% CI 0.23 to 0.62; 6541 participants),
G12P[6] (RR 0.31, 95% CI 0.13 to 0.74; 6541 participants), and
G12P[8] (RR 0.31, 95% CI 0.10 to 0.96; 6541 participants).
The included Rotavac trials did not report separate data on im-
munocompromised or malnourished subgroups.
3.4 Sensitivity analyses
3.4.1 Primary outcomes with high heterogeneity according
to allocation concealment
There were no primary outcomes with high heterogeneity (I2
statistic > 75%).
‘Summary of findings’
Summary of findings of primary outcomes are presented in
Summary of findings 5 (Rotavac, high-mortality countries),
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Patient or population: children
Settings: high-mortality countries (WHO strata D and E)
Intervention: RV1
Comparison: placebo or no intervent ion
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no interven-
tion
RV1
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 1 year
60 per 1000 22 per 1000
(14 to 36)
RR 0.37
(0.23 to 0.60)
6114
(3 studies)
⊕⊕⊕⊕
high
RV1 reduces severe ro-
tavirus diarrhoea com-
pared to placebo or no
intervent ion at up to
one year follow-up
We did not downgrade
for inconsistency as the
heterogeneity observed
in the pooled data (I
2 stat ist ic = 57%) was
due to within-study het-
erogeneity (RV1 Madhi
2010-AF results split by
country)
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 2 years
43 per 1000 28 per 1000
(22 to 35)
RR 0.65
(0.51 to 0.83)
13,768* *
(2 studies)
⊕⊕⊕⊕
high
RV1 reduces severe ro-
tavirus diarrhoea com-
pared to placebo or no
intervent ion at up to
two years follow-up
Sensit ivity analysis ex-
cluding the cluster-RCT
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(RV1 Zaman 2017-BGD)
that contributed data to
this outcome showed
no signif icant change in
ef fect est imate or 95%
CI (RR 0.58, 95% CI 0.
42 to 0.79, n = 2764, 1
RCT)
Severe cases of all-
cause diarrhoea
Follow-up: up to 1 year
176 per 1000 129 per 1000
(99 to 167)
RR 0.73
(0.56 to 0.95)
5639
(2 studies)
⊕⊕⊕⊕
high
RV1 reduces severe all-
cause diarrhoea com-
pared to placebo or no
intervent ion at up to
one year follow-up
We did not downgrade
for inconsistency as the
heterogeneity observed
in the pooled data (I
2 stat ist ic = 75%) was
due to within-study het-
erogeneity (RV1 Madhi
2010-AF results split by
country)
Severe cases of all-
cause diarrhoea
Follow-up: up to 2 years
233 per 1000 191 per 1000
(166 to 222)
RR 0.82
(0.71 to 0.95)
2764
(1 study)
⊕⊕⊕©
moderatea
due to indirectness
RV1 probably slight ly
reduces severe all-
cause diarrhoea com-
pared to placebo or no
intervent ion at up to
two years follow-up
All- cause death
Follow-up: 2 months to
2 years
24 per 1000 21 per 1000
(16 to 30)
RR 0.88
(0.64 to 1.22)
8181
(8 studies)
⊕⊕©©
lowb
due to imprecision
RV1 may make lit t le
or no dif ference to all-
cause death compared
to placebo or no inter-
vent ion
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All serious adverse
events
Follow-up: 2 months to
2 years
95 per 1000 84 per 1000
(72 to 99)
RR 0.89
(0.76 to 1.04)
7481
(7 studies)
⊕⊕⊕⊕
high
RV1 makes lit t le or no
dif ference to serious
adverse events com-
pared to placebo or no
intervent ion
Serious
adverse events: intus-
susception
Follow-up: 2 months to
2 years
0 per 100,000 0 per 100,000
(0 to 0)
RR 1.49
(0.06 to 36.63)
17,492* *
(4 studies)
⊕⊕©©
lowc
due to imprecision
RV1 may make lit t le or
no dif ference to intus-
suscept ion compared
to placebo or no inter-
vent ion
Sensit ivity analysis ex-
cluding the cluster-RCT
(RV1 Zaman 2017-BGD)
that contributed data to
this outcome showed
no change in ef fect es-
t imate or 95% CI
* The basis for the assumed risk is the control group risk across studies included in the meta-analysis. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* *Number of part icipants in this table shows the true number of part icipants for this outcome; the number of events and the number of part icipants in the analysis has been
adjusted for the included cluster trial RV1 Zaman 2017-BGD using a design ef fect of 2.53.
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
aDowngraded by one for indirectness. Trials were conducted in Malawi and South Af rica, so generalizat ion to any high-
mortality country is dif f icult .
bDowngraded by two for imprecision. These trials were not powered to detect an ef fect on mortality.
cDowngraded by two for imprecision. There was a 1:10,000 to 1:32,000 increased risk of intussuscept ion with a previous
rotavirus vaccine (Bines 2005), so these trials were not powered to detect an associat ion between RV1 and intussuscept ion.
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Patient or population: children
Settings: low-mortality countries (WHO strata A and B)
Intervention: RV5
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV5
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 1 year
17 per 1000 1 per 1000
(1 to 5)
RR 0.08
(0.03 to 0.22)
4132
(5 studies)
⊕⊕⊕©
moderatea
due to imprecision
RV5 probably reduces
severe rotavirus di-
arrhoea compared to
placebo at up to one
year follow-up
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 2 years
25 per 1000 4 per 1000
(2 to 10)
RR 0.18
(0.08 to 0.39)
7318
(4 studies)
⊕⊕⊕©
moderateb
due to inconsistency
RV5 probably reduces
severe rotavirus di-
arrhoea compared to
placebo at up to two
years follow-up
Severe all- cause diar-
rhoea
Follow-up: up to 1 year
- - - - - We found no studies
that reported on this
outcome in this sett ing
Severe all- cause diar-
rhoea
Follow-up: up to 2 years
- - - - - We found no studies
that reported on this
outcome in this sett ing
All- cause death
Follow-up: 2 months to
2 years
1 per 1000 1 per 1000
(0 to 1)
RR 1.13
(0.65 to 1.96)
77,642
(9 studies)
⊕⊕©©
lowc
due to imprecision
RV5 may make lit t le
or no dif ference to all-
cause death compared
to placebo
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All serious adverse
events
Follow-up: 2 months to
2 years
27 per 1000 25 per 1000
(23 to 28)
RR 0.93
(0.86 to 1.02)
75,672
(8 studies)
⊕⊕⊕⊕
high
RV5 makes lit t le or no
dif ference to serious
adverse events com-
pared to placebo
Serious
adverse events: intus-
susception
Follow-up: 2 months to
2 years
1 per 1000 0 per 1000
(0 to 1)
RR 0.77
(0.41 to 1.45)
78,907
(12 studies)
⊕⊕©©
lowd
due to imprecision
RV5 may make lit t le or
no dif ference to intus-
suscept ion compared
to placebo
* The basis for the assumed risk is the control group risk across studies included in the meta-analysis. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
aDowngraded by one for imprecision. The total number of events was very low.
bDowngraded by one for inconsistency. We found substant ial heterogeneity (I2 stat ist ic = 44%). Consistency was restored
when removing the one study carried out only in a very low-mortality (stratum A) country, with results then showing a slight ly
smaller ef fect (RR 0.22, 95% CI 0.13 to 0.36, 6291 part icipants, 3 studies).
cDowngraded by two for imprecision. These trials were not powered to detect an ef fect on mortality.
dDowngraded by two for imprecision. There was a 1:10,000 to 1:32,000 increased risk of intussuscept ion with a previous
rotavirus vaccine (Bines 2005), so these trials were not powered to detect an associat ion between RV1 and intussuscept ion.
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Patient or population: children
Settings: high-mortality countries (WHO strata D and E)
Intervention: RV5
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo RV5
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 1 year
30 per 1000 13 per 1000
(9 to 19)
RR 0.43
(0.29 to 0.62)
5916
(2 studies)
⊕⊕⊕⊕
high
RV5 reduces severe ro-
tavirus diarrhoea com-
pared to placebo at up
to one year follow-up
Severe cases of ro-
tavirus diarrhoea
Follow-up: up to 2 years
63 per 1000 37 per 1000
(27 to 51)
RR 0.59
(0.43 to 0.82)
5885
(2 studies)
⊕⊕⊕⊕
high
RV5 reduces severe ro-
tavirus diarrhoea com-
pared to placebo at up
to two years follow-up
Severe cases of all-
cause diarrhoea
Follow-up: up to 1 year
77 per 1000 62 per 1000
(45 to 85)
RR 0.8
(0.58 to 1.11)
4085
(1 study)
⊕⊕⊕©
moderatea
due to indirectness
RV5 probably makes
lit t le or no dif ference
to severe all-cause di-
arrhoea compared to
placebo at up to one
year follow-up
Severe cases of all-
cause diarrhoea
Follow-up: up to 2 years
130 per 1000 110 per 1000
(97 to 127)
RR 0.85
(0.75 to 0.98)
5977
(2 studies)
⊕⊕⊕⊕
high
RV5 slight ly reduces
severe all-cause di-
arrhoea compared to
placebo at up to two
years follow-up
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All- cause death
Follow-up: 2 months to
2 years
26 per 1000 23 per 1000
(17 to 32)
RR 0.92
(0.68 to 1.24)
6806
(3 studies)
⊕⊕©©
lowb
due to imprecision
RV5 may make lit t le
or no dif ference to all-
cause death compared
to placebo
All serious adverse
events
Follow-up: 2 months to
2 years
21 per 1000 19 per 1000
(14 to 27)
RR 0.92
(0.66 to 1.28)
6830
(4 studies)
⊕⊕⊕©
moderatec
due to imprecision
RV5 probably makes lit -
t le or no dif ference to
serious adverse events
compared to placebo
Serious
adverse events: intus-
susception
Follow-up: 2 months to
2 years
See comment See comment Not est imable 6588
(2 studies)
⊕⊕©©
lowd
due to imprecision
No events were re-
ported. RV5 may make
lit t le or no dif ference to
intussuscept ion com-
pared to placebo
* The basis for the assumed risk is the control group risk across studies included in the meta-analysis. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High-certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate-certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: we are very uncertain about the est imate.
aDowngraded by one for indirectness. Single trial conducted in three Af rican countries (Mali, Ghana, and Kenya), so
generalizat ion to any high-mortality country is dif f icult .
bDowngraded by two for imprecision. These trials were not powered to detect an ef fect on mortality.
cDowngraded by one for imprecision. The 95% CI includes both no ef fect and appreciable harm.
dDowngraded by two for imprecision. There was a 1:10,000 to 1:32,000 increased risk of intussuscept ion with a previous
rotavirus vaccine (Bines 2005), so these trials were not powered to detect an associat ion between RV1 and intussuscept ion.
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Patient or population: children
Settings: one high-mortality country (India) (WHO stratum D)
Intervention: Rotavac
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Rotavac
Severe cases of ro-
tavirus diarrhoea
f ollow-up: up to 1 year
31 per 1000 13 per 1000
(9 to 19)
RR 0.43
(0.30 to 0.60)
6799
(1 study)
⊕⊕⊕©
moderatea
due to indirectness
Rotavac probably re-
duces severe rotavirus
diarrhoea compared to
placebo at up to one
year follow-up
Severe cases of ro-
tavirus diarrhoea f ol-
low-up: up to 2 years
47 per 1000 21 per 1000
(16 to 28)
RR 0.46
(0.35 to 0.60)
6541
(1 study)
⊕⊕⊕©
moderatea
due to indirectness
Rotavac probably re-
duces severe rotavirus
diarrhoea compared to
placebo at up to two
years follow-up
Severe cases of all-
cause diarrhoea
f ollow-up: up to 2 years
93 per 1000 78 per 1000
(66 to 91)
RR 0.84
(0.71 to 0.98)
6799
(1 study)
⊕⊕⊕©
moderatea
due to indirectness
Rotavac
probably slight ly re-
duces severe all-cause
diarrhoea compared to
placebo at up to one
year follow-up
All- cause death
f ollow-up: up to 2 years
7 per 1000 6 per 1000
(4 to 11)
RR 0.92
(0.52 to 1.62)
8155
(2 studies)
⊕©©©
very lowb,c
due to indirectness and im-
precision
We are uncertain
whether Rotavac re-
duced all-cause death
as the certainty of the
evidence is very low
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All serious adverse
events
f ollow-up: up to 2 years
204 per 1000 189 per 1000
(173 to 208)
RR 0.93
(0.85 to 1.02)
8210
(3 studies)
⊕⊕⊕©
moderateb
due to indirectness
Rotavac probably
makes lit t le or no dif -
ference to serious ad-
verse events compared
to placebo
Serious
adverse events: intus-
susception
f ollow-up: up to 2 years
1 per 1000 1 per 1000
(0 to 5)
RR 1.33
(0.35 to 5.02)
8582
(4 studies)
⊕©©©
very lowb,d
due to indirectness and im-
precision
No events were re-
ported in three of the
four studies. We are
uncertain whether Ro-
tavac has an ef fect on
intussuscept ion as the
certainty of the evi-
dence is very low
*The basis for the assumed risk is the control group risk across studies included in the meta-analysis. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: We are very uncertain about the est imate.
aDowngraded by one for indirectness. Single trial conducted in India, so generalizat ion to any high-mortality country is dif f icult .
bDowngraded by one for indirectness. All t rials were conducted in India, so generalizat ion to any high-mortality country is
dif f icult .
cDowngraded by two for imprecision. These trials were not powered to detect an ef fect on mortality.
dDowngraded by two for imprecision. There was a 1:10,000 to 1:32,000 increased risk of intussuscept ion with a previous
rotavirus vaccine (Bines 2005), therefore, these trials were not powered to detect an associat ion between Rotavac and
intussuscept ion.
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D I S C U S S I O N
Rotavirus vaccines have been under development since the 1980s,
and to date three have been prequalified by the WHO (RV1,
RV5 andRotavac). Three additional rotavirus vaccines are licensed
for use in individual countries (LLR, Rotasiil, and Rotavin, see
Appendix 10). RRV-TV (RotaShield) has not been used since
1999. The three vaccines prequalified by the WHO (RV1, RV5,
Rotavac), and currently in use, are the focus of this review.
Summary of main results
We included 55 trials with a total of 216,480 participants, that
evaluated RV1 (36 trials), RV5 (15 trials), and Rotavac (4 trials).
Our analysis stratified the primary outcomes by WHO mortality
strata (high-mortality countries, with high child mortality; and
low-mortality, with low or very low child mortality; WHO 1999).
The trials were not designed or powered to detect an effect on
preventing death or on the occurrence of possible rare serious
adverse events, such as intussusception.
1. RV1 in countries with low child mortality
(WHO strata A and B)
Fourteen trials were conducted in Asia, six in Europe, four in Latin
America, four in North America, and one in Europe and Latin
America.
In infants under one year
RV1 prevents 84% of cases of severe rotavirus diarrhoea: RR 0.16,
95% CI 0.09 to 0.26; 43,779 participants, 7 trials; high-certainty
evidence.
RV1 prevents 41% of cases of severe all-cause diarrhoea: RR 0.59,
95% CI 0.47 to 0.74; 28,053 participants, 3 trials; moderate-
certainty evidence.
In children up to two years
RV1 prevents 82% of cases of severe rotavirus diarrhoea: RR 0.18,
95% CI 0.14 to 0.23; 36,002 participants, 9 trials; high-certainty
evidence.
RV1 prevents 37% of severe all-cause diarrhoea episodes: Rate
ratio 0.63, 95% CI 0.56 to 0.71; 39,091 participants, 2 trials;
moderate-certainty evidence.
For all-cause death, an effect of the vaccine has not been shown:
RR 1.22, 95%CI 0.87 to 1.71; 97,597 participants, 22 trials; low-
certainty evidence.
For serious adverse events, children receiving RV1 had 12% fewer
events than those receiving placebo: RR 0.88, 95% CI 0.83 to
0.93; 96,233 participants, 24 trials; high-certainty evidence.
For intussusception, RV1 was not associated with a higher risk:
RR 0.69, 95%CI 0.45 to 1.04; 96,513 participants, 17 trials; low-
certainty evidence.
See Summary of findings for the main comparison.
2. RV1 in countries with high child mortality
(WHO strata D and E)
Two trials were conducted in Bangladesh, one in India, one in
Peru, three in South Africa, and one in South Africa and Malawi.
In infants under one year
RV1 prevents 63% of cases of severe rotavirus diarrhoea: RR 0.37,
95% CI 0.23 to 0.60; 6114 participants, 3 trials; high-certainty
evidence.
RV1 prevents 27% of cases of severe all-cause diarrhoea: RR 0.73,
95% CI 0.56 to 0.95; 5639 participants, 2 trials; high-certainty
evidence.
In children up to two years
RV1 prevents 35% of cases of severe rotavirus diarrhoea: RR 0.65,
95% CI 0.51 to 0.83; 13,768 participants, 2 trials; high-certainty
evidence.
RV1 prevents 17% of cases of severe all-cause diarrhoea: RR 0.83,
95% CI 0.72 to 0.96; 2764 participants, 1 trial; moderate-cer-
tainty evidence.
For all-cause death, an effect of the vaccine has not been shown:
RR 0.88, 95% CI 0.64 to 1.22; 8181 participants, 8 trials; low-
certainty evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.89, 95% CI 0.76 to 1.04; 7481 participants, 7 trials;
high-certainty evidence.
For intussusception, RV1 was not associated with a higher risk:
RR 1.49, 95%CI 0.06 to 36.63; 17,492 participants, 4 trials; low-
certainty evidence.
See Summary of findings 2.
3. RV5 in countries with low child mortality
(WHO strata A and B)
Three trials were conducted in Asia, two in Europe, three in North
America, one in Europe and the USA, one in Europe and the
Americas.
In infants under one year
RV5 prevents 92% of cases of severe rotavirus diarrhoea: RR 0.08,
95% CI 0.03 to 0.22; 4132 participants, 5 trials; moderate-cer-
tainty evidence.
We found noRV5 trials that reported on severe all-cause diarrhoea.
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In children up to two years
RV5 prevents 82% of cases of severe rotavirus diarrhoea: RR 0.18,
95% CI 0.08 to 0.39; 7318 participants, 4 trials; moderate-cer-
tainty evidence.
We found noRV5 trials that reported on severe all-cause diarrhoea.
For all-cause death, an effect of the vaccine has not been shown:
RR 1.13, 95% CI 0.65 to 1.96; 77,642 participants, 9 trials; low-
certainty evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.93, 95% CI 0.86 to 1.02; 75,672 participants, 8
trials; high-certainty evidence.
For intussusception, RV5 was not associated with a higher risk:
RR 0.77, 95%CI 0.41 to 1.45; 78,907 participants, 12 trials; low-
certainty evidence.
See Summary of findings 3.
4. RV5 in countries with high child mortality
(WHO strata D and E)
Two trials were conducted in Asia and two in Africa.
In infants under one year
RV5 prevents 57% of cases of severe rotavirus diarrhoea: RR 0.43,
95% CI 0.29 to 0.62; 5916 participants, 2 trials; high-certainty
evidence.
Data on severe all-cause diarrhoea was reported in one trial. This
suggested a protective effect, but the results were not statistically
significant: RR 0.80, 95% CI 0.58 to 1.11; 4085 participants, 1
trial; moderate-certainty evidence.
In children up to two years
RV5 prevents 41% of cases of severe rotavirus diarrhoea: RR 0.59,
95% CI 0.43 to 0.82; 5885 participants, 2 trials; high-certainty
evidence.
RV5 prevents 15% of cases of severe all-cause diarrhoea: RR 0.85,
95% CI 0.75 to 0.98; 5977 participants, 2 trials; high-certainty
evidence.
For all-cause death, an effect of the vaccine has not been shown:
RR 0.92, 95% CI 0.68 to 1.24; 6806 participants, 3 trials; low-
certainty evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.92, 95% CI 0.66 to 1.28; 6830 participants, 4 trials;
moderate-certainty evidence.
For intussusception, RV5 was not associated with a higher risk:
no cases were reported, 6588 participants, 2 trials; low-certainty
evidence.
See Summary of findings 4.
5. Rotavac in countries with high child mortality
(WHO stratum D)
Four trials were conducted in India.
In infants under one year
Rotavac prevents 57% of cases of severe rotavirus diarrhoea: RR
0.43, 95% CI 0.30 to 0.60; 6799 participants, 1 trial; moderate-
certainty evidence.
In children up to two years
Rotavac prevents 54% of cases of severe rotavirus diarrhoea: RR
0.46, 95% CI 0.35 to 0.60; 6541 participants, 1 trial; moderate-
certainty evidence.
Rotavac prevents 16% of cases of severe all-cause diarrhoea: RR
0.84, 95%CI 0.71 to 0.98; 6799 participants, one trial; moderate-
certainty evidence.
For all-cause death, an effect of the vaccine has not been shown:
RR 0.92, 95% CI 0.52 to 1.62; 8155 participants, 2 trials; very
low-certainty evidence.
For serious adverse events, an effect of the vaccine has not been
shown: RR 0.93, 95% CI 0.85 to 1.02; 8210 participants, 3 trials;
moderate-certainty evidence.
For intussusception, Rotavac was not associated with a higher risk:
RR 1.33, 95% CI 0.35 to 5.02; 8582 participants, 4 trials; very
low-certainty evidence.
See Summary of findings 5.
Overall completeness and applicability of
evidence
We carried out this systematic review using RCTs. All the included
trials were placebo-controlled, except for two RV1 trials that com-
pared vaccine to no intervention (RV1 Colgate 2016-BGD; RV1
Zaman 2017-BGD). We could not evaluate potential herd pro-
tection afforded by vaccination. The trials provided only limited
data for special groups of children, such as malnourished or im-
munocompromised children.
Efficacy by setting
RV1 and RV5 were highly efficacious in reducing severe rotavirus
diarrhoea episodes in low-mortality countries; widespread roll-out
of rotavirus vaccines has led to major reductions in rotavirus hos-
pitalizations in such settings (Hungerford 2015; Jonesteller 2017).
In contrast, trials of RV1 and RV5 in high-mortality countries in
Africa and Asia demonstrated a relatively lower vaccine efficacy.
However, because of the higher burden of rotavirus disease in such
countries, the absolute number of events prevented by vaccination
is greater than in low-mortality countries (RV1 Madhi 2010-AF).
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Efficacy by age
Results from RV1 and RV5 found higher vaccine efficacy against
severe rotavirus diarrhoea in the first year compared to the cumu-
lative efficacy for the first and second years. The efficacy was lower
but the differences between the first and second years were greater
in high-mortality (RV1: 63% up to one year versus 54% up to two
years; RV5: 57% versus 41%) compared to low-mortality coun-
tries (RV1: 84% up to one year versus 82% up to two years; RV5:
92% versus 82%). Trials with Rotavac were not carried out in any
low-mortality country.
Reduced vaccine efficacy in high-mortality countries in trials re-
porting two years of follow-up could be explained either bywaning
of vaccine-induced immunity, or some protection in the placebo
group resulting from more frequent exposure to natural rotavirus
infection (RV1 Madhi 2010-AF). Post-introduction studies have
shown reduced effectiveness in the second year of life in some, but
not all, high-burden settings (Bar-Zeev 2015; Groome 2014). Ad-
ditional vaccine doses have been explored to extend the duration
of protection in high disease-burden settings (Cunliffe 2016).
Efficacy by schedule
Children in trials performed in low-mortality countries received
the vaccines according to the country’s immunization schedule.
Trials performed in high-mortality countries examined the efficacy
of RV1when administered at 10 to 14weeks of age, a later age than
is recommended in the Expanded Programme on Immunization
(EPI) schedule. However, the 6- and 10-week RV1 schedule used
in EPI programmes has now been extensively evaluated following
vaccine roll-out in high-mortality countries in Africa, with effec-
tiveness comparable to efficacy trial estimates (Bar-Zeev 2015).
All-cause diarrhoea
The impact of rotavirus vaccination on severe all-cause diarrhoea
from a public health perspective is important, as laboratories in
low-income countries may not routinely test for rotavirus infec-
tion. The effect on all-cause diarrhoea is a function of the contri-
bution of rotavirus to all diarrhoea and the efficacy of the vaccine
against rotavirus. Surprisingly, few trials reported vaccine efficacy
against all-cause diarrhoea. Vaccine efficacy against all-cause diar-
rhoea of any severity was lower, meaning that vaccination may not
have a noticeable impact on milder episodes of diarrhoea occur-
ring in the community (Hungerford 2018).
Mortality data
The included trials were not individually powered to detect a mor-
tality effect. This review did not detect a difference in the number
of deaths for children receiving any of the vaccines or placebo. Two
post-vaccine implementation national surveillance studies from
Mexico and Brazil reported that the introduction of RV1 into
the national immunization programme was associated with a de-
cline in the number of diarrhoea-related deaths (Do Carmo 2011;
Richardson 2010) in comparison with historical controls. A study
from ruralMalawi showed that diarrhoea deaths reduced by a third
following RV1 introduction (Bar-Zeev 2018).
Safety data
There was no detectable difference in the number of cases of intus-
susception for children receiving vaccine or placebo. While both
RV1 and RV5 have been associated with a low risk of intussus-
ception in post-marketing studies in Europe, Americas and Aus-
tralia, the benefits of vaccination are considered to outweigh the
risk of vaccine-associated intussusception (Yen 2016). However,
the risk of intussusception after administration of RV1 was not
higher than the background risk of intussusception in seven lower-
income sub-Saharan African countries (Tate 2018).
Subgroup analyses
Rotavirus G-types
All three rotavirus vaccines showed efficacy against most of the
specific rotavirus G-types that were assessed (G1,G2, G3, G4, G8,
G9, and G12), although results were often inconsistent between
different countries and imprecise due to few events.
Immunocompromised children
One RV1 trial and two RV5 trials reported on immunocompro-
mised children, all exposed to or infected with HIV. We found no
differences for efficacy or safety, but samples were not sufficiently
powered. It is now strongly recommended that all HIV-infected or
HIV-exposed infants be vaccinatedwith oral rotavirus vaccine, un-
less severely immunocompromised (Calles 2010). While we lack
specific information on many immunodeficiencies, infants with
known severe combined immunodeficiency should not receive live
rotavirus vaccine (Pinto 2016; Vesikari 2015).
Children with malnutrition
One RV1 trial (RV1 Salinas 2005-LA) found that RV1 was signif-
icantly better than placebo in preventing rotavirus diarrhoea in a
subgroup of malnourished children.
Certainty of the evidence
The trials included in this updated review were placebo-controlled
(53 trials) or compared vaccine to no intervention (RV1 Colgate
2016-BGD; RV1 Zaman 2017-BGD), were conducted in Latin
America, North America, Europe, Asia, and Africa, and the largest
included over 60,000 children (RV1 Ruiz-Palac 06-LA/EU; RV5
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Vesikari 2006b-INT); we identified the need for such trials in
the original version of the review (Soares-Weiser 2004). However,
most children were followed for safety outcomes only.
The certainty of the evidence for efficacy outcomes (rotavirus di-
arrhoea of any severity and severe, and all-cause diarrhoea of any
severity and severe) was either high or moderate. This was because
most trials were assessed at low risk of bias, especially more recent
trials, and pooled samples were usually large enough to generate
more precise estimates. When we downgraded efficacy outcomes
tomoderate certainty, this was due to selective reporting bias (only
half of the studies reporting on severe rotavirus diarrhoea reported
on severe all-cause diarrhoea), imprecision (lownumber of events),
attrition bias (incomplete outcome data were not clearly reported),
or indirectness (only one study carried out in one high-mortality
country or neighbouring high-mortality countries makes it diffi-
cult to generalize to any high-mortality country).
The certainty of the evidence for all-cause mortality was low be-
cause the trials were not powered to detect an effect on mortality,
and results were consequently imprecise with wide 95% CIs.
The certainty of the evidence for all serious adverse events was
mostly high but downgraded to moderate for RV5 in high-mor-
tality countries due to imprecise results, and for Rotavac due to
indirectness (all trials were carried out in India). For the rare se-
rious adverse event intussusception, evidence was of low certainty
for RV1 and RV5 due to imprecision because trials were not pow-
ered to detect an association between RV1 and intussusception.
For Rotavac evidence on intussusception was of very low certainty,
due to imprecision and indirectness as previously described.
Potential biases in the review process
We stratified all analyses by WHO mortality strata, which may
not reflect the current situation in the member countries. The use
of the strata may not be sensitive enough to show differences at
the country level, and perhaps stratifying by prevalence/burden of
rotavirus may be a better method to group the analyses. In addi-
tion, not all countries are represented by the studies performed,
and some strata (e.g. C) are lacking sufficient data.
Agreements and disagreements with other
studies or reviews
We identified three systematic reviews of RCTs evaluating RV1 or
RV5 or both that have been conducted since the 2012 update of
this Cochrane Review:
• Lamberti 2016 included RCTs and observational studies
and evaluated region-specific effectiveness of RV1, RV5 and
Rotavac. The systematic review found that rotavirus vaccination
was both efficacious and effective in preventing rotavirus
diarrhoea, severe rotavirus diarrhoea and rotavirus
hospitalizations among children under five across all regions,
with higher efficacy in more developed regions.
• Velázquez 2017 included RCTs and post-licensure
observational studies from Latin America and the Caribbean,
and found that RV1 reduced the risk of any-severity rotavirus-
related gastroenteritis by 65% and of severe gastroenteritis by
82% versus placebo. Both RV1 and RV5 vaccines significantly
reduced the risk of hospitalization and emergency visits by 85%
for RV1 and by 90% for RV5. Vaccination with RV5 or RV1 did
not increase the risk of death, intussusception, or other severe
adverse events.
• Buyse 2014 presented an integrated meta-analysis of safety
and reactogenicity data of 28 RV1 RCTs and found that RV1 has
a reactogenicity and safety profile similar to placebo.
The findings of these systematic reviews agree with the findings
of our review, although the scope of these reviews was narrower;
they reviewed efficacy or safety only, or were limited to a specific
geographical region, or reviewed only one of the vaccines. Conse-
quently, we included more trials in our review. Finally, the major
findings of this review update, including new evidence from 14
trials of RV1, RV5, and Rotavac, are not significantly different
from the previous Soares-Weiser 2012b review.
Relationship to current policies
The data in this review support the WHO’s Strategic Advisory
Groupof Experts (SAGE) on Immunization’s recommendation for
“the inclusion of rotavirus vaccination of infants into all national
immunization programmes” with a stronger recommendation for
countries where “diarrhoeal deaths account for≥10%ofmortality
among children aged <5 years” (SAGE 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• RV1, RV5 and Rotavac are efficacious vaccines in
preventing rotavirus diarrhoea with comparable safety and
efficacy profiles. The systematic review data support the global
WHO rotavirus vaccine recommendation (SAGE 2009; SAGE
2012).
• The data from the included RCTs exclude a risk of
intussusception with RV1, RV5, and Rotavac of the magnitude
observed with the first licensed vaccine (RRV-TV, RotaShield).
However, since the data cannot exclude a smaller risk of
intussusception or other rare serious adverse events, routine
vaccine introduction should be accompanied by safety
surveillance (Buttery 2011; Patel 2011; Shui 2012; Weintraub
2014).
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Implications for research
Placebo-controlled efficacy trials of RV1 and RV5 have been un-
dertaken in representative populations of low- and high-mortality
countries and do not require repetition; efficacy or effectiveness
trials of Rotavac outside of India should be considered if Rotavac
is introduced globally. Further research would be valuable in the
following areas:
• Continued post-introduction studies to examine the impact
and effectiveness of rotavirus vaccination, particularly in high-
mortality countries.
• A greater understanding of the lower vaccine efficacy
observed in high-mortality countries compared to low-mortality
countries in Africa and Asia in the first and second years of life.
• Studies to assess the potential benefit of alternative dosage
schedules of rotavirus vaccine, especially in high-mortality
countries (e.g. neonatal dosing, additional dosing).
• Continued post-introduction studies in representative
countries should examine vaccine safety with particular respect
to intussusception and should analyze the risk/benefit of
rotavirus vaccination (Patel 2011). Post-introduction safety
studies of Rotavac are currently lacking (Dutta 2017). Given the
rarity of the event, data from different countries may need to be
pooled (Escolano 2011; Escolano 2015), or self-controlled case
series analyses may need to be carried out (Carlin 2013; Stowe
2016; Tate 2018; Yih 2014).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
RV1 Anh 2011-PHL
Methods RCT
Length of follow-up: 1 month after last dose
Adverse event data collection methods: not reported
Participants Number: 375 enrolled; ATP safety cohort: 345; ATP immunogenicity cohort: 292
Inclusion criteria: healthy infants aged 5 - 10 weeks at the time of the first study
vaccination dose with a birth weight of > 2 kg
Exclusion criteria:use of any investigational drug or vaccine other than the study vaccine
or confirmed immunosuppression/immunodeficient conditions or allergy to RIX4414
vaccine/placebo components
Interventions 1. 2 doses of RIX4414* plus 1 dose of placebo according to a PL-V-V schedule
2. 2 doses of RIX4414* plus 1 dose of placebo according to a V-PL-V schedule
3. 3 placebo doses
* Human rotavirus (RV1) liquid vaccine, oral suspension (GSK Biologicals, Belgium),
containing at least 106.0 median Cell Culture Infective Dose 50 percent (CCID50) of
live attenuated RIX4414 human rotavirus strain (G1P[8])
Schedule: 3 doses according to a 0-, 1-, and 2-month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity, including fever, diarrhoea and vomiting, 8 days after each dose (col-
lected from GSK report)
2. Adverse events leading to discontinuation
3. Serious adverse events
4. Fatal serious adverse events
5. Dropouts
6. * Rotavirus diarrhoea, rotavirus antigen isolated from any of the stool samples collected
from children with diarrhoea episodes, up to 1 month after last dose
7. * All-cause diarrhoea, up to 1 month after last dose
Outcomes to measure immunogenicity
8. Anti-rotavirus IgA antibody seroconversion, ≥ 20 U/mL
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when 2 formulae for the standard error (SE) converged
Immunization status Commercially-available diphtheria, tetanus, whole-cell pertussis (DTPw), hepatitis B
(HBV) and oral poliovirus (OPV) vaccines were administered concomitantly with the
study vaccine/placebo as part of the routine Expanded Programme of Immunization
(EPI) in the Philippines
Location Philippines (single centre)
WHO mortality stratum B
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RV1 Anh 2011-PHL (Continued)
Notes Study known as RIX GSK[063] 2008-AS in previously published versions of this review
Date: March to September 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “This study will provide data on the immune response and safety of
GSK Biologicals’ HRV [human rotavirus] liquid vaccine when given along with the
routine infant immunizations in Philippines.” “The study also[...]explored the potential
effect of scheduling of the HRV [human rotavirus] vaccine doses with respect to the
existing routine vaccination schedules”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Quote: “Block randomization scheme (2:
2:1 ratio) with standard SAS program was
used”
Allocation concealment (selection bias) Low risk Central allocation
Quote: “Based on the block size, the vac-
cine doses were distributed to each of the
study centers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded
Quote: “The study was double-blind with
respect to the RIX4414 oral suspension
(liquid formulation), placebo and schedul-
ing of doses. The parents/guardians of in-
fants, investigators and study personnel
were unaware of the study vaccine/ placebo
administered”
Quote: “The placebo was identical to the
vaccine in composition”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for dropout/exclusion reported
Selective reporting (reporting bias) Low risk All prepublished outcomes included
Other bias Low risk No apparent other bias
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RV1 Anh 2011-VNM
Methods RCT
Length of follow-up: 1 month after last dose
Adverse event data collection methods: not reported
Participants Number: 375 enrolled; ATP safety cohort: 352; ATP immunogenicity cohort: 330
Inclusion criteria: healthy infants aged 6 to 10 weeks at the time of the first study
vaccination dose with a birth weight of > 2 kg
Exclusion criteria:use of any investigational drug or vaccine other than the study vaccine
or confirmed immunosuppression/immunodeficient conditions or allergy to RIX4414
vaccine/placebo components
Interventions 1. 2 doses of RIX4414* plus 1 dose of placebo according to a V-V-PL schedule
2. 2 doses of RIX4414* plus 1 dose of placebo according to a V-PL-V schedule
3. 3 placebo doses
* Human rotavirus [RV1] liquid vaccine, oral suspension (GSK Biologicals, Belgium),
containing at least 106 median Cell Culture Infective Dose 50 percent (CCID50) of live
attenuated RIX4414 human rotavirus strain (G1P[8])
Schedule: 3 doses according to a 0-, 1-, and 2-month schedule
Outcomes Clinical outcome measures (Safety and Efficacy)
1. Reactogenicity, including fever, diarrhoea and vomiting, 8 days after each dose (col-
lected from GSK report)
2. Adverse events leading to discontinuation
3. Serious adverse events
4. Fatal serious adverse events
5. Dropouts
6. * Rotavirus diarrhoea, rotavirus antigen isolated from any of the stool samples collected
from children with diarrhoea episodes, up to 1 month after last dose (outcome not
included in the prepublished protocol)
7. * All-cause diarrhoea, up to 1 month after last dose (outcome not included in the
prepublished protocol)
Outcomes to measure immunogenicity
8. Anti-rotavirus IgA antibody seroconversion, ≥ 20 U/ML
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when 2 formulae for the standard error (SE) converged
Immunization status Commercially-available diphtheria, tetanus, whole-cell pertussis (DTPw), hepatitis B
(HBV) and oral poliovirus (OPV) vaccines were administered concomitantly with the
study vaccine/placebo as part of the routine Expanded Programme of Immunization
(EPI) in Vietnam
Location Vietnam (11 satellite centres)
WHO mortality stratum B
Notes Study known as RIX GSK[051] 2008-AS in previously published versions of this review
Date: September 2006 to March 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “To provide specific data on immunogenicity of GSK Biologicals’ hu-
man rotavirus liquid vaccine, when co-administered with the routine Expanded Program
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RV1 Anh 2011-VNM (Continued)
of Immunization (EPI) in Vietnam. The study will also assess reactogenicity and safety
of the human rotavirus liquid vaccine relative to the placebo”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Quote: “Block randomization scheme (2:
2:1 ratio) with standard SAS program was
used”
Allocation concealment (selection bias) Low risk Central allocation
Quote: “Based on the block size, the vac-
cine doses were distributed to each of the
study centers”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded
Quote: “The study was double-blind with
respect to the RIX4414 oral suspension
(liquid formulation), placebo and schedul-
ing of doses. The parents/guardians of in-
fants, investigators and study personnel
were unaware of the study vaccine/ placebo
administered”
Quote: “The placebo was identical to the
vaccine in composition”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for dropout/exclusion reported
Selective reporting (reporting bias) Unclear risk One outcome (rotavirus diarrhoea) not in-
cluded in the prepublished protocol
Other bias Low risk No apparent other bias
RV1 Bernstein 1998-USA
Methods RCT
Length of follow-up: outcomes measured up to 1 month after the second dose
Adverse event data collection methods: participants or their parents filled out a diary
card for 7 days after each dose (passive method)
Participants Number: 42 enrolled; 42 evaluable
Inclusion criteria: all infants aged 6 to 26 weeks recruited from private practice offices
in Cincinnati
Exclusion criteria: not stated
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RV1 Bernstein 1998-USA (Continued)
Interventions RV1
1. RIX4414 (RV1): 105 PFU; 21 participants
2. Placebo: 20 participants
Schedule: 2 doses given 6 to 10 weeks apart
Outcomes Clinical outcome measures
1. Reactogenicity: diarrhoea defined as > 3 stools that were looser than normal in a 24-
hour period; fever defined as a temperature > 100.4 °F obtained rectally in infants
2. Serious adverse events
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Vaccine virus shedding: rotavirus shedding after immunization; combined time points
(review includes data from combined time points)
5. Seroconversion: ≥ 4-fold rise in rotavirus IgA antibody (serum and stool) (review
includes data from after dose 1 and dose 2)
Immunization status Rotavirus vaccine was separated from all other infant vaccines by at least 2 weeks
Location Cincinnati, USA
WHO mortality stratum A
Notes Date: August to November 1995
Source of funding: Virus Research Institute, Inc. (now Avant Immunotherapeutics Inc.
)
1 participant in the placebo group did not complete the study because of persistent otitis
media
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Trial report does not provide enough details
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RV1 Bernstein 1999-USA
Methods RCT
Length of follow-up: outcomes measured at 2 years
Adverse event data collectionmethods: “diary card for 7days after vaccine. Allmoderate
to severe side effects were reported by the investigator to an independent study monitor
on a continuous basis during the study” (passive method); “telephoned parents every 2
weeks after the first immunisation, and then weekly during the expected rotavirus season
(Jan 1-May 31) as a reminder and to collect data on any adverse events” (active method)
Participants Number: 215 randomized; 214 evaluable
Age range: 3 to 6 months
Inclusion criteria: healthy children aged 10 to 16 weeks at the time of the first dose
Exclusion criteria: fever; premature labour; an immunosuppressed or pregnant individ-
ual in the same household; birth at < 36 weeks of gestation; participation in any other
investigational clinical trial; or no telephone in the household
Interventions 89-12 (a precursor of RIX4414 (RV1)
1. 89-12 (a precursor of RIX4414 (RV1)): 105 PFU; 2 doses given 6 to 10 weeks apart;
108 participants
2. Placebo: 105 PFU; 2 doses given 6 to 10 weeks apart; 107 participants
“Infants received an oral dose of 1.0 mL vaccine (105 PFU) or placebo immediately after
2.0 mL of an antacid containing 160 mg aluminium hydroxide and 160 mg magnesium
hydroxide to buffer stomach acid. The infant was not fed for 1 h before or after the
immunisation”
Outcomes Clinical outcome measures
1. All-cause diarrhoea: gastroenteritis defined as vomiting (> 1 hour after feeding), diar-
rhoea (≥ 3 looser than normal stools in a 24-hour period), or both; measured up to 2
years
2. Severe rotavirus diarrhoea: severity assessed using a scoring system with a “20-point
scale identical to that used in previous rotavirus trials. In this system, points are assigned
according to the duration and severity of diarrhoea and vomiting, the severity of fever,
and the presence of dehydration or hospital admissions for each episode of gastroenteritis.
A score greater than 8 was prospectively defined as severe, and a score more than 14 as
very severe”; measured up to 2 years
3. Rotavirus diarrhoea: “An illness was classified as caused by rotavirus if a stool specimen
collected no later than 7 days after resolution of symptoms contained rotavirus antigen.
All episodes of rotavirus gastroenteritis occurring between the second vaccination and
the end of the study were included”; measured up to 7 days
4. Reactogenicity: “Parents filled out a diary card for 7 days after each dose. Signs included
were: daily (evening) rectal temperatures, diarrhoea, vomiting, and the number and
consistency of all stools”; measured up to 7 days
5. All-cause death; measured up to 2 years
6. Emergency department visit; measured up to 2 years
7. Rotavirus diarrhoea requiring hospitalization
Outcomes to measure immunogenicity
8. Vaccine virus shedding (review includes after dose 2 data)
9. Immunogenicity (ELISA): “Serum samples were analysed for IgA and IgG antibody
to rotavirus by an ELISA” and “neutralising antibody to the 89-12 strains by an antigen
reduction assay” (only rotavirus-specific IgA results reported in this review from after
dose 2 time point)
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RV1 Bernstein 1999-USA (Continued)
Immunization status Other vaccines separated from the trial vaccines by at least 2 weeks
Location Cincinnati, Baltimore, and Sellersviller, USA
WHO mortality stratum A
Notes Date: August 1997 to June 1998
Source of funding: Virus Research Institute, Inc. (now Avant Immunotherapeutics Inc.
)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Infants were assigned to receive
either 89-12 or placebo according to a
computer-generated randomization sched-
ule (one/one) in blocks of ten provided by
the sponsor
The intention-to-treat analysis included all
participants who received at least one dose
of study vaccine. Before the code was bro-
ken, all cases of rotavirus gastroenteritis and
the severity of each episode were verified”
Allocation concealment (selection bias) Low risk As above
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind, no details
Incomplete outcome data (attrition bias)
All outcomes
Low risk No impact on intervention effect estimate
Quote: “Of the 215 children enrolled, 213
received both doses of vaccine or placebo,
and 214 were followed up for gastrointesti-
nal disease. One child in the vaccine group
did not receive the vaccine because of per-
sistent fever at the time of the scheduled
revaccination, and one child in the placebo
group was found to have a congenital tra-
cheal malformation while in the trial and
was not revaccinated”
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Unclear risk Insufficient information
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RV1 Colgate 2016-BGD
Methods RCT, open-label non-placebo controlled trial
Length of follow-up: outcomes measured at 1 year
Adverse event data collection methods: Passive: All adverse events following interven-
tions were captured for 48 hours following each intervention and were scored for proba-
ble, possible, or unlikely relationship to each intervention. All missing protocol-defined
events were captured as protocol deviations and reported annually. Comprehensive safety
reports were submitted semi-annually to the study’s Independent Medical Monitor and
to the Data and Safety Monitoring Board
Participants Number: 700 enrolled; 593 evaluable
Age range: birth to age 7 days at enrolment, 10 - 17 weeks at vaccine administration
Inclusion criteria: Healthy infant aged 0 to 7 days, no obvious congenital abnormali-
ties or birth defects, no abnormal (frequency and consistency) stools since birth, stable
household with no plans to leave the area for the next one year
Exclusion criteria: Parents are not willing to have child vaccinated at the field clinic
or to have child’s blood drawn, parents are planning to enrol child into another clinical
study, mother not willing to have blood drawn and breast milk extracted, parents not
willing to have field research assistant in home twice a week, history of seizures or other
apparent neurologic disorders, infant received any vaccines before start of study, except
Bacillus Calmette-Guerin (BCG), infant has any sibling currently or previously enrolled
in this study (including a twin)
Interventions 1. RV1 dose 1 at 10 weeks, dose 2 at 17 weeks (350 enrolled participants)
2. No RV1 vaccine (350 enrolled participants)
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea (severe)
2. All-cause diarrhoea (severe)
3. All-cause deaths
4. Rotavirus diarrhoea (any severity)
5. All-cause diarrhoea (any severity)
6. Dropouts from the trial
Immunization status Along with Rotarix at 10 and 17 weeks of age, the polio vaccine intervention was the
administration of an injected, inactivated polio vaccine (IPV) dose replacing the fourth
dose of tOPV at 39 weeks of age. In addition to the vaccine interventions, study children
received all standard EPI vaccines through the study clinic.The national Bangladesh
ExpandedProgramon Immunizations (EPI) schedule includesBCGat birth; pentavalent
vaccine (DPT, HepB, Hib) at 6, 10, and 14 weeks; bivalent Measles-Rubella at 40 weeks;
and monovalent Measles at 65 weeks
Location Single site, Bangladesh
WHO mortality stratum D
Notes Date: May 2011 to November 2013
Source of funding: Bill and Melinda Gates Foundation
Study rationale: The primary objective was to determine the efficacy of a 2-dose Rotarix
oral rotavirus vaccine (given at 10 and 17 weeks of age) to prevent rotavirus diarrhoea
in the first year of life
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RV1 Colgate 2016-BGD (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized using permuted blocks with
random block size selection
Allocation concealment (selection bias) Low risk All clinical investigators and laboratories
were masked to vaccine arm, but medical
officers were not
Blinding (performance bias and detection
bias)
All outcomes
High risk RV1 versus no intervention, unable to
blind (no placebo)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary ITT analysis, moderate attrition.
Selective reporting (reporting bias) Low risk All relevant outcomes appear to be re-
ported, protocol published
Other bias Low risk No other bias apparent
RV1 Dennehy 2005-NA
Methods RCT
Length of follow-up: 10 to 12 months
Adverse event data collection methods: “For the 15 days after each dose of vaccine, the
parent or guardian maintained a daily record that included fever, irritability/fussiness,
diarrhoea, vomiting, loss of appetite and cough/runny nose. In addition, the parent or
guardian was asked to record any gastroenteritis episode occurring in the period from the
first dose until 2 months after the second dose of vaccine.” (passive method); “Subjects
were also monitored for any serious adverse events occurring throughout participation
in the study (10-12 months in total) and for unsolicited adverse events occurring within
43 days after each dose of vaccine or placebo” (active method)
Participants Number: 529 enrolled; 479 evaluable
Age range: 1 to 3 months (beginning)
Inclusion criteria:healthy infants aged 5 to 15weeks at the time of the first dose. Vaccine
administration delayed if acute illness present (fever > 38 °C/gastroenteritis/antibiotics
within 7 days before scheduled vaccination)
Exclusion criteria: premature labour (< 36 weeks); chronic condition; (chronic gas-
trointestinal disease, immunosuppressive diseases); household contact with immunosup-
pressed individuals/pregnant women
Interventions RV1
1. RIX4414 (RV1)
1.1. 105.2; 212 participants
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1.2. 106.4; 209 participants
2. Placebo: 108 participants
Schedule: 2 doses given 7 weeks apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: fever, irritability/fussiness, diarrhoea, vomiting, loss of appetite and
cough/runny nose; measured during 15 days post-vaccination
2. Serious adverse events
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Viral shedding: viral shedding in any stool specimen collected between first dose and
2 months after second vaccine dose (review includes after dose 2 data)
5. Seroconversion: anti-rotavirus IgA ELISA≥ 20 Units/mL in participants negative for
rotavirus antibody before the first dose of vaccine (review includes data from 2 months
after dose 2)
Immunization status Vaccine or placebo given concomitantly with diphtheria-tetanus-acellular pertussis, in-
activated poliovirus, H. influenzae type b, and Streptococcus pneumoniae conjugate vac-
cines for participants in USA or with a diphtheria-tetanus-acellular pertussis/inactivated
poliovirus/H. influenza type b combination vaccine for participants in Canada
“Routine hepatitis B vaccinations were administered according to local practice”
Location 41 centres in USA and Canada
WHO mortality stratum A
Notes Date: 13 December 2000 to 2 August 2002
Source of funding: GlaxoSmithKline Biologicals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Quote: “double blind randomized unbal-
anced allocation scheme (2:2:1 ratio)”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel; Quote:
“Study personnel and families were blinded
to group assignment until study comple-
tion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Quote: “Fifty-nine subjects, who were pro-
portionately distributed among vaccine
groups, did not complete the entire 10- to
12-month study”
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Selective reporting (reporting bias) Unclear risk No details
Other bias Unclear risk No details
RV1 GSK[021] 2007-PAN
Methods RCT
Length of follow-up: 1 month after dose 3
Adverse event data collection methods: not reported
Participants Number: 228 enrolled; 203 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 12 weeks of age at the time of the first dose of the study vaccination course; free
of obvious health problems as established by medical history and clinical examination
before entering into study
Exclusion criteria: any clinically significant history of chronic gastrointestinal disease
including any uncorrected congenital malformation of the gastrointestinal tract or other
serious medical condition as determined by the investigator and previous confirmed
occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU*; 177 participants (randomized)
1.1 Received modified vaccine formulation
1.2 Received a licensed RV1 vaccine
*Dose unclear; in the same study, some use 106.5 PFU and some 105 PFU
2. Placebo: 51 participants (randomized)
2.1 Received a placebo of the modified vaccine formulation
2.2 Received a placebo of the licensed RV1 vaccine
Schedule: 3 doses at 2, 4, and 6 months of age
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 31
days after vaccine/placebo
3. Dropouts: measured up to 31 days after vaccine/placebo
4. All-cause death
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Viral shedding: number (%) of participants with rotavirus in at least 1 stool (review
includes data from combined time points)
7. Seroconversion: appearance of anti-rotavirus antibody concentration ≥ 20 U/mL
in participants negative for rotavirus before vaccination (review includes data from 2
months after dose 1 and 2 months after dose 2, and 1 month after dose 3)
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Immunization status Use of other vaccines not mentioned
Location 1 centre in Panama
WHO mortality stratum B
Notes Date: 23 August 2002 to 9 May 2003
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to compare the immunogenicity and safety of a modified vaccine
formulation to the licensed human rotavirus [Rotarix] vaccine”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk 203/228 participants completed the study.
Reasons for withdrawal were reported and
balanced between groups
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No details
RV1 GSK[033] 2007-LA
Methods RCT
Length of follow-up: 1 month after dose 2
Adverse event data collection methods: not reported
Participants Number: 854 enrolled; 795 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 12 weeks of age at the time of the first dose of the study vaccination course, free
of obvious health problems as established by medical history and clinical examination
before entering into the study
Exclusion criteria: any clinically significant history of chronic gastrointestinal disease
including any uncorrected congenital malformation of the gastrointestinal tract or other
serious medical condition as determined by the investigator and previous confirmed
occurrence of rotavirus gastroenteritis
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Interventions RV1
1. RIX4414 (RV1): 106.5 PFU*; 730 participants (randomized)
1.1. Received RV1 vaccine Lot A
1.2. Received RV1 vaccine Lot B
1.3. Received RV1 vaccine Lot C
*Dose unclear, some use 106.5 PFU and some 105 PFU
2. Placebo: 124 participants (randomized)
Schedule: 2 oral doses given at 2 and 4 months; visits 1, 2, and 3 correspond to months
0, 2, and 4 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 31
days after vaccine/placebo
3. Dropouts: measured up to 31 days after vaccine/placebo
4. All-cause death
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Vaccine virus shedding: presence of rotavirus antigen in stool samples collected on
day of vaccination and on planned days following each dose in a subset of participants
[review includes data from combined time points]
7. Seroconversion: appearance of serum anti-rotavirus IgA antibody concentrations ≥
20 U/mL [review includes data from 2 months after dose 2]
Immunization status Use of other vaccines not mentioned
Location 7 study centres (2 in Colombia, 1 in Mexico, and 4 in Peru)
WHO mortality strata B, D
Notes Date: 8 August 2003 to 29 January 2004
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess the clinical consistency of 3 production lots of human ro-
tavirus vaccine in terms of immunogenicity and safety when given to healthy infants at
2 and 4 months of age”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
82Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV1 GSK[033] 2007-LA (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk 795/854 completed the study. Reasons for
dropping out were reported and were bal-
anced between study groups
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No details
RV1 GSK[041] 2007-KOR
Methods RCT
Length of follow-up: 2 months after dose 2
Adverse event data collection methods: not reported
Participants Number: 155 enrolled; 151 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: full-term infants; healthy infants aged between 6 and 12 weeks (42
to 90 days) at the time of the first vaccination for whom the vaccination history was
available
Exclusion criteria: previous confirmed occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 103 participants (randomized)
2. Placebo: 52 participants (randomized)
Schedule: 2 oral doses starting at about 2 months of age; second dose at 4 months of
age
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (days 0 to 14) solicited follow-up period after each dose; occurrence of
unsolicited adverse events within 43 days (days 0 to 42) after each dose, according to
MedDRA classification; up to 43 days after vaccine/placebo
2. Serious adverse events: no definition; occurrence throughout the entire study period
(up to 2 months after dose 2)
3. Dropouts: measured up to 2 months after dose 2
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of vaccine/placebo up to 2 months after dose 2
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Seroconversion: appearance of anti-rotavirus immunoglobulin A antibody concentra-
tion 20 U/mL in participants who were seronegative before vaccination (review includes
data from 2 months after dose 2)
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Immunization status H. influenzae type b vaccine administered concomitantly along with the 2 doses of
vaccine/placebo and at 2 months after dose 2; other routine childhood vaccines were to
be given at least 14 days before trial vaccine/placebo
Location 6 centres in Korea
WHO mortality stratum B
Notes Date: 15 July 2005 to 11 May 2006
Registration number: NCT00134732
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess immunogenicity and safety of 2 doses of the HRV [human
rotavirus] vaccine in Korean infants aged approximately 2 months at the time of the first
dose”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/103 participants in the vaccine arm did
not complete the study
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No details
RV1 GSK[101555] 2008-PHL
Methods RCT
Length of follow-up: outcomes measured 1 month after last dose of vaccine/placebo
Adverse event data collection methods: not reported
Participants Number: 150 enrolled; 145 evaluable
Age range: 6 to 12 weeks
Inclusion criteria: healthy, full-term infants aged 6 to 12 weeks; male or female infants
between, and including, 6 and 12 weeks of age at the time of the first vaccination, free
of obvious health problems, born after a normal gestation period (between 36 and 42
weeks) or with a birth weight > 2000 g
Exclusion criteria: infants with previous confirmed occurrence of rotavirus gastroen-
teritis
84Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV1 GSK[101555] 2008-PHL (Continued)
Interventions RV1
1. RIX4414 (RV1): 106.5; 100 participants*
1.1 Licensed formulation
1.2 Lyophilized formulation
2. Placebo: 50 participants*
2.1 Normal placebo
2.2 Lyophilized formulation
Schedule: 2 doses starting at 6-12 weeks of age according to a 0, 2 month schedule
*Data from the lyophilized formulation, which is not yet approved or marketed, are not
reported in review
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (day 0 to 14) solicited follow-up period after each dose; occurrence of un-
solicited adverse events within 31 (day 0 to 30) days after any doses of RV1 vaccine or
placebo, according to MedDRA classification
2. Serious adverse events: occurrence throughout entire study period (up to 31 days after
final dose of vaccine/placebo)
3. Dropouts: measured up to 31 days after final dose of vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis stools collected until 1
month after dose 2
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Vaccine viral shedding in stool (review includes data from combined time points)
8. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL
in participants initially (i.e. before first dose of vaccine/placebo) negative for rotavirus
(review includes data from 2 months after dose 1, 1 month after dose 2, and combined
dose 1 and 2 at 1 month after dose 2)
Immunization status Use of other vaccines not mentioned
Location 1 study centre in the Philippines
WHO mortality stratum B
Notes Date: 11 May 2004 to 13 September 2004
Source of funding: GlaxoSmithKline Biologicals
Trial objective: “To assess the immunogenicity and safety of 2 different formulations of
live attenuated HRV [human rotavirus] vaccine given as a two-dose primary vaccination
in healthy infants previously uninfected with HRV”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The ATP cohort for immuno-
genicity included all vaccinated subjects: -
who had received at least one dose of study
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vaccine/control according to their random
assignment, - for whom the randomization
code had not been broken”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details; Quote: “Double-blind with re-
spect to each HRV [RV1] vaccine formu-
lation and its respective placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/100 participants withdrawn from the
vaccine group
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No details
RV1 Kawamura 2011-JPN
Methods RCT
Length of follow-up: up to the age of 2 years
Adverse event data collection methods: not reported
Participants Number: 765
Age range: 6 to 14 weeks
Inclusion criteria: full-term healthy infants aged 6 to 14 weeks at the time of the first
dose
Exclusion criteria: use of any other investigational or non-registered product (drug or
vaccine) within 30 days preceding the first dose of human rotavirus vaccine; history of
use of experimental rotavirus vaccine; chronic administration of immunosuppressants
or other immune-modifying drugs since birth; concurrently participating in another
clinical study; any clinically significant history of a serious medical condition; previous
confirmed occurrence of rotavirus gastroenteritis
Interventions 1. RV1, 508 participants
2. Placebo, 257 participants
Schedule: 2 doses according to a 0-, 1-month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Any rotavirus gastroenteritis leading to medical intervention and caused by the circu-
lating wild-type rotavirus strains, from 2 weeks after dose 2 up to 2 years of age, stool
sample collected as soon as possible but preferably not later than 7 days after the start of
the episode
2. Severe rotavirus gastroenteritis (≥ 11 on the Vesikari scale) leading to a medical
intervention and caused by the circulating wild-type rotavirus strains (a) of G1 type, (b)
of non-G1 types, from 2 weeks after dose 2 up to 2 years of age
3. Each type of solicited symptom (including: cough, diarrhoea, fever, irritability, loss of
appetite and vomiting) during the 8-day follow-up period after each dose
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4. Adverse events leading to discontinuation of the trial
5. Serious adverse events, including intussusception, up to 2 years of age
6. Fatal serious adverse events
7. Dropouts before the end of the trial
Outcomes to measure immunogenicity
8. Seroconversion in terms of anti-rotavirus IgA antibody, from 2 months after dose
2. Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A
antibody concentration over 20 units (U)/millilitre (mL) in infants initially (i.e. prior to
the first dose of RV1) seronegative
Immunization status Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis
B (HBV) vaccines were allowed to be co-administered along with RV1 vaccine/placebo
Location Japan
WHO mortality stratum A
Notes Date: June 2007 to November 2009
Source of funding: GlaxoSmithKline
Registration number: NCT00480324
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Low risk Protocol published a priori, all prepub-
lished outcomes reported
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: 2 months post-dose 2
Adverse event data collection methods: passive; “Diary cards were provided to the
parents/guardians of infants to record the solicited general symptoms occurring during
the 15 day follow up period after each vaccine dose. The solicited general symptoms
were loss of appetite, fussiness/irritability, fever, diarrhoea, vomiting and cough/runny
nose. The intensity of each of these symptoms was graded on a 3-point scale where “0”
indicates normal and “3” indicates severe”
Participants Number: 450 enrolled; ATP safety cohort: 447; ATP immunogenicity cohort: 339
Inclusion criteria: healthy infants aged 6 to 12 weeks at the time of the first vaccination
Exclusion criteria: any other investigational drug or vaccine; a history of gastrointestinal
disease or rotavirus gastroenteritis; allergy to any of the vaccine components; a history
of immunosuppressive or immunodeficient condition
Interventions 1. RIX4414* vaccine reconstituted in buffer stored at 2 °C - 8 °C, n = 174
2. RIX4414* vaccine reconstituted in water stored at 2° C - 8 °C, n = 174
3. RIX4414* vaccine reconstituted in buffer stored at 37 °C for 7 days, n = 50
4. Placebo reconstituted in buffer, n = 26
5. Placebo reconstituted in water, n = 26
* Lyophilized formulation containing at least 106.0 CCID50 of the RIX4414 strain
Schedule: 2 doses at month 0 and 2
Outcomes Clinical outcome measures
1. * Rotavirus diarrhoea, stool sample collected during diarrhoea episode, up to 2months
post-dose 2
2. * All-cause diarrhoea, up to 2 months post-dose 2
3. Reactogenicity, including fever, vomiting and diarrhoea, 15-day follow-up period after
each dose (collected from GSK report)
4. Serious adverse events, up to 2 months post-dose 2
5. Fatal serious adverse events
6. Adverse events resulting in discontinuation (collected from GSK report)
7. Dropouts: measured up to 2 months after dose 2 (collected from GSK report)
Outcomes to measure immunogenicity
8. Seroconversion, anti-rotavirus IgA antibody levels (cut off: ≥ 20 U/mL by ELISA ),
2 months post-dose 2
9. Rotavirus antigen shedding in stool (review includes data from combined time points)
(collected from GSK report)
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
estimated by using the values when 2 formulae for the standard error (SE) converged
Immunization status “During the study period, participating infants were offered commercially available GSK
Biologicals’ diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated polio and
H. influenzae type b combination vaccine (InfanrixTM -IPV/Hib) at two and fourmonths
of age and diphtheria toxoid, tetanus toxoid, acellular pertussis, hepatitis B, inactivated
polio and H. influenzae type b combination vaccine (Infanrix hexaT M ) at six months of
age”
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Location 2 centres in Thailand
WHO mortality stratum B
Notes Study known as RIX GSK[039] 2007-AS, in previously published versions of this review
Date: March to December 2005
Source of funding: GSK Biologicals
Study rationale: This study evaluated the stability of lyophilized RIX4414 vaccine in
terms of immunogenicity when reconstituted in water instead of regular buffer, and
when stored at tropical room temperature (37 °C) for 7 days before reconstitution
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
High risk Partially blind study. Quote: “Single
blind”, not reported whether personnel or
participants were blinded
Quote: “The placebo was identical in ap-
pearance and composition to the active vac-
cine”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons for withdrawal reported
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No apparent other bias
RV1 Kim 2012-KOR
Methods RCT
Length of follow-up: 1 month post-dose 2
Adverse event data collection methods: Passive: Adverse events were recorded during
the 8-day and 31-day follow-up period after each dose of RIX4414/placebo, respectively.
SAEs were recorded during the entire study period
Participants Number: 684 enrolled; 642 evaluable
Age range: 6 to 12 weeks
Inclusion criteria: Infants who the investigator believes that their parents/guardians can
and will comply with the requirements of the protocol should be enrolled in the study:
male or female between, and including, 6 to 12 weeks of age at the time of the first
dose of the vaccination, healthy infants as established by medical history and clinical
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examination, born after a normal gestation period of between 37 and 41 weeks + 6 days
inclusive, available vaccination history from vaccination diary cards or medical charts
Exclusion criteria: Use of any investigational or non-registered product (drug or vac-
cine) other than the study vaccine(s) within 30 days preceding the dose of study vac-
cine, or planned use during the study period, chronic administration (defined as more
than 14 days) of immunosuppressants or other immune-modifying drugs since birth,
planned administration/ administration of a vaccine not foreseen by the study protocol
within 30 days of the first dose of vaccine, with the exception of the routine infant vac-
cines, concurrently participating in another clinical study, confirmed or suspected im-
munosuppressive or immunodeficient condition, clinically significant history of chronic
gastrointestinal disease including any uncorrected congenital malformation of the gas-
trointestinal tract or other serious medical condition as determined by the investigator,
history of allergic disease or reactions likely to be exacerbated by any component of the
vaccine, acute disease at the time of enrolment, administration of immunoglobulins or
any blood products, or both, since birth or planned administration during the study
period, gastroenteritis (GE) within 7 days preceding the study vaccine administration,
previous confirmed occurrence of RV GE, previous vaccination with rotavirus vaccine
or planned use during the study period
Interventions 1. RV1
2. Placebo
Schedule: 2 oral doses according to a 0-, 1-, or 2-month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause deaths
2. All serious adverse events
3. Serious adverse events: intussusception
4. Rotavirus diarrhoea: of any severity (up to 2 months follow-up)
5. All-cause diarrhoea: of any severity (up to 2 months follow-up)
6. Reactogenicity: vomiting, diarrhoea, fever
7. Adverse events requiring discontinuation
8. Dropouts from the trial
Outcomes to measure immunogenicity
9. Seroconversion
Immunization status Routine childhood vaccines as recommended by the local vaccination schedule were
allowed to be administered concomitantly with RIX4414/placebo. These vaccines in-
cluded the combined diphtheria-tetanus-acellular pertussis vaccine,Haemophilus influen-
zae type b vaccine, inactivated poliovirus vaccine and pneumococcal vaccine. The infants
had received the BCG vaccine and 2 doses of hepatitis B vaccine prior to study enrolment
Location 19 sites, Republic of Korea
WHO mortality stratum B
Notes Date: August 2009 to July 2010
Source of funding: GlaxoSmithKline
Study rationale: To evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™
Vaccine in Korean Infants
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All infants receiving RIX4414 or
placebo were allocated into their respective
groups using an internet based randomiza-
tion tool SBIR (Internet based randomiza-
tion system) according to 3:1 ratio”
Quote: “A standard SAS® program gener-
ated a randomization list used to number
the vaccines. A randomized (3:1) blocking
scheme maintained the balance between
the two treatments where a unique treat-
ment number identified the study vaccine
to be administered to the infants.”
Allocation concealment (selection bias) Low risk The person in charge of the vaccination ac-
cessed the randomization system on Inter-
net. Upon providing a participant number
and the age (6 - 12weeks) for the infant, the
randomization system used the minimiza-
tion algorithm to determine the treatment
number to be used for the participant.
The actual treatment number used for first
vaccination of the participant was recorded
by the investigator in the eCRF (Randomi-
sation/Treatment Allocation Section)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Each dose of RIX4414 or placebo
was administered in a blinded manner
where the parents/guardians and the physi-
cians were unaware of the vaccine admin-
istered”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 462/684 completed the study, reasons for
attrition provided
Selective reporting (reporting bias) Low risk No indication of selective reporting bias
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: 1 month
Adverse event data collection methods: Passive: diary cards were provided to partici-
pants or their parents/guardians to record solicited adverse events for 8 days after each
vaccination (day 0 - 7). Serious adverse events were recorded for the duration of the study
Participants Number: 50 enrolled; 50 evaluable
Age range: 2 to 6 years old
Inclusion criteria: participants were required to be of Chinese origin, in good health
and free of obvious health problems
Interventions 1. single dose of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine
(444563). Each 1.5ml dose of the liquid humanRV vaccine contained at least (CCID50)
of the live attenuated RIX4414 human RV strain
2. single dose placebo
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
Immunization status Children were allowed to receive routine childhood vaccinations according to local im-
munization practice during the study period, with a minimum interval of at least 7 days
between the administration of routine vaccines and the study vaccine or placebo
Location Single site, China
WHO mortality stratum B
Notes Date: March 2010 to April 2010
Source of funding: GlaxoSmithKline
Study rationale:To assess the safety of a single oral dose of HRV vaccine when compared
to placebo group, in terms of solicited adverse events (AEs) in healthy children aged 2
to 6 years
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment allocation at the investigator site
was performed using an internet-based ran-
domization system (SBIR)
Allocation concealment (selection bias) Low risk Treatment allocation at the investigator site
was performed using an internet-based ran-
domization system (SBIR)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was conducted in a double-blind
manner with respect to HRV vaccine and
placebo. The parents/LARs of the infants,
the study personnel and the investigator
were unaware of the study vaccine admin-
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RV1 Li 2013a-CHN (Continued)
istered (liquid HRV vaccine or placebo).
The laboratory in charge of the laboratory
testing was blinded to the treatment, and
codes were used to link the participant and
study (without any link to the treatment
attributed to the participant) to each sam-
ple
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk Planned outcomes fully reported
Other bias Low risk No apparent other bias
RV1 Li 2013b-CHN
Methods RCT
Length of follow-up: 1 month after second dose
Adverse event data collection methods: Passive: diary cards were provided to partici-
pants or their parents/guardians to record solicited adverse events for 8 days after each
vaccination (day 0 - 7). Serious adverse events were recorded for the duration of the study
Participants Number: 50 enrolled; 50 evaluable
Age range: 6 to 16 weeks
Inclusion criteria: Infants were required to be aged 6 - 16 weeks at the time of first
vaccination. Participants were required to be of Chinese origin, in good health and free
of obvious health problems
Interventions 1. RV1, each 1.5 ml dose of the liquid HRV vaccine contained at least 106.0 median
cell culture infective dose (CCID50) of the live attenuated RIX4414 human RV strain
2. Placebo
Schedule: 2 oral doses according to a 0-, 1-month schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause deaths
2. Serious adverse events
3. Intussusception
4. Reactognicity: fever, diarrhoea, vomiting
5. Dropouts before the end of the trial
6. Adverse event requiring discontinuation
Outcomes to measure immunogenicity
7. Vaccine shedding
8. Seroconversion
Immunization status Infants were allowed to receive routine childhood vaccinations according to local im-
munization practice during the study period, with a minimum interval of at least 7 days
between the administration of routine vaccines and the study vaccine or placebo
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Location Single site, China
WHO mortality stratum B
Notes Date: April to June 2010
Source of funding: GlaxoSmithKline
Study rationale:To assess the safety of a single oral dose of HRV vaccine when compared
to placebo group, in terms of solicited adverse events (AEs) in healthy infants aged 6-16
months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment allocation at the investigator site
was performed using an internet-based ran-
domization system (SBIR)
Allocation concealment (selection bias) Low risk Treatment allocation at the investigator site
was performed using an internet-based ran-
domization system (SBIR)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was conducted in a double-blind
manner with respect to HRV vaccine and
placebo. The parents/LARs of the infants,
the study personnel and the investigator
were unaware of the study vaccine admin-
istered (liquid HRV vaccine or placebo).
The laboratory in charge of the laboratory
testing was blinded to the treatment, and
codes were used to link the participant and
study (without any link to the treatment
attributed to the participant) to each sam-
ple
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk Planned outcomes fully reported
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: 2 years
Adverse event data collectionmethods: (not reported if active or passive) serious adverse
events were recorded throughout the study period
Participants Number: 3333 enrolled; 3148 evaluable
Age range: 6 to 16 weeks
Inclusion criteria: participants who the investigator believes that their parents/LARs
can and will comply with the requirements of the protocol, male or female infant of
Chinese origin between, and including, 6 and 16 weeks of age at the time of the first
vaccination, healthy infants as established by medical history and clinical examination
before entering into the study, born after a gestation period of 36 to 42 weeks inclusive
Exclusion criteria: child in care; use of any investigational or non-registered product
other than the study vaccine within 30 days preceding the first dose of study vaccine, or
planned use during the study period; any clinically significant history of gastrointestinal
disease; any confirmed or suspected immunosuppressive or immunodeficient condition;
history of confirmed rotavirus gastroenteritis; acute disease and/or fever at the time of
enrolment; gastroenteritis within 7 days preceding the study vaccine or placebo admin-
istration
Interventions 2 cohorts
1. 1st RV season RIX4414 (1575 participants) or placebo (1573 participants)
2. 2nd RV season RIX4414 (1500 participants) or placebo (1479 participants)
Schedule: 2 doses of Rotarix™ vaccine, liquid formulation, at day 0 and at month 1
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea, severe and any severity
2. Rotavirus diarrhoea, severe and any severity
3. Rotavirus diarrhoea requiring hospitalization
4. All-cause mortality
5. Serious adverse events
6. Intussusception
7. Reactogenicity: fever, diarrhoea, vomiting
8. Adverse events requiring discontinuation
9. Dropouts before end of the trial
Outcomes to measure immunogenicity
10. Seroconversion
Immunization status As part of the routine childhood vaccination according to the Expanded Program of
Immunization (EPI) recommendations in China, participants also received 3 doses of
Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the In-
stitute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The
Infanrix™ and the OPV vaccines were administered independently of (sub-cohort 1)
or concomitantly with (sub-cohort 2) the Rotarix™ vaccine. When administered con-
comitantly, participants received the 3 doses of Infanrix™ vaccine at months 1, 2, and
3, and the 3 doses of the OPV vaccine at day 0, month 1 and month 2. The Rotarix™
and OPV vaccines were administered orally; the Infanrix™ vaccine was administered
intramuscularly in the left anterolateral thigh
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Location 4 sites, China
WHO mortality stratum B
Notes Date: August 2010 to May 2012
Source of funding: GlaxoSmithKline
Study rationale: The aim of this study was to assess the efficacy, immunogenicity and
safety of two doses of GSK Biologicals’ HRV vaccine in healthy Chinese infants aged
between 6 and 16 weeks at the time of the first dose of vaccination
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization sequence generated using
software (MATEX developed for SAS)
Allocation concealment (selection bias) Low risk Treatment allocation at the investigator site
was performed using SBIR (internet ran-
domization tool)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Concealed from parents/guardians, study
personnel, and investigators, placebo-con-
trolled study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition provided
Selective reporting (reporting bias) Low risk Planned outcomes fully reported
Other bias Low risk No apparent other bias
RV1 Madhi 2010-AF
Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at 2 years
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 4939 enrolled; 4417 evaluable
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
Exclusion criteria: children HIV-positive that were immunosuppressed at < 6 weeks
before vaccination
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Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 3298 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 1641 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an enzyme-
linked immunosorbent assay (ELISA) (Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more *
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Programme on Immunization (EPI) were concomitantly administered with the vaccine
or placebo, including oral polio vaccine
Location South Africa and Malawi
WHO mortality stratum E
Notes This trial was conducted in Malawi and South Africa, with data reported separately by
country available under RV1 Madhi 2010-MWI and RV1 Madhi 2010-ZAF
Date: October 2005 to February 2007 (South Africa); October 2006 to July 2007
(Malawi)
Source of funding: PATH Rotavirus Vaccine Programme and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk A randomization list was generated at GSK
Biologicals, Rixensart, using a standard
SAS® (Statistical Analysis System) pro-
gramme and this was used to number the
vaccines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator was unaware of the
group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk No apparent other bias
RV1 Madhi 2010-MWI
Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at 2 years
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 1773 enrolled
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
Exclusion criteria: children HIV-positive that were immunosuppressed at < 6 weeks
before vaccination
Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 1182 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 591 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
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2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an ELISA
(Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more*
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Programme on Immunization (EPI) were concomitantly administered with the vaccine
or placebo, including oral polio vaccine
Location Malawi
WHO mortality stratum E
Notes This trial was conducted in Malawi and South Africa. This part presents data reported
for the Malawi cohort, while data reported for South Africa can be found under RV1
Madhi 2010-ZAF, data reported for both countries under RV1 Madhi 2010-AF
Date: October 2006 to July 2007
Source of funding: PATH Rotavirus Vaccine Programme and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomization list was generated at GSK
Biologicals, Rixensart, using a standard
SAS® (Statistical Analysis System) pro-
gram and this was used to number the vac-
cines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
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Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator was unaware of the
group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk No apparent other bias
RV1 Madhi 2010-ZAF
Methods RCT
Length of follow-up: outcomes measured 2 weeks after last dose to 1 year of age, and
at 2 years (only Cohort 2)
Adverse event data collection methods: active surveillance for all gastroenteritis
episodes was conducted by members of the study staff through weekly visits to parents
or guardians to collect diary cards and through the collection of data from health clinics
that served the study populations
Participants Number: 3166 enrolled
Age range: 1 to 6 months
Inclusion criteria: healthy infants aged 6 to 10 weeks for the group receiving 3 doses
and 10 to 14 weeks for the group receiving 2 doses of RV1
Exclusion criteria: children HIV-positive that were immunosuppressed at < 6 weeks
before vaccination
Interventions RV1
1. RIX4414 (RV1): dose same as commercial; 2116 participants
1.1 2 doses
1.2 3 doses
2. Placebo: 1050 participants
2.1 Normal placebo
Schedule: 2 to 3 doses given 1 month apart
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea
2. Rotavirus diarrhoea: stool samples were tested for rotavirus with the use of an ELISA
(Rotaclone, Meridian Bioscience)
3. Severe rotavirus diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more*
4. Severe all-cause diarrhoea: the severity of each episode of gastroenteritis was evaluated
with the use of the Vesikari scale 13 (on which scores range from 1 to 20, with higher
scores indicating greater severity) and was categorized as severe if the score was 11 or
more
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5. All-cause mortality: all serious adverse events including deaths were recorded for the
period between the date the first dose of vaccine or placebo was administered and the
date the child reached 1 year of age
6. Serious adverse events: all serious adverse events including deaths were recorded for
the period between the date the first dose of vaccine or placebo was administered and
the date the child reached 1 year of age
Outcomes to measure immunogenicity
7. Immunogenicity: ELISA - 1 month after the last dose to determine the serum con-
centrations of antirotavirus IgA antibody
*G types for severe rotavirus diarrhoea for the first year follow-up were reported and
added to the analyses, G types for any rotavirus diarrhoea were reported for the second
year only, and were not added to the analysis
Immunization status Vaccines that are administered routinely according to the guidelines of the Expanded
Programme on Immunization (EPI) were concomitantly administered with the vaccine
or placebo, including oral polio vaccine
Location South Africa
WHO mortality stratum E
Notes This trial was conducted in Malawi and South Africa. This part presents data reported
for the South Africa cohorts, data reported for Malawi can be found under RV1 Madhi
2010-MWI, and data reported for both countries under RV1 Madhi 2010-AF
Date: October 2005 to February 2007
Source of funding: PATH Rotavirus Vaccine Programme and GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomization list was generated at GSK
Biologicals, Rixensart, using a standard
SAS® (Statistical Analysis System) pro-
gram and this was used to number the vac-
cines
Allocation concealment (selection bias) Low risk The vaccine doses were distributed to each
study centre while respecting the random-
izations block size
Blinding (performance bias and detection
bias)
All outcomes
Low risk The site investigator was unaware of the
group assignments of the children
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk All expected outcomes reported
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Other bias Low risk No apparent other bias
RV1 Narang 2009-IND
Methods RCT
Length of follow-up: 1 month after dose 2
Adverse event data collection methods: passive, parents/guardians filled in diary cards
of any symptoms
Participants Number: 363 enrolled; 344 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy male or female infants between and including 8 to 10 weeks
of age at the time of first vaccination; free of obvious health problems as established by
medical history and clinical examination before entering into the study;
Exclusion criteria: history of confirmed rotavirus gastroenteritis or with prior adminis-
tration of experimental rotavirus vaccine
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 182 participants (randomized)
2. Placebo: 181 participants (randomized)
Schedule: 2 oral doses given at age 2 and 4 months
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (days 0 to 7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (days 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: no definition; occurrence throughout entire study period (up
to 31 days after vaccine/placebo)
3. Dropouts: no definition; measured up to 31 days after vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of RV1 vaccine/placebo up to 2 months after dose 2; measured up to 31
days after vaccine/placebo
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Seroconversion: appearance of anti-rotavirus immunoglobulin A (IgA) antibody con-
centration≥ 20 U/mL in participants who were seronegative before vaccination (review
includes data from 1 month after dose 2)
Immunization status Routine vaccinations (diphtheria-tetanus-whole cell pertussis-hepatitis b, H. influenzae
type b, and oral poliovirus vaccine) were administered at 6, 10, and 14 weeks of age
(given with a 2-week separation from the first and subsequent dose of the RV1 vaccine
or placebo)
Location 4 centres in India
WHO mortality stratum D
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Notes Date: 10 February 2006 to 8 September 2006
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to assess the immunogenicity and safety of 2 doses of oral live atten-
uated human rotavirus vaccine in healthy infants in India”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “a treatment number identified
uniquely the vaccine doses to be admin-
istered to the same subject” and “subjects
were administered the vaccine dosewith the
lowest treatment number available at the
study centre”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Low risk No apparent other bias
RV1 NCT00158756-RUS
Methods RCT
Length of follow-up: 1 year
Adverse event data collection methods: Not reported
Participants Number: 308 enrolled; 209 evaluated (1 study arm was not included in analyses of this
review)
Age range: 11 to 17 weeks of age at the time of the first vaccination
Inclusion criteria: infants who the investigator believes that their parent/guardian can
and will comply with the requirements of the protocol, administration of 1 dose of
hepatitis B vaccine at birth, male or female between and including 11 and 17 weeks
of age at the time of the first DTPw vaccination, free of obvious health problems as
established by medical history and clinical examination before entering into the study
Exclusion criteria: use of any investigational or non-registered product (drug or vaccine)
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other than the study vaccine(s) within 30 days preceding the first dose of study vaccine,
or planned use during the study period, chronic administration of immunosuppressants
or other immune-modifying drugs since birth, any confirmed or suspected immuno-
suppressive or immunodeficient condition based on medical history and physical exam-
ination (no laboratory testing is required), administration of immunoglobulins or any
blood products, or both, since birth or planned administration during the study period
Interventions 1. RV1 at 3 and 4½ months + DTPw-HBV at 3, 4½ and 6 months (80 participants)
2. Placebo at 3 and 4½ months + DTPw-HBV at 3, 4½ and 6 months (25 participants)
3. RV1 at 3 and 4½months + DTPw-HBV Kft. at 3, 4½ and 6months (81 participants)
4. Placebo at 3 and 4½ months + DTPw-HBV Kft. at 3, 4½ and 6 months (23 partici-
pants)
5. DTPwcsl +HBV at 3, 4½ and 6months (99 participants), this group was not included
in analyses of this review
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity
2. Serious adverse events
3. All-cause death
4. Intussusception
5. Dropouts
Outcomes to measure immunogenicity
6. Seroconversion
Immunization status GlaxoSmithKline (GSK) Biologicals’ Tritanrix™HepB and GSK Biologicals Kft’s DT-
PwHBV Vaccines as compared to concomitant administration of Commonwealth
Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (En-
gerix™B), when co-administered with GSK Biologicals’ oral live attenuated Human
Rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth
dose of Hepatitis B vaccine
Location 9 sites, Russian Federation
WHO mortality strata: C
Notes Date: September 2005 to November 2006
Source of funding: GlaxoSmithKline
Study rationale: To compare the 2 formulations of GSK Biologicals’ DTPw-HBV vac-
cine to concomitant administration of CSL’s DTPw vaccine and GSK Biologicals’ HBV
with respect to the antibody response to the diphtheria antigen after a 3-dose primary
vaccination course
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized (4:1:4:1:5) using GSK Bi-
ologicals central randomization system
(SBIR)
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Allocation concealment (selection bias) Low risk Cental allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was conducted in a double-blind
manner with respect to the Rotarix and
placebo groups and in single-blinded man-
ner with respect to the Tritanrix-HepB and
Zilbrix groups. The study was open with
respect to the Triple Antigen + Engerix-B
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No apparent other bias
RV1 Omenaca 2012-EU
Methods RCT
Length of follow-up: 30 to 83 days after dose 2
Adverse events data collection methods: active surveillance: at each study visit parents
were asked about AEs; passive surveillance: throughout the trial, parents were asked to
immediately report AEs to the investigator
Participants Number: 1009
Age range: 6 to 12 weeks of age at the time of the first study vaccination
Inclusion criteria: medically stable pre-term infants, born within a gestational period
of 27 - 36 weeks, planned to be discharged from hospital’s neonatal stay on or before the
day of the first human rotavirus vaccine/placebo administration
Exclusion criteria: use of any investigational or non-registered product (drug or vaccine)
other than the human rotavirus vaccine within 30 days preceding the first dose of human
rotavirus vaccine; any clinically significant history of chronic gastrointestinal disease; any
confirmed or suspected immunosuppressive or immunodeficient condition; history of
allergic disease; major congenital defects or serious chronic illness
Each study group is further stratified into 2 subgroups depending on the gestational
age at birth of the participant: Stratum I: very pre-term infants, born after a gestational
period of 27 to 30 weeks (189 to 216 days) (20% of enrolment);
Stratum II: mild pre-term infants born after a gestational period of 31 to 36 weeks (217
to 258 days) (80% of enrolment)
Interventions 1. RV1, 670 participants
2. Placebo, 339 participants
Schedule: 2 oral doses of vaccine or placebo, 1 dose at day 0 and 1 dose at months 1 or
2, depending on the country
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Outcomes Clinical outcome measures
1. Serious adverse events, including fatal events and intussusception, from day 0 up to
83 days after dose 2 of RV1 vaccine/placebo
2. Solicited symptoms, within 15 days after each RV1 vaccine/placebo dose. Solicited
symptoms included diarrhoea (3 or more looser than normal stools/day), fever (axillary
temperature over 37.5 °C), irritability, loss of appetite, and vomiting
3. All-cause gastroenteritis and rotavirus gastroenteritis, from dose 1 up to 83 days after
dose 2 of RV1 vaccine/placebo. Gastroenteritis: diarrhoea with or without vomiting.
Rotavirus gastroenteritis: a gastroenteritis episode was a rotavirus gastroenteritis episode
if a stool sample taken during or not later than 7 days after the episode was rotavirus
positive by ELISA
4. Dropouts before the end of the trial
Outcomes to measure immunogenicity
5. Seroconversion to anti-rotavirus IgA antibody, at Visit 3, 1month after Dose 2 of RV1
vaccine/placebo. Number of participants with anti-rotavirus IgA antibody concentration
over 20 units/mL
Immunization status In accordance with the local National Plan of Immunisation schedule in each of the
respective participating countries, GSK Biologicals’ Infanrix Hexa® (DTPa-HBV-IPV/
Hib), InfanrixQuinta® (DTPa-IPV-Hib), Infanrix®+IPV+Hib (DTPa+IPV+Hib) and/
or Engerix-B® (HBV) will be co-administered (at a maximum interval of 2 days from
each other) with each human rotavirus vaccine or placebo dose
Hepatitis B and BCG vaccines at birth are allowed if included in the local National Plan
of Immunisation schedule in participating countries
At the discretion of the investigator the following vaccines may be administered during
each infant’s study participation:
• Vaccine against S. pneumoniae (Prevenar®) in France and Spain (concomitantly
with human rotavirus vaccine/placebo).
• Vaccine against Neisseria meningitidis (Neis Vacc C®) is allowed if there is at least
a 14-day interval with respect to the administration of the human rotavirus vaccine/
placebo
Location France, Poland, Portugal, Spain
WHO mortality strata A, B
Notes Study known as RV1 NCT00420745 2009-EU in previously published versions of this
review
Date: January 2007 to March 2008
Source of funding: GlaxoSmithKline
Registration number: NCT00420745
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomiza-
tions
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RV1 Omenaca 2012-EU (Continued)
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced between groups
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Low risk No apparent other bias
RV1 Phua 2005-SGP
Methods RCT
Length of follow-up: until infants aged 18 months (i.e. about 13 to 15 months of
follow-up)
Adverse events data collection methods: “diary cards during a 15-day follow-up period
after each vaccine dose was administered, and the symptoms were graded according to
severity. AEs occurring up to 42 days after administration of each study vaccine was
recorded” (passive method)
Participants Number: 2464 enrolled; 2365 evaluable
Age range: 3 to 6 months
Inclusion criteria:male or female infants, born after a normal gestation period of 36 to
42 weeks; aged 11 to 17 weeks at time of first dose of study vaccine; free of obvious health
problems as established by medical history and clinical examination before entering into
the study
Exclusion criteria: “Subjects with previous confirmed occurrence of rotavirus gastroen-
teritis, previous vaccination against or history of diphtheria, tetanus, pertussis, polio and/
or Hib, had a history of allergic reaction to any vaccine component, were immunocom-
promised or had contact with immunosuppressed individual or pregnant women in their
household, had any clinically significant history of chronic gastrointestinal (GI) disease
including any uncorrected congenital malformation of GI tract or subjects with use of
antibiotics within 7 days preceding Dose 1”
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.7 FFU; 510 participants
1.2. 105.2 FFU; 648 participants
1.3. 106.1 FFU; 653 participants
2. Placebo; 653 participants
All vaccines given in 2 doses with a 1-month interval
Outcomes measured at ~15 months (efficacy data from 2 weeks after second dose to 18
months of age)
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Outcomes Clinical outcome measures
1. All-cause diarrhoea: episodes of acute gastroenteritis; parents instructed to record
(diary cards) body temperature, the number of episodes of vomiting, the number of
looser-than-normal stools, and whether they sought medical intervention or medication,
and were asked to obtain at least 2 stool samples on 2 different days within 7 days of the
onset of symptoms; measured at 2 weeks to 18 months
2. Rotavirus diarrhoea: see all-cause diarrhoea; “Rotavirus gastroenteritis was confirmed
if at least 1 of the 2 stool specimens was found to be positive for rotavirus by ELISA.
Rotavirus isolates were G-typed by use of reverse-transcriptase polymerase chain reaction
(RT-PCR)”; measured at 2 weeks to 18 months
3. Severe all-cause diarrhoea: severity of each episode of gastroenteritis graded using a
20-point scoring system described by Ruuska 1990
4. Severe rotavirus diarrhoea: see severe all-cause diarrhoea
5. All-cause death
6. All-cause hospital admission
7. Emergency department visit
8. Serious adverse events
9. Reactogenicity: fever if rectal temperature > 38 ºC
10. Adverse events requiring discontinuation
11. Rotavirus diarrhoea requiring hospitalization
12. Dropouts
Outcomes to measure immunogenicity
11. Shedding of vaccine virus: in stool samples on day of each vaccination and on days
7 and 15 after each vaccination (from 50 participants/group, the “stool sample subset”)
(review includes data from 1 month after dose 1 and 1 month after dose 2)
12. Seroconversion: serum anti-rotavirus IgA antibody seroconversion rate; “seroconver-
sion” “defined by an anti-rotavirus IgA antibody concentration of ≥ 20 U/mL, for in-
fants who were initially (i.e. before administration of the first vaccine dose) seronegative
for anti-rotavirus IgA antibodies (i.e. a concentration of <20 U/mL) and/or who had a
stool sample that was negative for rotavirus antigen. Any detection of RIX4414 antigen
in stool samples was taken as evidence of a vaccine response”
Immunization status Hepatitis B vaccine, diphtheria-tetanus-acellular pertussis, poliovirus, and H. influenzae
type b co-administered with interventions
Location 8 centres in Singapore
WHO mortality stratum A
Notes Date: 4 January 2001 to 15 April 2003
Funding: GlaxoSmithKline Biologicals
Other: 93% of population were Asian
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
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Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
Selective reporting (reporting bias) Unclear risk Reasons for low number of rotavirus gas-
troenteritis; “A smaller number of ro-
tavirus-related gastroenteritis cases than ex-
pected were documented during the study.
For 41% (160/387) of the reported gas-
troenteritis episodes, stool sampleswere not
available for determination of the etiology
of the gastroenteritis. No results were avail-
able for 6% (24/387) of the gastroenteritis
episodes because of an insufficient quantity
of stool samples collected or because of in-
valid results”
Other bias Low risk No apparent other bias
RV1 Phua 2009-AS
Methods RCT
Length of follow-up: 2 weeks post-dose 2 to 3 years
Adverse events data collection methods: passive method, using diary cards
Participants Number: 10,708 enrolled; 10,519 evaluable
Age range: 3 to 6 months
Inclusion criteria: healthy infants 6 to 12 weeks of age in Hong Kong and Taiwan, or
11 to 17 weeks of age in Singapore at the time of the first dose
Exclusion criteria: ”they did not have a history of chronic administration of immuno-
suppressants since birth, any confirmed or suspected immunosuppressive or immunod-
eficient condition, history of allergic disease or reaction likely to be exacerbated by any
vaccine component, had not received any investigational drugs/vaccines from 30 days
before Dose 1 or planned use during the study, had not received immunoglobulins and/
or blood products since birth or planned administration during the study period, did
not have any clinically significant history of chronic gastrointestinal disease including
any uncorrected congenital malformation of the gastrointestinal tract or other serious
medical condition as determined by the investigator, and did not have first or second
degree of consanguinity of parents“
Interventions RV1
1. RIX4414 (RV1) 106 FFU; 5359 participants
2. Placebo; 5349 participants
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All vaccines given in 2 doses with a 1 to 2 month interval
Outcomes Clinical outcome measures
1. All-cause diarrhoea: a gastroenteritis episode was defined as occurrence of diarrhoea
with or without vomiting (diarrhoea was defined as the passage of 3 or more looser-than-
normal stool within a 24-hour period)
2. Severe all-cause diarrhoea: severe gastroenteritis was defined as an episode of diarrhoea
with or without vomiting that required overnight hospitalization or rehydration therapy,
or both (equivalent to WHO plan B or C) in a medical facility and with a score of 11
points on the 20-point Vesikari scale
3. Rotavirus diarrhoea: stool samples collected during gastroenteritis episodes were tested
for the presence of rotavirus using ELISA method (RotacloneT M , Meridian Bioscience)
atGlaxoSmithKline Biologicals’ laboratories inRixensart, Belgium. All rotavirus-positive
stool samples were tested by reverse transcriptase polymerase chain reaction (RT-PCR)
followed by reverse hybridization assay, and optional sequencing, at Delft Diagnostic
Laboratory, The Netherlands, to determine G and P types, and differentiation of G1P[8]
vaccine type
4. Severe rotavirus diarrhoea*: see above
5. Emergency department visit: active surveillance was conducted at hospitals and medi-
cal facilities in the study area to capture gastroenteritis episodes requiring hospitalization
and/or re-hydration therapy (equivalent toWHO plan B or C) in a medical facility from
day of the first vaccine or placebo dose until the follow-up visit at 24 months of age
6. Serious adverse events: intussusception and SAEs were followed during the study
duration. A case of definite intussusception required confirmation at surgery or autopsy
or by using imaging techniques such as gas or liquid contrast enema or abdominal
ultrasound. Abstractable data for all serious adverse events and Kawasaki disease were
only provided for the third year of follow-up. Intussusception data for the third year
follow-up was not included in the analysis as the follow-up population was smaller (RV1:
2/4272; placebo: 1/4226)
7. All-cause deaths
Outcomes to measure immunogenicity
None
*G types for severe rotavirus diarrhoea up to two years follow-up was reported and added
to the analyses, data for the third year was reported but not included in the analysis as
the follow-up population was smaller”
Immunization status Infants received other routine paediatric immunizations (combined diphtheria toxoid-
tetanus toxoid-acellular pertussis (DTPa) inactivated poliovirus (IPV) andH. influenzae
type b (HiB) vaccine and hepatitis B vaccine (HBV)) during the study period according
to local schedules. Almost all infants received BCG dose at birth. If oral polio vaccine
(OPV) was given as part of the routine schedule in the participating countries, a time
interval of 2 weeks was observed between the OPV doses and RIX4414 vaccine/placebo
doses. One dose of oral polio vaccine (OPV) was given at birth in Hong Kong (99.8%
participants) and Taiwan (0.7% participants). However, during the study period, > 95%
of infants in the 3 countries received DTPa-IPV-HiB concomitantly with both doses of
RIX4414 vaccine/placebo as per local schedules. 50.9% of participants were male and
the study population was predominantly Chinese (76.3%)
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Location Hong Kong, Singapore, Taiwan
WHO mortality stratum A
Notes Date: 8 December 2003 to 31 August 2005
Funding: GlaxoSmithKline
Other: all enrolled infants received the first dose of RIX4414 vaccine or placebo, and
10,551 (98.5%) received both doses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomization list was generated at GSK
Biologicals, Rixensart, using a standard
SAS®programme and was used to number
the vaccines
Allocation concealment (selection bias) Low risk A randomizationblocking schemewas used
to ensure that the balance between treat-
ments was maintained. Treatment alloca-
tion at the investigator sites was performed
using a central randomization system on
the Internet
Blinding (performance bias and detection
bias)
All outcomes
Low risk Data analysis was performed at GSK Bi-
ologicals. The treatment code remains
masked, except for statisticians and the
database administrator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis of efficacy was performed
from 2 weeks post-dose 2 until 2 years of
age on the ATP cohort that included partic-
ipants who completed the full 2-dose vac-
cination course and complied with the pro-
tocol. The total vaccinated cohort was used
to calculate vaccine efficacy starting from
the first dose onwards
Selective reporting (reporting bias) Low risk All expected outcomes included
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: 17 weeks
Adverse events data collection methods: not reported
Participants Number: 200
Age range: 6 to 14 weeks of age at the time of the first study vaccination
Inclusion criteria: healthy infants with a live twin living in the same household who is
also enrolled in this study, born after a gestation period of over 32 weeks
Exclusion criteria: use of any investigational or non-registered product other than the
study vaccine(s); any confirmed or suspected immunosuppressive or immunodeficient
condition; any clinically significant history of chronic gastrointestinal disease; history of
allergic disease; acute disease at time of enrolment; gastroenteritis within 7 days preceding
the first study vaccine administration; documented HIV-positive infant
Interventions 1. RV1 (RIX 4414) Vaccine, 100 participants
2. Placebo, 100 participants
Schedule: both vaccine and placebo 2 doses at Day 0 (Visit 1) and Week 7 (Visit 2)
Notes: 1 complimentary dose of RV1 was administered to all infants enrolled in this
study (both study groups) who are aged less than 6 months at Visit 3 (Week 13) as a
benefit to the placebo group for participation in the study
Outcomes Clinical outcome measures (safety and efficacy)
1. Gastroenteritis, up to week 17
2. Rotavirus gastroenteritis, up to week 13. Rotavirus gastroenteritis episodes were de-
fined as gastroenteritis episodes for which the stool sample temporally closest to the onset
day of the gastroenteritis episode was positive for rotavirus by ELISA
3. Serious adverse events, including fatal serious adverse events and intussusception, up
to week 17
4. Dropouts from the study
Outcomes to measure immunogenicity
5. Anti-rotavirus IgA antibody seroconversion and concentration in each group, at visit
3
Immunization status All infants received 3 doses of combined diphtheria, tetanus, acellular pertussis, hepatitis
B, inactivated poliovirus and H. influenzae vaccine
Location Dominican Republic
WHO mortality stratum B
Notes Study known as RV1 NCT00396630 2009-LA in previously published versions of this
review.
Date: January 2007 to February 2008
Source of funding: GlaxoSmithKline
Registration number: NCT00396630
Aim: “to explore horizontal transmission of the HRV [human rotavirus] vaccine strain
within a family from the twin vaccinated with Rotarix to the twin receiving placebo”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A randomization list was gener-
ated at GlaxoSmithKline (GSK) Biologi-
cals, Rixensart, using a standard SAS® pro-
gram. A randomization blocking scheme
(1:1 ratio, block size = 2) was used to en-
sure balance between the treatment arms; a
treatment number uniquely identified the
vaccine doses to be administered to the
same infant”
Allocation concealment (selection bias) Low risk Quote: “No investigator or any person in-
volved in the clinical trial (including lab-
oratory personnel, statisticians and data
management) was aware of the treatment
groups during the course of the study”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The studywas double-blinded and
the parents/guardians of infants, investiga-
tor and the study personnel were unaware
of the study vaccine administered”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced between
groups
Selective reporting (reporting bias) Low risk Trial report does not provide enough details
Other bias Low risk No apparent other bias
RV1 Ruiz-Palac 06-LA/EU
Methods RCT
Length of follow-up: 9 to 10 months
Adverse events data collection methods: active surveillance system established at hos-
pital and medical facilities in study areas to capture intussusceptions and severe gastroen-
teritis episodes (active method)
Participants Number: 63,225 enrolled for safety and 20,169 enrolled for efficacy; 59,308 evaluable
for safety, and 17,882 evaluable for first-year efficacy and 14,615 for second-year efficacy
Age range: 1 to 3 months (start) and 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 12 weeks (in all countries except Chile)
or 6 to 13 weeks (in Chile) at time of first dose of RV1 or placebo; “healthy infants 6-
13 weeks of age at the time of the first study vaccination whose parent/guardian sign
a written informed consent and whose parents/guardians can and will comply with the
requirements of the protocol (e.g., completion of the diary cards, return for follow-up
visits)”
Exclusion criteria (from NCT00140673): use of any investigational or non-registered
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product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the
first dose of study vaccine or placebo, or planned use during the study period; chronic
administration (defined as > 14 days) of immunosuppressants or other immune-modi-
fying drugs since birth (topical steroids allowed); child unlikely to remain in the study
area for the duration of the study; any confirmed or suspected immunosuppressive or
immunodeficient condition, including HIV infection; history of allergic disease or re-
action likely to be exacerbated by any component of the vaccine; administration of im-
munoglobulins or blood products or both since birth or planned administration during
the study period; any clinically significant history of chronic gastrointestinal disease in-
cluding any uncorrected congenital malformation of the gastrointestinal tract or other
serious medical condition as determined by the investigator
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 31,673 participants (safety), 10,159 participants (effi-
cacy)
2. Placebo; 31,552 participants (safety), 10,010 participants (efficacy)
Both vaccine and placebo given in 2 doses with 4 to 8 weeks interval
Both vaccine and placebo reconstituted in 1.3 mL of liquid calcium carbonate buffer
Outcomes Clinical outcome measures
1. Serious adverse events: “defined as any new health-related problems that resulted
in death, were life-threatening, necessitated hospitalization or prolongation of existing
hospitalization, or resulted in disability or incapacity”; “case of definite intussusception
required confirmation at surgery or autopsy or with the use of imaging techniques,
such as imaging with gas- or liquid-contrast enema or abdominal ultrasonography”;
measured up to 30 days after vaccination and during the first year follow-up for efficacy;
intussusception measured up to 100 days after dose 1. Final intussusception results taken
from CDC report (CDC 2010)
2. Severe all-cause diarrhoea: severe gastroenteritis measured as an “episode of diarrhoea
with or without vomiting that required hospitalization and/or re-hydration therapy
(equivalent to WHealth O plan B or C) in a medical facility”; measured from 2 weeks
after second dose up to 2 years follow-up
3. All-cause diarrhoea; measured from 2 weeks after second dose up to 2 years follow-up
4. Rotavirus diarrhoea; measured from 2 weeks after second dose up to 2 years follow-
up
5. Severe rotavirus diarrhoea: severe rotavirus gastroenteritis defined as an “an episode of
severe gastroenteritis occurring at least 2 weeks after the full vaccination course in which
rotavirus other than vaccine strain was identified in a stool sample collected during the
episode of severe gastroenteritis”; measured from 2 weeks after second dose up to 2 years
follow-up
6. All-cause death; measured up to 30 days after vaccination
7. All-cause hospital admission; from 2 weeks after second dose up to 2 years follow-up
8. Reactogenicity; up to 30 days after vaccination
9. Dropouts; measured up to 2 years follow-up
11. Rotavirus diarrhoea requiring hospitalizations
12. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
13. Seroconversion: serum rotavirus IgA antibody concentrations in a subset of 100
participants per country (except in Finland) at Visits 1 and 3 (data not included in review
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RV1 Ruiz-Palac 06-LA/EU (Continued)
because it was not a random sample)
Outcomes measured up to 30 days after second dose of vaccine (safety outcomes) and
up to 2 years (efficacy outcomes)
Immunization status Routine immunizations according to local regulations; oral poliovirus vaccination at least
2 weeks before or after rotavirus vaccine
Location Latin America and Europe (Argentina, Brazil, Chile, Colombia, Dominican Republic,
Finland, Honduras, Mexico, Nicaragua, Panama, Peru, and Venezuela); second year
follow-up in all locations except Finland and Peru
WHO mortality strata A, B, D
Notes Date: 5 August 2003 to 20 October 2005
Source of funding: GlaxoSmithKline Biologicals
Data extracted from appendix accompanying main report and GlaxoSmithKline com-
panion reports
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “GlaxoSmithKline Biologicals pro-
vided vaccine supplies that were numbered
with a computer-generated randomization
list. We used a blocking scheme random-
ization. GSK did the masking and conceal-
ment”
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas done by a cen-
tral Internet randomization system”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Treatment allocation remained
concealed from investigators and parents of
participating infants throughout the study.
GSK did the masking and concealment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “full GSK report account for all
withdrawals regardless of reason”
Selective reporting (reporting bias) High risk The trial reported only on severe episodes
of rotavirus diarrhoea and all-cause diar-
rhoea, and not on diarrhoea of any severity,
which is unusual in these trials
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: up to 2 years (stated in GlaxoSmithKline report)
Adverse event data collection methods: diary cards were supplied to the parents to
record occurrence of specific solicited symptoms for 15 days after each vaccination (pas-
sive method); any other unsolicited symptoms were recorded during 43 days after each
vaccination (passive method); serious adverse events were recorded throughout the study
Participants Number: 2155 enrolled; 2004 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks or with a birth weight > 2000 g; aged 6 to 12 weeks at the time of the first
vaccination; free of obvious health problems as established bymedical history and clinical
examination before entering into the study
Exclusion criteria: previous confirmed occurrence of rotavirus gastroenteritis; previous
vaccination against or history of diphtheria, tetanus, pertussis, polio and/orH. influenzae
type b vaccine (HiB); any clinically significant history of chronic gastrointestinal disease
including any uncorrected congenital malformation of gastrointestinal tract; use of an-
tibiotics within 7 days preceding dose 1; immunocompromised or were in household
contact with an immunosuppressed individual or pregnant woman
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.7 PFU; 538 participants (randomized)
1.2. 105.2 PFU; 540 participants (randomized)
1.3. 105.8 PFU; 540 participants (randomized)
2. Placebo: 537 participants (randomized)
Schedule: 2 doses given every 2 months
An additional 200 participants were randomized to RV1 x placebo to receive 3 doses.
This is not mentioned in the main publication, only in the GlaxoSmithKline report (no
data available)
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: no definition; measured during follow-up (2 years)
2. Reactogenicity: no definition; measured up to 43 days after vaccination
3. All-cause diarrhoea: gastroenteritis defined as diarrhoea characterized by ≥ 3 looser
than normal stools within a day; minimum of 5 days required between episodes for them
to be considered as separate events; measured during follow-up (2 years)
4. Severe all-cause diarrhoea: information on diary cards was used to assess the severity
of each gastroenteritis episode according to a 20-point scoring system; measured during
follow-up (2 years)
5. Rotavirus diarrhoea: all rotavirus-positive specimens were tested by RT-PCR at Glax-
oSmithKline to determine the G type; any G1 rotavirus detected until 2 months after the
second dose were analyzed to differentiate between vaccine strain and wild G1 strains;
only gastroenteritis episodes in which wild rotavirus other than the vaccine strain was
identified in a stool specimen were included in the efficacy analysis; measured during
follow-up (2 years)
6. Severe rotavirus diarrhoea: see above; measured during follow-up (2 years)
7. All-cause hospital admission: no definition; measured during follow-up (2 years)
8. All-cause mortality: no definition; measured during follow-up (2 years)
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RV1 Salinas 2005-LA (Continued)
9. Rotavirus diarrhoea resulting in hospitalization
Outcomes to measure immunogenicity
10. Vaccine take: rotavirus shedding in stool specimens (review includes data from day
7 after dose 2)
11. Seroconversion: “percentages of infants with post-antirotavirus IgA antibody con-
centration 20 units/mL in infants who were negative for rotavirus before the first dose
of RIX4414 or placebo” (review includes data from 2 months after dose 1 and 2 months
after dose 2)
Immunization status Oral polio vaccine given after 2 weeks, not together with RV1
Location Belem (Brazil), Mexico City (Mexico), Valencia (Venezuela)
WHO mortality stratum B
Notes Date: 25 May 2001 to 8 November 2003
Source of funding: GlaxoSmithKline Biologicals
Malnutrition: reported in Journal of Infectious Disease, 2007, 196(4): 537-40
Other: main publication did not report that the trial included 2 subsets:
• 2 doses of human rotavirus or placebo subset: these participants received 2 oral
doses of RV1 vaccine or placebo according to a 0-, 2-months schedule, and routine
vaccinations (DTPw- Hepatitis B vaccine (HBV) + Hib vaccine) at a 0-, 2-, and 4-
months schedule
• 3 doses of RV1 or placebo subset: these participants received 3 oral doses of RV1
vaccine or placebo, and routine vaccinations (DTPw-HBV + Hib vaccine)
concomitantly with each dose of human rotavirus vaccine and placebo at a 0-, 2-, and
4-months schedule
Immunogenicity sampling: “A subset of infants (N 800) provided blood samples 2
months after the first dose (serology for antirotavirus IgA antibodies) and 2 months
after the second dose (serology for antirotavirus IgA antibodies and antibodies against
antigens of routine infant vaccines). The first 200 enrolled infants in each participating
country constituted this subset, and the remaining 200 infants were included according
to the order of enrolment irrespective of country”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Quote:“The participating infants were ran-
domly assigned to one of the 4 study groups
(3 vaccine groups and a placebo group) fol-
lowing a 1:1:1:1 allocation ratio accord-
ing to a computer-generated randomiza-
tion list”
Allocation concealment (selection bias) Low risk Central allocation
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double blinding was maintained
during the entire study period”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) High risk Not all prespecified outcomes reported
Other bias Unclear risk GlaxoSmithKline final report stated that
part of the population received 3 doses of
rotavirus vaccine. This was not mentioned
on the original published report
RV1 Steele 2008-ZAF
Methods RCT
Length of follow-up: up to 6 months after last vaccine given
Adverse event data collection methods: “The infants were monitored for at least 30
min after each vaccination. Parents received a diary card to record information daily
about solicited general symptoms (fever, fussiness/irritability, diarrhoea, vomiting, loss
of appetite or cough/runny nose) for 15 days after each dose of RIX4414 or placebo, and
any other adverse events occurring until the next study visit.Weekly supervisionwas done
by Health Care Workers fromMadibeng District Health Centre. The study physician or
his staff questioned the parents on their child’s health and verified the completed diary
card at each visit”
Participants Number: 450 enrolled; 406 evaluable
2 cohorts were vaccinated: 1st cohort before the rotavirus season (271 participants); 2nd
cohort after the rotavirus season (179) participants
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
5 to 10 weeks of age at the time of the first study visit; free of obvious health problems as
established by medical history and clinical examination before entering into the study.
There were no restrictions on feeding the infants before or after vaccination
Exclusion criteria: infants were excluded if they had a clinically significant history of
gastrointestinal disease or malformation, had received vaccines or treatment prohibited
by the protocol, were immuno-compromised or were in household contact with an
immunosuppressed individual or pregnant woman. BCG and OPV vaccinations at birth
were allowed according to the local EPI schedule. Vaccination was postponed if the infant
had fever (≥ 37.5 ºC axillary or ≥ 38 ºC rectal) or gastroenteritis within the previous 7
days
Interventions RV1
1. RIX4414 (RV1): 105 FFU; 2 doses given 1 month apart; 300 participants (random-
ized)
1.1. RV1 vaccine + oral polio vaccine + diphtheria-tetanus-acellular pertussis/H. influen-
zae type b vaccine
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1.2. RV1 vaccine + oral polio vaccine placebo + diphtheria-tetanus-acellular pertussis
inactivated polio-H. influenzae type b vaccine
1.3. RV1 placebo + diphtheria-tetanus-acellular pertussis inactivated polio-H. influenzae
type b vaccine
2. Placebo: 2 doses given 1 month apart; 150 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity (see Adverse event data collection methods above)
2. Serious adverse events: Infants who experienced a serious adverse event and required
hospitalization were admitted at the local district hospital in the study sites or at Ga-
Rankuwa Hospital, the referral hospital for the study site and surrounding areas. Parents
were informed on the symptoms of intussusception and were instructed to contact the
study physician or clinic if any signs of intussusception became apparent. Any suspected
cases were immediately referred to Ga-Rankuwa Hospital. All serious adverse events
were reported to the sponsor and the Ethics committees and followed up until resolved.
Parents were contacted 6 months after the second dose of RIX4414 or placebo to obtain
information on any serious adverse events since the final study visit. All serious adverse
events were reviewed periodically by an independent safety monitoring committee
3. All-cause death
4. Dropouts
5. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
6. Vaccine virus shedding: vaccine virus in stool sample (review includes data from
combined time points)
7. Seroconversion: appearance of anti-rotavirus IgA antibody (concentration ≥ 20 U/
mL) in participants negative for rotavirus before vaccination (review includes data from
289 participants)
Immunization status Diphtheria-tetanus-acellular pertussis, polio virus, and H. influenzae type b co-admin-
istered in trial
Location Madibeng District, North West Province, South Africa
WHO mortality stratum E
Notes Date: 1st cohort started from 22 November 2001; 2nd cohort from 23 October 2002
to 15 October 2003
Source of funding: The study (e-Track 444563-014/NCT00346892) was sponsored by
a public-private partnership RAPID and GSK Biologicals. The RAPID partnership con-
sists of public sector partners (including the WHO, US Agency for International Devel-
opment, National Institutes of Health, Children’s Vaccine Programme and the Centers
for Disease Control), academic institutions (International Centre for Diarrhoeal Disease
Research, Bangladesh and Medical University of Southern Africa) and GlaxoSmithKline
Biologicals
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Very likely
Quote: “This study was conducted un-
der the WHO RAPID (Rotavirus Action
Partnership for Immunization and Devel-
opment) programme that facilitates con-
duct of rotavirus vaccine trials in devel-
oping countries, specifically in Africa and
Asia, to address specific developing coun-
try needs. The RAPID partnership con-
sists of public sector partners (including the
WHO, US Agency for International De-
velopment, National Institutes of Health,
Children’s Vaccine Programme and the
Centers for Disease Control), academic in-
stitutions (International Centre for Diar-
rhoeal Disease Research, Bangladesh and
Medical University of Southern Africa) and
GlaxoSmithKline Biologicals”
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “a unique randomization number
identified the vials to be administered to
the same subject” and “subjects were ad-
ministered the vaccine dose with the low-
est treatment number available at the study
centre”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of oral polio vaccine co-adminis-
tration not completely blinded
Quote: “OPV and its placebo used in the
first cohort were identical in appearance al-
lowing for double blinding while this was
not possible in the second cohort due to
differences in appearance of OPV and its
placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All infants who had received at
least one dose of RIX4414 or placebo (to-
tal vaccinated cohort) were included in the
primary analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No apparent other bias
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Methods RCT
Length of follow-up: up to 31 days after each vaccine dose and 42 days after the last
vaccine dose
Adverse event data collection methods: all solicited general symptoms (fever, fussiness
/irritability, diarrhoea, vomiting, loss of appetite, cough/runny nose) and unsolicited
symptoms were recorded during the 15-day and 31-day postvaccination follow-up pe-
riod after each RIX4414/placebo dose, respectively. The intensity of adverse events was
assessed on a 4-point scale, where ’0’ indicated no symptoms; ’1’ mild; ’2’ moderate; and
’3’ severe symptoms. Symptoms of Grade 3 intensity were defined as follows: rectal tem-
perature≥ 39.5 °C (fever),≥6 looser-than-normal stools a day (diarrhoea),≥ 3 episodes
of vomiting a day (vomiting), refusing food intake (loss of appetite), and preventing nor-
mal activity (cough/runny nose, fussiness/irritability). Grade 2 symptoms were defined
as rectal temperature of 38.5 °C to 39.5 °C (fever), 4 to 5 looser-than-normal stools a
day (diarrhoea), 2 episodes of vomiting a day (vomiting), eating lesser than usual, which
interfered with normal activity (loss of appetite), and interfering with normal activity
(cough/runny nose, fussiness /irritability). Occurrence of SAEs was recorded throughout
the study period
Participants Number: 100 enrolled; 100 evaluable for safety, 50 for immunogenicity
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: only HIV-positive infants (confirmed at screening) who were clini-
cally asymptomatic or mildly symptomatic (clinical stages I and II according to WHO
classification) and aged 6 to 10 weeks at the time of Dose 1 of RIX4414/placebo were
enrolled. There were no restrictions on feeding the infants before or after vaccination
Exclusion criteria: infants were not included in the study if they were confirmed HIV-
negative, had received any other investigational drug or vaccine 30 days before receiving
the first dose of study vaccine, or had a history of chronic gastroenteritis or previous
documented rotavirus gastroenteritis
Interventions 1. RV1: 3 doses at least 106.0 CCID50 viral concentration
2. Placebo
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity (see Adverse event data collection methods above)
2. All-cause diarrhoea; A gastroentiritis episode was defined as diarrhoea (3 or more,
looser-than-normal stools a day) with or without vomiting. Stool samples were collected
on days 0, 7, 15, and 22 of Doses 1 and 2 and on days 0, 7, 15, 30, 45, and 60 of Dose
3
3. Rotavirus diarrhoea; measured from 1 week after second dose up to 2 months’ follow-
up
4. Serious adverse events: infants who experienced a serious adverse event and required
hospitalization were admitted at the local district hospital in the study sites or at Ga-
Rankuwa Hospital, the referral hospital for the study site and surrounding areas. Parents
were informed on the symptoms of intussusception and were instructed to contact the
study physician or clinic if any signs of intussusception became apparent. Any suspected
cases were immediately referred to Ga-Rankuwa Hospital. All serious adverse events
were reported to the sponsor and the Ethics committees and followed up until resolved.
Parents were contacted 6 months after the second dose of RIX4414 or placebo to obtain
information on any serious adverse events since the final study visit. All serious adverse
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events were reviewed periodically by an independent safety monitoring committee
5. All-cause death
6. Dropouts
Outcomes to measure immunogenicity
7. Vaccine take: defined as serum antirotavirus IgA concentration 20 U/mL in post-
vaccination sera or rotavirus vaccine shedding in any stool sample collected from dose 1
to 2 months post-dose 3 for infants initially negative for rotavirus
8. Seroconversion: appearance of anti-rotavirus IgA antibody (concentration ≥ 20 U/
mL) in participants negative for rotavirus before vaccination (review includes data from
289 participants)
Immunization status RV1 vaccine was concomitantly administered with 3 doses of combined diphtheria,
tetanus and whole-cell pertussis, hepatitis B, and H. influenzae type b vaccine (Tritan-
rixHepBHib) and OPV (PolioSabin)
Location Pretoria, South Africa
WHO mortality stratum E
Notes Registration number: ISRCTN11877362/NCT00263666
Source of funding: RAPID trials (USA); WHO (Switzerland) and GlaxoSmithKline
Biologicals
For infants who developed clinical symptoms of HIV (WHO stages III or IV disease)
anytime after enrolment, access to antiretroviral therapy (cotrimoxazole) according to
the South African national guidelines was facilitated. Infants who needed treatment were
referred to antiretroviral therapy centres by the investigators
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Very likely
Quote: “This study was conducted un-
der the WHO RAPID (Rotavirus Action
Partnership for Immunization and Devel-
opment) programme that facilitates con-
duct of rotavirus vaccine trials in devel-
oping countries, specifically in Africa and
Asia, to address specific developing coun-
try needs. The RAPID partnership con-
sists of public sector partners (including the
WHO, US Agency for International De-
velopment, National Institutes of Health,
Children’s Vaccine Programme and the
Centers for Disease Control), academic in-
stitutions (International Centre for Diar-
rhoeal Disease Research, Bangladesh and
Medical University of Southern Africa) and
GlaxoSmithKline Biologicals”
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Allocation concealment (selection bias) Unclear risk 1:1 randomization, no further details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The placebo was similar to
RIX4414 in appearance and contained the
same constituents as the active vaccine ex-
cept that it did not contain the vaccine
virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All infants who had received at
least one dose of RIX4414 or placebo (to-
tal vaccinated cohort) were included in the
primary analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No apparent other bias
RV1 Steele 2010b-ZAF
Methods RCT
Length of follow-up: up to 6 months after last dose of vaccine or placebo
Adverse event data collection methods: “The infants were monitored for at least 30
min after each vaccination. Parents received a diary card to record information daily
about solicited general symptoms (fever, fussiness/irritability, diarrhoea, vomiting, loss
of appetite or cough/runny nose) for 15 days after each dose of RIX4414 or placebo, and
any other adverse events occurring until the next study visit.Weekly supervisionwas done
by Health Care Workers fromMadibeng District Health Centre. The study physician or
his staff questioned the parents on their child’s health and verified the completed diary
card at each visit”
Participants Number: 475 participants enrolled; 420 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of ≥ 36 weeks;
6 to 10 weeks of age at the time of the first study visit; free of obvious health problems as
established by medical history and clinical examination before entering into the study,
and mothers had confirmed negative HIV status
Exclusion criteria: infants were excluded if they had a clinically significant history of
gastrointestinal disease or malformation, had received vaccines or treatment prohibited
by the protocol, were immuno-compromised or were in household contact with an
immuno-suppressed individual or pregnant woman. BCGandOPV vaccinations at birth
were allowed according to the local EPI schedule. Infants with acute disease at the time
of enrolment or gastroenteritis (diarrhoea) within 7 days before administration of the
study vaccine were also excluded. In addition, vaccination was postponed if the infant
had fever (≥ 37.5 °C axillary or ≥ 38 °C rectal) or gastroenteritis within the previous 7
days
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Interventions RV1
1. RIX4414 (RV1): at least 106.0 PFU CCID50
1.1. 2 doses, 1 month apart (at 10 and 14 weeks) plus 1 dose of placebo (at 6 weeks);
190 participants (randomized)
1.2. 3 doses, 1month apart (at 6, 10, and 14weeks of age); 189 participants (randomized)
2. Placebo: 3 doses, 1 month apart (at 6, 10, and 14 weeks of age); 96 participants
(randomized)
Schedule: Visits 1 (Dose 1), 2 (Dose 2), 3 (Dose 3), 4 and 5 correspond to months 0,
1, 2, 4, and 8 to 11 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day (days 0 to 14) solicited follow-up period after each dose; occurrence of
unsolicited adverse events within 43 days (days 0 to 42) after each dose, according to
MedDRA classification; measured up to 43 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period; measured up to 6
months
5. All-cause death: fatal adverse events measured up to 6 months
6. Dropouts: measured up to 6 months
7. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
8. Viral shedding: presence of rotavirus in any stool sample (review includes data from
combined time points (these combined data for 2 and 3 doses))
9. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/
mL in participants negative for rotavirus before first dose (review includes data from 1
month after dose 1 and 2 months after dose 3)
Immunization status Infants received routine vaccinations according to the local EPI schedule in South Africa.
BCG and OPV vaccinations were given at birth; all other routine vaccinations (includ-
ing diphtheria-tetanus toxoids-whole cell pertussis, hepatitis B, H. influenzae type b,
and OPV) were administered concomitantly with the study vaccine. All of the infants
received a dose of OPV concomitantly with each dose of study vaccine or placebo at all
administration times
Location 7 centres in South Africa
WHO mortality stratum E
Notes Study known as RIX GSK[013] 2007-AF in previously published versions of this review
Date: 5 September 2003 to 25 October 2004
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “The aim of this study was to determine if there was a difference in
immune response between the two different schedules that were tested”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Very likely. This study was conducted un-
der the auspices of WHO (eTrack 444563/
013/NCT00383903)
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “a randomization number uniquely
identified the three vials to be administered
to the same subject” and “subjects were ad-
ministered the vaccine dose with the lowest
number available at the study centre”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The placebo was similar to
RIX4414 in appearance and contained the
same constituents as the active vaccine ex-
cept that it did not contain the vaccine
virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All infants who had received at
least one dose of RIX4414 or placebo (to-
tal vaccinated cohort) were included in the
primary analysis of reactogenicity”
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Low risk No apparent other bias
RV1 Tregnaghi 2011-LA
Methods RCT
Length of follow-up: up to 1 year of age
Adverse event data collection methods: not reported
Participants Number: 6568 enrolled; 6349 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: boys or girls between and including 6 and 12 weeks (42 to 90 days)
of age at the time of the first vaccination according to the country recommendations
for the routine vaccination schedules; free of obvious health problems as established by
medical history and clinical examination before entering into the study
Exclusion criteria: history of chronic gastrointestinal disease including any uncorrected
congenital malformation of the gastrointestinal tract or other serious medical condition
as determined by the investigator
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 2 doses at 1 or 2months; 4376 participants (randomized)
2. Placebo: 2 doses at 1 or 2 months; 2192 participants (randomized)
Schedule: both groups received RV1 vaccine or placebo vaccine orally; first dose at
month 0 then second dose at month 1 or month 2
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2 cohorts: there were two periods of enrolment, each with its own visit schedule:
• Cohort enrolled in 2003 to 2004: visits 1, 2, 3, 4 (for a subset only) and 5
corresponded to month 0 (vaccine dose 1), month 1 to 2 (vaccine dose 2), month 2 to
4, month 3 to 6, and month 10 in the schedule
• Cohort enrolled in 2005: visits 1, 2 (for a subset only), 3, 4 (for a subset only), 5,
6 (for a subset only), and 7 corresponded to month 0 (vaccine dose 1), month 1,
month 2 (vaccine dose 2), month 3, month 4, month 5, and month 10 in the schedule
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: occurrence of severe rotavirus gastroenteritis (requiring hospital-
izations or rehydration therapy or both in a medical facility) caused by the wild rotavirus
strains during the period starting from 2 weeks after dose 2 until 1 year of age; measured
up to 1 year after vaccine/placebo
2. Serious adverse events: occurrence throughout the entire study period; measured up
to 1 year after vaccine/placebo
3. Dropouts: measured up to 1 year after vaccine/placebo
4. All-cause death: fatal serious adverse events; measured up to 1 year after vaccine/
placebo
5. Adverse events resulting in discontinuation
6. All-cause diarrhoea - severe
Outcomes to measure immunogenicity
7. Seroconversion: serum rotavirus immunoglobulin A (IgA) antibody concentrations 1
to 2 months after second study vaccine dose (at visit 3) in a subset of 300 participants
enrolled in year 2003 - 2004 (review includes data from 1 to 2 months after dose 2)
Immunization status All participants received routine infant vaccinations (Hepatitis B vaccine), diphtheria-
tetanus-acellular pertussis, poliovirus, and H. influenzae type b) according to Expanded
Programme of Immunization (EPI) recommendations in each country
First 2 doses of routine EPI vaccinations were co-administered with the RV1 vaccine or
placebo doses; the third routine EPI vaccination was administered 1 to 2 months later
according to the national plan of immunization in each country
Location Multiple sites in 6 countries in Latin America (Argentina, Brazil, Colombia, Dominican
Republic, Honduras, and Panama)
WHO mortality stratum B
Notes Date: 3 December 2003 to 20 March 2007
Source of funding: GlaxoSmithKline Biologicals
Study rationale: “to evaluate the efficacy, immunogenicity and safety of 2 doses of oral
live attenuated human rotavirus [RV1] vaccine given concomitantly with routine EPI
vaccinations (including DTPw [licensed combined diphtheria and tetanus toxoids and
whole-cell pertussis vaccine], HBV [licensed hepatitis type B vaccine], Hib [licensed H.
influenzae type b vaccine] and OPV [oral polio vaccine]) in healthy infants”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96.7% completed the study
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No details
RV1 Vesikari 2004a-FIN
Methods RCT
Length of follow-up: 8 to 30 days after each dose
Adverse event data collection methods: diary cards provided to participants or par-
ticipants’ parents/guardians to record solicited general symptoms on the day of each
vaccination and for 7 subsequent days (passive method)
Participants Number: 192 enrolled; 178 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks; 6 to 12 weeks of age at the time of the first dose of the study vaccination course;
free of obvious health problems as established bymedical history and clinical examination
before entering into the study
Exclusion criteria: participating in any other clinical trial; acute disease; history of
allergic reaction to any vaccine component; history of chronic gastrointestinal disease
or other serious medical condition; undergone immunosuppressive therapy; received
antibiotics within 14 days preceding the study vaccine administration and during the
first 7 days after vaccine administration; any confirmed or suspected immunosuppressive
or immunodeficient condition, had received any immunoglobulin therapy or blood
products before start or during the trial; abnormal stool pattern or household contact
with an immunosuppressed individual or pregnant woman; for the infants, previous
confirmed occurrence of rotavirus gastroenteritis
Interventions RV1
1. RIX4414 (RV1)
1.1. 104.1 PFU; 32 participants (randomized)
1.2. 104.7 PFU; 64 participants (randomized) *
1.3. 105.8 PFU; 32 participants (randomized)
2. Placebo: 64 participants (randomized)
Schedule: 2 doses given 2 months apart
*Half of infants receiving 104.7 PFU of RV1 were tested with prior administration of
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Mylanta as buffer; in the other half vaccine was diluted in a buffer containing calcium
carbonate
Feeding was not allowed for an hour before and after study vaccine administration
Outcomes Clinical outcome measures (safety and efficacy)
1. Adverse events requiring discontinuation: no definition; measured at 31-day follow-
up after each dose
2. Serious adverse events: no definition; measured at 31-day follow-up after each dose
3. Reactogenicity: no definition; measured at 31-day follow-up after each dose
4. Dropouts: no definition; measured at 31-day follow-up after each dose
5. All-cause mortality: no definition; measured at 31-day follow-up after each dose
Outcomes to measure immunogenicity
6. Rotavirus shedding in stool (review includes data from day 7 to 9 after dose 2)
7. Seroconversion: appearance of serum anti-rotavirus IgA antibody to rotavirus in post-
vaccination sera at a titre of ≥ 20 U/mL in previously uninfected infants; measured in
infants only (review includes data from 2 months after dose 1 and 1 month after dose 2)
Immunization status Infant routine vaccinations were separated from the study vaccines by 2 weeks
Location 2 centres in Finland
WHO mortality stratum A
Notes Date: 29 May to 18 December 2000
Source of funding: GlaxoSmithKline Biologicals
Trial report also includes results for a study in adults and in previously rotavirus-infected
children; neither included in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “A randomisation or subject num-
ber identified uniquely the vaccine dose to
be administered to the subject”, and “sub-
jects were administered the vaccine dose
with the lowest number available at the
study site”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “The study was performed under
double-blind with respect to the groups
within each study part”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 14/192 participants dropped out of the
study, balanced between groups with rea-
sons provided
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No information
RV1 Vesikari 2004b-FIN
Methods RCT
Unbalanced randomization (2:1)
Length of follow-up: 1 and 2 years of follow-up are reported
Adverse event data collection methods: to assess reactogenicity, parents recorded daily
on diary cards rectal temperature, any diarrhoea, vomiting, irritability, and loss of appetite
for 15 days after each vaccination. Any other symptoms or signs occurring during a 43-
day follow-up period after each vaccination were recorded as unsolicited symptoms (or
signs) (passive method)
Participants Number: 405 enrolled; 372 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, born after a normal gestation period of 36 to 42
weeks; 6 to 12 weeks of age at the time of the first dose of the study vaccination course;
free of obvious health problems as established bymedical history and clinical examination
before entering into the study
Exclusion criteria: premature labour; vaccination was delayed if infant had fever (rectal
temperature > 38 °C) or had gastroenteritis within the previous 7 days
Interventions RV1
1. RIX4414 (RV1): 104.7 PFU; 2 doses given 2 months apart; 270 participants (ran-
domized)
2. Placebo: 2 doses given 2 months apart; 135 participants (randomized)
Feeding was not allowed for 1 hour before administration of the study vaccine
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: occurrence of rotavirus gastroenteritis during the period starting
from 2 weeks after dose 2 until the end of the first rotavirus season following vaccination
as detected byRT-PCR in stool samples; occurrence of asymptomatic rotavirus infections
during the period starting from 1 month after dose 2 until the end of each rotavirus
season following vaccination; G type of the wild rotavirus strain by RT-PCR; measured
at 1 year (first report) and 2 years (second report)
2. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 15-day solicited follow-up period after each dose; measured at 15 days after each
dose
3. Adverse events requiring discontinuation: occurrence of unsolicited symptoms within
42 days after each dose, according to WHO’s classification; measured 42 days after each
dose
4. Serious adverse events: no definition; measured at all follow-ups
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5. All-cause diarrhoea: gastroenteritis was defined as diarrhoea (≥ 3 looser-than-normal
stools within any day) and/or vomiting (≥ 1 episodes of forceful emptying of partially
digested stomach contents > 1 hour after feeding within any day); 2 occurrences of
gastroenteritis were classified as separate episodes if there were ≥ 5 symptom-free days
between them
6. Severe rotavirus diarrhoea: score of < 7 prospectively defined as mild; score of 7 to 10
as moderate; and a score > 11 as severe
7. Rotavirus diarrhoea resulting in hospitalization
8. All-cause death
9. Dropouts
Outcomes to measure immunogenicity
10. Seroconversion: anti-rotavirus antibody IgA concentration of ≥ 20 units/mL in
infants negative for this before the first dose (review includes data from 1 month after
dose 2)
Immunization status Infant routine vaccinations (diphtheria tetanus toxoids-pertussis, H. influenzae type b,
and inactivated poliovirus vaccines) were separated from the study vaccines by at least 2
weeks
Location 6 centres in Finland
WHO mortality stratum A
Notes Date: 21 August 2000 to 11 July 2002
Source of funding: GlaxoSmithKline Biologicals
Other: GSK 444663/004 (rota-004annex) reports a second year extension of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible infants were randomly as-
signed (2:1 ratio) to 2 study groups accord-
ing to a computer-generated randomiza-
tion list to receive the vaccine or placebo by
mouth”
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “A randomisation or subject num-
ber identified uniquely the vaccine dose to
be administered to each subject”, and “sub-
jects were administered the vaccine dose
with the lowest number available at the
study site”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The placebo had the same con-
stituents and identical appearance as the ac-
tive vaccine, but did not contain the vac-
cine virus”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 33/405 participants dropped out of the
study, balanced between groups with rea-
sons provided
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias Unclear risk No information
RV1 Vesikari 2007a-EU
Methods RCT
Length of follow-up: 1 and 2 years of follow-up in all countries, and a third year follow-
up in Finland (GSK109810)
Adverse event data collection methods: “active surveillance for gastroenteritis episodes
and serious adverse events from the day of the first vaccine or placebo dose (8 September
2004) until the follow-up visit at the end of the second rotavirus epidemic season (10
August 2006) ... Study staff contacted parents every week” (active method); “During
every episode, we asked parents to record in a daily diary card the number of looser
than normal stools, axillary or rectal temperature, number of vomiting episodes, any
rehydration or other medication administered, and any medical attention (defined as
medical personnel contact, advice, or visit; emergency roomcontact or visit; or admission)
” (passive method)
Participants Number: 3994 enrolled; 3848 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 14 weeks who weighed > 2000 g at birth
Exclusion criteria: acute disease at the time of enrolment; history of chronic administra-
tion of immunosuppressants since birth; received any vaccines or treatments prohibited
by the protocol; or had any disorders or illnesses excluded by the protocol
Interventions RV1
1. RIX4414 (RV1): 106.5 PFU; 2 doses given 1 or 2 months apart; 2646 participants
(randomized)
2. Placebo: 2 doses given 1 or 2 months apart; 1348 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause diarrhoea: gastroenteritis defined as diarrhoea characterized by at least 3
looser-than-normal stools within a day, with or without vomiting; measured 2 weeks
after dose 2 until end of 2 years follow-up
2. Rotavirus diarrhoea: trialists deemed a gastroenteritis episode to be caused by rotavirus
if a rotavirus strain was identified in a stool sample collected during the episode or within
7 days after resolution of symptoms, or before the next episode if fewer than 7 days
had fallen between the end of 1 episode and the start of the next, in cases of multiple
episodes; measured 2 weeks after dose 2 until end of 2 years follow-up
3. Severe rotavirus diarrhoea: score < 7 was defined prospectively as mild, score of 7 to
10 as moderate, and a score of ≥ 11 as severe
4. Severe all-cause diarrhoea: as for severe rotavirus diarrhoea
5. Emergency department visit: no definition
131Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV1 Vesikari 2007a-EU (Continued)
6. All-cause hospitalization admission: no definition
7. Serious adverse events: no definition
8. Rotavirus diarrhoea resulting in hospitalization
9. Rotavirus diarrhoea requiring medical attention (defined as “medical personnel con-
tact, advice, or visit; emergency room contact or visit; or admission”)
10. Reactogenicity
Outcomes to measure immunogenicity
11. Seroconversion: appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/
mL in participants seronegative for rotavirus before vaccination (review includes data
from 1 to 2 months after dose 2)
Immunization status Concomitant vaccines included 7 valent pneumococcal polysaccharide conjugate vac-
cine (Prevenar) and meningococcal group c conjugate vaccine (Meningitec); Hepatitis
B vaccine, diphtheria-tetanus-acellular pertussis, polio virus, and H. influenzae type b
vaccines were co-administered
Location 98 centres in 6 European countries (Czech Republic, Finland, France, Germany, Italy,
and Spain)
WHO mortality stratum A
Notes Date: 12 February 2007 to 08 August 2007
Source of funding: funded by GlaxoSmithKline Biologicals
Other: vaccination postponed if baby either had a temperature of ≥ 37.5 °C (axillary)
or of 38.0 °C (rectal) or had gastroenteritis within 7 days before planned vaccination
Study aim: “to assess the efficacy and safety of HRV [RV1] vaccine during the 3rd year
of age in subjects primed with a 2-dose schedule in study 102247, with the first dose
administered at the age of 6 to 14 weeks”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “GSK Biologicals provided vaccine
supplies that were numbered with a com-
puter-generated randomization list”
Allocation concealment (selection bias) Low risk Quote: “randomization was done by a cen-
tral Internet randomization system. Infants
were randomly allocated in a 2/1 ratio two
doses of either RIX4414 or placebo”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Treatment allocation remained
concealed from investigators and the par-
ents of participating infants throughout the
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
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Selective reporting (reporting bias) Unclear risk Data are provided only for rotavirus gas-
troenteritis and for severe gastroenteritis,
not for all gastroenteritis episodes
Other bias Unclear risk No information
RV1 Vesikari 2011-FIN
Methods RCT
Length of follow-up: 2 months
Adverse event data collection methods: passive. “Parents/guardians of infants were
provided diary cards to record solicited general symptoms (loss of appetite, fussiness/
irritability, fever, diarrhoea, vomiting, and cough/runny nose) during a 15-day post-
vaccination follow-up period. The intensity of each adverse event was assessed using a
4-point scale where ”0“ refers to ‘absent’ and ”3“ refers to ‘severe”’
Participants Number: 250 enrolled and randomized; ATP safety cohort: 240; ATP immunogenicity
cohort: 237
Inclusion criteria: healthy infants aged 6 to 10 weeks with a birth weight > 2 kg
Exclusion criteria: any other investigational drug or vaccine 30 days prior to the ad-
ministration of the first dose of the study vaccine; a history of allergy; rotavirus gastroen-
teritis; infants with acute illness at the time of enrolment could not receive the vaccine
until the condition was resolved
Interventions 1. Liquid formulation of RIX4414*/(RV1), 1.5 mL (n=100)
2. Placebo corresponding to liquid vaccine formulation (n=25)
3. Lyophilized formulation RIX4414*/(RV1), 1 mL (n=100)
4. Placebo corresponding to lyophilized vaccine formulation (n=25)
* vaccine containing at least 106 median CCID50 of live attenuated RIX4414 human
rotavirus strain
Schedule: 2 oral doses at month 0 and 1 (minimum time interval between doses: 14
days)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity, occurrence of the symptom within the 15-day solicited follow-up
period after each dose (collected from GSK report)
2. Serious adverse events, occurrence throughout study period
3. * Rotavirus diarrhoea, stool samples collected during diarrhoea episodes tested for
rotavirus strains
4. * All-cause diarrhoea, up to 1 month post-dose 2
5. Dropouts: up to 2 months after dose 2 (collected from GSK report)
6. All-cause death (collected from GSK report)
7. Adverse events resulting in discontinuation (collected from GSK report)
Outcomes to measure immunogenicity
8. Seroconversion, antirotavirus IgA antibody concentration > 20 U/mL, 1 month after
each dose (collected from GSK report)
9. Rotavirus vaccine virus shedding in stools, reported at peak (day 7 post-dose 1)
* Outcome reported as proportion (P) with 95% CI. Events (n) and totals (N) were
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estimated by using the value when 2 formulae for the standard error (SE) converged
Immunization status Routine childhood vaccinations were allowed according to local practice, but at least 14
days apart from each dose of study vaccine
Location 5 centres in Finland
WHO mortality stratum A
Notes Study known as RIX GSK[048] 2007-EU in previously published versions of this review
Date: August to November 2005
Source of funding: GlaxoSmithKline Biologicals
Study rationale: the immunogenicity, reactogenicity and safety of the RV1 liquid for-
mulation were compared with lyophilized formulation and placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Quote: “A standard SAS® program was
used for generating the randomization list
and a block randomization was used in or-
der to ensure that the balance between the
treatment arms were maintained”
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “a unique randomization number
identified the vials to be administered to
the same subject” and “subjects were ad-
ministered the vaccine dose with the low-
est treatment number available at the study
centre”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were
blinded as far as technically possible
Quote: “The study was double blind with
respect to each of the vaccine formula-
tion and their respective placebo; however,
blinding between the two vaccine formula-
tions was not technically possible because
of the difference in appearance of the vac-
cines”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across study groupswith
reasons for dropout/exclusion reported
Selective reporting (reporting bias) Low risk All pre-published outcomes reported
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Other bias Low risk No apparent other bias
RV1 Ward 2006-USA
Methods RCT
Length of follow-up: 7 days following each vaccination; 3 to 5 weeks after second
vaccination
Adverse event data collection methods: unclear
Participants Number: 117 enrolled; 111 evaluable
Age range: 3 to 6 months (beginning); 3 to 6 months (end)
Inclusion criteria: not specified
Exclusion criteria: not specified
Interventions RV1
1. RIX4414 (RV1)
1.1. 1 x 105 dose; 41 participants (randomized)
1.2. 1 x 106 dose; 39 participants (randomized)
2. Placebo: 37 participants
Schedule: 2 doses given at a 6- to 10-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vom-
iting; measured for 7 days after each dose
*Although mentioned in the methods, no results are presented
Outcomes to measure immunogenicity
2. Vaccine take: faecal shedding of rotavirus antigen (review includes data from after
either dose 1 or 2)
3. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after either dose 1 or 2)
Immunization status Not specified
Location Cincinnati and Baltimore, USA
WHO mortality stratum A
Notes Date: July to December 1996
Source of funding: “Avant Immunotherapeutics, to which the 89-12 vaccine candidate
was licensed and which sublicensed its product to GlaxoSmithKline (which developed
Rotarix from 89-12).”
89-12 was the precursor to RV1
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk Quote: “double-blinded, placebo-
controlled study designed”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “double-blinded, placebo-
controlled study designed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No impact on intervention effect estimate
Quote: “Of the 80 vaccine recipients in this
trial, 2 had evidence of natural rotavirus
infection before administration of the first
dose, determined on the basis of rotavirus
IgA in their serum. These, along with the 3
who received only 1 dose of vaccine, were
eliminated from further analyses”
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information
RV1 Zaman 2009-BGD
Methods RCT
Length of follow-up: 31 days after each vaccination (total of 14 weeks)
Adverse event data collection methods: “active surveillance for reactogenicity and
safety was conducted via daily home visits by study personnel for 8 days after each dose
of vaccine or placebo dose and bi-weekly home visits thereafter until one month after
last dose” (active method); “During every episode, parents were asked to record in a
daily diary card the number of looser than normal stools, axillary or rectal temperature,
number of vomiting episodes, any rehydration or other medication administered, and
any medical attention (defined as medical personnel contact, advice, or visit; emergency
room contact or visit; or admission)” (passive method); serious adverse events were
reviewed periodically by an independent committee
Participants Number: 300 enrolled; 290 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 6 to 7 weeks
Exclusion criteria: acute disease at the time of enrolment;malnourished children; history
of chronic administration of immunosuppressants since birth; received any vaccines or
treatments prohibited by the protocol; or had any disorders or illnesses excluded by the
protocol
Interventions RV1
1. RIX4414 (RV1)
1.1. 1 x 106.5 dose + OPV; 100 participants (randomized)
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1.2. 1 x 106.5 dose; 100 participants (randomized)
2. Placebo:
2.1. Placebo + OPV; 50 participants (randomized)
2.2. Placebo; 50 participants (randomized)
Schedule: 2 doses given at a 6- to 12-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: for each type of solicited symptom, occurrence of the symptomwithin
the 8-day (Day 0 to7) solicited follow-upperiod after each dose; occurrence of unsolicited
adverse events within 31 days (Day 0 to 30) after each dose, according to MedDRA
classification; measured up to 31 days after vaccine/placebo
2. Serious adverse events: occurrence throughout entire study period (up to 105 days
after vaccine/placebo)
3. Dropouts: measured up to 105 days after vaccine/placebo
4. Rotavirus diarrhoea: presence of rotavirus in gastroenteritis episode stools collected
from dose 1 of vaccine/placebo up to 2 months after dose 2; measured up to 105 days
after vaccine/placebo
5. All-cause death
6. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
7. Viral shedding: % participants with rotavirus antigen in stool samples collected at
predetermined time points (ATP cohort for immunogenicity, stool analysis subset) (re-
view includes data from combined time points)
8. Seroconversion: appearance of anti-rotavirus immunoglobulin A antibody concen-
tration ≥ 20 U/mL in participants who were negative for rotavirus before vaccination
(review includes data from 1 month after dose 2)
Immunization status All children in the study received the standard EPI vaccines starting at 6 weeks of age,
including oral polio vaccine for 1 RV1 vaccine arm and 1 placebo arm
Location Single site in urban Dhaka at Mirpur, Bangladesh
WHO mortality stratum D
Notes Date: June 2005 to January 2006
Source of funding: funded by GlaxoSmithKline Biologicals and the Rotavirus Vaccine
Program (RVP) at the Program for Appropriate Technology in Health (PATH)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using a SAS pro-
gramme
Allocation concealment (selection bias) Low risk Likely to be adequate: treatment masked to
investigators
Quote: “A treatment number identified
uniquely the vaccine doses to be adminis-
tered to the same subject”, and “subjects
137Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV1 Zaman 2009-BGD (Continued)
were administered the study vaccine dose
(HRV vaccine or placebo) with the lowest
number available at the study site”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Parent/guardian and study personnel were
not aware of the treatment administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed appropriately
Selective reporting (reporting bias) Low risk All planned outcomes were reported
Other bias Unclear risk No information
RV1 Zaman 2017-BGD
Methods Cluster-RCT, open-label, cluster-randomized (by village), parallel-group field trial with
an observed-only control group
Length of follow-up: 2 years
Adverse event data collection methods: (not reported if active of passive)“Serious ad-
verse events among infants vaccinated with HRV were assessed by the principal investi-
gator or trained study physicians and followed to resolution”
Participants Number: 12,318 enrolled; 11,004 evaluable
Age range: 6 to 20 weeks
Inclusion criteria: 6 to 20 weeks of age, having primary residence at the time of DTP1
receipt in a village selected for introduction of HRV, and having a parent or guardian
provide written informed consent
Exclusion criteria: history of intussusception, hypersensitivity to the active substance or
any component in the vaccine, uncorrected congenital malformation of the gastrointesti-
nal tract, or known or suspected immunodeficiency. Infants with an acute febrile illness
were temporarily excluded from HRV vaccination only if that illness was severe enough
to warrant postponement of other EPI vaccinations. Infants with current diarrhoea or
vomiting or both were not excluded unless the illness met the aforementioned temporary
exclusion criterion
Interventions 1. RV1; 1-ml dose of HRV (Rotarix; GSKBiologicals, Rixensart, Belgium) (n=71 villages
with 6527 age-eligible infants)
2. Non-placebo controlled (observed only controls) (n=71 villages with 5791 age-eligible
infants)
Schedule: at 6 and 10 weeks of age
Outcomes Clinical outcome measures (safety and efficacy)
1. Severe rotavirus diarrhoea
2. Serious adverse events
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Immunization status HRVwas scheduled to be given along with other standard infant vaccines including OPV
at the DTP1 and DTP2 immunization visits, recommended in Bangladesh to occur at
6 and 10 weeks of age
Location 142 study sites (cluster-randomized villages), Bangladesh
WHO mortality stratum D
Notes Date: September 2008 to March 2011
Source of funding: GAVI and PATH
Study rationale: The primary objective of the trial was to estimate the overall effective-
ness of an HRV vaccination programme in reducing the risk of presenting with acute
rotavirus diarrhoea to a treatment facility among all children who had been age-eligible
for vaccination with HRV during the vaccination programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Villages were randomized in a 1:1 ratio for
introduction of HRV or not. Prior to study
initiation, PATH computer-generated the
allocation sequences using block random-
ization with block sizes of 12
Allocation concealment (selection bias) Unclear risk The generated allocation sequences were
securely transferred to the principal investi-
gator, who distributed the sequences to the
field supervisors who oversaw HRV vacci-
nations
Blinding (performance bias and detection
bias)
All outcomes
High risk The study was conducted open-label with-
out masking, and field staff conducting the
vaccinations were unblinded. Medical staff
collecting clinical data on diarrhoeal pre-
sentations and laboratory personnel con-
ducting assays on stools were not informed
of previous HRV receipt of participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome data available for 11,004/12,318
enrolled participants
Selective reporting (reporting bias) High risk Online registration of
trial ( NCT00737503) indicates all-cause
diarrhoea as an outcome but results were
not reported for this outcome in the study
report
Other bias Unclear risk Cluster-randomized trial.
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RV5 Armah 2010-AF
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
A subset had active surveillance: “A subset of 300 participants enrolled in Kenya was
followed up for 42 days for all adverse events, including vomiting, diarrhoea, and high
temperature. Home visits were attempted on days 3, 5, 7, 14, 21, and 42 after all
vaccinations”
Participants Number: 5560 enrolled; 5468 randomized, 5225 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breast-feeding was
not restricted; no enrolment restrictions based on HIV status - infants in Kenya were
offered routine HIV testing, and a subset were followed up for safety
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Special group:HIV-infected participants
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 2733 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 2735 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by enzyme
immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
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8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Kassena-Nankana district (Ghana), rural Karemo division, Siaya district
(Kenya), and urban area of Bamako (Mali)
WHO mortality strata D, E
Notes This trial was conducted in Ghana, Kenya and Mali; data reported separately by country
can be found under RV5 Armah 2010-GHA; RV5 Armah 2010-KEN and RV5 Armah
2010-MLI.
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
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Other bias Low risk No apparent other bias
RV5 Armah 2010-GHA
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
Participants Number: 2200 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breast-feeding was
not restricted; no enrolment restrictions based on HIV status
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 1098 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 1102 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
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IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Kassena-Nankana district, Ghana
WHO mortality stratum D
Notes This trial was conducted in Ghana, Kenya and Mali; this part presents data for the
Ghana cohort. Data reported separately for the other countries can be found under RV5
Armah 2010-KEN and RV5 Armah 2010-MLI data reported for all countries under
RV5 Armah 2010-AF
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
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Other bias Low risk No apparent other bias
RV5 Armah 2010-KEN
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
A subset had active surveillance: “A subset of 300 participants enrolled in Kenya was
followed up for 42 days for all adverse events, including vomiting, diarrhoea, and high
temperature. Home visits were attempted on days 3, 5, 7, 14, 21, and 42 after all
vaccinations”
Participants Number: 1322 enrolled; 1308 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breast-feeding was
not restricted; no enrolment restrictions based on HIV status - infants in Kenya were
offered routine HIV testing, and a subset were followed up for safety
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Special group:HIV-infected participants
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 656 participants (received at least one
dose)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 652 participants (received at least one
dose)
Schedule: 3 doses given at a 4 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
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6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
*Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Karemo division, Siaya district, Kenya
WHO mortality stratum E
Notes This trial was conducted in Ghana, Kenya and Mali; this part presents data for the
Kenya cohort. Data reported separately for the other countries can be found under RV5
Armah 2010-GHA and RV5 Armah 2010-MLI, and for all countries under RV5 Armah
2010-AF
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
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assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No apparent other bias
RV5 Armah 2010-MLI
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 21 months for
efficacy outcomes
Adverse event data collection methods: “Study physicians reported and documented
all serious adverse events occurring within 14 days of any dose and deaths or vaccine-
related serious adverse events occurring at any time during the study”
Participants Number: 2011 enrolled; 1960 randomized and evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks; “no symptoms of active gastroin-
testinal disease and could be adequately followed up for safety by home visit or telephone
contact (1 week and 2 weeks after any dose of vaccine or placebo)”; breast-feeding was
not restricted; no enrolment restrictions based on HIV status
All children exposed to or infected with HIV were referred for appropriate HIV care
and treatment; voluntary counselling and testing were also offered to mothers of infants
exposed to HIV
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 2 mL (every dose had an estimated potency of 107 infectious units per
reassortant rotavirus); 3 doses given 4 weeks apart; 979 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 981 participants (randomized)
Schedule: 3 doses given at a 4 week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events (including intussusception)
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
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7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
* Data on fever and vomiting are provided only on figure 2 and data could not be
extracted reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in urban area of Bamako, Mali
WHO mortality stratum D
Notes This trial was conducted in Ghana, Kenya and Mali; this part presents data for the Mali
cohort
Date: 28 April 2007 to 31 March 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Registration number: NCT00362648
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No apparent other bias
RV5 Block 2007-EU/USA
Methods RCT
Length of follow-up: up to 42 days for safety/immunogenicity; up to 1 year for efficacy
Adverse event data collection methods: parents or guardians contacted by the study site
on day 7, day 14, and day 42 after each vaccination and asked about serious adverse events
(active method); parents or guardians were provided diary cards and were instructed to
record daily temperatures for the infant for 7 days after each vaccination (passive method)
Participants Number: 1312 enrolled; 1200 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, 6 through 12 weeks of age, who had no known
history of congenital abdominal disorders, intussusception, or abdominal surgery; no
known or suspected impairment of immunological function; no known hypersensitivity
to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no
fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of immunization;
no history of known prior rotavirus disease, chronic diarrhoea, or failure to thrive; no
clinical evidence of active gastrointestinal illness; no receipt of intramuscular, oral, or
intravenous corticosteroid treatment within the 2 weeks before vaccination; did not
reside in a household with an immunocompromised person; no prior receipt of a blood
transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus
vaccine during the course of the study or within 42 days before first dose of vaccine/
placebo; any infant who could not be adequately followed for safety by telephone or home
visit; and no condition, which, in the opinion of the investigator, may have interfered
with the evaluation of the study objectives
Exclusion criteria: see above
Interventions RV5
1. WC3 (RV5): 1.1 x 107 PFU; 651 participants (randomized)
2. Placebo: 661 participants (randomized)
Schedule: 3 doses given 4 to 10 weeks apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: potential cases of intussusception were adjudicated by an
independent blinded committee; all study personnel remained blinded to the treatment
arm and adjudication results of the potential intussusception cases; data on cases of
intussusception, deaths, or other serious adverse events determined to be vaccine-related
by the investigator were collected throughout the trial; measured up to 42 days, and up
to 1 year (for vaccine-related serious adverse events)
2. Reactogenicity: no definition; measured up to 42 days
3. Dropouts: no definition: measured up to 1 year
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4. Rotavirus diarrhoea: case of rotavirus gastroenteritis defined as meeting both of the
following criteria: (a) > 3 watery or looser-than-normal stools within a 24-hour period
or forceful vomiting, or both; and (b) rotavirus antigen detection by EIA in the stool
sample. Primary analysis of efficacy included only cases caused by naturally-occurring
rotavirus of serotypes G1, G2, G3, or G4 as confirmed by RT-PCR occurring at least
14 days after the third dose
5. Severe rotavirus diarrhoea: each episode graded on a 24-point scale, where a score < 8
designated as mild, > 8 as moderate-and-severe, and > 16 as a severe disease
6. All-cause death
7. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
8. Seroconversion: pre-vaccination and post-vaccination sera analyzed for serotype-spe-
cific rotavirus neutralizing antibody and for serum anti-rotavirus immunoglobulin A
(IgA) (review includes data from after dose 3)
Immunization status Use of oral poliovirus vaccine during the course of the study or within 42 days before
first dose of vaccine/placebo was an exclusion criterion; administration of other vaccines
permitted
Location 30 sites; 27 in USA, and 3 in Finland
WHO mortality stratum A
Notes Date: 24 September 2002 (first participant in) to 11 February 2004
Source of funding: Merck & Co., Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Enrolled infants were randomly
assigned 1:1 by using computer-generated
allocation schedules to receive either vac-
cine or visibly indistinguishable placebo in
a sucrose citrate buffer administered orally
as three 2-mL doses 4 to 10 weeks apart”
Allocation concealment (selection bias) Low risk Sequential identical containers (see quote
above)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote:“This randomized, clinical trial
blinded to investigator, parent or guardian,
and sponsor”
“The placebo was identical to the vaccine
except that it did not contain the rotavirus
reassortants or trace trypsin”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
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Selective reporting (reporting bias) High risk Key expected outcome (episodes of gas-
troenteritis) not included
Other bias Unclear risk Relevant information needed for assess-
ment not provided
RV5 Ciarlet 2009-EU
Methods RCT
Length of follow-up: up to 42 days after last dose
Adverse event data collection methods: see outcome measures; passive method used
for reactogenicity, and active method used for serious adverse events
Participants Number: 403 enrolled; 403 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants, aged 6 to 12 weeks; mothers negative for hepatitis B
surface antigen; no known history of congenital abdominal disorders; intussusception, or
abdominal surgery; no known or suspected impairment of immunological function; no
history of seizure with or without fever; no known hypersensitivity to any component of
rotavirus vaccine or INFANRIX hexa; no prior receipt of any rotavirus, DTaP, DTP, H.
influenzae type b, Hepatitis B, injectable poliovirus vaccine, or oral polio vaccine during
the course of the study, within 42 days before first dose of RV5 or before final blood
draw (42 days after dose 3); no fever, with a rectal temperature < 38.1 °C (< 100.5 °F)
at the time of immunization; no history of known rotavirus disease, chronic diarrhoea,
or failure to thrive; no clinical evidence of active gastrointestinal illness; no prior receipt
of intramuscular, oral, or intravenous corticosteroids treatment within 2 weeks before
vaccination; did not reside in a household with an immunocompromised person; no
receipt of a blood transfusion or blood products, including immunoglobulin; did not
participate in another clinical study within 42 days before or during current study; could
be adequately followed for safety
Exclusion criteria: as above
Interventions RV5
1. WC3 (RV5) plus Infanrix hexa: RV5 (2 mL; 3 doses given 4 to 6 weeks apart); 201
participants (randomized)
2. Placebo plus Infanrix hexa: placebo (2 mL; 3 doses given 4 to 6 weeks apart); 202
participants (randomized)
Infanrix hexa: comes in 2 parts; first part is a white, milky liquid (0.5 mL) in a pre-
filled syringe that consists of the combined diphtheria, tetanus, pertussis, hepatitis b,
and inactivated poliovirus vaccine; second part is the H. influenzae type b vaccine and
is a white pellet in a separate glass vial; both parts mixed together before being injected
intramuscularly
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: in both groups, at each study visit, parents/legal guardians received
Vaccination Report Cards (VRCs) which they completed for 7 days with information on
fever, diarrhoea, and vomiting starting from the day of office visit and returned completed
VRCs to the study site at the next visit
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2. Serious adverse events: parents/legal guardians of all participants were contacted by
telephone or home visit on approximately day 14 after each office visit in either group
for safety follow-up and asked about all serious adverse experiences; measured up to 42
days
3. All-cause death
4. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
None specific to review
Immunization status Hepatitis B vaccine, diphtheria-tetanus-acellular pertussis, polio virus, andH. influenzae
type b co-administered
Location 26 study sites in Austria, Belgium, and Germany
WHO mortality stratum A
Notes Date: 22 February 2006 to 13 November 2006
Source of funding: Merck & Co., Inc.
Other: only data about serious adverse events and adverse events leading to discontinu-
ation are provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomized 1:1 to
receive hexavalent vaccine concomitantly
with either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, parents/guardians
and study personnel (internal and exter-
nal) were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In
both treatment groups (RV5+Hexavalent
and Placebo+Hexavalent), ~84% of the in-
fants reported 1 or more adverse events
within 14 days after vaccination. One sub-
ject discontinued in the concomitant-use
group because of abdominal pain (consid-
ered non-serious)” (Merck 2012)
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Selective reporting (reporting bias) High risk Not all prespecified outcomes reported
Other bias Unclear risk No details
RV5 Clark 2003-USA
Methods RCT
Length of follow-up: up to 1 year
Adverse event data collection methods: parents/guardians recorded temperatures 4 to
6 hours after each dose and then daily thereafter for 7 days and the number of episodes of
vomiting and diarrhoea daily for 7 days (passive method); also recorded any behavioural
or systemic adverse experience on a VRC and was asked to report any serious adverse
experience immediately to the study site; telephone call made to each parent/guardian
14 days after each dose to verify that no serious adverse experiences had occurred (active)
Participants Number: 731 enrolled; 681 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Special groups: breast-fed; infants in the vaccine control group (Group 1) received the
reassortants as administered in previous studies within 30 minutes of feeding Enfamil
formula (30 ml) or Mylanta Double Strength (0.5 ml/kg). Infants in a corresponding
placebo group (Group 2) were pre-fed as in Group 1
Inclusion criteria: healthy infants 2 to 4 months of age
Exclusion criteria: known hypersensitivity to any component of the rotavirus vaccine;
known or suspected immunologic impairment; prior administration of any rotavirus
vaccine; fever at the time of vaccination; history of chronic diarrhoea; failure to thrive or
gastrointestinal illness; recent receipt of oral polio vaccine or blood products; residence
in the household with an immunocompromised person; and failure to fast for 1 hour
before vaccination
Interventions RV5
1. WC3 (RV5): 107 PFU; 581 participants (randomized)
2. Placebo: 150 participants (randomized)
Schedule: 3 doses given 42 to 56 days apart
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: parents/guardians recorded temperatures 4 to 6 hours after each dose
and then daily thereafter for 7 days and the number of episodes of vomiting and diarrhoea
daily for 7 days; fever defined as 38.1 °C (rectal) or 37.5 °C (oral, otic, or axillary);
measured up to 42 days after vaccine/placebo
2. Rotavirus diarrhoea: case of rotavirus gastroenteritis defined as ≥ 3 watery or looser-
than-normal stools within a 24-hour period or forceful vomiting, or both, occurring at
least 14 days after the third dose of vaccine/placebo and detection by ELISA of wild-type
G1 or G2 rotavirus or both in a stool specimen collected within 14 days of symptom
onset; measured up to 1 year
3. Severe rotavirus diarrhoea: clinical scoring system used to assess severity of illness for
each episode of rotavirus acute gastroenteritis; measured up to 1 year
4. Serious adverse events: defined as: death; life-threatening events; experiences that
resulted in hospitalization, persistent disability, or that prolonged a hospitalization; and
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other importantmedical events. Data on deaths or any serious adverse experiences judged
to be vaccine-related were collected for the duration of the study; measured up to 1 year
5. Intussusception, data from correspondence with Merck (Merck 2012)
6. Dropouts
Outcomes to measure immunogenicity
7. Viral shedding: at least a 3-fold rise in serum-neutralizing antibody to total stool IgA
(review includes data from after dose 3)
8. Seroconversion: at least a 3-fold rise in serum-neutralizing antibody to serum IgA
(review includes data from after dose 3)
Immunization status Children that had recently received oral polio vaccine were excluded from the study
Location 19 centres in the USA
WHO mortality stratum A
Notes Date: September 1997 through September 1998
Source of funding: Merck & Co., Inc.
Other: active surveillance for cases of rotavirus gastroenteritis at each study site began
when the local laboratory confirmed at least 3 cases of rotavirus gastroenteritis or on 31
January 1998, whichever came first
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Quote: “Children who met all eligibility
criteria were randomized to one of eight
treatment groups”
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel
Quote: “Parents of participating infants
and study personnel were blinded to receipt
of vaccine/placebo but not to the volume
administered or to the prefeeding require-
ment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk Not all prespecified outcomes reported
Quote: “Because there were relatively few
confirmed cases of RV [rotavirus] caused
by serotypes G1 and G2, the evidence is
insufficient to declare that the efficacy of
any buffered formulation is > 0.0%”
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Other bias High risk Poor reporting of efficacy data
RV5 Clark 2004-USA
Methods RCT
Length of follow-up: up to 1 year (season)
Adverse event data collectionmethods: episodes of fever (subjective assessment of fever)
, vomiting, diarrhoea, behavioural changes, and any other adverse experiences during the
14 days after each dose were also reported on the diary card (passive method); parents
were asked to report any serious adverse experience immediately to the study site (passive
method); telephone call made to each participant 14 days after each vaccination to ask
about serious adverse experiences (active method)
Participants Number: 439 enrolled; 416 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants approximately 2 to 6 months of age were enrolled
and followed for episodes of acute gastroenteritis
Exclusion criteria: known hypersensitivity to any component of the rotavirus vaccine;
known or suspected immunologic impairment; prior administration of any rotavirus
vaccine; fever at time of vaccination (> 38.1 °C rectal); history of chronic diarrhoea or
failure to thrive; clinical evidence of gastrointestinal illness; receipt of any other vaccines
within 14 days; immunocompromised resident in the home; or any condition, which, in
the opinion of the investigator, might interfere with the evaluation of the study objectives
Interventions RV5
1.WC3 (RV5): 107 PFU; 3 doses at 6 to 8 week intervals; 218 participants (randomized)
2. Placebo: 3 doses at 6 to 8 week intervals; 221 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case of rotavirus disease in a study participant defined as ≥ 3
watery or looser-than-normal stools within a 24-hour period or forceful vomiting, or
both, occurring at least 14 days after the third dose of vaccine/placebo and identification
of rotavirus in a stool specimen obtained within 14 days of symptom onset; measured
up to 1 year
2. Severe rotavirus diarrhoea: based on a clinical scoring system for evaluating the severity
of an episode of infant acute gastroenteritis (0 to 24 points) they consider severe above
16 points; measured up to 1 year
3. Dropouts: measured up to 1 year
4. Serious adverse events: serious adverse experiences included death, life-threatening
events, and experiences that resulted in hospitalization, persistent disability, or that pro-
longed a hospitalization; deaths or any serious adverse experiences judged to be vaccine-
related were recorded for the duration of the study; measured up to 1 year, including
intussusception (data from correspondence with Merck, Merck 2012).
5. Reactogenicity: all participants were followed for clinical adverse experiences for 14
days after each vaccination
6. Adverse events requiring discontinuation; measured up to 1 year
Outcomes to measure immunogenicity
7. Viral shedding: stools were collected to evaluate vaccine strain shedding among subsets
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of infants at different time periods after each dose (review includes data from after dose
3)
8. Seroconversion: pre-vaccination and post-vaccination sera assayed for anti-rotavirus
immunoglobulin A (IgA) and anti-rotavirus IgG (units/mL, based on pooled human
serum standards); ≥ 3-fold rise in titre from baseline to after dose 3 (review includes
data from after dose 3)
Immunization status Receipt of any other vaccines within 14 days was not allowed
Location 10 study sites in the USA
WHO mortality stratum A
Notes Date: August 1993 to June 1994
Source of funding: Merck & Co., Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Infants who met all eligibility cri-
teria were randomly assigned in a 1:1 ra-
tio”. No further details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The vials of vaccine and placebo
were visibly indistinguishable”
Quote: “The placebo was identical to the
vaccine except that it did not contain the
rotavirus reassortants”. Investigators, study
personnel (internal and external), and par-
ents/guardians were blinded throughout
trial. (Merck 2012)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk ≥ 1 outcome of interest reported incom-
pletely
Quote: “Only wild-type (ie, non-vaccine
related) rotavirus cases were considered for
the primary case definition”
Other bias Unclear risk Not enough detail to make a judgement
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Methods RCT
Length of follow-up: 28 days after 3rd dose
Adverse event data collection methods: Active and passive: “participants were observed
for 30 min post vaccination for immediate adverse events at the study site. Subsequently,
the subject’s parents/guardians were given a thermometer, a Symptom Diary (SD) cov-
ering Days 0-6 and a second SD covering Days 7-27 for safety follow up following
each of the three doses. They were instructed to observe and record their child’s axillary
temperature twice daily as well as any AEs up to 7 days after each dose in the first SD,
and from day 7 to day 27 in the second SD. Parents/guardians were instructed to bring
the study infants to the study clinic on Day 7 and Day 28 after each administration of
the BRV-TV vaccine/RotaTeq/Placebo as an outpatient and whenever any symptoms
developed.The diary card contained list of solicited events and blank spaces to capture
any unsolicited events”
Participants Number: 100 enrolled; 100 evaluated
Age range: 6 - 8 weeks of age at time of enrolment
Inclusion criteria:Healthy infants, of either sex, 6 - 8 weeks of age at time of enrolment;
born after a gestational period of 36 - 42 weeks with birth weight > 2 kg
Exclusion criteria: History of congenital abdominal disorders, intussusception, or ab-
dominal surgery; infants exhibiting signs of severe malnutrition; known or suspected
impairment of immunological function in participant or immediate family; develop-
mental delay or neurological disorder; known hypersensitivity to any component of the
rotavirus vaccine; fever; history of known rotavirus disease, chronic diarrhoea, or failure
to thrive; any conditions which, in the opinion of the investigator, might interfere with
the evaluation of the study objectives
Interventions 1. RV5 (2.0 mL)
2. BRV-TV (2.0 mL), antigen concentration (105.0 FFU per serotype per dose)
3. BRV-TV (2.0 mL), antigen concentration (105.8 FFU per serotype per dose)
4. BRV-TV (2.0 mL), antigen concentration (106.4 FFU per serotype per dose)
5. Placebo (2.0 mL)
Schedule: 3 doses of vaccines/comparator/placebo were administered at 6 - 8, 10 - 12
and 14 - 16 weeks of age
Outcomes Clinical outcome measures (safety and efficacy)
1. All serious adverse events
2. Reactogenicity: fever, diarrhoea, vomiting
3. Dropouts before the end of the trial
Outcomes to measure immunogenicity
4. Rotavirus vaccine shedding
Immunization status Infants concomitantly received a combined Diphtheria, Tetanus, Whole-cell pertussis,
Hepatitis B and Haemophilus influenzae type b (DTPwHB-Hib) pentavalent vaccine
and Trivalent Oral Polio Vaccine
Location 2 sites, India
WHO mortality stratum D
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Notes Alongside the infant cohort, the study also included an additional cohort of healthy
adult volunteers
Date: July 2012 - not reported
Source of funding: Shantha Biotechnics Limited
Study rationale: study was carried out with the long-term aim to produce a locally
licensed vaccine which is equally safe and immunogenic as compared to available licensed
vaccines
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization.
Allocation concealment (selection bias) Low risk Likely to be adequate
Quote: “Pre-numbered or coded identical
containers”
Blinding (performance bias and detection
bias)
All outcomes
High risk Single-blind, participant and outcome as-
sessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data presented for all 100 partic-
ipants
Selective reporting (reporting bias) Low risk No indication of selective outcome report-
ing
Other bias Low risk No apparent other bias
RV5 Iwata 2013-JPN
Methods RCT
Length of follow-up: 25 months
Adverse event data collection methods: any death, vaccine-related serious adverse
events and intussusception were collected during the study period; parents/guardians
asked to record adverse events on a standardized VRC during 14 days after each vacci-
nation
Participants Number: 762
Age range: 6 to 12 weeks
Inclusion criteria: healthy Japanese Infants
Exclusion criteria: history of known prior rotavirus gastroenteritis; infants who are con-
currently participating in or are anticipated to participate in other studies of investiga-
tional products at any time during the study period
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Interventions 1. Rotavirus vaccine, live, oral, pentavalent [RV5], 381 participants
2. Placebo (unspecified), 381 participants
Schedule: 3 doses, 28 to 70 days apart, with 14 days of safety follow-up after each
vaccination, and follow-up for acute gastroenteritis episodes until the end of the study
Outcomes 1. Efficacy against rotavirus gastroenteritis of any severity, at least 14 days following the
3rd vaccination
2. Efficacy against moderate to severe and severe rotavirus gastroenteritis, at least 14 days
following the 3rd vaccination
3. Serious adverse events, including intussusception (data from correspondence with
Merck; Merck 2012).
4. Reactogenicity (fever, vomiting, diarrhoea)
5. Dropouts before the end of the trial
6. Adverse events leading to discontinuation of the trial
7. Number of deaths (data from correspondence with Merck; Merck 2012)
Immunization status No information about other vaccines given
Location 32 sites in Japan
WHO mortality stratum A
Notes Date: August 2008 to September 2009
Registration number: NCT00718237
Source of funding: Merck Sharp & Dohme Corp
Rationale: “to evaluate whether V260 is effective and well tolerated in Japanese healthy
infants”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Allocation number was assigned
and the subject was randomized to the
group receiving RV5 or the group receiv-
ing placebo in a 1:1 ratio according to the
randomization code prepared by a com-
puter at the US Merck Headquarters Of-
fice” (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated and al-
located centrally for participants (Merck
2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external) and parents/guardians
were blinded throughout trial (Merck
2012)
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RV5 Iwata 2013-JPN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition/exclusions balanced across groups
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Low risk No apparent other bias
RV5 Kim 2008-KOR
Methods RCT
Length of follow-up: up to 42 days after last dose
Adverse event data collection methods: diary cards (passive method)
Participants Number: 178 enrolled; 171 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants; 6 to 12 weeks of age
Exclusion criteria: history of congenital abdominal disorders, intussusception, or ab-
dominal surgery; known or suspected impairment of immunological function; known
hypersensitivity to any component of the rotavirus vaccine; prior receipt of any rotavirus
vaccine; fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of im-
munization; history of known prior rotavirus disease, chronic diarrhoea, or failure to
thrive; clinical evidence of active gastrointestinal illness (infants with gastro-oesophageal
reflux disease were permitted to participate in the study as long as the gastro-oesophageal
reflux disease was well controlled with or without medication); receipt of intramuscular,
oral, or intravenous corticosteroid treatment between the 2 weeks before first vaccination
and 2 weeks after last vaccination; reside in a household with an immunocompromised
person; prior receipt of a blood transfusion or blood products, including immunoglob-
ulins; receipt of OPV during the course of the study or within 42 days before first dose
of vaccine/placebo; and condition, which, in the opinion of the investigator, may have
interfered with the evaluation of the study objectives
Interventions RV5
1.WC3 (RV5): 6.9 to 8.6 x 107 PFU; 3 doses given 4 to 10 weeks apart; 115 participants
(randomized)
2. Placebo: 3 doses given 4 to 10 weeks apart; 63 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events: no definition; measured up to 42 days
2. Reactogenicity: no definition; measured up to 14 days
3. Adverse events resulting in discontinuation
Outcomes to measure immunogenicity
4. Seroconversion: sero-response serum anti-rotavirus immunoglobulin A (IgA) defined
as an increase in antibody titre by a factor of ≥ 3 from baseline (data could not be
extracted for review)
Immunization status Infants excluded if they had or were to receive oral poliovirus vaccine at any time during
the study or in the 42 days before the first dose; concomitant administration of other
licensed vaccines and breast-feeding was not restricted
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Location 8 study centres in South Korea
WHO mortality stratum B
Notes Date: 2 August 2005 (first participant in) to 25 May 2006 (last dose given); last partic-
ipant completed follow-up on 5 July 2006
Source of funding: Merck & Co., Inc.
Other: most of the outcome data are not provided in the reports
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomized 2:1 to
receive hexavalent vaccine concomitantly
with either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants, investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo, investigators, study personnel (in-
ternal and external), and parents/guardians
were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason related to outcome
Selective reporting (reporting bias) High risk Key expected outcome not included
Other bias Unclear risk Information not provided
RV5 Lawrence 2012-CHN
Methods RCT
Length of follow-up: 2 weeks after last dose
Adverse event data collection methods: not reported
Participants Number: Infant cohort: 48 enrolled and randomized, child cohort: 48 enrolled and
randomized
Inclusion criteria: healthy infants aged 6 to 12 weeks, and healthy children aged 2 to 6
years, there was also a cohort of adults (not reported in this review)
Exclusion criteria: receiving other live vaccines 14 days before or after study vaccine;
prior administration of any rotavirus vaccine; elevated temperature, with axillary temper-
ature ≥ 37.1 °C 24 hours before study vaccine; prior or active gastrointestinal illnesses;
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immunodeficiency
Interventions 1. 2.0 mL RV5 (V260) administered orally. The vaccine consists of an oral solution of
5 live human-bovine reassortant rotaviruses (24 infants, 24 children)
2. 2.0 mL matching placebo to RV5 administered orally (24 infants, 24 children)
Schedule: infant cohort: 3 doses of RV5/placebo at 3 separate visits scheduled 28 to 70
days apart. The third dose was administered by 32 weeks of age; child cohort: one dose
Outcomes Clinical outcome measures
1. Serious adverse events, up to 14 days post-vaccination, including intussusception (data
from correspondence with Merck; Merck 2012).
2. Adverse events requiring discontinuation
3. Dropouts from the trial
4. Number of deaths (data from correspondence with Merck; Merck 2012).
5. Reactogenicity
Outcomes to measure immunogenicity
6. Vaccine virus shedding in stools, day 3 to day 7 following each of the 3 doses of RV5/
placebo
Immunization status Other live vaccines 14 days before or after study vaccine were not allowed
Location China
WHO mortality stratum B
Notes Date: September 2009 to March 2010
Source of funding: Merck Sharp & Dohme Corp
Study rationale: “This study will assess the safety and tolerability of RV5 (V260) in
the healthy Chinese populations. Approximately 144 participants will be enrolled and
equally stratified into three age cohorts, Cohort I ages 19-47 years, Cohort II ages 2-6
years, and Cohort III ages 6-12 weeks”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All participants were randomized accord-
ing to a computer-generated allocation
schedule (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants; investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo; investigators, study personnel (in-
ternal and external) and parents/guardians
were blinded throughout trial (Merck
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2012)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced across groups with rea-
sons reported for withdrawal
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Other bias Low risk No apparent other bias
RV5 Levin 2017-AF
Methods RCT
Length of follow-up: 6 weeks after last dose
Adverse event data collection methods: Active: At each visit, data were recorded on
adverse events observed by the caretaker and investigator, including signs/symptoms ≥
grade 1 and new clinically significant diagnoses
Participants Number: 202 enrolled; 202 evaluable
Age range: infants 2 to < 15 weeks
Inclusion criteria: Participant was born to anHIV-infected mother; presence or absence
of HIV RNA or DNA in the blood of the infant; CD4% documented at screening
Exclusion criteria: concurrent participation in any study of an investigational drug or
vaccine, except for studies for prevention of perinatal HIV transmission; gastrointestinal
illness or fever; any condition, which would, in the opinion of the site investigator, place
the participant at an unacceptable risk of injury or render the participant unable to meet
the requirements of the protocol
Interventions 1. RV5, 2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and
P1A which contains a minimum of 2.0 2.8 x 106 infectious units (IU) per individual
reassortant dose, depending on the serotype, and not greater than 116 x 106 IUs per
aggregate dose in 62 HIV-uninfected but exposed and 37 HIV-infected participants
2. Placebo in 64 HIV-uninfected but exposed and 39 HIV-infected participants
Schedule: 3 doses of RV5 or placebo at intervals of 4 - 10 weeks with the third dose
administered by 32 weeks of age
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause deaths
2. All-cause serious adverse events
3. Hospitalization
4. Reactiogenicity: fever, diarrhoea, vomiting
Outcomes to measure immunogenicity
4. Rotavirus vaccine shedding (after 3rd dose)
5. Seroconversion
Immunization status Enrolmentwas closed in participating countries whenRV1was added to national vaccine
schedules
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Location Botswana (2 sites), United Republic of Tanzania (1 site) , Zambia (1 site) and Zimbabwe
(2 sites)
WHO mortality stratum E
Notes Date: December 2009 - January 2014
Source of funding: Merck & Co., Inc. and the International Maternal, Pediatric, and
Adolescent AIDS Clinical Trial Network (IMPAACT) through the National Institute of
Health
Study rationale: evaluate the safety and immunogenicity of the Rotavirus vaccine Ro-
taTeq, in HIV infected and uninfected children born to HIV infected mothers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported to be randomized, but no
details provided on the randomization pro-
cess
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo-controlled but no details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition, reasons provided
Selective reporting (reporting bias) Low risk All relevant outcomes reported
Other bias Unclear risk Nine infants were unblinded after their first
or second dose when rotavirus vaccine be-
came available at their site. The 4 infants
found to be on RV5 continued to receive
their remaining study doses. Of the 5 in-
fants on placebo, 2 were given the 2 recom-
mended doses of Rotarix, but 3 were too
old to receive Rotarix
RV5 Merck[009] 2005-USA
Methods RCT
Length of follow-up: up to 42 days after vaccination
Adverse event data collection methods: not reported
Participants Number: 793 enrolled; 706 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants; 6 to 12 weeks of age
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Exclusion criteria: history of congenital abdominal disorders, intussusception, or ab-
dominal surgery; known or suspected impairment of immunological function; known
hypersensitivity to any component of the rotavirus vaccine; prior receipt of any rotavirus
vaccine; fever, with a rectal temperature ≥ 38.1 °C (≥ 100.5 °F) at the time of immu-
nization; history of known prior rotavirus disease, chronic diarrhoea, or failure to thrive;
clinical evidence of active gastrointestinal illness (infants with gastro-oesophageal reflux
disease were permitted to participate in the study as long as the gastro-oesophageal reflux
disease was well controlled with or without medication); receipt of intramuscular, oral,
or intravenous corticosteroid treatment between the 2 weeks before first vaccination and
2 weeks after last vaccination; reside in a household with an immunocompromised per-
son; prior receipt of a blood transfusion or blood products, including immunoglobulins;
receipt of oral polio vaccine during the course of the study or within 42 days before first
dose of vaccine/placebo; and condition, which, in the opinion of the investigator, may
have interfered with the evaluation of the study objectives
Interventions RV5
1.WC3 (RV5): 2mL (10.7PFU); 3 doses given at 4 to 10week intervals; 680 participants
(randomized)
2. Placebo: 3 doses given at 28 to 70 day intervals; 113 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Reactogenicity: no definition; measured 7 days after vaccination
2. Dropouts: measured up to 42 days
3. Adverse events requiring discontinuations: measured up to 42 days, (data from corre-
spondence with Merck; Merck 2012)
4. Serious adverse events: not defined; measured up to 42 days, including intussusception
(data from correspondence with Merck; Merck 2012)
5. Number of deaths (data from correspondence with Merck; Merck 2012)
Outcomes to measure immunogenicity
None
Immunization status Infants were excluded if they had or were to receive oral poliovirus vaccine at any time
during the study or in the 42 days before the first dose; concomitant administration of
other licensed vaccines and breast-feeding was not reported
Location 10 centres in USA
WHO mortality stratum A
Notes Date: 9 May 2003 to 13 August 2004
Source of funding: Merck & Co., Inc.
Study objective: “Comparison of the Immunogenicity and Safety of Three Consistency
Lots of RotaTeq in Healthy Infants”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated randomization to 1
of 4 treatment groups. A randomization
scheme of 2:2:2:1, with a blocking factor
of 14 was used, and participants received
either 1 of 3 lots of RV5 or placebo (Merck
2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for par-
ticipants; investigators, adults, and par-
ents/guardians of children were blinded
throughout trial (Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk RV5 was visibly indistinguishable from
placebo; investigators, study personnel (in-
ternal and external) and parents/guardians
were blinded throughout trial (Merck
2012)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Unclear risk Insufficient information
RV5 Mo 2017-CHN
Methods RCT
Length of follow-up: 2 years
Adverse event data collection methods: Passive: All adverse events were collected for
30 days following each dose
Participants Number: 4040 enrolled; 4040 evaluable
Age range: 6 - 12 weeks (at start of study)
Inclusion criteria: Healthy infants at least 6 weeks and up to 12 weeks of age at the
time of the first study vaccination
Exclusion criteria:History of congenital abdominal disorders, prior rotavirus gastroen-
teritis, chronic diarrhoea, failure to thrive, or abdominal surgery; history of intussuscep-
tion; impairment of immunological function; acute disease, severe chronic disease, or
chronic disease during the acute period; participation in another interventional study;
any condition which, in the opinion of the investigator, may interfere with the evaluation
of the study objectives
Interventions 1. RV5, 2 mL (n=2020 randomized)
1.1 RV5 alongside staggered EPI (OPV administered as a 1 g oral solution at age ~2½,
3½, and 4½ months, and DTaP administered as a 0.5 mL intramuscular injection at age
~3½, 4½, and 5½ months)
1.2.RV5 with concomitant EPI (OPV administered as a 1 g oral solution at age ~2, 3,
165Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV5 Mo 2017-CHN (Continued)
and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3,
4, and 5 months)
2. Placebo (n=2020 randomized)
2.1 placebo alongside staggered EPI (OPV administered as a 1 g oral solution at age
~2½, 3½, and 4½ months, and DTaP administered as a 0.5 mL intramuscular injection
at age ~3½, 4½, and 5½ months)
2.2 placebo with concomitant EPI (OPV administered as a 1 g oral solution at age ~2,
3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3,
4, and 5 months)
Schedule: RV5 or placebo at age 2, 3, and 4 months
Outcomes Clinical outcome measures (safety and efficacy)
1. Severe Rotavirus diarrhoea
2. All-cause deaths
3. Serious adverse events
4. Intussusception
5. Rotavirus diarrhoea (any severity)
6. Reactogenicity: fever, diarrhoea, vomiting
7. Adverse events due to discontinuation
8. Dropouts from the trial
Immunization status Routine EPI vaccines (OPV, DTaP) either staggered or concomitantly with RV5 or
placebo
Location 5 sites, China
WHO mortality stratum B
Notes Date: May 2014 - June 2015
Source of funding: Merck Sharp & Dohme Corp.
Study rationale: assess the efficacy, safety, and immunogenicity of a 3 dose regimen of
RotaTeq™ (V260) in healthy Chinese infants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported to be randomized, but no
details provided on the randomization pro-
cess
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded for vaccine versus placebo, not for
staggered versus concomitant
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition and reasons provided
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Selective reporting (reporting bias) Low risk All relevant outcomes reported
Other bias Low risk No apparent other bias
RV5 Vesikari 2006a-FIN
Methods RCT
Length of follow-up: 1 to 3 rotavirus seasons (1 to 3 years)
Adverse event data collection methods: diary cards (passive method); telephone calls
to parents/legal guardians to ask about serious adverse events (active method)
Note: the per-protocol population used for the primary efficacy analysis included 1496
participants after exclusion of 450 participants (23.1%). The modified intention-to-
treat population used in a secondary efficacy analysis consisted of the 1647 participants,
including protocol violators, who had any valid post-dose 3 efficacy data
Participants Number: 1946 enrolled; 1496 evaluable (after 2 years)
Age range: 3 to 6 months (beginning); > 6 months (end)
Inclusion criteria: healthy infants between 2 and 8 months of age
Exclusion criteria: not described
Interventions RV5
1. WC3 (RV5)
1.1. G1-4, P1A (2.69 x 107 , 7.92 x 106, 2.41 x 106); 3 doses given 4 to 8 weeks apart;
1027 participants (randomized)
1.2. G1-4 (2.9 x 107); 3 doses given 4 to 8 weeks apart; 270 participants (randomized)
1.3. P1A (9.24 x 107); 3 doses given 4 to 8 weeks apart; 327 participants (randomized)
2. Placebo: 3 doses given 4 to 8 weeks apart; 322 participants (randomized)
We excluded the 2 arms dealing with different G or P serotypes and compared a single
arm to placebo
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required: (1) ≥ 3 wa-
tery or looser-than-normal stools within a 24-hour period or forceful vomiting, or both;
and (2) rotavirus antigen detection by EIA. The primary analysis of efficacy considered
episodes as positive only when caused by wild-type rotavirus with a vaccine G serotype
(G1, G2, G3, or G4) confirmed by PCR occurring at least 14 days after the third dose
of vaccine; measured 1 to 3 years
2. Severe rotavirus diarrhoea: clinical scoring system based on the intensity and duration
of symptoms of fever, vomiting, diarrhoea, and behavioural changes was used to rate
the severity of gastroenteritis, using a 24-point severity scale where a score of 1 to 8 was
designated as mild, > 8 was designated as moderate-and-severe, and > 16 was designated
as severe; measured 1 to 3 years
3. Reactogenicity: not definedother than all participantswere followed for clinical adverse
events for 42 days after each dose of vaccine or placebo; parents/guardians were provided
with diary cards to record adverse events
4. Serious adverse events: not defined; noted that they were to be reported immediately.
Parents/legal guardians were contacted by phone approximately 14 days after each dose
and asked about serious adverse events. Data on deaths and serious adverse events judged
167Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
RV5 Vesikari 2006a-FIN (Continued)
by the investigator to be vaccine-related were collected for the duration of the study (up
to 42 days)
5. All-cause death
Outcomes to measure immunogenicity
6. Seroconversion: prevaccination and post-vaccination sera assayed for rotavirus-specific
IgA by ELISAwith seroconversion defined as≥ 3-fold rise in antibody titre frombaseline
to 2 weeks after dose 3 (review includes data from 14 days after dose 3)
Immunization status Licensed vaccines could be administered throughout the study, but were not given on the
same day as study vaccine; inactivated poliovirus vaccine was exclusively used in Finland
at the time of the study
Location 4 sites (Tampere, Espoo, Lahti, Pori) in Finland
WHO mortality stratum A
Notes Date: June 1998 and June 2001
Source of funding: Merck & Co., Inc.
Other: in total, 1946 infants (1300 in the first year and 646 in the second year of
the study) were enrolled in the study and received at least the first dose of 1 of the 5
active vaccines or placebo. Overall, 1813 (93.2%) participants received 3 doses and were
followed for ≥ 42 days after the final dose. 1800 participants (92.5%) were followed
through the first rotavirus season after vaccination; 1740 participants (89.4%) were
followed through a second rotavirus season. Of the 1300 participants enrolled in the
first year, 880 (67.7%) were followed through a third rotavirus season
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated (Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for
participants; investigators and parents/
guardians were blinded throughout trial
(Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Sequential identical containers
Quote: “The vials containing either vaccine
or placebo were visibly indistinguishable.”
Participants and key personnel
Quote: “This randomized clinical trial
blinded to subject, investigator, parent/le-
gal guardian, and sponsor. The placebo was
identical to the vaccine except that it did
not contain rotavirus reassortants or trace
trypsin”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions
Selective reporting (reporting bias) High risk ≥1 outcome of interest reported incom-
pletely
Other bias Unclear risk Insufficient information to assess
RV5 Vesikari 2006b-INT
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on days 7, 14, and 42 after each dose and
every 6 weeks thereafter for 1 year after the first dose with respect to intussusception and
serious adverse events (active method)
Participants Number: 70,301 enrolled and 69,274 randomized (efficacy study subpopulation of
5673); 57,134 evaluable for safety outcomes; for efficacy outcomes, 4512 evaluable in
year 1 and 1569 evaluable in year 2
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants between 6 and 12 weeks of chronological age were el-
igible regardless of gestational age; no known history of congenital abdominal disorders,
intussusception, or abdominal surgery; no known or suspected impairment of immuno-
logical function; no known hypersensitivity to any component of the rotavirus vaccine;
no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥ 38.1 °C
(≥ 100.5 °F) at the time of immunization; no history of known prior rotavirus disease,
chronic diarrhoea, or failure to thrive; no clinical evidence of active gastrointestinal ill-
ness; no receipt of intramuscular, oral, or intravenous corticosteroid treatment within
the 2 weeks before vaccination; did not reside in a household with an immunocom-
promised person; no prior receipt of a blood transfusion or blood products, including
immunoglobulins; no receipt of oral poliovirus vaccine during the course of the study
or within 42 days prior to the first dose of vaccine/placebo
Exclusion criteria: see above for details
Special group: infants born at < 36 weeks of gestational age were considered premature
and infants born at < 32 weeks of gestational age were considered extremely premature;
no formal safety or efficacy hypotheses were prespecified for premature infants
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 to 10 weeks apart; 34,
644 participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 to 10 weeks apart; 34,630 participants (randomized)
Outcomes Clinical outcome measures (safety and efficacy)
1. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in
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a stool specimen taken within 14 days after the onset of symptoms. Only naturally-
occurring “rotavirus AGEs” caused by the composite of the human rotavirus G-serotypes
in the vaccine (G1, G2, G3, and G4) occurring through the first rotavirus season that
began at least 14 days following the third vaccination were included in the primary
analysis; measured up to 2 years follow-up
2. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 24-point severity scale; scores > 16 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
3. Emergency department visit: hospitalizations and emergency department visits for
acute gastroenteritis; measured up to 1 year of follow-up
4. All-cause hospital admission: see above; measured up to 1 year of follow-up
5. All-cause mortality: measured up to 1 year of follow-up
6. Dropouts: no definition; measured up to 2 years follow-up
7. Serious adverse events: monitored for at least 42 days after each dose for serious adverse
events, including intussusception. All suspected cases of intussusception were reported to
an independent, blinded adjudication committee, which included a paediatric surgeon,
a paediatric radiologist, and a paediatrician with extensive experience in emergency
medicine. The committee adjudicated potential cases of intussusception according to a
prespecified case definition that required confirmation of the diagnosis by radiography or
at surgery or autopsy; measured up to 1 year of follow-up. Final intussusception results
taken from CDC report (CDC 2010)
8. Reactogenicity: not defined; measured up to 43 days after vaccine
9. Adverse events requiring discontinuation: not defined;measured up to 1 year of follow-
up
10. Rotavirus diarrhoea resulting in hospitalization
Outcomes to measure immunogenicity
11. Seroconversion: defined as an increase in the antibody titre by a factor of ≥ 3 from
baseline (review includes data from 14 days after dose 3)
Immunization status Administration of other licensed childhood vaccines and breast-feeding were not re-
stricted; for a subset of participants in the USA (U.A. concomitant use cohort), Merck
also provided the licensed paediatric vaccines that were administered concomitantly
(same day) with RV5 or placebo, which included Comvax, Infanrix, Ipol, and Prevnar
Location 356 primary study sites in Belgium, Costa Rica, Finland, Germany, Guatemala, Italy,
Jamaica, Mexico, Puerto Rico, Sweden, Taiwan, and the USA
WHO mortality strata A, B, D
Notes Date: 12 January 2001 to 6 October 2004
Source of funding: Merck & Co., Inc.
Other: there is a full report on premature babies that will be data-extracted separately
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated randomized 1:1 to
receive either RV5 (RotaTeq) or placebo
(Merck 2012)
Allocation concealment (selection bias) Low risk Allocation numbers were generated for
participants; investigators and parents/
guardians were blinded throughout trial
(Merck 2012)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel
Quote: “Randomized, multicenter, double
blinded (operated under in-house blind-
ing procedures), placebo controlled, safety
and efficacy trial. The placebo was an exact
match minus the virus”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Unclear risk Difficult to judge, as some important in-
formation about randomization/allocation
concealment are not provided
RV5 Zaman 2010-AS
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 2119 enrolled; 2036 randomized, 2016 evaluable
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breast-feeding was not restricted
and there was no enrolment restrictions based on HIV status, although HIV testing was
not done
Exclusion criteria: see above
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RV5 Zaman 2010-AS (Continued)
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 1018
participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 1018 participants (randomized)
Schedule: 3 doses given at 4-week intervals
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Matlab (Bangladesh) and urban and peri-urban Nha Trang (Vietnam)
WHO mortality strata B, D
Notes This trial was conducted inBangladesh andVietnam; data reported separately by country
can be found under RV5 Zaman 2010-BGD and RV5 Zaman 2010-VNM.
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
sizes of six”
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RV5 Zaman 2010-AS (Continued)
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No apparent other bias
RV5 Zaman 2010-BGD
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 1136 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breast-feeding was not restricted
and there were no enrolment restrictions based on HIV status, although HIV testing
was not done
Exclusion criteria: see above
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RV5 Zaman 2010-BGD (Continued)
Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 568
participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 568 participants (randomized)
Schedule: 3 doses given at a 4-week interval
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity *: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4 fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in rural Matlab, Bangladesh
WHO mortality stratum D
Notes This trial was conducted in Bangladesh and Vietnam; this part presents data for the
Bangladesh cohort, data reported separately for Vietnam can be found under RV5 Zaman
2010-VNM and data for both countries under RV5 Zaman 2010-AS
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
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RV5 Zaman 2010-BGD (Continued)
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No apparent other bias
RV5 Zaman 2010-VNM
Methods RCT
Length of follow-up: up to 43 days for safety outcomes, and up to 2 years for efficacy
outcomes
Adverse event data collection methods: active surveillance was used to obtain safety
data; parents or legal guardians were contacted on the first 14 days after each dose and
every month thereafter for 1 year after the first dose with respect to intussusception
and serious adverse events (active method). “Serious adverse events were classified with
the US regulatory definition, in line with ICH guidance, and identified by monthly
query and parental reporting at any time or identification by study staff in hospitals or
clinics. Intussusception at any time was assessed with an additional detailed protocol. All
these events were monitored by an independent, unmasked, data and safety monitoring
board that met about twice a year during the course of the investigation. The board also
provided guidance about enrolment and severity scoring”
Participants Number: 900 randomized
Age range: 1 to 3 months (beginning); 3 to 6 months (end)
Inclusion criteria: healthy infants aged 4 to 12 weeks. Breast-feeding was not restricted
and there were no enrolment restrictions based on HIV status, although HIV testing
was not done
Exclusion criteria: see above
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Interventions RV5
1. WC3 (RV5): 2 mL (6.7 to 12.4 x 107 PFU); 3 doses given 4 weeks apart; 450
participants (randomized)
2. Placebo: 2 mL; 3 doses given 4 weeks apart; 450 participants (randomized)
Schedule: 3 doses given at 4-week intervals
Outcomes Clinical outcome measures (safety and efficacy)
1. Serious adverse events
2. Death due to serious adverse events
3. Rotavirus diarrhoea: case definition for rotavirus gastroenteritis required participants
to meet both of the following criteria: (1)≥ 3 watery or looser-than-normal stools within
a 24-hour period or forceful vomiting, or both, and (2) rotavirus detected by EIA in a
stool specimen taken within 14 days after the onset of symptoms
4. Severe rotavirus diarrhoea: an established clinical scoring system based on the intensity
and duration of fever, vomiting, diarrhoea, and changes in behaviour used to categorize
episodes of rotavirus gastroenteritis on a 20-point severity scale; scores > 11 were con-
sidered to indicate severe disease; measured up to 2 years follow-up
5. All-cause diarrhoea
6. All-cause diarrhoea - severe
7. Reactogenicity*: symptoms of rotavirus illness, including fever, diarrhoea, and vomit-
ing; measured for 7 days after each dose (review includes data from for the end of follow-
up)
Data on fever and vomiting are provided only on figure 2 and data could not be extracted
reliably
Outcomes to measure immunogenicity
8. Seroconversion: serum rotavirus IgA responses (increases in level of serum rotavirus
IgA ≥ 4-fold) (review includes data from after dose 2)
Immunization status All children in the study received the standard EPI vaccines (including oral poliovirus
vaccine) starting at 6 weeks of age
Location Sites in urban and peri-urban Nha Trang, Vietnam
WHO mortality stratum B
Notes This trial was conducted in Bangladesh and Vietnam; this part presents data for the
Vietnam cohort. Data reported separately for Bangladesh can be found under RV5
Zaman 2010-BGD and data for both countries under RV5 Zaman 2010-AS
Date: March 29, 2007 to March 31, 2009
Source of funding: funded by PATH (GAVI Alliance grant) and Merck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Unique allocation numbers were
designated at Merck as pentavalent ro-
tavirus vaccine or placebo with computer
generated block randomization, with block
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RV5 Zaman 2010-VNM (Continued)
sizes of six”
Allocation concealment (selection bias) Low risk Quote: “Vaccine and placebo packages
were then labelled with allocation numbers
and provided to sites in identical presenta-
tions. Sites were instructed to assign alloca-
tion numbers to participants in sequential
order as they were enrolled”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and staff
Quote: “Participants were enrolled by
study staff, who remained masked to treat-
ment assignment throughout the trial”
Researchers
Quote: “The statistician from Merck who
analysed the data and theMerck and PATH
protocol teams were masked to treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data balanced across groups
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk No apparent other bias
VAC Bhandari 2006-IND
Methods Phase I RCT
Length of follow-up: 28 days
Adverse event data collection methods: Caregivers reported any symptoms or illnesses
on diary cards or to physician on-call 24 hours; physicians and field investigators visited
participants twice daily the first 14 days
Participants Number: 90 enrolled, 90 randomized, 83 evaluable
Age range: 8 weeks at enrollment and first dose
Inclusion criteria: healthy, non-malnourished infants
Exclusion criteria: Evidence of renal, cardiovascular, liver or other reticuloendothelial,
neurological, gastrointestinal, haematologic, rheumatologic or immunologic disease
Interventions Rotavac
1. Rotavac vaccine (116E) (105 FFU), n = 30
2. Rotavirus vaccine candidate I321, n = 30
3. Placebo, n = 30
Schedule: 1 dose given at 8 weeks of age
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause death
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VAC Bhandari 2006-IND (Continued)
2. Intussusception
3. Serious adverse events
4. Reactogenicity (up to 14 days)
Outcomes to measure immunogenicity
5. Immunogrnicity: seroconversion (4-fold rise in titre of IgA)
6. Immunogenicity: shedding
Immunization status Infants were vaccinated with DPT, Hep B and OPV separately from rotavirus vaccine
Location 1 site (Delhi) in India
WHO mortality stratum D
Notes Date: January to May 2005
Registration number: NCT00280111; ISRCTN57452882
Source of funding: Bharat Biotech International Ltd.
Notes: study arm administered vaccine candidate I321 was excluded from data analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For randomisation, a sequence of
codes was generated using Stata, version 8
(Statacorp, College Station, TX, USA) by a
statistician not otherwise involved with the
trial.”
Allocation concealment (selection bias) Low risk Quote: “Two copies of the randomisation
code were prepared; one was sent to the
Division of Microbiology and Infectious
Diseases (DMID) at the NIH under sealed
cover, and the second was given to a physi-
cian, not otherwise involved in the study,
for reconstituting the vaccine/placebo at
the time of enrolment.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double-blind”
Quote: “The placebo was constituted by
adding a crystal of potassium perman-
ganate to sodium bicarbonate buffer and
appeared identical to the vaccines but did
not contain the virus.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition, reasons for loss to follow-
up were reported and evenly spread across
groups
Selective reporting (reporting bias) Low risk No indicationof selective reporting, all out-
comes in the trial register reported
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Other bias Low risk No apparent other bias
VAC Bhandari 2009-IND
Methods RCT
Length of follow-up: 12 weeks
Adverse event data collection methods: Caregivers reported any symptoms or illnesses
to physician on-call 24 hours; infants were visited at home daily the first 14 days after
each administration
Participants Number: 369 enrolled and randomized, 367 received at least one dose
Age range: 8 to 9 weeks
Inclusion criteria: healthy infants
Exclusion criteria: family without access to a telephone, unavailable for follow-up,
weight-for-height z score of < 3 standard deviations, resided with an immunocompro-
mised individual, born at a gestational age of < 37 weeks, major congenital abnormality,
history of hospitalization for sepsis, pneumonia, or meningitis, diarrhoea in the previous
7 days, blood in stools any time after birth, need for daily medication, cardiovascular or
neurological disease
Interventions Rotavac
1. Rotavac vaccine (116E) (1 x 104 (low dose) or 1 x 105 FFU (high dose)), n = 185
2. Placebo, n = 184
Schedule: 3 doses given at 4-week intervals at 8, 12, and 16 weeks of age
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause death
2. Intussusception (level 1 Brighton definition)
3. Serious adverse events
4. Reactogenicity (up to 14 days)
Outcomes to measure immunogenicity
5. Immunogenicity: shedding
6. Immunogenicity: seroconversion (4-fold increase in IgA antibody titer to rotavirus)
Immunization status Infants received 3 doses of DTP; OPV; and Hep B at 6, 10, and 14 weeks of age
Location 1 site (New Delhi) in India
WHO mortality stratum D
Notes Date: November 2006 to February 2008
Registration number: NCT00439660; ISRCTN57452882
Source of funding: Department of Biotechnology, Government of India and PATH
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Infants were assigned to either the vaccine
or placebo groups in a 1:1 ratio with use of
a randomization sequence generated by a
statistician not otherwise involved with the
study (Stata software, version 8.0) with a
fixed block length of 4
Allocation concealment (selection bias) Low risk Allocation concealment was achieved by
using serially-numbered sealed opaque en-
velopes. One set of envelopes was available
with the independent vaccine-dispensing
team and another with the study data safety
monitoring board
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Study reported to be double-blind but no
further details were reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intussusception data reported for all en-
rolled participants, immunogenicity and
reactogenicity were not reported for all par-
ticipants and the reason was not clear
Selective reporting (reporting bias) Low risk No indication of selective outcome report-
ing
Other bias Low risk No apparent other bias
VAC Bhandari 2014-IND
Methods RCT
Length of follow-up: up to 2 years of age
Adverse event data collection methods: All participants were contacted weekly at home
by trained field workers to identify gastroenteritis, signs and symptoms of suspected
intussusception, hospitalizations, and other illnesses. In addition, families reported any
adverse events
Participants Number: 6799 enrolled, randomized and received at least one dose
Age range: 6 to 7 weeks at recruitment
Inclusion criteria: parents consented to participation and had no plans to move out of
the study area during the next 24 months
Exclusion criteria: infants were excluded if they had received a rotavirus vaccine, had
documented immunodeficiency or chronic gastroenteritis or any other condition judged
by the investigator as an exclusion criterion. Presence of any illness requiring hospital
referral and diarrhoea on the day of enrolment was a temporary exclusion
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VAC Bhandari 2014-IND (Continued)
Interventions Rotavac
1. Rotavac (ORV 116E) vaccine (1 x 105 FFU), n = 4532
2. Placebo, n = 2267
Schedule: 3 doses given at 4-week intervals (6 to 7 weeks, ≥ 10 weeks, and ≥ 14 weeks
of age)
Outcomes Clinical outcome measures (safety and efficacy)
1. Severe rotavirus gastroenteritis (≥ 11 on the 20-point Vesikari scoring scale)
2. All-cause death
3. Intussusception (Brighton criteria level 1)
4. Serious adverse events
5. Severe all-cause diarrhoea
6. Rotavirus diarrhoea: any severity
Outcomes to measure immunogenicity
7. Seroconversion (4-fold rise in titre from paired serum samples)
Immunization status Other childhood vaccines (DTPw, Hib, Hep B, and OPV) given concurrently
Location 3 sites: Delhi, Pune, and Vellore in India
WHO mortality stratum D
Notes Date: March 2011 to November 2012
Registration number: NCT01305109; CTRI/2010/091/000102
Source of funding: The Department of Biotechnology, and Biotechnology Industry
ResearchAssistanceCouncil,Government of India; theBill&MelindaGates Foundation
to PATH; Research Council of Norway; Department for International Development,
UK; National Institutes of Health, USA; Bharat Biotech International Ltd
Moved from ongoing Other NCT01305109 and Other CTRI-091-000102
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was performed by Cen-
duit, LLC, Germany, with stratification by
site, and a block size of 12
Allocation concealment (selection bias) Low risk The letter code on the vaccine/placebo vial
was masked with the participant identifica-
tion number before sending the vial to the
clinical co-ordinator administering the test
article to the enrolled infant
Blinding (performance bias and detection
bias)
All outcomes
Low risk The placebowas identical in content, pack-
aging, and appearance to the vaccine but
did not contain the virus
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Incomplete outcome data (attrition bias)
All outcomes
Low risk < 1% loss to follow-up
Selective reporting (reporting bias) Low risk No indicationof selective reporting, all out-
comes in the trial register reported
Other bias Low risk No apparent other bias
VAC Chandola 2017-IND
Methods RCT
Length of follow-up: 1 year
Adverse event data collectionmethods:Daily contacts through telephone calls or home
visit for 14 days after each dose. Thereafter, weekly contacts were made until infants were
1 year of age
Participants Number: 1356 enrolled and randomized, 1327 completed 1 year follow-up
Age range: 6 to 8 weeks
Inclusion criteria: healthy infants whose parents were willing to participate and had no
plans for moving away were eligible for enrolment
Exclusion criteria: had already received the first dose of the childhood vaccines or any
other rotavirus vaccine, had immunodeficiency disease or chronic gastroenteritis disease,
and/or any condition warranting exclusion by the investigator
Interventions Rotavac
1. Rotavac vaccine, 1 x 104 FFU, in 3 production lots, n = 1017
2. Placebo, n= 339
Schedule: 3 doses given at a 4- to 8-week intervals (6 - 7 weeks, 10 - < 14, and 14 - <
18 weeks of age)
Outcomes Clinical outcome measures (safety and efficacy)
1. All-cause death
2. Serious adverse events
3. Intussusception (level 1 Brighton criteria)
4. Reactogenicity
Outcomes to measure immunogenicity
5. Immunogenicity: seroconversion (≥4 fold rise in IgA antibody titer to rotavirus)
Immunization status Co-administered with EPI vaccines: OPV and combined DPT, HepB and Hib
Location 1 site in Delhi, India
WHO mortality stratum D
Notes Date: May 2014 to August 2015
Registration number: CTRI/2014/05/004592
Source of funding: PATH, USA
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was done by Di-
agnosearch Life Sciences Pvt. Ltd. and the
randomization list was available with an in-
dependent biostatistician”
Allocation concealment (selection bias) Low risk Central allocation
Quote: “Randomization was done by Di-
agnosearch Life Sciences Pvt. Ltd. and the
randomization list was available with an in-
dependent biostatistician”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The placebo was identical in con-
tent, packaging, and appearance to the
vaccine. The study team received RO-
TAVAC® or placebo vials labeled with
the subject Identification (ID) number to
maintain blinding. The study team, vac-
cine administrators and laboratory person-
nel were not aware of the treatment status.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat population was analyzed
for safety outcomes. Less than 5% loss to
follow-up
Selective reporting (reporting bias) Low risk No indicationof selective reporting, all out-
comes in the trial register reported
Other bias Low risk No apparent other bias
ATP: according to protocol; BCG: bacillus Calmette-Guerin; eCRF: electronic case report form; ELISA: Enzyme Linked Immunosor-
bent Assay; FF: focus-forming unit; ITT: intention-to-treat; LAR: legally acceptable representative; MedDRA: Medical Dictionary
for Regulatory Activities; OPV: oral poliovirus; PFU: plaque-forming unit; RCT: randomized controlled trial; RT-PCR: reverse
transcriptase-polymerase chain reaction; (S)AE: (serious) adverse event; VRC: vaccine report card
Immunogenicity: only data for review-relevant outcomes listed in these tables.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
OTHER Armah 2013 RCT of withdrawn RV vaccine RRV-TV
OTHER Bines 2015 Neonatal RV vaccine RV3-BB in development
OTHER Bines 2018 RCT of unlicensed neonatal RV3-BB rotavirus vaccine (ACTRN12612001282875)
OTHER Bucardo 2018 Prospective cohort study
OTHER Bucher 2012 Diagnostic test accuracy study
OTHER Chatterjee 2012 RCT, not rotavirus vaccine
OTHER Cowley 2017 RCT of unlicensed neonatal RV3-BB rotavirus vaccine
OTHER CTRI/2009/091/000821 RCT of Rotasiil versus placebo
OTHER Dang 2012 RCT evaluating safety and immunogenicity of vaccine licensed in Vietnam (NCT01377571);
vaccine not prequalified by the WHO
OTHER de Palma 2010 Case-control study
OTHER Dickson 2017 Brief narrative report
OTHER Diness 2010 Study of vitamin A supplementation with Bacille Calmette-Guerin vaccine for rotavirus diar-
rhoea outcomes
OTHER Dutta 2011 RCT, not rotavirus vaccine
OTHER Ella 2018 All infants received rotavirus vaccine, and were randomized to Rotavac (116E) with or without
buffering agent. (CTRI/2014/04/004548)
OTHER Friedrich 2017 Editorial on Rotasiil rotavirus vaccine
OTHER Gagneur 2011 Observational study (IVANHOE)
OTHER Groome 2017 RCT in infants of RV vaccine in development: parenteral P2-VP8-P[8] subunit RV vaccine
(NCT02109484)
OTHER Hiramatsu 2018 Prospective cohort study
OTHER Isanaka 2017-NER Reporting on an RCT (NCT02145000) that evaluates safety and efficacy in a vaccine licensed
in India but not prequalified by the WHO
OTHER Kempe 2007 Survey of paediatricians about rotavirus disease and rotavirus vaccines
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(Continued)
OTHER Kulkarni 2017 Reporting on an RCT (NCT02133690) that evaluates safety and efficacy in a vaccine licensed
in India but not prequalified by the WHO
OTHER Muhsen 2010 Case-control study
OTHER NCT00981669 RCT included adults aged 18 - 40 years
OTHER NCT01195844 Observational study, prematurely terminated for poor recruitment
OTHER NCT01236066 Ongoing observational study
OTHER NCT01375907 Ongoing study with adult participants
OTHER NCT01571505 RCT in infants comparing RV vaccine administered with IPV or OPV
OTHER Rivera 2011 RCT, no placebo comparison
OTHER Thyagarajan 2011 Procedural codes for rotavirus vaccination in the USA
OTHER Yin 2017 Oral RV vaccine (not specified, could be both RV1 and RV5) was administered before versus
after other injected vaccines to compare injection site pain of the other vaccines
OTHER Zade 2014a-IND Reporting on an RCT that evaluates safety in a vaccine licensed in India but not prequalified
by the WHO
OTHER Zade 2014b-IND Reporting on an RCT (CTRI/2010/091/003064) that evaluates safety in a vaccine licensed in
India but not prequalified by the WHO
RV1 / RV5 Libster RCT of RV1 and RV5 combined in different sequences
RV1 Ali 2014 Comparing different age schedules of RV1
RV1 Armah 2016 Comparing alternative dosing schedules
RV1 Buyse 2014 Integrated analysis
RV1 Correia 2010 Case-control study
RV1 CTRI/2012/02/002454 Ongoing RCT with no placebo group
RV1 Dennehy 2008 RCT of RV1 vaccine, but no placebo group reported
RV1 Emperador 2016 No placebo group: RV1 on a staggered versus concomitant schedule with other vaccines
RV1 GSK[107077-057] 2008 RCT of RV1 vaccine, but no placebo group reported
RV1 GSK[107876-061] 2008 RCT of RV1 vaccine, but no placebo group reported
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(Continued)
RV1 GSK[444563-020] 2007 RCT, but excluded because report mentioned that “4 groups received an investigational vac-
cination regimen”, but no details are provided about this vaccine (may be related to Glaxo-
SmithKline’s RV1 vaccine)
RV1 Herrera 2013 Not an RCT
RV1 Kazi 2017 1 arm of an RCT (RV1 Ali 2014) was included in this sub-study analysing histo-blood group
antigens
RV1 Kompithra 2014 No placebo group: immunogenicity for 3 versus 5 doses RV1
RV1 Lazarus 2017 All received RV vaccine with or without zinc and/or probiotic supplements
RV1 Lu 2013 Not an RCT
RV1 NCT00353366 Ongoing non-randomized study
RV1 NCT00382772 2008 RCT comparing RV1 liquid formulation to lyophilized formulation, no placebo
RV1 NCT00653198 Ongoing case-control study
RV1 NCT00655187 Ongoing case-control study
RV1 NCT01162590 Ongoing study with adult participants
RV1 NCT01177826 Ongoing observational study
RV1 NCT01273077 Ongoing observational study
RV1 NCT01339221 Ongoing observational study
RV1 Plosker 2011 Economic analysis
RV1 Ramani 2016 No placebo group: RV1 co-administered with IPV or with OPV was compared
RV1 Rojas 2007 Viral conversion on the same population of RV1 Ruiz-Palac 06-LA/EU (included trial)
RV1 Rongsen-Chandola 2014 Infants were breastfed versus not breastfed 30 mins prior and post RV1 administration. No
placebo group
RV1 Suryakiran 2011 Not RCT, integrated safety summary
RV1 Taddio 2015 To assess pain at injection site of other vaccines, participants were randomised to
1. oral RV1 then other injected vaccines then oral sucrose, or to
2. oral sucrose then other injected vaccines then oral RV1
RV1 Zaman 2016 Study investigated co-administration of Measles-rubella vaccines with RV vaccine
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(Continued)
RV5 / BRV-TV Saluja 2017 RCT of BRV-TV versus RV5
RV5 ACTRN12611000559910 Ongoing observational study
RV5 Ciarlet 2008 RCT of RV5 vaccine, but no placebo group reported
RV5 El Khoury 2011 Mathematical model in Brazil
RV5 El Khoury 2011a Mathematical model in six Asian countries
RV5 Martinon-Torres 2017 RCT comparing standard versus alternative formulation of RV5
RV5 McGrath 2014 Not an RCT
RV5 NCT00130832 2010 Not RCT; open-label study investigating different schedules of rotavirus and polio vaccine
combinations without placebo
RV5 NCT00496054 Ongoing non-randomized study
RV5 NCT01926015 Staggered versus concomitant administration of DTP-IPV with RV5
RV5 Saleh 2018 Standard versus alternative schedule RV5 (NCT01960725)
RV5 Tugcu 2009 RCT of RV5 vaccine, no placebo group reported
RV5 Uprety 2017 Sub-study of RV5 Levin 2017-AF, this sub-study only included participants in the vaccine arm
and comparied HIV-positive to HIV-exposed but uninfected infants
RV5 Vesikari 2011 RCT of RV5 and MenCC vaccines - concomitant or sequential administration, no placebo
group reported
RV5 Weinberg 2017 Sub-study of selected participants fromRV5Levin 2017-AF, reporting only irrelevant outcomes
for this review.
Characteristics of ongoing studies [ordered by study ID]
OTHER ACTRN12610000525088
Trial name or title “A Phase 1 double-blind, randomized study to compare the safety, tolerability and immunogenicity of oral
RV3-BB rotavirus vaccine and placebo in infants, children and male adults”
Methods “Randomized controlled trial, parallel assignment”
Participants Number: 60 (target)
Description: cohort 3: infants (male and female) aged 6 to 8 weeks inclusive, in good health
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OTHER ACTRN12610000525088 (Continued)
Interventions 1 mL oral dose administered once
1. live attenuated human rotavirus vaccine RV3-BB
2. Placebo
Outcomes 1. Adverse events
2. Serologic markers of rotavirus immunity (immunoglobulin G (IgG) and immunoglobulin A (IgA), neu-
tralizing antibodies (NAs))
3. Presence of RV3-BB rotavirus vaccine in faecal extracts
Starting date 27 January 2010
Completion: not stated
Contact information Dr Carl Kirkwood, Murdoch Childrens Research Institute 4th Floor, Front Entry Building Royal Children’s
Hospital Flemington Road Parkville, Victoria 3052, Australia carl.kirkwood@mcri.edu.au
Notes Location: Australia
Registration number: ACTRN12610000525088 (Australian New Zealand Clinical Trials Registry)
Source of funding: Murdoch Childrens Research Institute
OTHER CTRI/2015/07/006034
Trial name or title “Clinical trial on Rotavirus vaccine to check consistency of different lots of vaccines manufactured and to
check vaccine interference with other childhood vaccines given under universal immunization program in
India”
Methods Randomized, parallel-group, multiple arm trial
Participants Number: 1500
Description: Healthy infants, age 6-8 weeks
Interventions 1.3 doses Rotasiil/BRV-PV
2. 3 doses RV1
2 mL orally with routine vaccinations at 6, 4 and 10 weeks of age
Outcomes 1. Rotavirus Immunogenicity
2. Immunogenicity of other vaccines
3. Immediate adverse events
Starting date November 2015
Completion: not stated
Contact information Dr Prasad Kulkarni; drpsk@seruminstitute.com
Notes Location: India
Registration number: CTRI/2015/07/006034
Source of funding: Serum Institute of India Pvt Ltd.
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OTHER CTRI/2015/12/006428
Trial name or title “Randomized open label study to compare immunogenicity and safety of ROTAVAC® and ROTARIX®
rotavirus vaccine”
Methods Randomized, parallel-group, active controlled trial
Participants Number: 464
Description: Healthy infants, age 6 - 8 weeks
Interventions 1. 3 doses ROTAVAC®: 0.5 mL single dose containing NLT 105.0 FFU of live rotavirus116E
2. 2 doses RV1: Each 1-mL dose contains a suspension of at least 106.0 median Cell Culture Infective Dose
(CCID50)
Schedule: 4-week interval between doses
Outcomes 1. Immunogenicity (GMTs)
2. Safety solicited for 7 days
3. SAEs throughout the study period
Starting date December 2015
Completion: not stated
Contact information Dr Binod Sah, binod3161@bharatbiotech.com
Notes Location: India
Registration number: CTRI/2015/12/006428
Source of funding: Bharat Biotech
OTHER NCT01061658
Trial name or title “Phase I/II, Randomized, Double-blind, Placebo-controlled, Dosage Selection (10e5.5 or 10e6.25 FFU of
Each Constituent Serotype Per 0.5 mL) Study to Evaluate the Safety, Tolerability, and Immunogenicity of a
3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-
TV] Administered to Healthy Indian Infants”
Methods “Randomized, Placebo Control, Safety Study, Parallel Assignment, Double Blind (Subject, Caregiver, Inves-
tigator)”
Participants Number: 90 (target)
Description: healthy infants of either sex, 6 to 8 weeks of age at time of enrolment
Interventions 1. Live attenuated tetravalent (G1 - G4) bovine-human reassortant rotavirus vaccine
2. Placebo
Outcomes 1. Reactogenicity
2. Adverse events
3. Shedding of vaccine rotavirus in stool samples
4. Seroconversion rate
5. Sero-response rate
6. GMT of serum IgA antibody against rotavirus
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OTHER NCT01061658 (Continued)
Starting date 1 July 2010
Completion: not stated
Contact information Gagandeep Kang, MD PhD, gkang@cmcvellore.ac.in
Notes Location: India
Registration number: NCT01061658
Source of funding: Shantha Biotechnics Limited
OTHER NCT02153866
Trial name or title “The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR
Vaccine”
Methods Randomized, open label
Participants Number: 2800 (target)
Description: 8 ~ 9 months healthy child
Interventions 1. RV vaccine
2. measles-rubella vaccine
3. measles-mumps-rubella vaccine
4. RV + measles-rubella vaccine
5. RV + measles-mumps-rubella vaccine
Outcomes 1. General reactions
2. Severe adverse events
3. Antibody geometric mean titres
Starting date December 2013
Completion: August 2014
Contact information Rui Ao, Sichuan Center for Disease Control and Prevention
Notes Location: China
Registration number: NCT02153866
Source of funding: Sichuan Center for Disease Control and Prevention
OTHER NCT02193061
Trial name or title “Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and
RV1 Using Seven Combined Anti-rotavirus Prevention Programs”
Methods Randomized, controlled, single-blind
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OTHER NCT02193061 (Continued)
Participants Number: 1498 (target)
Description: healthy infants 6 - 10 weeks old
Interventions 1. 1 dose RV1
2. 1 dose RV5
3. 1 dose RV1 + 2 doses RV5
4. 1 dose RV5 + 2 doses RV1
5. 2 doses RV5 + 1 dose RV1
6. 1 dose RV5 + 1 dose RV1 + 1 dose RV5
7. 1 dose RV1 + 1 dose RV5 + 1 dose RV1
Outcomes 1. Temperature
2. Evacuations
Starting date November 2013
Completion: November 2017
Contact information Mercedes Macias Parra, MSc, National Institute of Pediatrics, Mexico
Notes Location: Mexico
Registration number: NCT02193061
Source of funding: National Institute of Pediatrics, Mexico; Centro Nacional para la Salud de la Infancia y
la Adolescencia; Merck Sharp & Dohme Corp
OTHER NCT02542462
Trial name or title “Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study”
Methods Prospective randomized clinical trial , phase 4
Participants Number: 101
Description: Healthy infants aged 6 - 13 weeks
Interventions 1. RV1, single oral dose of licensed rotavirus vaccine, given alone
2. RV1, with other routine vaccines
3. RV5, single oral dose of licensed rotavirus vaccine given alone
4. RV5, with other routine vaccines
Outcomes 1. The effects of RV1 and RV5 with or without other routine immunizations on gastrointestinal anatomy
2. The feasibility of conducting a larger-scale study as determined by study recruitment rates and percentage
of completed study visits
Starting date November 2015
Completion: May 2017 (actual primary completion date), May 2018 (estimated study completion date)
Contact information Mary A. Staat, MD, MPH Children’s Hospital Medical Center, Cincinnati Ohio, United States, 45219
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OTHER NCT02542462 (Continued)
Notes Location: USA
Registration number: NCT02542462
Source of funding: Children’s Hospital Medical Center, Cincinnati, USA
OTHER NCT02646891
Trial name or title “Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and
Infants”
Methods Phase I/II double-blind, randomized, placebo-controlled trial
Participants Number: 609
Description: Healthy adults (≥ 18 and ≤ 45 years), toddlers (≥ 2 and ≤ 3 years), and infants (≥ 6 and ≤ 8
weeks)
Interventions 1. Trivalent P2VP8 (15 mcg)
2. Trivalent P2VP8 (30 mcg)
3. Trivalent P2VP8 (90 mcg)
4. Placebo
Outcomes 1. Serious adverse events
2. Adverse events
3. Participants with vaccine-related reactogenicity events
4. Proportion of infants with anti-P2VP8 IgG sero-responses
5. Proportion of infants with anti-P2VP8 IgA sero-responses
6. Proportion of infants with neutralizing antibody responses
Starting date February 2016
Completion: January 2018
Contact information Michelle Groom, MBBCh Chris Hani Baragwanath Hospital
Notes Location: South Africa
Registration number: NCT02646891
Source of funding: PATH
OTHER NCT02847026
Trial name or title “Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study (fIPV)”
Methods Open-label phase IV, randomized controlled trial
Participants Number: 1144
Description: Infants 6 weeks of age (range: 42 - 48 days)
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OTHER NCT02847026 (Continued)
Interventions 1. RV1 at 6 and 10 weeks of age
1.1 RV1 + full dose of IPV at 14 and 22 weeks of age
1.2 RV1 + full dose of IPV at 14 weeks of age and a fractional dose IPV at 22 weeks of age
1.3 RV1 + full dose of IPV at 6 weeks of age and a fractional dose IPV at 22 weeks of age
1.4 RV1 + fractional doses of IPV at 6, 14, and 22 weeks of age
2. RV5 at 6, 10, and 14 weeks of age
2.1 RV5 + full dose of IPV at 14 and 22 weeks of age
2.2 RV5 + full dose of IPV at 14 weeks of age and a fractional dose IPV at 22 weeks of age
2.3 RV5 + full dose of IPV at 6 weeks of age and a fractional dose IPV at 22 weeks of age
2.4 RV5 + fractional doses of IPV at 6, 14, and 22 weeks of age
Outcomes 1. Seroconversion
4. Rotavirus IgA geometric mean titres
5. Rotavirus IgA seroconversion and geometric mean titres by secretor status, Lewis and salivary ABO blood
group phenotype
Starting date September 2016
Completion: December 2017
Contact information Centers for Disease Control and Prevention
Notes Location: Bangladesh
Registration number: NCT02847026
Source of funding: Centers for Disease Control and Prevention
OTHER NCT03462108
Trial name or title “Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates”
Methods Phase 1, mixed methods study; double-blind, randomized study (neonates); open-label study (adults and
children)
Participants Number: 100
Description: Adults, children and neonates
Interventions 1. Rotavirus (Bio Farma) Vaccine
2. Placebo
Outcomes 1. Solicited symptoms
2. Adverse events
3. Serious adverse events
4. Number of infants who have abnormality value of routine haematology and biochemical evaluation that
probably related to the vaccination
5. Excretion of rotavirus in stools in neonates group
6. Number of infants with≥ 3 times increasing antibody from baseline to post-investigational product dosing
7. Serum anti-rotavirus immunoglobulin (Ig)A
8. Serum neutralizing antibody
9. Geometric mean titre
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OTHER NCT03462108 (Continued)
Starting date April 2018
Completion: December 2018 (estimated)
Contact information Novilia Sjafri Bachtiar; novilia@biofarma.co.id
Notes Location: Indonesia
Registration number: NCT03462108
Source of funding: PT Bio Farma
OTHER NCT03483116
Trial name or title “A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus
Vaccine”
Methods Phase II randomized, controlled trial. Double-blind
Participants Number: 688
Description: up to 18 weeks (Child)
Interventions 1. RV3-BB
2. Placebo
Outcomes 1.Cumulative anti-rotavirus serum IgA response
2. Cumulative vaccine take and components of vaccine take (serum anti rotavirus IgA response or shedding
of RV3-BB)
3. Adverse events
4. Serious adverse events
5. Diarrhoea
Starting date April 2018
Completion: May 2019 (primary completion date estimated), August 2019 (Estimated study completion
date)
Contact information Julie Bines, MD, +61393454107, julie.bines@mcri.edu.au
Notes Location: Malawi
Registration number: NCT03483116
Source of funding: Murdoch Childrens Research Institute
RV1 ISRCTN86632774
Trial name or title “A phase II, double blind randomized, placebo controlled study to assess the safety reactogenicity and im-
munogenicity of three doses of GSK Biologicals (South Africa)”
Methods “randomized, controlled study with three parallel groups with balanced allocation (1:1:1)”
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RV1 ISRCTN86632774 (Continued)
Participants Target number: 271
Description: participants’ parents/guardians who could comply with the protocol requirements (e.g. com-
pletion of diary cards, return for follow-up visits); male or female aged 6 to 10 weeks of age at the time of
first vaccination; written informed consent from parents/guardians; born after a gestation period of 36 to 42
weeks
Interventions 1. RIX4414 (RV1): 2 doses vaccine at 106.5 CCID50 viral concentration plus 1 dose of placebo
2. Placebo: 3 doses
Outcomes 1. Seroprotection for each polio serotype (primary)
2. Vaccine take
3. Viral shedding
4. Presence of rotavirus in diarrhoeal stools
5. Anti-poliovirus antibody titres
6. Serum anti-rotavirus immunoglobulin A (IgA) antibody titres
7. Solicited symptoms
8. Unsolicited adverse events
9. Serious adverse events
Starting date 1 January 2001
Anticipated end date: 1 January 2003, completed
Contact information Dr Duncan Steele (steeled@who.int), WHO
Notes Location: South Africa
Registration number: ISRCTN86632774
Source of funding: RAPID trials (USA); WHO (Switzerland)
RV1 NCT02941107
Trial name or title “Optimising Rotavirus Vaccine in Aboriginal Children”
Methods Phase 4, double-blind, randomized controlled trial
Participants Number: 1000
Description: infants aged ≥ 6 months and < 12 months
Interventions 1. RV1
2. Placebo
Outcomes 1.Time to medical attendance (hospitalization, emergency department or medical clinic presentation) for
which primary reason for presentation is presumed or confirmed acute gastroenteritis or acute diarrhoea illness
before age 36 months
2. Anti-rotavirus IgA seroconversion
3.Time to hospitalization for which the primary coded reason for admission is presumed or confirmed acute
gastroenteritis or acute diarrhoea illness before age 36 months
4. Time to hospitalization for which rotavirus confirmed diarrhoea illness occurs before age 36 months
5. Rotavirus infection meeting the jurisdictional case definition
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RV1 NCT02941107 (Continued)
6. Change in anti-rotavirus IgA log titre between administration of intervention (RV1/placebo) and 28 to 55
days post-dose
7. The occurrence of intussusception fulfilling Brighton criteria
8. Serious adverse events
Starting date March 2018
Completion: December 2020 (estimated)
Contact information Tom Snelling, tom.snelling@telethonkids.org.au
Carly McCallum, carly.foulis@telethonkids.org.au
Notes Location: Australia
Registration number: NCT02941107
Source of funding: Telethon Kids Institute
RV1 Tatochenko 2008
Trial name or title Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv vaccines: immunogenicity and
reactogenicity in healthy infants
Methods Randomized controlled trial
Participants Number: 308
Description: healthy infants 11 to 17 weeks of age
Interventions 1. RIX4414 vaccine
2. Placebo
Outcomes 1. Immunogenicity
2. Safety
Starting date Not reported
Contact information GlaxoSmithKline
Notes Location: not reported
Registration number: not reported
Source of funding: GlaxoSmithKline
RV5 NCT02728869
Trial name or title “Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants”
Methods Phase I/II, randomized, single-blind trial
Participants Number: 100
Description: Healthy infants of either sex, 6 - 8 weeks of age; healthy adults
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RV5 NCT02728869 (Continued)
Interventions 1. Hilleman Labs heat stable pentavalent vaccine
2. RV5
Schedule: 3 doses at 4-week intervals
Outcomes 3. Any adverse event
4. Serious adverse events
5. Anti-Rotavirus IgA sero-response rate
7. Viral shedding
Starting date June 2016
Completion: April 2017
Contact information K Zaman, MBBS, PhD; International Center for Diarrheal Disease Research, Bangladesh
Notes Location: Bangladesh
Registration number: NCT02728869
Source of funding: MSDWellcome Trust Hilleman Laboratories Pvt. Ltd.
BRV: bovine-human reassortant vaccine; GMT: geometric mean titre; SAE: serious adverse event
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D A T A A N D A N A L Y S E S
Comparison 1. RV1 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rotavirus diarrhoea: severe (up
to 1 year follow-up)
11 49893 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.14, 0.34]
1.1 Low-mortality countries
(WHO strata A & B)
7 43779 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.09, 0.26]
1.2 High-mortality countries
(WHO strata D & E)
4 6114 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.23, 0.60]
2 Rotavirus diarrhoea: severe (up
to 2 years follow-up)
12 Risk Ratio (Fixed, 95% CI) 0.34 [0.29, 0.41]
2.1 Low-mortality countries
(WHO strata A & B)
9 Risk Ratio (Fixed, 95% CI) 0.18 [0.14, 0.23]
2.2 High-mortality countries
(WHO strata D & E)
3 Risk Ratio (Fixed, 95% CI) 0.65 [0.51, 0.83]
3 All-cause diarrhoea: severe cases
(up to 1 year follow-up)
6 33690 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.54, 0.80]
3.1 Low-mortality countries
(WHO strata A & B)
3 28051 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.47, 0.74]
3.2 High-mortality countries
(WHO strata D & E)
3 5639 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.56, 0.95]
4 All-cause diarrhoea: severe cases
(up to 2 years follow-up)
5 12181 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.54, 0.92]
4.1 Low-mortality countries
(WHO strata A & B)
3 9417 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.36, 1.02]
4.2 High-mortality countries
(WHO strata D & E)
2 2764 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.72, 0.96]
5 All-cause diarrhoea: severe
episodes (up to 1 year
follow-up)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
5.1 Low-mortality countries
(WHO strata A & B)
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 All-cause diarrhoea: severe
episodes (up to 2 years
follow-up)
2 Rate Ratio (Fixed, 95% CI) Subtotals only
6.1 Low-mortality countries
(WHO strata A & B)
2 Rate Ratio (Fixed, 95% CI) 0.63 [0.56, 0.71]
7 All-cause death 30 105778 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.82, 1.30]
7.1 Low-mortality countries
(WHO strata A & B)
22 97597 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.87, 1.71]
7.2 High-mortality countries
(WHO strata D & E)
8 8181 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.64, 1.22]
8 All serious adverse events 31 103714 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.83, 0.93]
8.1 Low-mortality countries
(WHO strata A & B)
24 96233 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.83, 0.93]
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8.2 High-mortality countries
(WHO strata D & E)
7 7481 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.76, 1.04]
9 Serious adverse events:
intussusception
21 Risk Ratio (Fixed, 95% CI) 0.70 [0.46, 1.05]
9.1 Low-mortality countries
(WHO strata A & B)
17 Risk Ratio (Fixed, 95% CI) 0.69 [0.45, 1.04]
9.2 High-mortality countries
(WHO stratum E)
4 Risk Ratio (Fixed, 95% CI) 1.49 [0.06, 36.63]
10 Serious adverse events:
Kawasaki disease
3 13117 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.30, 10.61]
11 Serious adverse events requiring
hospitalization
2 63675 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.81, 0.96]
12 Rotavirus diarrhoea: of any
severity (up to 2 months
follow-up)
12 4294 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.69, 2.00]
12.1 Low-mortality countries
(WHO strata A & B)
9 3537 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.66, 2.50]
12.2 High-mortality countries
(WHO strata D & E)
3 757 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.41, 2.41]
13 Rotavirus diarrhoea: of any
severity (up to 1 year follow-up)
8 15197 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.23, 0.50]
13.1 Low-mortality countries
(WHO strata A & B)
4 9083 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.13, 0.40]
13.2 High-mortality countries
(WHO stratum E)
4 6114 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.35, 0.68]
14 Rotavirus diarrhoea: of
any severity (up to 2 years
follow-up)
7 11692 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.28, 0.47]
14.1 Low-mortality countries
(WHO strata A & B)
6 10441 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.25, 0.48]
14.2 High-mortality countries
(WHO stratum E)
1 1251 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.28, 0.62]
15 All-cause diarrhoea: all cases
(up to 2 months follow-up)
7 3132 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.72, 1.10]
15.1 Low-mortality countries
(WHO strata A & B)
6 3032 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.67, 1.09]
15.2 High-mortality countries
(WHO stratum E)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.69, 1.58]
16 All-cause diarrhoea: all cases
(up to 1 year follow-up)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Low-mortality countries
(WHO strata A & B)
2 2204 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.82, 1.03]
16.2 High-mortality countries
(WHO strata D & E)
1 700 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.93, 1.05]
17 All-cause diarrhoea: all cases
(up to 2 years follow-up)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Low-mortality countries
(WHO strata A & B)
3 5937 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.87, 1.00]
18 All-cause diarrhoea: all episodes
(up to 1 year follow-up)
2 Rate Ratio (Fixed, 95% CI) Subtotals only
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18.1 Low-mortality countries
(WHO strata A & B)
2 Rate Ratio (Fixed, 95% CI) 0.98 [0.88, 1.10]
19 All-cause diarrhoea: all episodes
(up to 2 years follow-up)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
19.1 Low-mortality countries
(WHO strata A & B)
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
20 All-cause hospitalizations (up
to 2 years follow-up)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 Low-mortality countries
(WHO strata A & B)
2 65646 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.27, 1.47]
21 Rotavirus diarrhoea: requiring
hospitalization
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 Up to 1 year follow-up
(at least 1 rotavirus season)
8 48718 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.09, 0.33]
21.2 Second year follow-up
(at least 2 rotavirus seasons)
7 35331 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.11, 0.22]
22 Rotavirus diarrhoea: requiring
medical attention
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 Up to 1 year follow-up
(at least 1 rotavirus season)
1 3874 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.04, 0.16]
22.2 Second year follow-up
(at least 2 rotavirus seasons)
3 7017 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.16, 0.31]
23 All-cause diarrhoea: cases
requiring hospitalization
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 Up to one year of follow-
up (at least 1 rotavirus season)
2 14393 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.17, 1.11]
23.2 Second year of follow-up
(at least 2 rotavirus seasons)
2 14367 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.27, 0.99]
24 All-cause diarrhoea: episodes
requiring hospitalization
1 Rate Ratio (Fixed, 95% CI) Subtotals only
24.1 Up to 1 year of follow-
up (at least 1 rotavirus season)
1 Rate Ratio (Fixed, 95% CI) 0.58 [0.47, 0.71]
24.2 Second year of follow-up
(at least 2 rotavirus seasons)
1 Rate Ratio (Fixed, 95% CI) 0.53 [0.46, 0.61]
25 Reactogenicity: fever 28 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 After dose 1 25 16192 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.17]
25.2 After dose 2 24 15630 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.92, 1.06]
25.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.13]
25.4 End of follow-up 18 11926 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.93, 1.01]
26 Reactogenicity: diarrhoea 27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 After dose 1 25 18732 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.88, 1.17]
26.2 After dose 2 24 15630 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.86, 1.21]
26.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.35, 1.36]
26.4 End of follow-up 17 14305 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
27 Reactogenicity: vomiting 27 Risk Ratio (M-H, Random, 95% CI) Subtotals only
27.1 After dose 1 25 18732 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.94, 1.12]
27.2 After dose 2 24 15630 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.05]
27.3 After dose 3 4 1390 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.71, 2.50]
27.4 End of follow-up 17 14305 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.04]
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28 Adverse events requiring
discontinuation (end of
follow-up)
26 94980 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.83, 1.26]
29 Immunogenicity: rotavirus
vaccine shedding (end of
follow-up)
16 2638 Risk Ratio (M-H, Random, 95% CI) 10.94 [4.90, 24.43]
30 Immunogenicity:
seroconversion
31 Risk Ratio (M-H, Random, 95% CI) Subtotals only
30.1 After dose 1 9 2537 Risk Ratio (M-H, Random, 95% CI) 20.39 [8.48, 49.01]
30.2 After dose 2 27 8742 Risk Ratio (M-H, Random, 95% CI) 11.44 [8.01, 16.32]
30.3 After dose 3 5 1137 Risk Ratio (M-H, Random, 95% CI) 6.89 [3.59, 13.24]
31 Dropouts before the end of the
trial
28 93106 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.90, 1.00]
32 Subgroup analysis: rotavirus
diarrhoea of any severity (by G
type)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
32.1 G1 6 27583 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.10, 0.44]
32.2 G2 5 26835 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.31, 0.56]
32.3 G3 4 8968 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.05, 0.39]
32.4 G4 2 5720 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.07, 0.59]
32.5 G9 3 8868 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.18, 0.75]
33 Subgroup analysis: severe cases
of rotavirus diarrhoea (by G
type)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
33.1 G1 7 39428 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.16, 0.38]
33.2 G2 7 44682 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.18, 0.50]
33.3 G3 5 20505 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.05, 0.56]
33.4 G4 1 2421 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.00, 2.95]
33.5 G8 2 4417 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.02, 2.37]
33.6 G9 6 26815 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.13, 0.40]
33.7 G12 2 4417 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.23, 0.97]
34 Subgroup analysis: rotavirus
diarrhoea in malnourished
children
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
34.1 Up to 1 year of follow-
up (at least 1 rotavirus season)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
35 Subgroup analysis: rotavirus
diarrhoea in HIV-infected
children
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.26, 3.78]
Comparison 2. RV5 versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rotavirus diarrhoea: severe (up
to 1 year follow-up)
9 10048 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.22, 0.44]
1.1 Low-mortality countries
(WHO strata A & B)
5 4132 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.03, 0.22]
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1.2 High-mortality countries
(WHO strata D & E)
4 5916 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.29, 0.62]
2 Rotavirus diarrhoea: severe (up
to 2 years follow-up)
8 13203 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.23, 0.60]
2.1 Low-mortality countries
(WHO strata A & B)
4 7318 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.08, 0.39]
2.2 High-mortality countries
(WHO strata D & E)
4 5885 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.43, 0.82]
3 All-cause diarrhoea: severe cases
(up to 1 year follow-up)
3 4085 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.11]
3.1 Low-mortality countries
(WHO stratum A)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 High-mortality countries
(WHO strata D & E)
3 4085 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.58, 1.11]
4 All-cause diarrhoea: severe cases
(up to 2 years follow-up)
4 5977 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.75, 0.98]
4.1 Low-mortality countries
(WHO strata A & B)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 High-mortality countries
(WHO strata D & E)
4 5977 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.75, 0.98]
5 All-cause death 14 84448 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.74, 1.25]
5.1 Low-mortality countries
(WHO strata A & B)
9 77642 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.65, 1.96]
5.2 High-mortality countries
(WHO strata D & E)
5 6806 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.68, 1.24]
6 All serious adverse events 14 82502 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.86, 1.01]
6.1 Low-mortality countries
(WHO strata A & B)
8 75672 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.86, 1.02]
6.2 High-mortality countries
(WHO strata D & E)
6 6830 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.66, 1.28]
7 Serious adverse events:
intussusception
16 85495 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.41, 1.45]
7.1 Low-mortality countries
(WHO strata A & B)
12 78907 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.41, 1.45]
7.2 High-mortality countries
(WHO strata D & E)
4 6588 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Rotavirus diarrhoea: of any
severity (up to 1 year follow-up)
8 13450 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.28, 0.50]
8.1 Low-mortality countries
(WHO strata A & B)
5 8644 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.25, 0.37]
8.2 High-mortality countries
(WHO strata D & E)
3 4806 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.94]
9 Rotavirus diarrhoea: of any
severity (up to 2 years
follow-up)
7 12888 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.33, 0.65]
9.1 Low-mortality countries
(WHO strata A & B)
3 6144 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.26, 0.43]
9.2 High-mortality countries
(WHO strata D & E)
4 6744 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.45, 0.83]
10 All-cause diarrhoea: of any
severity (up to 1 year follow-up)
1 1059 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.11]
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10.1 Low-mortality countries
(WHO strata A & B)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 High-mortality countries
(WHO stratum E)
1 1059 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.11]
11 All-cause diarrhoea: of
any severity (up to 2 years
follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 High-mortality countries
(WHO stratum E)
1 1059 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.68, 1.16]
12 All-cause hospitalizations (up
to 2 years follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
12.1 High-mortality countries
(WHO strata D & E)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Rotavirus diarrhoea: requiring
hospitalization
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
13.1 Up to 1 year of follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Rotavirus diarrhoea: requiring
medical attention
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14.1 Up to 1 year of follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Reactogenicity: fever 12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 After dose 1 4 7124 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.91, 1.45]
15.2 After dose 2 2 4322 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.69, 1.01]
15.3 After dose 3 2 4294 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.90, 1.27]
15.4 End of follow-up 11 18391 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.09]
16 Reactogenicity: diarrhoea 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 After dose 1 2 4745 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.95, 1.32]
16.2 After dose 2 1 3905 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.72, 1.10]
16.3 End of follow-up 10 17087 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
17 Reactogenicity: vomiting 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 After dose 1 2 4745 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.12]
17.2 After dose 2 1 3905 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.32, 1.49]
17.3 After dose 3 1 3878 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.16, 1.32]
17.4 End of follow-up 9 16294 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.90, 1.06]
18 Adverse events requiring
discontinuation (end of
follow-up)
10 15471 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.57, 1.39]
19 Immunogenicity: rotavirus
vaccine shedding (after dose 3)
5 Risk Ratio (M-H, Random, 95% CI) Totals not selected
20 Immunogenicity:
seroconversion
10 Risk Ratio (M-H, Random, 95% CI) Totals not selected
20.1 After dose 3 10 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
21 Dropouts before the end of the
trial
13 85855 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.90, 1.08]
22 Subgroup analysis: rotavirus
diarrhoea of any severity (by G
type)
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 G1 4 11022 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.21, 0.32]
22.2 G2 3 9907 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.16, 0.78]
22.3 G3 4 11022 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.08, 2.02]
22.4 G4 3 9907 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.13, 1.33]
22.5 G9 2 9537 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.20, 0.54]
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23 Subgroup analysis: severe cases
of rotavirus diarrhoea (by G
type)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 G1 3 76606 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.03, 1.74]
23.2 G2 3 76606 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.13, 1.37]
23.3 G3 3 76606 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.05, 2.74]
23.4 G4 3 76606 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.03, 0.46]
23.5 G9 3 76606 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.05, 0.34]
24 Subgroup analysis:
HIV-infected children
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24.1 Rotavirus diarrhoea:
severe (up to two years follow-
up)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 2.45 [0.11, 56.68]
24.2 All-cause diarrhoea:
severe (up to two years follow-
up)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 4.05 [0.52, 31.43]
24.3 All-cause death 2 114 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.51, 3.21]
24.4 Serious adverse events
(up to 24 weeks)
2 113 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.59, 3.97]
Comparison 3. Rotavac versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Rotavirus diarrhoea: severe (up
to 1 year follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Rotavirus diarrhoea: severe (up
to 2 years follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 All-cause diarrhoea: severe cases
(up to 1 year follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 All-cause death 2 8155 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.52, 1.62]
5 All serious adverse events 3 8210 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.85, 1.02]
6 Serious adverse events:
intussusception
4 8582 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.35, 5.02]
7 Rotavirus diarrhoea: of any
severity (up to 1 year follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Rotavirus diarrhoea: of any
severity (up to 2 years
follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Rotavirus diarrhoea: requiring
medical attention
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Up to 1 year follow-up (at
least 1 rotavirus season)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Reactogenicity: fever 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 After dose 1 2 427 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.35, 1.94]
10.2 After dose 2 1 356 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.33, 1.77]
10.3 After dose 3 1 358 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.52, 2.36]
11 Reactogenicity: diarrhoea 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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11.1 After dose 1 2 427 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.62, 1.30]
11.2 After dose 2 1 356 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.00, 2.41]
11.3 After dose 3 1 358 Risk Ratio (M-H, Fixed, 95% CI) 4.09 [2.11, 7.92]
12 Reactogenicity: vomiting 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 After dose 1 2 427 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.71, 2.55]
12.2 After dose 2 1 356 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.64, 3.66]
12.3 After dose 3 1 358 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.39, 2.66]
13 Immunogenicity: rotavirus
vaccine shedding (end of
follow-up)
2 427 Risk Ratio (M-H, Random, 95% CI) 9.86 [2.58, 37.63]
14 Immunogenicity:
seroconversion
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 After dose 1 1 121 Risk Ratio (M-H, Fixed, 95% CI) 3.58 [2.03, 6.29]
14.2 After dose 2 1 117 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [1.78, 4.98]
14.3 After dose 3 3 1699 Risk Ratio (M-H, Fixed, 95% CI) 2.82 [2.26, 3.51]
15 Dropouts before the end of the
trial
3 8215 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.62, 1.06]
16 Subgroup analysis: severe cases
of rotavirus diarrhoea by G and
P types (up to 1 year follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 G1P[8] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.36, 1.20]
16.2 G2P[4] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.22, 0.69]
16.3 G12P[6] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.13, 0.74]
16.4 G12P[8] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.07, 1.26]
17 Subgroup analysis: severe cases
of rotavirus diarrhoea by G
and P types (up to 2 years
follow-up)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 G1P[8] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.38, 0.93]
17.2 G2P[4] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.23, 0.62]
17.3 G9P[4] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 4.52 [0.57, 35.66]
17.4 G12P[6] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.13, 0.74]
17.5 G12P[8] 1 6541 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.10, 0.96]
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Analysis 1.1. Comparison 1 RV1 versus placebo, Outcome 1 Rotavirus diarrhoea: severe (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 1 Rotavirus diarrhoea: severe (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 2/108 9/107 5.4 % 0.22 [ 0.05, 1.00 ]
RV1 Li 2014-CHN 8/1575 32/1573 9.9 % 0.25 [ 0.12, 0.54 ]
RV1 Phua 2009-AS 0/5263 15/5256 2.1 % 0.03 [ 0.00, 0.54 ]
RV1 Ruiz-Palac 06-LA/EU (1) 12/9009 77/8858 11.2 % 0.15 [ 0.08, 0.28 ]
RV1 Salinas 2005-LA 27/1392 34/454 12.0 % 0.26 [ 0.16, 0.42 ]
RV1 Tregnaghi 2011-LA 7/4211 19/2099 9.2 % 0.18 [ 0.08, 0.44 ]
RV1 Vesikari 2007a-EU 5/2572 60/1302 8.9 % 0.04 [ 0.02, 0.10 ]
Subtotal (95% CI) 24130 19649 58.8 % 0.16 [ 0.09, 0.26 ]
Total events: 61 (RV1), 246 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 15.41, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 6.91 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV1 Colgate 2016-BGD 14/350 39/350 11.3 % 0.36 [ 0.20, 0.65 ]
RV1 Madhi 2010-MWI (2) 52/1182 47/591 12.8 % 0.55 [ 0.38, 0.81 ]
RV1 Madhi 2010-ZAF (3) 16/2116 36/1050 11.3 % 0.22 [ 0.12, 0.40 ]
RV1 Steele 2010b-ZAF 5/379 3/96 5.9 % 0.42 [ 0.10, 1.74 ]
Subtotal (95% CI) 4027 2087 41.2 % 0.37 [ 0.23, 0.60 ]
Total events: 87 (RV1), 125 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 6.91, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 4.09 (P = 0.000044)
Total (95% CI) 28157 21736 100.0 % 0.22 [ 0.14, 0.34 ]
Total events: 148 (RV1), 371 (Placebo)
Heterogeneity: Tau2 = 0.37; Chi2 = 39.86, df = 10 (P = 0.00002); I2 =75%
Test for overall effect: Z = 6.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.84, df = 1 (P = 0.02), I2 =83%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort in Malawi
(3) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort in South Africa
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Analysis 1.2. Comparison 1 RV1 versus placebo, Outcome 2 Rotavirus diarrhoea: severe (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 2 Rotavirus diarrhoea: severe (up to 2 years follow-up)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA -1.8551 (0.6061) 2.0 % 0.16 [ 0.05, 0.51 ]
RV1 Kawamura 2011-JPN -2.4809 (0.7598) 1.3 % 0.08 [ 0.02, 0.37 ]
RV1 Li 2014-CHN -1.2742 (0.2443) 12.3 % 0.28 [ 0.17, 0.45 ]
RV1 Phua 2005-SGP -2.1168 (1.6323) 0.3 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS -3.24 (0.7206) 1.4 % 0.04 [ 0.01, 0.16 ]
RV1 Ruiz-Palac 06-LA/EU (1) -1.633 (0.1928) 19.7 % 0.20 [ 0.13, 0.29 ]
RV1 Salinas 2005-LA -1.5193 (0.9062) 0.9 % 0.22 [ 0.04, 1.29 ]
RV1 Vesikari 2004b-FIN -1.893 (0.6489) 1.7 % 0.15 [ 0.04, 0.54 ]
RV1 Vesikari 2007a-EU -1.934 (0.2577) 11.0 % 0.14 [ 0.09, 0.24 ]
Subtotal (95% CI) 50.6 % 0.18 [ 0.14, 0.23 ]
Heterogeneity: Chi2 = 9.86, df = 8 (P = 0.27); I2 =19%
Test for overall effect: Z = 14.09 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV1 Madhi 2010-MWI (2) -0.4791 (0.1735) 24.3 % 0.62 [ 0.44, 0.87 ]
RV1 Madhi 2010-ZAF (3) -0.8928 (0.4052) 4.5 % 0.41 [ 0.19, 0.91 ]
RV1 Zaman 2017-BGD (4) -0.2677 (0.1888) 20.6 % 0.77 [ 0.53, 1.11 ]
Subtotal (95% CI) 49.4 % 0.65 [ 0.51, 0.83 ]
Heterogeneity: Chi2 = 2.12, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 3.52 (P = 0.00044)
Total (95% CI) 100.0 % 0.34 [ 0.29, 0.41 ]
Heterogeneity: Chi2 = 66.78, df = 11 (P<0.00001); I2 =84%
Test for overall effect: Z = 12.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 54.79, df = 1 (P = 0.00), I2 =98%
0.005 0.1 1 10 200
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) Data from Malawi cohort only
(3) Assessment of vaccine effiicacy up to two years follow-up available from cohort 2 subjects only in South Africa
(4) Adjusted for clustering: design effect of 2.53, villages randomised to RV1 versus no intervention
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Analysis 1.3. Comparison 1 RV1 versus placebo, Outcome 3 All-cause diarrhoea: severe cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 3 All-cause diarrhoea: severe cases (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Ruiz-Palac 06-LA/EU 183/9009 300/8858 18.4 % 0.60 [ 0.50, 0.72 ]
RV1 Tregnaghi 2011-LA 116/4211 78/2099 14.9 % 0.74 [ 0.56, 0.98 ]
RV1 Vesikari 2007a-EU 116/2572 123/1302 16.2 % 0.48 [ 0.37, 0.61 ]
Subtotal (95% CI) 15792 12259 49.5 % 0.59 [ 0.47, 0.74 ]
Total events: 415 (RV1), 501 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.42, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 4.63 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV1 Colgate 2016-BGD 110/350 126/350 17.5 % 0.87 [ 0.71, 1.08 ]
RV1 Madhi 2010-MWI (1) 221/1182 139/591 18.2 % 0.79 [ 0.66, 0.96 ]
RV1 Madhi 2010-ZAF (2) 92/2116 86/1050 14.8 % 0.53 [ 0.40, 0.71 ]
Subtotal (95% CI) 3648 1991 50.5 % 0.73 [ 0.56, 0.95 ]
Total events: 423 (RV1), 351 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.11, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 2.37 (P = 0.018)
Total (95% CI) 19440 14250 100.0 % 0.66 [ 0.54, 0.80 ]
Total events: 838 (RV1), 852 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.45, df = 5 (P = 0.00066); I2 =77%
Test for overall effect: Z = 4.30 (P = 0.000017)
Test for subgroup differences: Chi2 = 1.45, df = 1 (P = 0.23), I2 =31%
0.5 0.7 1 1.5 2
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 6 - total vaccinated cohort in Malawi
(2) Data taken from main paper Supplementary Appendix, Table 6 - total vaccinated cohort in South Africa
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Analysis 1.4. Comparison 1 RV1 versus placebo, Outcome 4 All-cause diarrhoea: severe cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 4 All-cause diarrhoea: severe cases (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Li 2014-CHN 187/1575 206/1573 24.5 % 0.91 [ 0.75, 1.09 ]
RV1 Phua 2005-SGP 11/1779 10/642 7.4 % 0.40 [ 0.17, 0.93 ]
RV1 Vesikari 2007a-EU 149/2554 153/1294 23.6 % 0.49 [ 0.40, 0.61 ]
Subtotal (95% CI) 5908 3509 55.5 % 0.60 [ 0.36, 1.02 ]
Total events: 347 (RV1), 369 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 19.27, df = 2 (P = 0.00007); I2 =90%
Test for overall effect: Z = 1.89 (P = 0.059)
2 High-mortality countries (WHO strata D % E)
RV1 Madhi 2010-MWI (1) 287/1030 160/483 25.2 % 0.84 [ 0.72, 0.99 ]
RV1 Madhi 2010-ZAF (2) 76/843 48/408 19.2 % 0.77 [ 0.54, 1.08 ]
Subtotal (95% CI) 1873 891 44.5 % 0.83 [ 0.72, 0.96 ]
Total events: 363 (RV1), 208 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.010)
Total (95% CI) 7781 4400 100.0 % 0.70 [ 0.54, 0.92 ]
Total events: 710 (RV1), 577 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 22.70, df = 4 (P = 0.00015); I2 =82%
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Chi2 = 1.29, df = 1 (P = 0.26), I2 =22%
0.1 0.2 0.5 1 2 5 10
Favours RV1 Favours placebo
(1) Data from Malawi cohort only
(2) Data from South Africa cohort only
209Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.5. Comparison 1 RV1 versus placebo, Outcome 5 All-cause diarrhoea: severe episodes (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 5 All-cause diarrhoea: severe episodes (up to 1 year follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Ruiz-Palac 06-LA/EU (1) -0.511 (0.094) 0.60 [ 0.50, 0.72 ]
0.5 0.7 1 1.5 2
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
Analysis 1.6. Comparison 1 RV1 versus placebo, Outcome 6 All-cause diarrhoea: severe episodes (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 6 All-cause diarrhoea: severe episodes (up to 2 years follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2009-AS -0.361 (0.11) 28.2 % 0.70 [ 0.56, 0.86 ]
RV1 Ruiz-Palac 06-LA/EU (1) -0.494 (0.069) 71.8 % 0.61 [ 0.53, 0.70 ]
Subtotal (95% CI) 100.0 % 0.63 [ 0.56, 0.71 ]
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 7.81 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
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Analysis 1.7. Comparison 1 RV1 versus placebo, Outcome 7 All-cause death.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 7 All-cause death
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/281 0/64 0.6 % 0.69 [ 0.03, 16.78 ]
RV1 Anh 2011-VNM 0/279 0/73 Not estimable
RV1 Bernstein 1999-USA 1/108 0/107 0.4 % 2.97 [ 0.12, 72.16 ]
RV1 GSK[021] 2007-PAN 0/177 0/51 Not estimable
RV1 GSK[041] 2007-KOR 0/103 0/52 Not estimable
RV1 GSK[101555] 2008-PHL 0/100 0/50 Not estimable
RV1 Kawamura 2011-JPN 0/507 0/257 Not estimable
RV1 Kerdpanich 2010-THA 0/395 0/26 Not estimable
RV1 Kim 2012-KOR 0/508 0/176 Not estimable
RV1 Li 2013b-CHN 0/25 0/25 Not estimable
RV1 Li 2014-CHN 6/1666 7/1667 5.1 % 0.86 [ 0.29, 2.55 ]
RV1 NCT00158756-RUS 0/161 0/48 Not estimable
RV1 Omenaca 2012-EU 0/670 1/339 1.4 % 0.17 [ 0.01, 4.14 ]
RV1 Phua 2005-SGP 3/1779 0/642 0.5 % 2.53 [ 0.13, 48.89 ]
RV1 Phua 2009-AS 1/5263 3/5256 2.2 % 0.33 [ 0.03, 3.20 ]
RV1 Rivera 2011-DOM 0/100 0/100 Not estimable
RV1 Ruiz-Palac 06-LA/EU (1) 56/31673 43/31552 31.3 % 1.30 [ 0.87, 1.93 ]
RV1 Salinas 2005-LA 2/1618 1/537 1.1 % 0.66 [ 0.06, 7.31 ]
RV1 Tregnaghi 2011-LA 10/4376 2/2192 1.9 % 2.50 [ 0.55, 11.42 ]
RV1 Vesikari 2004b-FIN 0/267 0/133 Not estimable
RV1 Vesikari 2007a-EU 0/2613 0/1331 Not estimable
RV1 Vesikari 2011-FIN 0/200 0/50 Not estimable
Subtotal (95% CI) 52869 44728 44.5 % 1.22 [ 0.87, 1.71 ]
Total events: 80 (RV1), 57 (Placebo)
Heterogeneity: Chi2 = 4.99, df = 8 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
0.005 0.1 1 10 200
Favours RV1 Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 High-mortality countries (WHO strata D % E)
RV1 Colgate 2016-BGD 1/350 1/350 0.7 % 1.00 [ 0.06, 15.92 ]
RV1 GSK[033] 2007-LA (2) 3/730 0/124 0.6 % 1.20 [ 0.06, 23.03 ]
RV1 Madhi 2010-AF 83/3298 43/1641 41.7 % 0.96 [ 0.67, 1.38 ]
RV1 Narang 2009-IND 0/182 0/181 Not estimable
RV1 Steele 2008-ZAF 3/300 5/150 4.8 % 0.30 [ 0.07, 1.24 ]
RV1 Steele 2010a-ZAF 6/50 9/50 6.5 % 0.67 [ 0.26, 1.73 ]
RV1 Steele 2010b-ZAF 3/379 0/96 0.6 % 1.79 [ 0.09, 34.30 ]
RV1 Zaman 2009-BGD 1/200 0/100 0.5 % 1.51 [ 0.06, 36.68 ]
Subtotal (95% CI) 5489 2692 55.5 % 0.88 [ 0.64, 1.22 ]
Total events: 100 (RV1), 58 (Placebo)
Heterogeneity: Chi2 = 3.14, df = 6 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 58358 47420 100.0 % 1.03 [ 0.82, 1.30 ]
Total events: 180 (RV1), 115 (Placebo)
Heterogeneity: Chi2 = 9.92, df = 15 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.78)
Test for subgroup differences: Chi2 = 1.84, df = 1 (P = 0.18), I2 =46%
0.005 0.1 1 10 200
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) This study was conducted in four study centres in a high mortality country (Peru), but also in three study centres in two low mortality countries (Colombia and
Mexico)
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Analysis 1.8. Comparison 1 RV1 versus placebo, Outcome 8 All serious adverse events.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 8 All serious adverse events
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/281 1/64 0.1 % 0.23 [ 0.01, 3.59 ]
RV1 Anh 2011-VNM 15/279 1/73 0.1 % 3.92 [ 0.53, 29.23 ]
RV1 Bernstein 1998-USA 0/21 0/20 Not estimable
RV1 Dennehy 2005-NA 15/421 8/108 0.5 % 0.48 [ 0.21, 1.10 ]
RV1 GSK[021] 2007-PAN 18/177 9/51 0.6 % 0.58 [ 0.28, 1.20 ]
RV1 GSK[041] 2007-KOR 9/103 2/52 0.1 % 2.27 [ 0.51, 10.14 ]
RV1 GSK[101555] 2008-PHL 5/100 0/50 0.0 % 5.55 [ 0.31, 98.50 ]
RV1 Kawamura 2011-JPN 72/508 44/257 2.3 % 0.83 [ 0.59, 1.17 ]
RV1 Kerdpanich 2010-THA 11/396 4/51 0.3 % 0.35 [ 0.12, 1.07 ]
RV1 Kim 2012-KOR 17/508 13/176 0.8 % 0.45 [ 0.22, 0.91 ]
RV1 Li 2013b-CHN 2/25 0/25 0.0 % 5.00 [ 0.25, 99.16 ]
RV1 Li 2014-CHN 183/1666 246/1667 9.8 % 0.74 [ 0.62, 0.89 ]
RV1 NCT00158756-RUS 8/161 0/48 0.0 % 5.14 [ 0.30, 87.50 ]
RV1 Omenaca 2012-EU 34/670 23/339 1.2 % 0.75 [ 0.45, 1.25 ]
RV1 Phua 2005-SGP 144/1811 40/653 2.3 % 1.30 [ 0.93, 1.82 ]
RV1 Phua 2009-AS 10/4272 11/4226 0.4 % 0.90 [ 0.38, 2.12 ]
RV1 Rivera 2011-DOM 5/100 6/100 0.2 % 0.83 [ 0.26, 2.64 ]
RV1 Ruiz-Palac 06-LA/EU (1) 928/31673 1047/31552 41.8 % 0.88 [ 0.81, 0.96 ]
RV1 Salinas 2005-LA 156/1618 64/537 3.8 % 0.81 [ 0.62, 1.06 ]
RV1 Tregnaghi 2011-LA 505/4376 265/2192 14.1 % 0.95 [ 0.83, 1.10 ]
RV1 Vesikari 2004a-FIN 2/128 1/64 0.1 % 1.00 [ 0.09, 10.82 ]
RV1 Vesikari 2004b-FIN 28/267 9/133 0.5 % 1.55 [ 0.75, 3.19 ]
RV1 Vesikari 2007a-EU 290/2646 176/1348 9.3 % 0.84 [ 0.70, 1.00 ]
RV1 Vesikari 2011-FIN 3/193 0/47 0.0 % 1.73 [ 0.09, 32.97 ]
Subtotal (95% CI) 52400 43833 88.3 % 0.88 [ 0.83, 0.93 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 2461 (RV1), 1970 (Placebo)
Heterogeneity: Chi2 = 31.78, df = 22 (P = 0.08); I2 =31%
Test for overall effect: Z = 4.28 (P = 0.000018)
2 High-mortality countries (WHO strata D % E)
RV1 GSK[033] 2007-LA (2) 3/730 0/124 0.0 % 1.20 [ 0.06, 23.03 ]
RV1 Madhi 2010-AF 319/3298 189/1641 10.0 % 0.84 [ 0.71, 1.00 ]
RV1 Narang 2009-IND 3/182 2/181 0.1 % 1.49 [ 0.25, 8.82 ]
RV1 Steele 2008-ZAF 30/300 14/150 0.7 % 1.07 [ 0.59, 1.96 ]
RV1 Steele 2010a-ZAF 17/50 12/50 0.5 % 1.42 [ 0.76, 2.65 ]
RV1 Steele 2010b-ZAF 19/379 5/96 0.3 % 0.96 [ 0.37, 2.51 ]
RV1 Zaman 2009-BGD 1/200 0/100 0.0 % 1.51 [ 0.06, 36.68 ]
Subtotal (95% CI) 5139 2342 11.7 % 0.89 [ 0.76, 1.04 ]
Total events: 392 (RV1), 222 (Placebo)
Heterogeneity: Chi2 = 3.42, df = 6 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 57539 46175 100.0 % 0.88 [ 0.83, 0.93 ]
Total events: 2853 (RV1), 2192 (Placebo)
Heterogeneity: Chi2 = 35.23, df = 29 (P = 0.20); I2 =18%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru)
(2) This study was conducted in four study centres in a high mortality country (Peru), but also in three study centres in two low mortality countries (Colombia and
Mexico)
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Analysis 1.9. Comparison 1 RV1 versus placebo, Outcome 9 Serious adverse events: intussusception.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 9 Serious adverse events: intussusception
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Dennehy 2005-NA 0 (0) Not estimable
RV1 GSK[041] 2007-KOR 0 (0) Not estimable
RV1 Kawamura 2011-JPN 0 (0) Not estimable
RV1 Kim 2012-KOR -0.7917 (0.3579) 34.7 % 0.45 [ 0.22, 0.91 ]
RV1 Li 2013b-CHN 0 (0) Not estimable
RV1 Li 2014-CHN 0.0006 (1.4138) 2.2 % 1.00 [ 0.06, 15.98 ]
RV1 NCT00158756-RUS -0.0972 (1.6248) 1.7 % 0.91 [ 0.04, 21.92 ]
RV1 Omenaca 2012-EU 0 (0) Not estimable
RV1 Phua 2005-SGP -1.0201 (1.4135) 2.2 % 0.36 [ 0.02, 5.76 ]
RV1 Phua 2009-AS 0.6918 (0.6121) 11.9 % 2.00 [ 0.60, 6.63 ]
RV1 Rivera 2011-DOM 0 (0) Not estimable
RV1 Ruiz-Palac 06-LA/EU (1) -0.4346 (0.3562) 35.0 % 0.65 [ 0.32, 1.30 ]
RV1 Salinas 2005-LA -0.0031 (1.6322) 1.7 % 1.00 [ 0.04, 24.43 ]
RV1 Tregnaghi 2011-LA 0.0018 (0.8656) 5.9 % 1.00 [ 0.18, 5.46 ]
RV1 Vesikari 2004b-FIN 0 (0) Not estimable
RV1 Vesikari 2007a-EU 0.0187 (1.2243) 3.0 % 1.02 [ 0.09, 11.23 ]
RV1 Vesikari 2011-FIN 0 (0) Not estimable
Subtotal (95% CI) 98.3 % 0.69 [ 0.45, 1.04 ]
Heterogeneity: Chi2 = 5.07, df = 8 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-AF 0.4009 (1.6327) 1.7 % 1.49 [ 0.06, 36.63 ]
RV1 Steele 2008-ZAF 0 (0) Not estimable
RV1 Steele 2010b-ZAF 0 (0) Not estimable
RV1 Zaman 2017-BGD (2) 0 (0) Not estimable
Subtotal (95% CI) 1.7 % 1.49 [ 0.06, 36.63 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
Total (95% CI) 100.0 % 0.70 [ 0.46, 1.05 ]
Heterogeneity: Chi2 = 5.30, df = 9 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(1) This multinational study includes 12 Latin America countries, two of them with high mortality (Nicaragua and Peru). Data updated from
www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm134142.htm
(2) Adjusted for clustering: design effect of 2.53, villages randomised to RV1 versus no intervention
Analysis 1.10. Comparison 1 RV1 versus placebo, Outcome 10 Serious adverse events: Kawasaki disease.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 10 Serious adverse events: Kawasaki disease
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Phua 2005-SGP 2/1811 0/653 37.0 % 1.80 [ 0.09, 37.54 ]
RV1 Phua 2009-AS 1/4272 0/4226 25.3 % 2.97 [ 0.12, 72.83 ]
RV1 Salinas 2005-LA 1/1618 0/537 37.8 % 1.00 [ 0.04, 24.44 ]
Total (95% CI) 7701 5416 100.0 % 1.79 [ 0.30, 10.61 ]
Total events: 4 (RV1), 0 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 RV1 versus placebo, Outcome 11 Serious adverse events requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 11 Serious adverse events requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Ruiz-Palac 06-LA/EU 886/31673 1003/31552 99.9 % 0.88 [ 0.81, 0.96 ]
RV1 Steele 2008-ZAF 1/300 0/150 0.1 % 1.50 [ 0.06, 36.72 ]
Total (95% CI) 31973 31702 100.0 % 0.88 [ 0.81, 0.96 ]
Total events: 887 (RV1), 1003 (Placebo)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.12. Comparison 1 RV1 versus placebo, Outcome 12 Rotavirus diarrhoea: of any severity (up to 2
months follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 12 Rotavirus diarrhoea: of any severity (up to 2 months follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 1/270 1/66 6.7 % 0.24 [ 0.02, 3.86 ]
RV1 Anh 2011-VNM 0/275 0/71 Not estimable
RV1 GSK[041] 2007-KOR 1/103 1/52 5.6 % 0.50 [ 0.03, 7.91 ]
RV1 GSK[101555] 2008-PHL 4/100 1/50 5.6 % 2.00 [ 0.23, 17.43 ]
RV1 Kerdpanich 2010-THA 4/392 0/52 3.7 % 1.21 [ 0.07, 22.23 ]
RV1 Kim 2012-KOR 0/508 0/176 Not estimable
RV1 Omenaca 2012-EU 3/670 2/339 11.1 % 0.76 [ 0.13, 4.52 ]
RV1 Rivera 2011-DOM 10/100 6/100 25.1 % 1.67 [ 0.63, 4.41 ]
RV1 Vesikari 2011-FIN 4/169 0/44 3.3 % 2.38 [ 0.13, 43.44 ]
Subtotal (95% CI) 2587 950 61.0 % 1.28 [ 0.66, 2.50 ]
Total events: 27 (RV1), 11 (Placebo)
Heterogeneity: Chi2 = 2.78, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 High-mortality countries (WHO strata D % E)
RV1 Narang 2009-IND 0/182 0/181 Not estimable
RV1 Steele 2010a-ZAF 4/50 4/50 16.7 % 1.00 [ 0.26, 3.78 ]
RV1 Zaman 2009-BGD 8/196 4/98 22.3 % 1.00 [ 0.31, 3.24 ]
Subtotal (95% CI) 428 329 39.0 % 1.00 [ 0.41, 2.41 ]
Total events: 12 (RV1), 8 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 3015 1279 100.0 % 1.17 [ 0.69, 2.00 ]
Total events: 39 (RV1), 19 (Placebo)
Heterogeneity: Chi2 = 2.92, df = 8 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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Analysis 1.13. Comparison 1 RV1 versus placebo, Outcome 13 Rotavirus diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 13 Rotavirus diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 2/108 18/107 4.8 % 0.11 [ 0.03, 0.46 ]
RV1 Li 2014-CHN 27/1575 90/1573 13.5 % 0.30 [ 0.20, 0.46 ]
RV1 Salinas 2005-LA 58/1392 51/454 14.1 % 0.37 [ 0.26, 0.53 ]
RV1 Vesikari 2007a-EU 24/2572 94/1302 13.3 % 0.13 [ 0.08, 0.20 ]
Subtotal (95% CI) 5647 3436 45.7 % 0.22 [ 0.13, 0.40 ]
Total events: 111 (RV1), 253 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 15.34, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 5.03 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Colgate 2016-BGD 67/350 114/350 15.1 % 0.59 [ 0.45, 0.76 ]
RV1 Madhi 2010-MWI (1) 109/1182 85/591 15.0 % 0.64 [ 0.49, 0.84 ]
RV1 Madhi 2010-ZAF (2) 91/2116 128/1050 15.1 % 0.35 [ 0.27, 0.46 ]
RV1 Steele 2010b-ZAF 13/379 9/96 9.2 % 0.37 [ 0.16, 0.83 ]
Subtotal (95% CI) 4027 2087 54.3 % 0.49 [ 0.35, 0.68 ]
Total events: 280 (RV1), 336 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 12.38, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 4.20 (P = 0.000026)
Total (95% CI) 9674 5523 100.0 % 0.34 [ 0.23, 0.50 ]
Total events: 391 (RV1), 589 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 52.06, df = 7 (P<0.00001); I2 =87%
Test for overall effect: Z = 5.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.25, df = 1 (P = 0.02), I2 =81%
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 5 - total vaccinated cohort in Malawi
(2) Data taken from main paper Supplementary Appendix, Table 5 - total vaccinated cohort in South Africa
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Analysis 1.14. Comparison 1 RV1 versus placebo, Outcome 14 Rotavirus diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 14 Rotavirus diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Bernstein 1999-USA 8/108 33/107 9.5 % 0.24 [ 0.12, 0.50 ]
RV1 Li 2014-CHN 70/1575 167/1573 25.2 % 0.42 [ 0.32, 0.55 ]
RV1 Phua 2005-SGP 2/1779 4/642 2.2 % 0.18 [ 0.03, 0.98 ]
RV1 Salinas 2005-LA 23/332 9/109 9.2 % 0.84 [ 0.40, 1.76 ]
RV1 Vesikari 2004b-FIN 13/245 23/123 11.2 % 0.28 [ 0.15, 0.54 ]
RV1 Vesikari 2007a-EU 61/2554 110/1294 23.4 % 0.28 [ 0.21, 0.38 ]
Subtotal (95% CI) 6593 3848 80.9 % 0.35 [ 0.25, 0.48 ]
Total events: 177 (RV1), 346 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 11.06, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 6.33 (P < 0.00001)
2 High-mortality countries (WHO stratum E)
RV1 Madhi 2010-ZAF (1) 41/843 48/408 19.1 % 0.41 [ 0.28, 0.62 ]
Subtotal (95% CI) 843 408 19.1 % 0.41 [ 0.28, 0.62 ]
Total events: 41 (RV1), 48 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
Total (95% CI) 7436 4256 100.0 % 0.36 [ 0.28, 0.47 ]
Total events: 218 (RV1), 394 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.57, df = 6 (P = 0.07); I2 =48%
Test for overall effect: Z = 7.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
0.02 0.1 1 10 50
Favours RV1 Favours placebo
(1) Data from South Africa cohort only
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Analysis 1.15. Comparison 1 RV1 versus placebo, Outcome 15 All-cause diarrhoea: all cases (up to 2
months follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 15 All-cause diarrhoea: all cases (up to 2 months follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Anh 2011-PHL 29/270 8/66 8.8 % 0.89 [ 0.42, 1.85 ]
RV1 Anh 2011-VNM 44/275 11/71 11.9 % 1.03 [ 0.56, 1.89 ]
RV1 Kerdpanich 2010-THA 51/392 7/52 8.4 % 0.97 [ 0.46, 2.02 ]
RV1 Kim 2012-KOR 42/508 17/176 17.2 % 0.86 [ 0.50, 1.46 ]
RV1 Omenaca 2012-EU 55/670 36/339 32.6 % 0.77 [ 0.52, 1.15 ]
RV1 Vesikari 2011-FIN 15/169 5/44 5.4 % 0.78 [ 0.30, 2.03 ]
Subtotal (95% CI) 2284 748 84.3 % 0.86 [ 0.67, 1.09 ]
Total events: 236 (RV1), 84 (Placebo)
Heterogeneity: Chi2 = 0.77, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 High-mortality countries (WHO stratum E)
RV1 Steele 2010a-ZAF 24/50 23/50 15.7 % 1.04 [ 0.69, 1.58 ]
Subtotal (95% CI) 50 50 15.7 % 1.04 [ 0.69, 1.58 ]
Total events: 24 (RV1), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 2334 798 100.0 % 0.89 [ 0.72, 1.10 ]
Total events: 260 (RV1), 107 (Placebo)
Heterogeneity: Chi2 = 1.42, df = 6 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.63, df = 1 (P = 0.43), I2 =0.0%
0.2 0.5 1 2 5
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Analysis 1.16. Comparison 1 RV1 versus placebo, Outcome 16 All-cause diarrhoea: all cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 16 All-cause diarrhoea: all cases (up to 1 year follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Rivera 2011-DOM 32/100 31/100 8.8 % 1.03 [ 0.69, 1.55 ]
RV1 Salinas 2005-LA 573/1498 214/506 91.2 % 0.90 [ 0.80, 1.02 ]
Subtotal (95% CI) 1598 606 100.0 % 0.92 [ 0.82, 1.03 ]
Total events: 605 (RV1), 245 (Placebo)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 High-mortality countries (WHO strata D % E)
RV1 Colgate 2016-BGD (1) 298/350 302/350 100.0 % 0.99 [ 0.93, 1.05 ]
Subtotal (95% CI) 350 350 100.0 % 0.99 [ 0.93, 1.05 ]
Total events: 298 (RV1), 302 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) no intervention control group
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Analysis 1.17. Comparison 1 RV1 versus placebo, Outcome 17 All-cause diarrhoea: all cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 17 All-cause diarrhoea: all cases (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Li 2014-CHN 728/1575 759/1573 82.5 % 0.96 [ 0.89, 1.03 ]
RV1 Phua 2005-SGP 231/1779 100/642 16.0 % 0.83 [ 0.67, 1.04 ]
RV1 Vesikari 2004b-FIN 12/245 11/123 1.6 % 0.55 [ 0.25, 1.21 ]
Subtotal (95% CI) 3599 2338 100.0 % 0.93 [ 0.87, 1.00 ]
Total events: 971 (RV1), 870 (Placebo)
Heterogeneity: Chi2 = 3.30, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 1.97 (P = 0.049)
0.2 0.5 1 2 5
Favours RV1 Favours placebo
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Analysis 1.18. Comparison 1 RV1 versus placebo, Outcome 18 All-cause diarrhoea: all episodes (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 18 All-cause diarrhoea: all episodes (up to 1 year follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Rivera 2011-DOM 0.032 (0.252) 4.9 % 1.03 [ 0.63, 1.69 ]
RV1 Salinas 2005-LA -0.02 (0.057) 95.1 % 0.98 [ 0.88, 1.10 ]
Subtotal (95% CI) 100.0 % 0.98 [ 0.88, 1.10 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
Analysis 1.19. Comparison 1 RV1 versus placebo, Outcome 19 All-cause diarrhoea: all episodes (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 19 All-cause diarrhoea: all episodes (up to 2 years follow-up)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV1 Vesikari 2004b-FIN 0.016 (0.137) 1.02 [ 0.78, 1.33 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 1.20. Comparison 1 RV1 versus placebo, Outcome 20 All-cause hospitalizations (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 20 All-cause hospitalizations (up to 2 years follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV1 Phua 2005-SGP 10/1779 10/642 37.7 % 0.36 [ 0.15, 0.86 ]
RV1 Ruiz-Palac 06-LA/EU 886/31673 1003/31552 62.3 % 0.88 [ 0.81, 0.96 ]
Subtotal (95% CI) 33452 32194 100.0 % 0.63 [ 0.27, 1.47 ]
Total events: 896 (RV1), 1013 (Placebo)
Heterogeneity: Tau2 = 0.30; Chi2 = 3.97, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 1.07 (P = 0.28)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.21. Comparison 1 RV1 versus placebo, Outcome 21 Rotavirus diarrhoea: requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 21 Rotavirus diarrhoea: requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Up to 1 year follow-up (at least 1 rotavirus season)
RV1 Bernstein 1999-USA 0/108 2/107 3.8 % 0.20 [ 0.01, 4.08 ]
RV1 Li 2014-CHN 2/1575 14/1573 11.0 % 0.14 [ 0.03, 0.63 ]
RV1 Madhi 2010-AF (1) 20/3298 19/1641 21.9 % 0.52 [ 0.28, 0.98 ]
RV1 Phua 2009-AS 0/5263 13/5256 4.2 % 0.04 [ 0.00, 0.62 ]
RV1 Ruiz-Palac 06-LA/EU 9/9009 59/8858 20.8 % 0.15 [ 0.07, 0.30 ]
RV1 Salinas 2005-LA 9/1392 14/454 18.8 % 0.21 [ 0.09, 0.48 ]
RV1 Tregnaghi 2011-LA 4/4211 17/2099 15.3 % 0.12 [ 0.04, 0.35 ]
RV1 Vesikari 2007a-EU 0/2572 12/1302 4.2 % 0.02 [ 0.00, 0.34 ]
Subtotal (95% CI) 27428 21290 100.0 % 0.18 [ 0.09, 0.33 ]
Total events: 44 (RV1), 150 (Placebo)
Heterogeneity: Tau2 = 0.37; Chi2 = 15.41, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 5.40 (P < 0.00001)
2 Second year follow-up (at least 2 rotavirus seasons)
RV1 Kawamura 2011-JPN 1/498 2/250 2.4 % 0.25 [ 0.02, 2.75 ]
RV1 Li 2014-CHN 4/1575 21/1573 12.0 % 0.19 [ 0.07, 0.55 ]
RV1 Phua 2005-SGP 0/1779 1/642 1.3 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS 3/5263 48/5256 10.0 % 0.06 [ 0.02, 0.20 ]
RV1 Ruiz-Palac 06-LA/EU 22/7205 127/7081 66.8 % 0.17 [ 0.11, 0.27 ]
RV1 Vesikari 2004b-FIN 1/241 0/120 1.3 % 1.50 [ 0.06, 36.55 ]
RV1 Vesikari 2007a-EU 2/2554 13/1294 6.2 % 0.08 [ 0.02, 0.34 ]
Subtotal (95% CI) 19115 16216 100.0 % 0.15 [ 0.11, 0.22 ]
Total events: 33 (RV1), 212 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.66, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 9.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
(1) Data taken from main paper Supplementary Appendix, Table 3 - total vaccinated cohort.
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Analysis 1.22. Comparison 1 RV1 versus placebo, Outcome 22 Rotavirus diarrhoea: requiring medical
attention.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 22 Rotavirus diarrhoea: requiring medical attention
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year follow-up (at least 1 rotavirus season)
RV1 Vesikari 2007a-EU 10/2572 62/1302 100.0 % 0.08 [ 0.04, 0.16 ]
Subtotal (95% CI) 2572 1302 100.0 % 0.08 [ 0.04, 0.16 ]
Total events: 10 (RV1), 62 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 7.39 (P < 0.00001)
2 Second year follow-up (at least 2 rotavirus seasons)
RV1 Kawamura 2011-JPN 14/498 34/250 32.8 % 0.21 [ 0.11, 0.38 ]
RV1 Phua 2005-SGP 0/1779 3/642 3.7 % 0.05 [ 0.00, 1.00 ]
RV1 Vesikari 2007a-EU 31/2554 66/1294 63.5 % 0.24 [ 0.16, 0.36 ]
Subtotal (95% CI) 4831 2186 100.0 % 0.22 [ 0.16, 0.31 ]
Total events: 45 (RV1), 103 (Placebo)
Heterogeneity: Chi2 = 1.09, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 8.67 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.23. Comparison 1 RV1 versus placebo, Outcome 23 All-cause diarrhoea: cases requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 23 All-cause diarrhoea: cases requiring hospitalization
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Up to one year of follow-up (at least 1 rotavirus season)
RV1 Phua 2009-AS 60/5263 90/5256 55.8 % 0.67 [ 0.48, 0.92 ]
RV1 Vesikari 2007a-EU 11/2572 22/1302 44.2 % 0.25 [ 0.12, 0.52 ]
Subtotal (95% CI) 7835 6558 100.0 % 0.43 [ 0.17, 1.11 ]
Total events: 71 (RV1), 112 (Placebo)
Heterogeneity: Tau2 = 0.39; Chi2 = 5.75, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.74 (P = 0.082)
2 Second year of follow-up (at least 2 rotavirus seasons)
RV1 Phua 2009-AS 164/5263 240/5256 59.4 % 0.68 [ 0.56, 0.83 ]
RV1 Vesikari 2007a-EU 18/2554 26/1294 40.6 % 0.35 [ 0.19, 0.64 ]
Subtotal (95% CI) 7817 6550 100.0 % 0.52 [ 0.27, 0.99 ]
Total events: 182 (RV1), 266 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.31, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 2.00 (P = 0.046)
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Analysis 1.24. Comparison 1 RV1 versus placebo, Outcome 24 All-cause diarrhoea: episodes requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 24 All-cause diarrhoea: episodes requiring hospitalization
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 year of follow-up (at least 1 rotavirus season)
RV1 Ruiz-Palac 06-LA/EU -0.546 (0.105) 100.0 % 0.58 [ 0.47, 0.71 ]
Subtotal (95% CI) 100.0 % 0.58 [ 0.47, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.20 (P < 0.00001)
2 Second year of follow-up (at least 2 rotavirus seasons)
RV1 Ruiz-Palac 06-LA/EU -0.636 (0.076) 100.0 % 0.53 [ 0.46, 0.61 ]
Subtotal (95% CI) 100.0 % 0.53 [ 0.46, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.37 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
0.5 0.7 1 1.5 2
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Analysis 1.25. Comparison 1 RV1 versus placebo, Outcome 25 Reactogenicity: fever.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 25 Reactogenicity: fever
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 239/300 54/75 11.9 % 1.11 [ 0.95, 1.29 ]
RV1 Anh 2011-VNM 182/297 44/78 9.1 % 1.09 [ 0.88, 1.35 ]
RV1 Bernstein 1998-USA 3/21 6/20 0.6 % 0.48 [ 0.14, 1.65 ]
RV1 Bernstein 1999-USA 21/108 5/107 1.0 % 4.16 [ 1.63, 10.63 ]
RV1 Dennehy 2005-NA 83/421 21/108 3.8 % 1.01 [ 0.66, 1.56 ]
RV1 GSK[021] 2007-PAN 91/177 18/51 4.3 % 1.46 [ 0.98, 2.17 ]
RV1 GSK[033] 2007-LA 98/730 15/124 2.9 % 1.11 [ 0.67, 1.85 ]
RV1 GSK[041] 2007-KOR 10/100 3/52 0.6 % 1.73 [ 0.50, 6.03 ]
RV1 GSK[101555] 2008-PHL 39/100 11/50 2.3 % 1.77 [ 1.00, 3.16 ]
RV1 Kawamura 2011-JPN 38/508 12/257 2.0 % 1.60 [ 0.85, 3.01 ]
RV1 Kerdpanich 2010-THA 68/348 6/52 1.4 % 1.69 [ 0.77, 3.70 ]
RV1 Kim 2012-KOR 43/508 13/176 2.2 % 1.15 [ 0.63, 2.08 ]
RV1 Li 2013b-CHN 1/25 0/25 0.1 % 3.00 [ 0.13, 70.30 ]
RV1 Li 2014-CHN 41/1513 66/1514 4.5 % 0.62 [ 0.42, 0.91 ]
RV1 Narang 2009-IND 14/182 6/181 1.0 % 2.32 [ 0.91, 5.90 ]
RV1 NCT00158756-RUS 43/78 13/25 3.8 % 1.06 [ 0.69, 1.62 ]
RV1 Phua 2005-SGP 497/1811 183/653 12.3 % 0.98 [ 0.85, 1.13 ]
RV1 Salinas 2005-LA 1002/1618 346/537 15.5 % 0.96 [ 0.89, 1.03 ]
RV1 Steele 2008-ZAF 37/297 21/150 3.0 % 0.89 [ 0.54, 1.46 ]
RV1 Steele 2010b-ZAF 62/189 30/96 4.9 % 1.05 [ 0.73, 1.50 ]
RV1 Vesikari 2004a-FIN 8/122 3/62 0.5 % 1.36 [ 0.37, 4.93 ]
RV1 Vesikari 2004b-FIN 32/265 14/133 2.2 % 1.15 [ 0.63, 2.07 ]
RV1 Vesikari 2007a-EU 166/914 91/490 8.5 % 0.98 [ 0.78, 1.23 ]
RV1 Vesikari 2011-FIN 9/200 1/50 0.2 % 2.25 [ 0.29, 17.35 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(Continued . . . )
230Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Zaman 2009-BGD 16/196 12/98 1.6 % 0.67 [ 0.33, 1.35 ]
Subtotal (95% CI) 11028 5164 100.0 % 1.06 [ 0.97, 1.17 ]
Total events: 2843 (RV1), 994 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 38.19, df = 24 (P = 0.03); I2 =37%
Test for overall effect: Z = 1.30 (P = 0.20)
2 After dose 2
RV1 Anh 2011-PHL 197/296 45/75 9.8 % 1.11 [ 0.91, 1.36 ]
RV1 Anh 2011-VNM 141/286 36/73 6.5 % 1.00 [ 0.77, 1.30 ]
RV1 Bernstein 1998-USA 4/21 5/20 0.4 % 0.76 [ 0.24, 2.44 ]
RV1 Dennehy 2005-NA 82/394 31/101 3.9 % 0.68 [ 0.48, 0.96 ]
RV1 GSK[021] 2007-PAN 57/168 13/47 1.9 % 1.23 [ 0.74, 2.04 ]
RV1 GSK[033] 2007-LA 129/683 28/112 3.8 % 0.76 [ 0.53, 1.08 ]
RV1 GSK[041] 2007-KOR 8/99 6/52 0.5 % 0.70 [ 0.26, 1.91 ]
RV1 GSK[101555] 2008-PHL 29/98 22/50 2.6 % 0.67 [ 0.43, 1.04 ]
RV1 Kawamura 2011-JPN 33/499 12/250 1.2 % 1.38 [ 0.72, 2.62 ]
RV1 Kerdpanich 2010-THA 69/342 12/52 1.7 % 0.87 [ 0.51, 1.50 ]
RV1 Kim 2012-KOR 33/508 8/176 0.9 % 1.43 [ 0.67, 3.03 ]
RV1 Li 2013b-CHN 0/23 3/22 0.1 % 0.14 [ 0.01, 2.51 ]
RV1 Li 2014-CHN 46/1449 42/1446 2.9 % 1.09 [ 0.72, 1.65 ]
RV1 Narang 2009-IND 18/175 12/173 1.0 % 1.48 [ 0.74, 2.98 ]
RV1 NCT00158756-RUS 22/76 10/25 1.4 % 0.72 [ 0.40, 1.31 ]
RV1 Phua 2005-SGP 536/1779 186/642 16.2 % 1.04 [ 0.90, 1.20 ]
RV1 Salinas 2005-LA 826/1534 288/522 25.1 % 0.98 [ 0.89, 1.07 ]
RV1 Steele 2008-ZAF 34/282 12/143 1.3 % 1.44 [ 0.77, 2.69 ]
RV1 Steele 2010b-ZAF 91/369 13/90 1.8 % 1.71 [ 1.00, 2.91 ]
RV1 Vesikari 2004a-FIN 5/111 4/60 0.3 % 0.68 [ 0.19, 2.42 ]
RV1 Vesikari 2004b-FIN 69/255 31/124 3.6 % 1.08 [ 0.75, 1.56 ]
RV1 Vesikari 2007a-EU 244/905 142/486 12.1 % 0.92 [ 0.77, 1.10 ]
RV1 Vesikari 2011-FIN 10/196 3/49 0.3 % 0.83 [ 0.24, 2.91 ]
RV1 Zaman 2009-BGD 14/195 6/97 0.6 % 1.16 [ 0.46, 2.93 ]
Subtotal (95% CI) 10743 4887 100.0 % 0.99 [ 0.92, 1.06 ]
Total events: 2697 (RV1), 970 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 26.11, df = 23 (P = 0.30); I2 =12%
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.33 (P = 0.74)
3 After dose 3
RV1 Anh 2011-PHL 182/293 48/75 50.0 % 0.97 [ 0.80, 1.18 ]
RV1 Anh 2011-VNM 146/283 40/73 32.8 % 0.94 [ 0.74, 1.19 ]
RV1 GSK[021] 2007-PAN 63/168 18/46 10.9 % 0.96 [ 0.64, 1.44 ]
RV1 Steele 2010b-ZAF 76/364 13/88 6.3 % 1.41 [ 0.82, 2.43 ]
Subtotal (95% CI) 1108 282 100.0 % 0.98 [ 0.86, 1.13 ]
Total events: 467 (RV1), 119 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
4 End of follow-up
RV1 Dennehy 2005-NA 136/421 38/108 2.2 % 0.92 [ 0.69, 1.23 ]
RV1 GSK[033] 2007-LA 199/730 33/124 1.9 % 1.02 [ 0.75, 1.40 ]
RV1 GSK[041] 2007-KOR 17/100 8/52 0.3 % 1.11 [ 0.51, 2.39 ]
RV1 GSK[101555] 2008-PHL 47/100 24/50 1.5 % 0.98 [ 0.69, 1.40 ]
RV1 Kawamura 2011-JPN 62/508 22/257 0.9 % 1.43 [ 0.90, 2.26 ]
RV1 Kerdpanich 2010-THA 114/348 16/52 1.0 % 1.06 [ 0.69, 1.64 ]
RV1 Li 2014-CHN 83/1513 104/1514 2.4 % 0.80 [ 0.60, 1.06 ]
RV1 Narang 2009-IND 29/182 18/181 0.6 % 1.60 [ 0.92, 2.78 ]
RV1 Omenaca 2012-EU 54/203 29/100 1.3 % 0.92 [ 0.63, 1.34 ]
RV1 Rivera 2011-DOM 32/100 32/100 1.2 % 1.00 [ 0.67, 1.50 ]
RV1 Salinas 2005-LA 1238/1618 425/537 72.4 % 0.97 [ 0.92, 1.02 ]
RV1 Steele 2008-ZAF 64/297 28/150 1.2 % 1.15 [ 0.78, 1.72 ]
RV1 Steele 2010a-ZAF 30/50 28/50 1.7 % 1.07 [ 0.77, 1.50 ]
RV1 Vesikari 2004a-FIN 8/122 6/62 0.2 % 0.68 [ 0.25, 1.87 ]
RV1 Vesikari 2004b-FIN 86/265 33/133 1.6 % 1.31 [ 0.93, 1.84 ]
RV1 Vesikari 2007a-EU 310/914 192/490 9.3 % 0.87 [ 0.75, 1.00 ]
RV1 Vesikari 2011-FIN 18/200 4/50 0.2 % 1.13 [ 0.40, 3.18 ]
RV1 Zaman 2009-BGD 10/196 3/49 0.1 % 0.83 [ 0.24, 2.91 ]
Subtotal (95% CI) 7867 4059 100.0 % 0.97 [ 0.93, 1.01 ]
Total events: 2537 (RV1), 1043 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 15.47, df = 17 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
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Analysis 1.26. Comparison 1 RV1 versus placebo, Outcome 26 Reactogenicity: diarrhoea.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 26 Reactogenicity: diarrhoea
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 9/300 6/75 2.0 % 0.38 [ 0.14, 1.02 ]
RV1 Anh 2011-VNM 21/297 5/78 2.2 % 1.10 [ 0.43, 2.83 ]
RV1 Bernstein 1998-USA 2/21 1/20 0.4 % 1.90 [ 0.19, 19.40 ]
RV1 Bernstein 1999-USA 18/108 9/107 3.5 % 1.98 [ 0.93, 4.21 ]
RV1 Dennehy 2005-NA 28/421 10/108 4.2 % 0.72 [ 0.36, 1.43 ]
RV1 GSK[021] 2007-PAN 33/177 2/51 1.0 % 4.75 [ 1.18, 19.14 ]
RV1 GSK[033] 2007-LA 42/730 5/124 2.4 % 1.43 [ 0.58, 3.54 ]
RV1 GSK[041] 2007-KOR 5/100 3/52 1.0 % 0.87 [ 0.22, 3.49 ]
RV1 GSK[101555] 2008-PHL 6/100 3/50 1.1 % 1.00 [ 0.26, 3.83 ]
RV1 Kawamura 2011-JPN 26/508 8/257 3.3 % 1.64 [ 0.76, 3.58 ]
RV1 Kerdpanich 2010-THA 7/348 1/52 0.5 % 1.05 [ 0.13, 8.33 ]
RV1 Kim 2012-KOR 16/508 6/176 2.3 % 0.92 [ 0.37, 2.32 ]
RV1 Li 2013b-CHN 4/25 2/25 0.8 % 2.00 [ 0.40, 9.95 ]
RV1 Li 2014-CHN 80/1513 87/1514 22.8 % 0.92 [ 0.68, 1.24 ]
RV1 Narang 2009-IND 11/182 8/181 2.5 % 1.37 [ 0.56, 3.32 ]
RV1 NCT00158756-RUS 6/78 0/25 0.2 % 4.28 [ 0.25, 73.38 ]
RV1 Phua 2005-SGP 31/1811 13/653 4.8 % 0.86 [ 0.45, 1.63 ]
RV1 Salinas 2005-LA 111/1618 45/537 18.0 % 0.82 [ 0.59, 1.14 ]
RV1 Steele 2008-ZAF 29/297 14/150 5.4 % 1.05 [ 0.57, 1.92 ]
RV1 Steele 2010b-ZAF 19/189 11/96 4.0 % 0.88 [ 0.44, 1.77 ]
RV1 Vesikari 2004a-FIN 11/122 5/62 1.9 % 1.12 [ 0.41, 3.08 ]
RV1 Vesikari 2004b-FIN 20/265 7/133 2.8 % 1.43 [ 0.62, 3.31 ]
RV1 Vesikari 2007a-EU 68/2613 29/1331 10.7 % 1.19 [ 0.78, 1.84 ]
0.01 0.1 1 10 100
Favours RV1 Favours placebo
(Continued . . . )
233Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Vesikari 2011-FIN 10/200 2/50 0.9 % 1.25 [ 0.28, 5.53 ]
RV1 Zaman 2009-BGD 5/196 4/98 1.2 % 0.63 [ 0.17, 2.28 ]
Subtotal (95% CI) 12727 6005 100.0 % 1.01 [ 0.88, 1.17 ]
Total events: 618 (RV1), 286 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 21.56, df = 24 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 After dose 2
RV1 Anh 2011-PHL 4/296 0/75 0.3 % 2.30 [ 0.13, 42.31 ]
RV1 Anh 2011-VNM 8/286 0/73 0.4 % 4.38 [ 0.26, 75.08 ]
RV1 Bernstein 1998-USA 2/21 1/20 0.5 % 1.90 [ 0.19, 19.40 ]
RV1 Dennehy 2005-NA 16/394 5/101 3.1 % 0.82 [ 0.31, 2.19 ]
RV1 GSK[021] 2007-PAN 21/168 9/47 5.9 % 0.65 [ 0.32, 1.33 ]
RV1 GSK[033] 2007-LA 35/683 6/112 4.2 % 0.96 [ 0.41, 2.22 ]
RV1 GSK[041] 2007-KOR 5/99 6/52 2.3 % 0.44 [ 0.14, 1.37 ]
RV1 GSK[101555] 2008-PHL 6/98 4/50 2.0 % 0.77 [ 0.23, 2.59 ]
RV1 Kawamura 2011-JPN 23/499 8/250 4.7 % 1.44 [ 0.65, 3.17 ]
RV1 Kerdpanich 2010-THA 15/342 1/52 0.7 % 2.28 [ 0.31, 16.90 ]
RV1 Kim 2012-KOR 6/508 1/176 0.7 % 2.08 [ 0.25, 17.15 ]
RV1 Li 2013b-CHN 4/23 4/22 1.9 % 0.96 [ 0.27, 3.36 ]
RV1 Li 2014-CHN 57/1449 45/1446 20.1 % 1.26 [ 0.86, 1.86 ]
RV1 Narang 2009-IND 5/175 8/173 2.5 % 0.62 [ 0.21, 1.85 ]
RV1 NCT00158756-RUS 1/76 0/25 0.3 % 1.01 [ 0.04, 24.11 ]
RV1 Phua 2005-SGP 36/1779 7/642 4.6 % 1.86 [ 0.83, 4.15 ]
RV1 Salinas 2005-LA 116/1534 46/522 27.7 % 0.86 [ 0.62, 1.19 ]
RV1 Steele 2008-ZAF 22/282 9/143 5.3 % 1.24 [ 0.59, 2.62 ]
RV1 Steele 2010b-ZAF 33/369 7/90 4.8 % 1.15 [ 0.53, 2.51 ]
RV1 Vesikari 2004a-FIN 3/111 2/60 1.0 % 0.81 [ 0.14, 4.72 ]
RV1 Vesikari 2004b-FIN 11/255 2/124 1.3 % 2.67 [ 0.60, 11.88 ]
RV1 Vesikari 2007a-EU 15/905 9/486 4.4 % 0.90 [ 0.39, 2.03 ]
RV1 Vesikari 2011-FIN 5/196 2/49 1.1 % 0.63 [ 0.12, 3.13 ]
RV1 Zaman 2009-BGD 0/195 1/97 0.3 % 0.17 [ 0.01, 4.05 ]
Subtotal (95% CI) 10743 4887 100.0 % 1.02 [ 0.86, 1.21 ]
Total events: 449 (RV1), 183 (Placebo)
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 16.52, df = 23 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 After dose 3
RV1 Anh 2011-PHL 3/293 1/75 8.3 % 0.77 [ 0.08, 7.28 ]
RV1 Anh 2011-VNM 3/283 4/73 17.2 % 0.19 [ 0.04, 0.85 ]
RV1 GSK[021] 2007-PAN 18/168 4/46 29.3 % 1.23 [ 0.44, 3.46 ]
RV1 Steele 2010b-ZAF 28/364 9/88 45.2 % 0.75 [ 0.37, 1.54 ]
Subtotal (95% CI) 1108 282 100.0 % 0.69 [ 0.35, 1.36 ]
Total events: 52 (RV1), 18 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.11, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.07 (P = 0.28)
4 End of follow-up
RV1 Dennehy 2005-NA 41/421 14/108 4.6 % 0.75 [ 0.43, 1.33 ]
RV1 GSK[033] 2007-LA 74/730 11/124 4.1 % 1.14 [ 0.62, 2.09 ]
RV1 GSK[041] 2007-KOR 9/100 9/52 2.0 % 0.52 [ 0.22, 1.23 ]
RV1 GSK[101555] 2008-PHL 11/100 7/50 1.9 % 0.79 [ 0.32, 1.90 ]
RV1 Kawamura 2011-JPN 43/508 14/257 4.4 % 1.55 [ 0.87, 2.79 ]
RV1 Kerdpanich 2010-THA 20/348 2/52 0.7 % 1.49 [ 0.36, 6.21 ]
RV1 Li 2014-CHN 127/1513 123/1514 26.3 % 1.03 [ 0.81, 1.31 ]
RV1 Narang 2009-IND 16/182 15/181 3.3 % 1.06 [ 0.54, 2.08 ]
RV1 Omenaca 2012-EU 9/203 5/100 1.3 % 0.89 [ 0.31, 2.58 ]
RV1 Salinas 2005-LA 206/1618 85/537 27.4 % 0.80 [ 0.64, 1.02 ]
RV1 Steele 2008-ZAF 45/297 20/150 6.2 % 1.14 [ 0.70, 1.85 ]
RV1 Steele 2010a-ZAF 16/50 16/50 4.5 % 1.00 [ 0.56, 1.77 ]
RV1 Vesikari 2004a-FIN 11/122 7/62 1.8 % 0.80 [ 0.33, 1.96 ]
RV1 Vesikari 2004b-FIN 30/265 8/133 2.6 % 1.88 [ 0.89, 3.99 ]
RV1 Vesikari 2007a-EU 44/2613 25/1331 6.3 % 0.90 [ 0.55, 1.46 ]
RV1 Vesikari 2011-FIN 7/193 2/47 0.6 % 0.85 [ 0.18, 3.97 ]
RV1 Zaman 2009-BGD 11/196 8/98 1.9 % 0.69 [ 0.29, 1.65 ]
Subtotal (95% CI) 9459 4846 100.0 % 0.95 [ 0.84, 1.08 ]
Total events: 720 (RV1), 371 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.27, df = 16 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
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Analysis 1.27. Comparison 1 RV1 versus placebo, Outcome 27 Reactogenicity: vomiting.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 27 Reactogenicity: vomiting
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Anh 2011-PHL 56/300 5/75 0.9 % 2.80 [ 1.16, 6.74 ]
RV1 Anh 2011-VNM 39/297 6/78 1.1 % 1.71 [ 0.75, 3.89 ]
RV1 Bernstein 1998-USA 4/21 2/20 0.3 % 1.90 [ 0.39, 9.28 ]
RV1 Bernstein 1999-USA 16/108 10/107 1.3 % 1.59 [ 0.75, 3.33 ]
RV1 Dennehy 2005-NA 56/421 19/108 3.2 % 0.76 [ 0.47, 1.22 ]
RV1 GSK[021] 2007-PAN 36/177 10/51 1.8 % 1.04 [ 0.55, 1.94 ]
RV1 GSK[033] 2007-LA 115/730 22/124 4.2 % 0.89 [ 0.59, 1.34 ]
RV1 GSK[041] 2007-KOR 18/100 11/52 1.6 % 0.85 [ 0.43, 1.66 ]
RV1 GSK[101555] 2008-PHL 15/100 9/50 1.3 % 0.83 [ 0.39, 1.77 ]
RV1 Kawamura 2011-JPN 58/508 28/257 4.0 % 1.05 [ 0.68, 1.60 ]
RV1 Kerdpanich 2010-THA 103/348 13/52 2.9 % 1.18 [ 0.72, 1.95 ]
RV1 Kim 2012-KOR 78/508 30/176 4.9 % 0.90 [ 0.61, 1.32 ]
RV1 Li 2013b-CHN 2/25 1/25 0.1 % 2.00 [ 0.19, 20.67 ]
RV1 Li 2014-CHN 165/1513 176/1514 18.0 % 0.94 [ 0.77, 1.15 ]
RV1 Narang 2009-IND 24/182 24/181 2.6 % 0.99 [ 0.59, 1.68 ]
RV1 NCT00158756-RUS 9/78 1/25 0.2 % 2.88 [ 0.38, 21.66 ]
RV1 Phua 2005-SGP 102/1811 39/653 5.6 % 0.94 [ 0.66, 1.35 ]
RV1 Salinas 2005-LA 285/1618 89/537 15.3 % 1.06 [ 0.86, 1.32 ]
RV1 Steele 2008-ZAF 55/297 21/150 3.4 % 1.32 [ 0.83, 2.10 ]
RV1 Steele 2010b-ZAF 24/189 14/96 1.9 % 0.87 [ 0.47, 1.61 ]
RV1 Vesikari 2004a-FIN 20/122 14/62 1.9 % 0.73 [ 0.39, 1.34 ]
RV1 Vesikari 2004b-FIN 23/265 6/133 0.9 % 1.92 [ 0.80, 4.61 ]
RV1 Vesikari 2007a-EU 290/2613 141/1331 20.0 % 1.05 [ 0.87, 1.27 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Vesikari 2011-FIN 39/200 7/50 1.3 % 1.39 [ 0.66, 2.93 ]
RV1 Zaman 2009-BGD 22/196 8/98 1.2 % 1.38 [ 0.64, 2.98 ]
Subtotal (95% CI) 12727 6005 100.0 % 1.03 [ 0.94, 1.12 ]
Total events: 1654 (RV1), 706 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 20.22, df = 24 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
2 After dose 2
RV1 Anh 2011-PHL 32/296 5/75 2.0 % 1.62 [ 0.65, 4.02 ]
RV1 Anh 2011-VNM 27/286 7/73 2.5 % 0.98 [ 0.45, 2.17 ]
RV1 Bernstein 1998-USA 4/21 0/20 0.2 % 8.59 [ 0.49, 150.00 ]
RV1 Dennehy 2005-NA 30/394 15/101 4.3 % 0.51 [ 0.29, 0.92 ]
RV1 GSK[021] 2007-PAN 33/168 6/47 2.4 % 1.54 [ 0.69, 3.45 ]
RV1 GSK[033] 2007-LA 82/683 17/112 5.8 % 0.79 [ 0.49, 1.28 ]
RV1 GSK[041] 2007-KOR 21/99 10/52 3.3 % 1.10 [ 0.56, 2.16 ]
RV1 GSK[101555] 2008-PHL 8/98 1/50 0.4 % 4.08 [ 0.53, 31.73 ]
RV1 Kawamura 2011-JPN 32/499 14/250 4.0 % 1.15 [ 0.62, 2.11 ]
RV1 Kerdpanich 2010-THA 65/342 15/52 5.8 % 0.66 [ 0.41, 1.06 ]
RV1 Kim 2012-KOR 45/508 17/176 5.0 % 0.92 [ 0.54, 1.56 ]
RV1 Li 2013b-CHN 1/23 1/22 0.2 % 0.96 [ 0.06, 14.37 ]
RV1 Li 2014-CHN 91/1449 100/1446 12.1 % 0.91 [ 0.69, 1.19 ]
RV1 Narang 2009-IND 12/175 13/173 2.7 % 0.91 [ 0.43, 1.94 ]
RV1 NCT00158756-RUS 3/76 0/25 0.2 % 2.36 [ 0.13, 44.25 ]
RV1 Phua 2005-SGP 77/1779 26/642 6.8 % 1.07 [ 0.69, 1.65 ]
RV1 Salinas 2005-LA 189/1534 59/522 12.1 % 1.09 [ 0.83, 1.43 ]
RV1 Steele 2008-ZAF 47/282 14/143 4.5 % 1.70 [ 0.97, 2.99 ]
RV1 Steele 2010b-ZAF 60/369 17/90 5.7 % 0.86 [ 0.53, 1.40 ]
RV1 Vesikari 2004a-FIN 16/111 12/60 3.3 % 0.72 [ 0.37, 1.42 ]
RV1 Vesikari 2004b-FIN 16/255 11/124 2.8 % 0.71 [ 0.34, 1.48 ]
RV1 Vesikari 2007a-EU 53/905 46/486 8.2 % 0.62 [ 0.42, 0.90 ]
RV1 Vesikari 2011-FIN 31/196 6/49 2.4 % 1.29 [ 0.57, 2.92 ]
RV1 Zaman 2009-BGD 17/195 12/97 3.1 % 0.70 [ 0.35, 1.42 ]
Subtotal (95% CI) 10743 4887 100.0 % 0.92 [ 0.81, 1.05 ]
Total events: 992 (RV1), 424 (Placebo)
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.02; Chi2 = 28.02, df = 23 (P = 0.21); I2 =18%
Test for overall effect: Z = 1.18 (P = 0.24)
3 After dose 3
RV1 Anh 2011-PHL 18/293 1/75 8.6 % 4.61 [ 0.63, 33.96 ]
RV1 Anh 2011-VNM 27/283 3/73 20.3 % 2.32 [ 0.72, 7.44 ]
RV1 GSK[021] 2007-PAN 23/168 5/46 27.9 % 1.26 [ 0.51, 3.13 ]
RV1 Steele 2010b-ZAF 45/364 13/88 43.3 % 0.84 [ 0.47, 1.48 ]
Subtotal (95% CI) 1108 282 100.0 % 1.34 [ 0.71, 2.50 ]
Total events: 113 (RV1), 22 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.79, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 0.90 (P = 0.37)
4 End of follow-up
RV1 Dennehy 2005-NA 79/421 27/108 5.8 % 0.75 [ 0.51, 1.10 ]
RV1 GSK[033] 2007-LA 168/730 34/124 7.4 % 0.84 [ 0.61, 1.15 ]
RV1 GSK[041] 2007-KOR 27/100 17/52 3.8 % 0.83 [ 0.50, 1.37 ]
RV1 GSK[101555] 2008-PHL 21/100 9/50 2.2 % 1.17 [ 0.58, 2.36 ]
RV1 Kawamura 2011-JPN 74/508 36/257 6.1 % 1.04 [ 0.72, 1.50 ]
RV1 Kerdpanich 2010-THA 131/348 20/52 6.1 % 0.98 [ 0.68, 1.42 ]
RV1 Li 2014-CHN 213/1513 232/1514 13.2 % 0.92 [ 0.77, 1.09 ]
RV1 Narang 2009-IND 29/182 32/181 4.4 % 0.90 [ 0.57, 1.43 ]
RV1 Omenaca 2012-EU 52/203 27/100 5.5 % 0.95 [ 0.64, 1.41 ]
RV1 Salinas 2005-LA 403/1618 129/537 13.1 % 1.04 [ 0.87, 1.23 ]
RV1 Steele 2008-ZAF 82/297 31/150 6.2 % 1.34 [ 0.93, 1.92 ]
RV1 Steele 2010a-ZAF 19/50 15/50 3.3 % 1.27 [ 0.73, 2.20 ]
RV1 Vesikari 2004a-FIN 30/122 21/62 4.3 % 0.73 [ 0.46, 1.16 ]
RV1 Vesikari 2004b-FIN 34/265 14/133 3.0 % 1.22 [ 0.68, 2.19 ]
RV1 Vesikari 2007a-EU 154/2613 126/1331 10.7 % 0.62 [ 0.50, 0.78 ]
RV1 Vesikari 2011-FIN 34/193 6/47 1.7 % 1.38 [ 0.62, 3.09 ]
RV1 Zaman 2009-BGD 36/196 16/98 3.4 % 1.13 [ 0.66, 1.92 ]
Subtotal (95% CI) 9459 4846 100.0 % 0.93 [ 0.84, 1.04 ]
Total events: 1586 (RV1), 792 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 24.61, df = 16 (P = 0.08); I2 =35%
Test for overall effect: Z = 1.24 (P = 0.21)
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 1.28. Comparison 1 RV1 versus placebo, Outcome 28 Adverse events requiring discontinuation
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 28 Adverse events requiring discontinuation (end of follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Anh 2011-PHL 1/300 0/75 0.5 % 0.76 [ 0.03, 18.41 ]
RV1 Anh 2011-VNM 1/297 0/78 0.5 % 0.80 [ 0.03, 19.34 ]
RV1 Bernstein 1998-USA 1/21 0/20 0.3 % 2.86 [ 0.12, 66.44 ]
RV1 Dennehy 2005-NA 5/421 1/108 0.9 % 1.28 [ 0.15, 10.86 ]
RV1 GSK[021] 2007-PAN 0/177 1/51 1.3 % 0.10 [ 0.00, 2.35 ]
RV1 GSK[033] 2007-LA 4/730 0/122 0.5 % 1.51 [ 0.08, 27.95 ]
RV1 GSK[041] 2007-KOR 0/103 0/52 Not estimable
RV1 GSK[101555] 2008-PHL 0/100 0/50 Not estimable
RV1 Kawamura 2011-JPN 1/508 1/257 0.8 % 0.51 [ 0.03, 8.06 ]
RV1 Kerdpanich 2010-THA 0/348 0/52 Not estimable
RV1 Kim 2012-KOR 1/508 0/176 0.4 % 1.04 [ 0.04, 25.49 ]
RV1 Li 2013b-CHN 0/25 0/25 Not estimable
RV1 Li 2014-CHN 10/1666 15/1667 8.7 % 0.67 [ 0.30, 1.48 ]
RV1 Narang 2009-IND 1/182 0/181 0.3 % 2.98 [ 0.12, 72.76 ]
RV1 NCT00158756-RUS 2/161 0/48 0.4 % 1.51 [ 0.07, 30.97 ]
RV1 Phua 2009-AS 7/5263 12/5256 6.9 % 0.58 [ 0.23, 1.48 ]
RV1 Ruiz-Palac 06-LA/EU 118/31673 104/31552 60.2 % 1.13 [ 0.87, 1.47 ]
RV1 Steele 2008-ZAF 4/300 4/150 3.1 % 0.50 [ 0.13, 1.97 ]
RV1 Steele 2010a-ZAF 6/50 8/50 4.6 % 0.75 [ 0.28, 2.00 ]
RV1 Steele 2010b-ZAF 4/379 1/95 0.9 % 1.00 [ 0.11, 8.87 ]
RV1 Tregnaghi 2011-LA 12/4376 3/2192 2.3 % 2.00 [ 0.57, 7.09 ]
RV1 Vesikari 2004a-FIN 5/128 0/64 0.4 % 5.54 [ 0.31, 98.71 ]
RV1 Vesikari 2004b-FIN 6/270 2/135 1.5 % 1.50 [ 0.31, 7.33 ]
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Vesikari 2007a-EU 7/2646 6/1348 4.6 % 0.59 [ 0.20, 1.77 ]
RV1 Vesikari 2011-FIN 1/200 0/50 0.5 % 0.76 [ 0.03, 18.41 ]
RV1 Zaman 2009-BGD 1/196 0/98 0.4 % 1.51 [ 0.06, 36.67 ]
Total (95% CI) 51028 43952 100.0 % 1.03 [ 0.83, 1.26 ]
Total events: 198 (RV1), 158 (Placebo)
Heterogeneity: Chi2 = 11.59, df = 21 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
Analysis 1.29. Comparison 1 RV1 versus placebo, Outcome 29 Immunogenicity: rotavirus vaccine shedding
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 29 Immunogenicity: rotavirus vaccine shedding (end of follow-up)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Bernstein 1998-USA 17/20 0/20 4.7 % 35.00 [ 2.25, 544.92 ]
RV1 Bernstein 1999-USA 75/100 1/107 6.4 % 80.25 [ 11.37, 566.35 ]
RV1 Dennehy 2005-NA 184/328 2/78 7.9 % 21.88 [ 5.55, 86.22 ]
RV1 GSK[021] 2007-PAN 35/88 0/26 4.6 % 21.54 [ 1.37, 339.58 ]
RV1 GSK[033] 2007-LA 14/26 1/6 6.7 % 3.23 [ 0.52, 20.02 ]
RV1 GSK[101555] 2008-PHL 50/86 7/40 9.5 % 3.32 [ 1.66, 6.67 ]
RV1 Kerdpanich 2010-THA 198/337 1/51 6.4 % 29.96 [ 4.29, 209.08 ]
RV1 Li 2013b-CHN 2/15 1/17 5.6 % 2.27 [ 0.23, 22.56 ]
RV1 Salinas 2005-LA 44/267 1/93 6.3 % 15.33 [ 2.14, 109.68 ]
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours RV1
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Steele 2008-ZAF 19/76 0/39 4.6 % 20.26 [ 1.26, 326.90 ]
RV1 Steele 2010a-ZAF 15/23 7/22 9.5 % 2.05 [ 1.04, 4.05 ]
RV1 Steele 2010b-ZAF 41/109 0/23 4.6 % 18.11 [ 1.15, 284.20 ]
RV1 Vesikari 2004a-FIN 9/122 0/62 4.5 % 9.73 [ 0.58, 164.51 ]
RV1 Vesikari 2011-FIN 101/193 0/46 4.6 % 49.18 [ 3.11, 777.27 ]
RV1 Ward 2006-USA 74/75 0/36 4.6 % 72.54 [ 4.62, 1138.35 ]
RV1 Zaman 2009-BGD 45/71 7/36 9.5 % 3.26 [ 1.64, 6.49 ]
Total (95% CI) 1936 702 100.0 % 10.94 [ 4.90, 24.43 ]
Total events: 923 (RV1), 28 (Placebo)
Heterogeneity: Tau2 = 1.65; Chi2 = 62.38, df = 15 (P<0.00001); I2 =76%
Test for overall effect: Z = 5.84 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours RV1
241Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.30. Comparison 1 RV1 versus placebo, Outcome 30 Immunogenicity: seroconversion.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 30 Immunogenicity: seroconversion
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV1 Bernstein 1998-USA 16/20 0/21 6.9 % 34.57 [ 2.21, 540.36 ]
RV1 GSK[021] 2007-PAN 59/140 2/38 14.3 % 8.01 [ 2.05, 31.29 ]
RV1 GSK[101555] 2008-PHL 34/77 4/39 17.3 % 4.31 [ 1.65, 11.26 ]
RV1 Phua 2005-SGP 357/442 3/155 16.1 % 41.73 [ 13.60, 128.09 ]
RV1 Salinas 2005-LA 157/405 1/139 10.5 % 53.88 [ 7.61, 381.29 ]
RV1 Steele 2008-ZAF 72/201 2/110 14.2 % 19.70 [ 4.93, 78.76 ]
RV1 Steele 2010b-ZAF 30/283 0/65 6.8 % 14.18 [ 0.88, 228.86 ]
RV1 Vesikari 2004a-FIN 85/122 0/62 6.9 % 87.59 [ 5.53, 1388.36 ]
RV1 Vesikari 2011-FIN 130/176 0/42 6.9 % 63.41 [ 4.02, 998.86 ]
Subtotal (95% CI) 1866 671 100.0 % 20.39 [ 8.48, 49.01 ]
Total events: 940 (RV1), 12 (Placebo)
Heterogeneity: Tau2 = 0.91; Chi2 = 18.72, df = 8 (P = 0.02); I2 =57%
Test for overall effect: Z = 6.74 (P < 0.00001)
2 After dose 2
RV1 Bernstein 1998-USA 19/21 0/20 1.3 % 37.23 [ 2.40, 578.09 ]
RV1 Bernstein 1999-USA 98/107 0/106 1.3 % 195.18 [ 12.28, 3102.13 ]
RV1 Dennehy 2005-NA 197/271 4/63 4.3 % 11.45 [ 4.42, 29.64 ]
RV1 GSK[021] 2007-PAN 96/139 2/37 3.3 % 12.78 [ 3.30, 49.41 ]
RV1 GSK[033] 2007-LA 355/494 9/91 5.3 % 7.27 [ 3.90, 13.54 ]
RV1 GSK[041] 2007-KOR 32/48 1/24 2.2 % 16.00 [ 2.32, 110.13 ]
RV1 GSK[101555] 2008-PHL 60/76 6/39 4.9 % 5.13 [ 2.44, 10.81 ]
RV1 Kawamura 2011-JPN 29/34 1/20 2.2 % 17.06 [ 2.51, 115.83 ]
RV1 Kerdpanich 2010-THA 290/352 0/51 1.3 % 85.59 [ 5.42, 1350.73 ]
RV1 Kim 2012-KOR 280/318 5/114 4.6 % 20.08 [ 8.51, 47.35 ]
RV1 Li 2013b-CHN 18/20 2/21 3.4 % 9.45 [ 2.51, 35.60 ]
RV1 Li 2014-CHN 278/391 22/393 5.8 % 12.70 [ 8.42, 19.16 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Narang 2009-IND 67/115 7/112 5.0 % 9.32 [ 4.48, 19.42 ]
RV1 NCT00158756-RUS 83/115 0/34 1.3 % 50.39 [ 3.21, 791.58 ]
RV1 Omenaca 2012-EU 126/147 13/81 5.6 % 5.34 [ 3.23, 8.83 ]
RV1 Phua 2005-SGP 379/445 4/151 4.3 % 32.15 [ 12.22, 84.62 ]
RV1 Phua 2009-AS (1) 88/90 1/96 2.2 % 93.87 [ 13.36, 659.74 ]
RV1 Rivera 2011-DOM 50/80 17/80 5.7 % 2.94 [ 1.87, 4.63 ]
RV1 Ruiz-Palac 06-LA/EU 302/393 33/341 6.0 % 7.94 [ 5.72, 11.03 ]
RV1 Salinas 2005-LA 246/391 5/132 4.6 % 16.61 [ 7.01, 39.37 ]
RV1 Steele 2008-ZAF 86/182 5/106 4.6 % 10.02 [ 4.20, 23.89 ]
RV1 Tregnaghi 2011-LA 108/176 14/89 5.6 % 3.90 [ 2.38, 6.40 ]
RV1 Vesikari 2004a-FIN 106/122 0/62 1.3 % 109.10 [ 6.89, 1726.59 ]
RV1 Vesikari 2004b-FIN 168/209 0/112 1.3 % 181.34 [ 11.40, 2883.75 ]
RV1 Vesikari 2007a-EU 687/794 28/422 5.9 % 13.04 [ 9.11, 18.67 ]
RV1 Vesikari 2011-FIN 144/166 0/44 1.3 % 77.87 [ 4.94, 1226.73 ]
RV1 Zaman 2009-BGD 83/135 13/70 5.6 % 3.31 [ 1.99, 5.50 ]
Subtotal (95% CI) 5831 2911 100.0 % 11.44 [ 8.01, 16.32 ]
Total events: 4475 (RV1), 192 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 126.68, df = 26 (P<0.00001); I2 =79%
Test for overall effect: Z = 13.43 (P < 0.00001)
3 After dose 3
RV1 Anh 2011-PHL 155/240 3/52 19.0 % 11.19 [ 3.72, 33.71 ]
RV1 Anh 2011-VNM 178/247 10/65 31.2 % 4.68 [ 2.63, 8.33 ]
RV1 GSK[021] 2007-PAN 111/130 3/37 19.2 % 10.53 [ 3.55, 31.23 ]
RV1 Steele 2010a-ZAF 12/21 4/22 21.8 % 3.14 [ 1.20, 8.21 ]
RV1 Steele 2010b-ZAF 117/264 1/59 8.8 % 26.15 [ 3.73, 183.41 ]
Subtotal (95% CI) 902 235 100.0 % 6.89 [ 3.59, 13.24 ]
Total events: 573 (RV1), 21 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 8.24, df = 4 (P = 0.08); I2 =51%
Test for overall effect: Z = 5.79 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.31. Comparison 1 RV1 versus placebo, Outcome 31 Dropouts before the end of the trial.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 31 Dropouts before the end of the trial
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Anh 2011-PHL 8/300 1/75 0.1 % 2.00 [ 0.25, 15.75 ]
RV1 Anh 2011-VNM 16/297 5/78 0.3 % 0.84 [ 0.32, 2.22 ]
RV1 Colgate 2016-BGD 58/350 49/350 1.7 % 1.18 [ 0.83, 1.68 ]
RV1 GSK[021] 2007-PAN 19/177 6/51 0.3 % 0.91 [ 0.38, 2.16 ]
RV1 GSK[033] 2007-LA 47/730 12/124 0.7 % 0.67 [ 0.36, 1.22 ]
RV1 GSK[041] 2007-KOR 4/103 0/52 0.0 % 4.59 [ 0.25, 83.60 ]
RV1 GSK[101555] 2008-PHL 5/100 0/50 0.0 % 5.55 [ 0.31, 98.50 ]
RV1 Kawamura 2011-JPN 32/508 16/257 0.8 % 1.01 [ 0.57, 1.81 ]
RV1 Kerdpanich 2010-THA 9/348 0/52 0.0 % 2.89 [ 0.17, 48.85 ]
RV1 Kim 2012-KOR 5/508 0/76 0.0 % 1.66 [ 0.09, 29.80 ]
RV1 Li 2013b-CHN 2/25 3/25 0.1 % 0.67 [ 0.12, 3.65 ]
RV1 Li 2014-CHN 148/1666 168/1667 6.0 % 0.88 [ 0.71, 1.09 ]
RV1 Madhi 2010-AF 324/3298 198/1641 9.4 % 0.81 [ 0.69, 0.96 ]
RV1 Narang 2009-IND 9/182 10/181 0.4 % 0.90 [ 0.37, 2.15 ]
RV1 NCT00158756-RUS 13/161 1/48 0.1 % 3.88 [ 0.52, 28.88 ]
RV1 Omenaca 2012-EU 15/670 6/339 0.3 % 1.26 [ 0.50, 3.23 ]
RV1 Phua 2005-SGP 69/1811 25/653 1.3 % 1.00 [ 0.64, 1.56 ]
RV1 Rivera 2011-DOM 5/100 5/100 0.2 % 1.00 [ 0.30, 3.35 ]
RV1 Ruiz-Palac 06-LA/EU 1920/31673 1997/31552 71.2 % 0.96 [ 0.90, 1.02 ]
RV1 Steele 2008-ZAF 30/300 14/150 0.7 % 1.07 [ 0.59, 1.96 ]
RV1 Steele 2010a-ZAF 14/50 12/50 0.4 % 1.17 [ 0.60, 2.27 ]
RV1 Steele 2010b-ZAF 42/379 13/96 0.7 % 0.82 [ 0.46, 1.46 ]
RV1 Tregnaghi 2011-LA 142/4376 77/2192 3.7 % 0.92 [ 0.70, 1.21 ]
RV1 Vesikari 2004a-FIN 12/128 2/64 0.1 % 3.00 [ 0.69, 13.00 ]
RV1 Vesikari 2004b-FIN 21/270 12/135 0.6 % 0.88 [ 0.44, 1.72 ]
RV1 Vesikari 2007a-EU 33/2646 17/1348 0.8 % 0.99 [ 0.55, 1.77 ]
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Vesikari 2011-FIN 5/200 1/50 0.1 % 1.25 [ 0.15, 10.46 ]
RV1 Zaman 2009-BGD 3/196 1/98 0.0 % 1.50 [ 0.16, 14.23 ]
Total (95% CI) 51552 41554 100.0 % 0.95 [ 0.90, 1.00 ]
Total events: 3010 (RV1), 2651 (Placebo)
Heterogeneity: Chi2 = 16.56, df = 27 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
Analysis 1.32. Comparison 1 RV1 versus placebo, Outcome 32 Subgroup analysis: rotavirus diarrhoea of any
severity (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 32 Subgroup analysis: rotavirus diarrhoea of any severity (by G type)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV1 Kawamura 2011-JPN 5/498 19/250 16.7 % 0.13 [ 0.05, 0.35 ]
RV1 Li 2014-CHN 22/1575 46/1573 21.4 % 0.48 [ 0.29, 0.79 ]
RV1 Ruiz-Palac 06-LA/EU 3/9009 36/8858 14.6 % 0.08 [ 0.03, 0.27 ]
RV1 Salinas 2005-LA 25/1392 30/454 21.3 % 0.27 [ 0.16, 0.46 ]
RV1 Steele 2010a-ZAF 2/50 0/50 4.6 % 5.00 [ 0.25, 101.58 ]
RV1 Vesikari 2007a-EU 18/2572 89/1302 21.4 % 0.10 [ 0.06, 0.17 ]
Subtotal (95% CI) 15096 12487 100.0 % 0.21 [ 0.10, 0.44 ]
Total events: 75 (RV1), 220 (Placebo)
Heterogeneity: Tau2 = 0.57; Chi2 = 26.82, df = 5 (P = 0.00006); I2 =81%
Test for overall effect: Z = 4.22 (P = 0.000025)
0.002 0.1 1 10 500
Favours RV1 Favours placebo
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Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 G2
RV1 Li 2014-CHN 42/1575 102/1573 71.0 % 0.41 [ 0.29, 0.59 ]
RV1 Ruiz-Palac 06-LA/EU 6/9009 10/8858 8.6 % 0.59 [ 0.21, 1.62 ]
RV1 Salinas 2005-LA 1/1392 3/454 1.7 % 0.11 [ 0.01, 1.04 ]
RV1 Steele 2010a-ZAF 0/50 1/50 0.9 % 0.33 [ 0.01, 7.99 ]
RV1 Vesikari 2007a-EU 14/2572 17/1302 17.8 % 0.42 [ 0.21, 0.84 ]
Subtotal (95% CI) 14598 12237 100.0 % 0.41 [ 0.31, 0.56 ]
Total events: 63 (RV1), 133 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.83, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.81 (P < 0.00001)
3 G3
RV1 Li 2014-CHN 0/1575 11/1573 12.5 % 0.04 [ 0.00, 0.74 ]
RV1 Salinas 2005-LA 1/1392 2/454 17.4 % 0.16 [ 0.01, 1.79 ]
RV1 Steele 2010a-ZAF 0/50 1/50 9.9 % 0.33 [ 0.01, 7.99 ]
RV1 Vesikari 2007a-EU 3/2572 10/1302 60.2 % 0.15 [ 0.04, 0.55 ]
Subtotal (95% CI) 5589 3379 100.0 % 0.14 [ 0.05, 0.39 ]
Total events: 4 (RV1), 24 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.09, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00013)
4 G4
RV1 Salinas 2005-LA 1/1392 0/454 10.5 % 0.98 [ 0.04, 24.01 ]
RV1 Vesikari 2007a-EU 6/2572 18/1302 89.5 % 0.17 [ 0.07, 0.42 ]
Subtotal (95% CI) 3964 1756 100.0 % 0.20 [ 0.07, 0.59 ]
Total events: 7 (RV1), 18 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 2.95 (P = 0.0032)
5 G9
RV1 Li 2014-CHN 1/1575 5/1573 9.1 % 0.20 [ 0.02, 1.71 ]
RV1 Salinas 2005-LA 29/1392 15/454 40.8 % 0.63 [ 0.34, 1.17 ]
RV1 Vesikari 2007a-EU 38/2572 71/1302 50.1 % 0.27 [ 0.18, 0.40 ]
Subtotal (95% CI) 5539 3329 100.0 % 0.37 [ 0.18, 0.75 ]
Total events: 68 (RV1), 91 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 5.44, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.76 (P = 0.0058)
Test for subgroup differences: Chi2 = 7.26, df = 4 (P = 0.12), I2 =45%
0.002 0.1 1 10 500
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Analysis 1.33. Comparison 1 RV1 versus placebo, Outcome 33 Subgroup analysis: severe cases of rotavirus
diarrhoea (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 33 Subgroup analysis: severe cases of rotavirus diarrhoea (by G type)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV1 Kawamura 2011-JPN 1/498 6/250 4.2 % 0.08 [ 0.01, 0.69 ]
RV1 Li 2014-CHN 9/1575 25/1573 20.9 % 0.36 [ 0.17, 0.77 ]
RV1 Madhi 2010-MWI 6/1030 5/483 11.4 % 0.56 [ 0.17, 1.83 ]
RV1 Madhi 2010-ZAF 11/1944 18/960 21.3 % 0.30 [ 0.14, 0.64 ]
RV1 Phua 2009-AS 0/5263 21/5256 2.5 % 0.02 [ 0.00, 0.38 ]
RV1 Ruiz-Palac 06-LA/EU 10/7205 55/7081 23.8 % 0.18 [ 0.09, 0.35 ]
RV1 Tregnaghi 2011-LA 6/4211 16/2099 16.0 % 0.19 [ 0.07, 0.48 ]
Subtotal (95% CI) 21726 17702 100.0 % 0.24 [ 0.16, 0.38 ]
Total events: 43 (RV1), 146 (Placebo)
Heterogeneity: Tau2 = 0.11; Chi2 = 8.60, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 6.09 (P < 0.00001)
2 G2
RV1 Li 2014-CHN 11/1575 40/1573 58.4 % 0.27 [ 0.14, 0.53 ]
RV1 Madhi 2010-MWI 2/1030 1/483 4.5 % 0.94 [ 0.09, 10.32 ]
RV1 Madhi 2010-ZAF 1/1944 6/960 5.8 % 0.08 [ 0.01, 0.68 ]
RV1 Phua 2005-SGP 0/1779 1/642 2.5 % 0.12 [ 0.00, 2.95 ]
RV1 Phua 2009-AS 0/5263 2/5256 2.8 % 0.20 [ 0.01, 4.16 ]
RV1 Ruiz-Palac 06-LA/EU 5/9009 9/8858 21.6 % 0.55 [ 0.18, 1.63 ]
RV1 Tregnaghi 2011-LA 1/4211 2/2099 4.5 % 0.25 [ 0.02, 2.75 ]
Subtotal (95% CI) 24811 19871 100.0 % 0.30 [ 0.18, 0.50 ]
Total events: 20 (RV1), 61 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.95, df = 6 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.61 (P < 0.00001)
3 G3
RV1 Li 2014-CHN 0/1575 3/1573 15.1 % 0.14 [ 0.01, 2.76 ]
RV1 Madhi 2010-MWI 0/1030 0/483 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours RV1 Favours placebo
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(. . . Continued)
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV1 Madhi 2010-ZAF 2/1944 6/960 41.3 % 0.16 [ 0.03, 0.81 ]
RV1 Phua 2005-SGP 2/1779 0/642 14.5 % 1.81 [ 0.09, 37.57 ]
RV1 Phua 2009-AS 1/5263 18/5256 29.1 % 0.06 [ 0.01, 0.42 ]
Subtotal (95% CI) 11591 8914 100.0 % 0.17 [ 0.05, 0.56 ]
Total events: 5 (RV1), 27 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.89 (P = 0.0038)
4 G4
RV1 Phua 2005-SGP 0/1779 1/642 100.0 % 0.12 [ 0.00, 2.95 ]
Subtotal (95% CI) 1779 642 100.0 % 0.12 [ 0.00, 2.95 ]
Total events: 0 (RV1), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
5 G8
RV1 Madhi 2010-MWI 11/1030 10/483 65.4 % 0.52 [ 0.22, 1.21 ]
RV1 Madhi 2010-ZAF 0/1944 5/960 34.6 % 0.04 [ 0.00, 0.81 ]
Subtotal (95% CI) 2974 1443 100.0 % 0.22 [ 0.02, 2.37 ]
Total events: 11 (RV1), 15 (Placebo)
Heterogeneity: Tau2 = 2.05; Chi2 = 2.73, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.25 (P = 0.21)
6 G9
RV1 Li 2014-CHN 0/1575 3/1573 3.9 % 0.14 [ 0.01, 2.76 ]
RV1 Madhi 2010-MWI 8/1030 9/483 38.3 % 0.42 [ 0.16, 1.07 ]
RV1 Madhi 2010-ZAF 0/1944 0/960 Not estimable
RV1 Phua 2005-SGP 0/1779 2/642 3.7 % 0.07 [ 0.00, 1.50 ]
RV1 Phua 2009-AS 1/5263 12/5256 8.2 % 0.08 [ 0.01, 0.64 ]
RV1 Tregnaghi 2011-LA 7/4211 19/2099 45.8 % 0.18 [ 0.08, 0.44 ]
Subtotal (95% CI) 15802 11013 100.0 % 0.23 [ 0.13, 0.40 ]
Total events: 16 (RV1), 45 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.51, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.99 (P < 0.00001)
7 G12
RV1 Madhi 2010-MWI 14/1030 13/483 91.2 % 0.51 [ 0.24, 1.07 ]
RV1 Madhi 2010-ZAF 1/1944 2/960 8.8 % 0.25 [ 0.02, 2.72 ]
Subtotal (95% CI) 2974 1443 100.0 % 0.47 [ 0.23, 0.97 ]
Total events: 15 (RV1), 15 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 1.34. Comparison 1 RV1 versus placebo, Outcome 34 Subgroup analysis: rotavirus diarrhoea in
malnourished children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 34 Subgroup analysis: rotavirus diarrhoea in malnourished children
Study or subgroup RV1 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up (at least 1 rotavirus season)
RV1 Salinas 2005-LA 14/211 13/76 0.39 [ 0.19, 0.79 ]
0.1 0.2 0.5 1 2 5 10
Favours RV1 Favours placebo
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Analysis 1.35. Comparison 1 RV1 versus placebo, Outcome 35 Subgroup analysis: rotavirus diarrhoea in
HIV-infected children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 1 RV1 versus placebo
Outcome: 35 Subgroup analysis: rotavirus diarrhoea in HIV-infected children
Study or subgroup RV1 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV1 Steele 2010a-ZAF 4/50 4/50 100.0 % 1.00 [ 0.26, 3.78 ]
Total (95% CI) 50 50 100.0 % 1.00 [ 0.26, 3.78 ]
Total events: 4 (RV1), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV1 Favours placebo
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Analysis 2.1. Comparison 2 RV5 versus placebo, Outcome 1 Rotavirus diarrhoea: severe (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 1 Rotavirus diarrhoea: severe (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 0/551 6/564 4.8 % 0.08 [ 0.00, 1.39 ]
RV5 Clark 2004-USA 0/187 8/183 6.4 % 0.06 [ 0.00, 0.99 ]
RV5 Iwata 2013-JPN 0/380 10/381 7.8 % 0.05 [ 0.00, 0.81 ]
RV5 Vesikari 2006a-FIN 0/765 8/262 9.4 % 0.02 [ 0.00, 0.35 ]
RV5 Zaman 2010-VNM (1) 2/435 7/424 5.3 % 0.28 [ 0.06, 1.33 ]
Subtotal (95% CI) 2318 1814 33.7 % 0.08 [ 0.03, 0.22 ]
Total events: 2 (RV5), 39 (Placebo)
Heterogeneity: Chi2 = 3.46, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.96 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 15/981 42/989 31.2 % 0.36 [ 0.20, 0.64 ]
RV5 Armah 2010-KEN (3) 2/575 12/573 9.0 % 0.17 [ 0.04, 0.74 ]
RV5 Armah 2010-MLI (4) 4/845 4/843 3.0 % 1.00 [ 0.25, 3.98 ]
RV5 Zaman 2010-BGD (5) 17/556 31/554 23.1 % 0.55 [ 0.31, 0.98 ]
Subtotal (95% CI) 2957 2959 66.3 % 0.43 [ 0.29, 0.62 ]
Total events: 38 (RV5), 89 (Placebo)
Heterogeneity: Chi2 = 4.01, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 4.44 (P < 0.00001)
Total (95% CI) 5275 4773 100.0 % 0.31 [ 0.22, 0.44 ]
Total events: 40 (RV5), 128 (Placebo)
Heterogeneity: Chi2 = 14.74, df = 8 (P = 0.06); I2 =46%
Test for overall effect: Z = 6.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.36, df = 1 (P = 0.00), I2 =89%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data from RV5 Zaman 2010-AS for Vietnam only
(2) Total number of participants taken from Tapia et al. 2012, Table 4, data for Ghana only.
(3) Total number of participants taken from Tapia et al. 2012, Table 4, data for Kenya only.
(4) Total number of participants taken from Tapia et al. 2012, Table 4, data for Mali only.
(5) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.2. Comparison 2 RV5 versus placebo, Outcome 2 Rotavirus diarrhoea: severe (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 2 Rotavirus diarrhoea: severe (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 Mo 2017-CHN 11/1926 52/1937 15.0 % 0.21 [ 0.11, 0.41 ]
RV5 Vesikari 2006a-FIN 0/765 12/262 2.6 % 0.01 [ 0.00, 0.23 ]
RV5 Vesikari 2006b-INT (1) 2/813 17/756 7.1 % 0.11 [ 0.03, 0.47 ]
RV5 Zaman 2010-VNM (2) 5/435 15/424 10.9 % 0.32 [ 0.12, 0.89 ]
Subtotal (95% CI) 3939 3379 35.6 % 0.18 [ 0.08, 0.39 ]
Total events: 18 (RV5), 96 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 5.31, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 4.32 (P = 0.000016)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 26/982 57/989 17.4 % 0.46 [ 0.29, 0.72 ]
RV5 Armah 2010-KEN (4) 5/569 14/568 10.8 % 0.36 [ 0.13, 0.98 ]
RV5 Armah 2010-MLI (5) 48/832 58/835 18.3 % 0.83 [ 0.57, 1.20 ]
RV5 Zaman 2010-BGD (6) 33/556 56/554 17.9 % 0.59 [ 0.39, 0.89 ]
Subtotal (95% CI) 2939 2946 64.4 % 0.59 [ 0.43, 0.82 ]
Total events: 112 (RV5), 185 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.28, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 6878 6325 100.0 % 0.37 [ 0.23, 0.60 ]
Total events: 130 (RV5), 281 (Placebo)
Heterogeneity: Tau2 = 0.30; Chi2 = 27.24, df = 7 (P = 0.00030); I2 =74%
Test for overall effect: Z = 4.05 (P = 0.000052)
Test for subgroup differences: Chi2 = 7.75, df = 1 (P = 0.01), I2 =87%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low-mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Total number of participants taken from Tapia et al. 2012, Table 4, data for Ghana only.
(4) Total number of participants taken from Tapia et al. 2012, Table 4, data for Kenya only.
(5) Total number of participants taken from Tapia et al. 2012, Table 4, data for Mali only.
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.3. Comparison 2 RV5 versus placebo, Outcome 3 All-cause diarrhoea: severe cases (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 3 All-cause diarrhoea: severe cases (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO stratum A)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (1) 49/753 78/737 40.1 % 0.61 [ 0.44, 0.87 ]
RV5 Armah 2010-KEN (2) 21/481 22/477 21.6 % 0.95 [ 0.53, 1.70 ]
RV5 Armah 2010-MLI (3) 55/823 56/814 38.4 % 0.97 [ 0.68, 1.39 ]
Subtotal (95% CI) 2057 2028 100.0 % 0.80 [ 0.58, 1.11 ]
Total events: 125 (RV5), 156 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 2057 2028 100.0 % 0.80 [ 0.58, 1.11 ]
Total events: 125 (RV5), 156 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.70, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data collected from Tapia et al. 2012, Table 3, data for Ghana only.
(2) Data collected from Tapia et al. 2012, Table 3, data for Kenya only.
(3) Data collected from Tapia et al. 2012, Table 3, data for Mali only.
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Analysis 2.4. Comparison 2 RV5 versus placebo, Outcome 4 All-cause diarrhoea: severe cases (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 4 All-cause diarrhoea: severe cases (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (1) 80/747 101/725 26.5 % 0.77 [ 0.58, 1.01 ]
RV5 Armah 2010-KEN (2) 25/472 29/472 7.5 % 0.86 [ 0.51, 1.45 ]
RV5 Armah 2010-MLI (3) 147/797 148/795 38.3 % 0.99 [ 0.81, 1.22 ]
RV5 Zaman 2010-AS (4) 81/991 107/978 27.8 % 0.75 [ 0.57, 0.98 ]
Subtotal (95% CI) 3007 2970 100.0 % 0.85 [ 0.75, 0.98 ]
Total events: 333 (RV5), 385 (Placebo)
Heterogeneity: Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 3007 2970 100.0 % 0.85 [ 0.75, 0.98 ]
Total events: 333 (RV5), 385 (Placebo)
Heterogeneity: Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours RV5 Favours placebo
(1) Data collected from Tapia et al. 2012, Table 3, data for Ghana only.
(2) Data collected from Tapia et al. 2012, Table 3, data for Kenya only.
(3) Data collected from Tapia et al. 2012, Table 3, data for Mali only.
(4) This study was mainly conducted in high mortality Bangladesh, but also in low mortality Vietnam.
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Analysis 2.5. Comparison 2 RV5 versus placebo, Outcome 5 All-cause death.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 5 All-cause death
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 1/650 0/660 0.4 % 3.05 [ 0.12, 74.64 ]
RV5 Ciarlet 2009-EU 0/201 0/202 Not estimable
RV5 Iwata 2013-JPN 0/380 0/381 Not estimable
RV5 Lawrence 2012-CHN 0/24 0/24 Not estimable
RV5 Merck[009] 2005-USA 0/680 0/113 Not estimable
RV5 Mo 2017-CHN 0/2020 1/2020 1.4 % 0.33 [ 0.01, 8.18 ]
RV5 Vesikari 2006a-FIN 0/1027 0/322 Not estimable
RV5 Vesikari 2006b-INT (1) 24/34035 20/34003 18.1 % 1.20 [ 0.66, 2.17 ]
RV5 Zaman 2010-VNM (2) 0/450 1/450 1.4 % 0.33 [ 0.01, 8.16 ]
Subtotal (95% CI) 39467 38175 21.3 % 1.13 [ 0.65, 1.96 ]
Total events: 25 (RV5), 22 (Placebo)
Heterogeneity: Chi2 = 1.53, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 35/1098 43/1102 38.8 % 0.82 [ 0.53, 1.27 ]
RV5 Armah 2010-KEN (4) 38/656 34/652 30.9 % 1.11 [ 0.71, 1.74 ]
RV5 Armah 2010-MLI (5) 3/979 5/981 4.5 % 0.60 [ 0.14, 2.51 ]
RV5 Levin 2017-AF (6) 1/99 2/103 1.8 % 0.52 [ 0.05, 5.65 ]
RV5 Zaman 2010-BGD (7) 3/568 3/568 2.7 % 1.00 [ 0.20, 4.93 ]
Subtotal (95% CI) 3400 3406 78.7 % 0.92 [ 0.68, 1.24 ]
Total events: 80 (RV5), 87 (Placebo)
Heterogeneity: Chi2 = 1.53, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 42867 41581 100.0 % 0.96 [ 0.74, 1.25 ]
Total events: 105 (RV5), 109 (Placebo)
Heterogeneity: Chi2 = 3.47, df = 8 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) HIV positive infants and HIV exposed but uninfected infants
(7) Data from RV5 Zaman 2010-AS for Bangladesh only
Analysis 2.6. Comparison 2 RV5 versus placebo, Outcome 6 All serious adverse events.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 6 All serious adverse events
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 21/650 27/660 2.4 % 0.79 [ 0.45, 1.38 ]
RV5 Ciarlet 2009-EU 3/201 6/202 0.5 % 0.50 [ 0.13, 1.98 ]
RV5 Iwata 2013-JPN 7/380 9/381 0.8 % 0.78 [ 0.29, 2.07 ]
RV5 Kim 2008-KOR 6/115 7/63 0.8 % 0.47 [ 0.16, 1.34 ]
RV5 Lawrence 2012-CHN 0/24 3/24 0.3 % 0.14 [ 0.01, 2.62 ]
RV5 Mo 2017-CHN 116/2015 116/2019 10.5 % 1.00 [ 0.78, 1.29 ]
RV5 Vesikari 2006b-INT (1) 803/34035 859/34003 77.8 % 0.93 [ 0.85, 1.03 ]
RV5 Zaman 2010-VNM (2) 9/450 3/450 0.3 % 3.00 [ 0.82, 11.01 ]
Subtotal (95% CI) 37870 37802 93.5 % 0.93 [ 0.86, 1.02 ]
Total events: 965 (RV5), 1030 (Placebo)
Heterogeneity: Chi2 = 7.92, df = 7 (P = 0.34); I2 =12%
Test for overall effect: Z = 1.57 (P = 0.12)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 17/1098 18/1102 1.6 % 0.95 [ 0.49, 1.83 ]
RV5 Armah 2010-KEN (4) 20/649 21/643 1.9 % 0.94 [ 0.52, 1.72 ]
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV5 Armah 2010-MLI (5) 5/979 6/981 0.5 % 0.84 [ 0.26, 2.73 ]
RV5 Dhingra 2014-IND 0/20 1/20 0.1 % 0.33 [ 0.01, 7.72 ]
RV5 Levin 2017-AF (6) 7/99 8/103 0.7 % 0.91 [ 0.34, 2.42 ]
RV5 Zaman 2010-BGD (7) 16/568 17/568 1.5 % 0.94 [ 0.48, 1.84 ]
Subtotal (95% CI) 3413 3417 6.5 % 0.92 [ 0.66, 1.28 ]
Total events: 65 (RV5), 71 (Placebo)
Heterogeneity: Chi2 = 0.45, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
Total (95% CI) 41283 41219 100.0 % 0.93 [ 0.86, 1.01 ]
Total events: 1030 (RV5), 1101 (Placebo)
Heterogeneity: Chi2 = 8.37, df = 13 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) Includes HIV positive infants and HIV exposed but uninfected infants
(7) Data from RV5 Zaman 2010-AS for Bangladesh only
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Analysis 2.7. Comparison 2 RV5 versus placebo, Outcome 7 Serious adverse events: intussusception.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 7 Serious adverse events: intussusception
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 0/650 0/660 Not estimable
RV5 Ciarlet 2009-EU 0/201 0/202 Not estimable
RV5 Clark 2003-USA 0/573 0/148 Not estimable
RV5 Clark 2004-USA 0/218 0/221 Not estimable
RV5 Iwata 2013-JPN 0/380 0/381 Not estimable
RV5 Kim 2008-KOR 0/115 0/63 Not estimable
RV5 Lawrence 2012-CHN 0/24 0/24 Not estimable
RV5 Merck[009] 2005-USA 0/680 0/113 Not estimable
RV5 Mo 2017-CHN 2/2015 0/2019 2.3 % 5.01 [ 0.24, 104.29 ]
RV5 Vesikari 2006a-FIN 1/1027 0/322 3.5 % 0.94 [ 0.04, 23.08 ]
RV5 Vesikari 2006b-INT (1) 13/34002 19/33969 87.3 % 0.68 [ 0.34, 1.38 ]
RV5 Zaman 2010-VNM (2) 0/450 1/450 6.9 % 0.33 [ 0.01, 8.16 ]
Subtotal (95% CI) 40335 38572 100.0 % 0.77 [ 0.41, 1.45 ]
Total events: 16 (RV5), 20 (Placebo)
Heterogeneity: Chi2 = 1.85, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (3) 0/1098 0/1102 Not estimable
RV5 Armah 2010-KEN (4) 0/649 0/643 Not estimable
RV5 Armah 2010-MLI (5) 0/979 0/981 Not estimable
RV5 Zaman 2010-BGD (6) 0/568 0/568 Not estimable
Subtotal (95% CI) 3294 3294 Not estimable
Total events: 0 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 43629 41866 100.0 % 0.77 [ 0.41, 1.45 ]
Total events: 16 (RV5), 20 (Placebo)
Heterogeneity: Chi2 = 1.85, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
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(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data from RV5 Zaman 2010-AS for Vietnam only
(3) Data from RV5 Armah 2010-AF for Ghana only
(4) Data from RV5 Armah 2010-AF for Kenya only
(5) Data from RV5 Armah 2010-AF for Mali only
(6) Data from RV5 Zaman 2010-AS for Bangladesh only
Analysis 2.8. Comparison 2 RV5 versus placebo, Outcome 8 Rotavirus diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 8 Rotavirus diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 Block 2007-EU/USA 21/551 63/564 13.9 % 0.34 [ 0.21, 0.55 ]
RV5 Clark 2003-USA 5/342 7/114 5.3 % 0.24 [ 0.08, 0.74 ]
RV5 Clark 2004-USA 11/187 39/183 10.9 % 0.28 [ 0.15, 0.52 ]
RV5 Vesikari 2006a-FIN 51/766 43/264 16.1 % 0.41 [ 0.28, 0.60 ]
RV5 Vesikari 2006b-INT (1) 82/2834 315/2839 19.2 % 0.26 [ 0.21, 0.33 ]
Subtotal (95% CI) 4680 3964 65.3 % 0.30 [ 0.25, 0.37 ]
Total events: 170 (RV5), 467 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.45, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 11.90 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 31/981 70/989 15.3 % 0.45 [ 0.30, 0.68 ]
RV5 Armah 2010-KEN (3) 6/575 21/573 7.3 % 0.28 [ 0.12, 0.70 ]
RV5 Armah 2010-MLI (4) 22/845 24/843 12.1 % 0.91 [ 0.52, 1.62 ]
Subtotal (95% CI) 2401 2405 34.7 % 0.52 [ 0.28, 0.94 ]
Total events: 59 (RV5), 115 (Placebo)
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.18; Chi2 = 6.02, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.16 (P = 0.031)
Total (95% CI) 7081 6369 100.0 % 0.37 [ 0.28, 0.50 ]
Total events: 229 (RV5), 582 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 19.95, df = 7 (P = 0.01); I2 =65%
Test for overall effect: Z = 6.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.74, df = 1 (P = 0.10), I2 =64%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data collected from Tapia et al. 2012, Table 4 for Ghana only.
(3) Data collected from Tapia et al. 2012, Table 4 for Kenya only.
(4) Data collected from Tapia et al. 2012, Table 4 for Mali only.
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Analysis 2.9. Comparison 2 RV5 versus placebo, Outcome 9 Rotavirus diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 9 Rotavirus diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low-mortality countries (WHO strata A % B)
RV5 Iwata 2013-JPN 7/355 27/356 9.0 % 0.26 [ 0.11, 0.59 ]
RV5 Mo 2017-CHN 34/1927 109/1937 15.4 % 0.31 [ 0.21, 0.46 ]
RV5 Vesikari 2006b-INT (1) 36/813 88/756 15.4 % 0.38 [ 0.26, 0.55 ]
Subtotal (95% CI) 3095 3049 39.8 % 0.34 [ 0.26, 0.43 ]
Total events: 77 (RV5), 224 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 8.42 (P < 0.00001)
2 High-mortality countries (WHO strata D % E)
RV5 Armah 2010-GHA (2) 46/982 88/989 15.9 % 0.53 [ 0.37, 0.74 ]
RV5 Armah 2010-KEN (3) 9/569 24/568 9.7 % 0.37 [ 0.18, 0.80 ]
RV5 Armah 2010-MLI (4) 151/832 182/835 18.0 % 0.83 [ 0.69, 1.01 ]
RV5 Zaman 2010-AS (5) 65/991 109/978 16.7 % 0.59 [ 0.44, 0.79 ]
Subtotal (95% CI) 3374 3370 60.2 % 0.61 [ 0.45, 0.83 ]
Total events: 271 (RV5), 403 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.72, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 3.21 (P = 0.0013)
Total (95% CI) 6469 6419 100.0 % 0.46 [ 0.33, 0.65 ]
Total events: 348 (RV5), 627 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 34.28, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.85, df = 1 (P = 0.00), I2 =89%
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) This study was conducted mainly in European and Latin American low mortality countries, but also in high mortality Guatemala
(2) Data collected from Tapia et al. 2012, Table 4 for Ghana only.
(3) Data collected from Tapia et al. 2012, Table 4 for Kenya only.
(4) Data collected from Tapia et al. 2012, Table 4 for Mali only.
(5) This study was mainly conducted in high mortality Bangladesh, but also in low mortality Vietnam.
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Analysis 2.10. Comparison 2 RV5 versus placebo, Outcome 10 All-cause diarrhoea: of any severity (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 10 All-cause diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low-mortality countries (WHO strata A % B)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High-mortality countries (WHO stratum E)
RV5 Armah 2010-KEN (1) 66/525 82/534 100.0 % 0.82 [ 0.61, 1.11 ]
Subtotal (95% CI) 525 534 100.0 % 0.82 [ 0.61, 1.11 ]
Total events: 66 (RV5), 82 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 525 534 100.0 % 0.82 [ 0.61, 1.11 ]
Total events: 66 (RV5), 82 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
(1) Data from RV5 Armah 2010-AF for Kenya only
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Analysis 2.11. Comparison 2 RV5 versus placebo, Outcome 11 All-cause diarrhoea: of any severity (up to 2
years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 11 All-cause diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-mortality countries (WHO stratum E)
RV5 Armah 2010-KEN (1) 82/525 94/534 100.0 % 0.89 [ 0.68, 1.16 ]
Subtotal (95% CI) 525 534 100.0 % 0.89 [ 0.68, 1.16 ]
Total events: 82 (RV5), 94 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours RV5 Favours placebo
(1) Data from RV5 Armah 2010-AF for Kenya only
Analysis 2.12. Comparison 2 RV5 versus placebo, Outcome 12 All-cause hospitalizations (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 12 All-cause hospitalizations (up to 2 years follow-up)
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High-mortality countries (WHO strata D % E)
RV5 Levin 2017-AF 7/99 6/103 1.21 [ 0.42, 3.49 ]
0.001 0.01 0.1 1 10 100 1000
Favours RV5 Favours placebo
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Analysis 2.13. Comparison 2 RV5 versus placebo, Outcome 13 Rotavirus diarrhoea: requiring
hospitalization.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 13 Rotavirus diarrhoea: requiring hospitalization
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up
RV5 Vesikari 2006b-INT 6/28646 138/28488 0.04 [ 0.02, 0.10 ]
0.01 0.1 1 10 100
Favours RV5 Favours placebo
Analysis 2.14. Comparison 2 RV5 versus placebo, Outcome 14 Rotavirus diarrhoea: requiring medical
attention.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 14 Rotavirus diarrhoea: requiring medical attention
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year of follow-up
RV5 Vesikari 2006b-INT 13/28646 191/28488 0.07 [ 0.04, 0.12 ]
0.01 0.1 1 10 100
Favours RV5 Favours placebo
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Analysis 2.15. Comparison 2 RV5 versus placebo, Outcome 15 Reactogenicity: fever.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 15 Reactogenicity: fever
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 1
RV5 Block 2007-EU/USA 87/650 58/660 24.4 % 1.52 [ 1.11, 2.09 ]
RV5 Clark 2004-USA 25/213 27/218 14.2 % 0.95 [ 0.57, 1.58 ]
RV5 Mo 2017-CHN 154/2015 165/2019 32.0 % 0.94 [ 0.76, 1.15 ]
RV5 Vesikari 2006a-FIN 255/1027 64/322 29.4 % 1.25 [ 0.98, 1.59 ]
Subtotal (95% CI) 3905 3219 100.0 % 1.15 [ 0.91, 1.45 ]
Total events: 521 (RV5), 314 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.67, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 1.16 (P = 0.25)
2 After dose 2
RV5 Clark 2004-USA 26/208 35/209 16.8 % 0.75 [ 0.47, 1.19 ]
RV5 Mo 2017-CHN 146/1946 173/1959 83.2 % 0.85 [ 0.69, 1.05 ]
Subtotal (95% CI) 2154 2168 100.0 % 0.83 [ 0.69, 1.01 ]
Total events: 172 (RV5), 208 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
3 After dose 3
RV5 Clark 2004-USA 47/207 43/209 21.7 % 1.10 [ 0.77, 1.59 ]
RV5 Mo 2017-CHN 191/1932 182/1946 78.3 % 1.06 [ 0.87, 1.28 ]
Subtotal (95% CI) 2139 2155 100.0 % 1.07 [ 0.90, 1.27 ]
Total events: 238 (RV5), 225 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
4 End of follow-up
RV5 Block 2007-EU/USA 195/650 158/660 11.3 % 1.25 [ 1.05, 1.50 ]
RV5 Ciarlet 2009-EU 106/201 115/202 11.5 % 0.93 [ 0.78, 1.11 ]
RV5 Clark 2003-USA 157/568 36/147 4.7 % 1.13 [ 0.82, 1.54 ]
RV5 Clark 2004-USA 70/218 73/220 6.0 % 0.97 [ 0.74, 1.27 ]
RV5 Dhingra 2014-IND 7/20 6/20 0.6 % 1.17 [ 0.48, 2.86 ]
RV5 Iwata 2013-JPN 29/380 31/381 2.1 % 0.94 [ 0.58, 1.52 ]
0.5 0.7 1 1.5 2
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Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Lawrence 2012-CHN 9/24 5/24 0.6 % 1.80 [ 0.71, 4.59 ]
RV5 Levin 2017-AF 27/99 27/103 2.3 % 1.04 [ 0.66, 1.64 ]
RV5 Merck[009] 2005-USA 370/680 53/113 9.1 % 1.16 [ 0.94, 1.43 ]
RV5 Mo 2017-CHN 440/2015 461/2019 19.2 % 0.96 [ 0.85, 1.07 ]
RV5 Vesikari 2006b-INT 1974/4826 2073/4821 32.5 % 0.95 [ 0.91, 1.00 ]
Subtotal (95% CI) 9681 8710 100.0 % 1.01 [ 0.94, 1.09 ]
Total events: 3384 (RV5), 3038 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.45, df = 10 (P = 0.15); I2 =31%
Test for overall effect: Z = 0.36 (P = 0.72)
0.5 0.7 1 1.5 2
Favours RV5 Favours placebo
Analysis 2.16. Comparison 2 RV5 versus placebo, Outcome 16 Reactogenicity: diarrhoea.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 16 Reactogenicity: diarrhoea
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
RV5 Clark 2003-USA 127/565 33/146 21.7 % 0.99 [ 0.71, 1.39 ]
RV5 Mo 2017-CHN 218/2015 189/2019 78.3 % 1.16 [ 0.96, 1.39 ]
Subtotal (95% CI) 2580 2165 100.0 % 1.12 [ 0.95, 1.32 ]
Total events: 345 (RV5), 222 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 After dose 2
RV5 Mo 2017-CHN 143/1946 162/1959 100.0 % 0.89 [ 0.72, 1.10 ]
Subtotal (95% CI) 1946 1959 100.0 % 0.89 [ 0.72, 1.10 ]
0.1 0.2 0.5 1 2 5 10
Favours RV5 Favours placebo
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Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 143 (RV5), 162 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
3 End of follow-up
RV5 Ciarlet 2009-EU 57/201 65/202 3.8 % 0.88 [ 0.65, 1.19 ]
RV5 Clark 2003-USA 205/573 52/148 4.8 % 1.02 [ 0.80, 1.30 ]
RV5 Clark 2004-USA 97/218 80/220 4.6 % 1.22 [ 0.97, 1.54 ]
RV5 Dhingra 2014-IND 4/20 3/20 0.2 % 1.33 [ 0.34, 5.21 ]
RV5 Iwata 2013-JPN 46/380 47/381 2.7 % 0.98 [ 0.67, 1.44 ]
RV5 Lawrence 2012-CHN 13/24 8/24 0.5 % 1.63 [ 0.83, 3.19 ]
RV5 Levin 2017-AF 33/99 25/103 1.4 % 1.37 [ 0.88, 2.13 ]
RV5 Merck[009] 2005-USA 367/680 51/113 5.1 % 1.20 [ 0.96, 1.48 ]
RV5 Mo 2017-CHN 406/2015 406/2019 23.5 % 1.00 [ 0.89, 1.13 ]
RV5 Vesikari 2006b-INT 951/4826 921/4821 53.4 % 1.03 [ 0.95, 1.12 ]
Subtotal (95% CI) 9036 8051 100.0 % 1.04 [ 0.98, 1.10 ]
Total events: 2179 (RV5), 1658 (Placebo)
Heterogeneity: Chi2 = 8.56, df = 9 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
0.1 0.2 0.5 1 2 5 10
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Analysis 2.17. Comparison 2 RV5 versus placebo, Outcome 17 Reactogenicity: vomiting.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 17 Reactogenicity: vomiting
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
RV5 Clark 2003-USA 91/565 27/146 46.7 % 0.87 [ 0.59, 1.29 ]
RV5 Mo 2017-CHN 40/2015 49/2019 53.3 % 0.82 [ 0.54, 1.24 ]
Subtotal (95% CI) 2580 2165 100.0 % 0.84 [ 0.63, 1.12 ]
Total events: 131 (RV5), 76 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 After dose 2
RV5 Mo 2017-CHN 11/1946 16/1959 100.0 % 0.69 [ 0.32, 1.49 ]
Subtotal (95% CI) 1946 1959 100.0 % 0.69 [ 0.32, 1.49 ]
Total events: 11 (RV5), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
3 After dose 3
RV5 Mo 2017-CHN 5/1932 11/1946 100.0 % 0.46 [ 0.16, 1.32 ]
Subtotal (95% CI) 1932 1946 100.0 % 0.46 [ 0.16, 1.32 ]
Total events: 5 (RV5), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
4 End of follow-up
RV5 Ciarlet 2009-EU 62/201 49/202 5.2 % 1.27 [ 0.92, 1.75 ]
RV5 Clark 2003-USA 171/573 41/148 6.9 % 1.08 [ 0.81, 1.44 ]
RV5 Clark 2004-USA 58/218 52/220 5.5 % 1.13 [ 0.81, 1.56 ]
RV5 Dhingra 2014-IND 4/20 5/20 0.5 % 0.80 [ 0.25, 2.55 ]
RV5 Iwata 2013-JPN 31/380 29/381 3.1 % 1.07 [ 0.66, 1.74 ]
RV5 Lawrence 2012-CHN 9/24 12/24 1.3 % 0.75 [ 0.39, 1.44 ]
RV5 Levin 2017-AF 18/99 16/103 1.7 % 1.17 [ 0.63, 2.16 ]
RV5 Mo 2017-CHN 54/2015 71/2019 7.5 % 0.76 [ 0.54, 1.08 ]
RV5 Vesikari 2006b-INT 618/4826 646/4821 68.4 % 0.96 [ 0.86, 1.06 ]
Subtotal (95% CI) 8356 7938 100.0 % 0.98 [ 0.90, 1.06 ]
Total events: 1025 (RV5), 921 (Placebo)
Heterogeneity: Chi2 = 7.11, df = 8 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
0.1 0.2 0.5 1 2 5 10
Favours RV5 Favours placebo
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Analysis 2.18. Comparison 2 RV5 versus placebo, Outcome 18 Adverse events requiring discontinuation
(end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 18 Adverse events requiring discontinuation (end of follow-up)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
RV5 Armah 2010-AF 9/2733 15/2735 37.3 % 0.60 [ 0.26, 1.37 ]
RV5 Block 2007-EU/USA 1/650 5/660 12.4 % 0.20 [ 0.02, 1.73 ]
RV5 Ciarlet 2009-EU 1/201 0/202 1.2 % 3.01 [ 0.12, 73.57 ]
RV5 Clark 2004-USA 4/218 1/221 2.5 % 4.06 [ 0.46, 35.99 ]
RV5 Iwata 2013-JPN 1/381 3/381 7.5 % 0.33 [ 0.03, 3.19 ]
RV5 Kim 2008-KOR 0/115 0/63 Not estimable
RV5 Lawrence 2012-CHN 0/24 1/24 3.7 % 0.33 [ 0.01, 7.80 ]
RV5 Merck[009] 2005-USA 1/680 1/113 4.3 % 0.17 [ 0.01, 2.64 ]
RV5 Mo 2017-CHN 17/2015 12/2019 29.9 % 1.42 [ 0.68, 2.96 ]
RV5 Zaman 2010-AS 1/1018 0/1018 1.2 % 3.00 [ 0.12, 73.56 ]
Total (95% CI) 8035 7436 100.0 % 0.89 [ 0.57, 1.39 ]
Total events: 35 (RV5), 38 (Placebo)
Heterogeneity: Chi2 = 9.73, df = 8 (P = 0.28); I2 =18%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 2.19. Comparison 2 RV5 versus placebo, Outcome 19 Immunogenicity: rotavirus vaccine shedding
(after dose 3).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 19 Immunogenicity: rotavirus vaccine shedding (after dose 3)
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Clark 2003-USA 277/355 13/93 5.58 [ 3.36, 9.27 ]
RV5 Clark 2004-USA 104/159 2/155 50.69 [ 12.73, 201.81 ]
RV5 Dhingra 2014-IND 0/20 0/20 Not estimable
RV5 Lawrence 2012-CHN 6/23 0/24 13.54 [ 0.81, 227.50 ]
RV5 Levin 2017-AF 0/99 0/130 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours RV5
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Analysis 2.20. Comparison 2 RV5 versus placebo, Outcome 20 Immunogenicity: seroconversion.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 20 Immunogenicity: seroconversion
Study or subgroup RV5 Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 After dose 3
RV5 Armah 2010-AF 148/189 34/169 3.89 [ 2.86, 5.31 ]
RV5 Block 2007-EU/USA 64/67 9/73 7.75 [ 4.19, 14.32 ]
RV5 Ciarlet 2009-EU 184/201 12/202 15.41 [ 8.89, 26.72 ]
RV5 Clark 2003-USA 404/455 3/113 33.44 [ 10.95, 102.19 ]
RV5 Clark 2004-USA 162/185 3/185 54.00 [ 17.55, 166.11 ]
RV5 Dhingra 2014-IND 13/20 2/20 6.50 [ 1.68, 25.16 ]
RV5 Levin 2017-AF 72/89 22/89 3.27 [ 2.25, 4.77 ]
RV5 Vesikari 2006a-FIN 959/1027 43/322 6.99 [ 5.29, 9.24 ]
RV5 Vesikari 2006b-INT 180/189 23/161 6.67 [ 4.56, 9.75 ]
RV5 Zaman 2010-AS 115/131 24/132 4.83 [ 3.34, 6.97 ]
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours RV5
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Analysis 2.21. Comparison 2 RV5 versus placebo, Outcome 21 Dropouts before the end of the trial.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 21 Dropouts before the end of the trial
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Armah 2010-AF 376/2733 387/2735 21.2 % 0.97 [ 0.85, 1.11 ]
RV5 Block 2007-EU/USA 99/651 96/661 9.3 % 1.05 [ 0.81, 1.36 ]
RV5 Clark 2003-USA 97/581 36/150 6.0 % 0.70 [ 0.50, 0.98 ]
RV5 Clark 2004-USA 11/218 12/221 1.2 % 0.93 [ 0.42, 2.06 ]
RV5 Dhingra 2014-IND 1/20 1/20 0.1 % 1.00 [ 0.07, 14.90 ]
RV5 Iwata 2013-JPN 13/381 15/381 1.5 % 0.87 [ 0.42, 1.80 ]
RV5 Lawrence 2012-CHN 2/24 4/24 0.3 % 0.50 [ 0.10, 2.48 ]
RV5 Levin 2017-AF 1/99 4/103 0.2 % 0.26 [ 0.03, 2.29 ]
RV5 Merck[009] 2005-USA 71/680 16/113 3.0 % 0.74 [ 0.45, 1.22 ]
RV5 Mo 2017-CHN 90/2020 74/2020 7.3 % 1.22 [ 0.90, 1.64 ]
RV5 Vesikari 2006a-FIN 390/1624 60/322 10.1 % 1.29 [ 1.01, 1.65 ]
RV5 Vesikari 2006b-INT 5846/34035 5882/34003 36.6 % 0.99 [ 0.96, 1.03 ]
RV5 Zaman 2010-AS 27/1018 40/1018 3.2 % 0.68 [ 0.42, 1.09 ]
Total (95% CI) 44084 41771 100.0 % 0.98 [ 0.90, 1.08 ]
Total events: 7024 (RV5), 6627 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 16.79, df = 12 (P = 0.16); I2 =29%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 RV5 versus placebo, Outcome 22 Subgroup analysis: rotavirus diarrhoea of any
severity (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 22 Subgroup analysis: rotavirus diarrhoea of any severity (by G type)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV5 Block 2007-EU/USA 13/551 53/564 12.5 % 0.25 [ 0.14, 0.46 ]
RV5 Clark 2004-USA 10/187 26/183 9.0 % 0.38 [ 0.19, 0.76 ]
RV5 Mo 2017-CHN 10/1927 39/1937 9.3 % 0.26 [ 0.13, 0.51 ]
RV5 Vesikari 2006b-INT 72/2834 286/2839 69.2 % 0.25 [ 0.20, 0.32 ]
Subtotal (95% CI) 5499 5523 100.0 % 0.26 [ 0.21, 0.32 ]
Total events: 105 (RV5), 404 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 12.47 (P < 0.00001)
2 G2
RV5 Clark 2004-USA 1/187 2/183 11.3 % 0.49 [ 0.04, 5.35 ]
RV5 Mo 2017-CHN 1/1927 4/1937 13.5 % 0.25 [ 0.03, 2.25 ]
RV5 Vesikari 2006b-INT 6/2834 17/2839 75.1 % 0.35 [ 0.14, 0.90 ]
Subtotal (95% CI) 4948 4959 100.0 % 0.35 [ 0.16, 0.78 ]
Total events: 8 (RV5), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
3 G3
RV5 Block 2007-EU/USA 2/551 1/564 24.0 % 2.05 [ 0.19, 22.51 ]
RV5 Clark 2004-USA 0/187 10/183 19.9 % 0.05 [ 0.00, 0.79 ]
RV5 Mo 2017-CHN 2/1927 2/1937 29.0 % 1.01 [ 0.14, 7.13 ]
RV5 Vesikari 2006b-INT 1/2834 6/2839 27.1 % 0.17 [ 0.02, 1.39 ]
Subtotal (95% CI) 5499 5523 100.0 % 0.40 [ 0.08, 2.02 ]
Total events: 5 (RV5), 19 (Placebo)
Heterogeneity: Tau2 = 1.38; Chi2 = 6.03, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.11 (P = 0.27)
4 G4
RV5 Clark 2004-USA 0/187 1/183 13.5 % 0.33 [ 0.01, 7.96 ]
RV5 Mo 2017-CHN 0/1927 2/1937 14.9 % 0.20 [ 0.01, 4.18 ]
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(. . . Continued)
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
RV5 Vesikari 2006b-INT 3/2834 6/2839 71.6 % 0.50 [ 0.13, 2.00 ]
Subtotal (95% CI) 4948 4959 100.0 % 0.41 [ 0.13, 1.33 ]
Total events: 3 (RV5), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
5 G9
RV5 Mo 2017-CHN 20/1927 61/1937 95.3 % 0.33 [ 0.20, 0.54 ]
RV5 Vesikari 2006b-INT 1/2834 3/2839 4.7 % 0.33 [ 0.03, 3.21 ]
Subtotal (95% CI) 4761 4776 100.0 % 0.33 [ 0.20, 0.54 ]
Total events: 21 (RV5), 64 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.71, df = 4 (P = 0.79), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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Analysis 2.23. Comparison 2 RV5 versus placebo, Outcome 23 Subgroup analysis: severe cases of rotavirus
diarrhoea (by G type).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 23 Subgroup analysis: severe cases of rotavirus diarrhoea (by G type)
Study or subgroup Favours RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G1
RV5 Armah 2010-AF 42/2357 62/2348 34.2 % 0.67 [ 0.46, 0.99 ]
RV5 Mo 2017-CHN 5/1926 14/1937 31.9 % 0.36 [ 0.13, 1.00 ]
RV5 Vesikari 2006b-INT 16/34035 328/34003 33.9 % 0.05 [ 0.03, 0.08 ]
Subtotal (95% CI) 38318 38288 100.0 % 0.23 [ 0.03, 1.74 ]
Total events: 63 (Favours RV5), 404 (Placebo)
Heterogeneity: Tau2 = 3.13; Chi2 = 78.22, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.43 (P = 0.15)
2 G2
RV5 Armah 2010-AF 32/2357 44/2348 64.7 % 0.72 [ 0.46, 1.14 ]
RV5 Mo 2017-CHN 0/1926 2/1937 12.7 % 0.20 [ 0.01, 4.19 ]
RV5 Vesikari 2006b-INT 1/34035 8/34003 22.6 % 0.12 [ 0.02, 1.00 ]
Subtotal (95% CI) 38318 38288 100.0 % 0.41 [ 0.13, 1.37 ]
Total events: 33 (Favours RV5), 54 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 1.45 (P = 0.15)
3 G3
RV5 Armah 2010-AF 3/2357 8/2348 42.7 % 0.37 [ 0.10, 1.41 ]
RV5 Mo 2017-CHN 2/1926 0/1937 23.4 % 5.03 [ 0.24, 104.67 ]
RV5 Vesikari 2006b-INT 1/34035 15/34003 33.9 % 0.07 [ 0.01, 0.50 ]
Subtotal (95% CI) 38318 38288 100.0 % 0.38 [ 0.05, 2.74 ]
Total events: 6 (Favours RV5), 23 (Placebo)
Heterogeneity: Tau2 = 1.90; Chi2 = 5.61, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.96 (P = 0.34)
4 G4
RV5 Armah 2010-AF 0/2357 0/2348 Not estimable
RV5 Mo 2017-CHN 0/1926 2/1937 18.8 % 0.20 [ 0.01, 4.19 ]
RV5 Vesikari 2006b-INT 2/34035 18/34003 81.2 % 0.11 [ 0.03, 0.48 ]
Subtotal (95% CI) 38318 38288 100.0 % 0.12 [ 0.03, 0.46 ]
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(. . . Continued)
Study or subgroup Favours RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2 (Favours RV5), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
5 G9
RV5 Armah 2010-AF 1/2357 2/2348 15.5 % 0.50 [ 0.05, 5.49 ]
RV5 Mo 2017-CHN 4/1926 34/1937 73.2 % 0.12 [ 0.04, 0.33 ]
RV5 Vesikari 2006b-INT 0/34035 13/34003 11.3 % 0.04 [ 0.00, 0.62 ]
Subtotal (95% CI) 38318 38288 100.0 % 0.13 [ 0.05, 0.34 ]
Total events: 5 (Favours RV5), 49 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.09, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 4.17 (P = 0.000031)
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Analysis 2.24. Comparison 2 RV5 versus placebo, Outcome 24 Subgroup analysis: HIV-infected children.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 2 RV5 versus placebo
Outcome: 24 Subgroup analysis: HIV-infected children
Study or subgroup RV5 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Rotavirus diarrhoea: severe (up to two years follow-up)
RV5 Armah 2010-KEN 1/21 0/17 100.0 % 2.45 [ 0.11, 56.68 ]
Subtotal (95% CI) 21 17 100.0 % 2.45 [ 0.11, 56.68 ]
Total events: 1 (RV5), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 All-cause diarrhoea: severe (up to two years follow-up)
RV5 Armah 2010-KEN 5/21 1/17 100.0 % 4.05 [ 0.52, 31.43 ]
Subtotal (95% CI) 21 17 100.0 % 4.05 [ 0.52, 31.43 ]
Total events: 5 (RV5), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 All-cause death
RV5 Armah 2010-KEN 8/21 4/17 69.4 % 1.62 [ 0.59, 4.47 ]
RV5 Levin 2017-AF 1/37 2/39 30.6 % 0.53 [ 0.05, 5.57 ]
Subtotal (95% CI) 58 56 100.0 % 1.29 [ 0.51, 3.21 ]
Total events: 9 (RV5), 6 (Placebo)
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
4 Serious adverse events (up to 24 weeks)
RV5 Armah 2010-KEN 5/21 2/16 36.8 % 1.90 [ 0.42, 8.58 ]
RV5 Levin 2017-AF 5/37 4/39 63.2 % 1.32 [ 0.38, 4.53 ]
Subtotal (95% CI) 58 55 100.0 % 1.53 [ 0.59, 3.97 ]
Total events: 10 (RV5), 6 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 1.08, df = 3 (P = 0.78), I2 =0.0%
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Analysis 3.1. Comparison 3 Rotavac versus placebo, Outcome 1 Rotavirus diarrhoea: severe (up to 1 year
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 1 Rotavirus diarrhoea: severe (up to 1 year follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 60/4532 70/2267 0.43 [ 0.30, 0.60 ]
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
Analysis 3.2. Comparison 3 Rotavac versus placebo, Outcome 2 Rotavirus diarrhoea: severe (up to 2 years
follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 2 Rotavirus diarrhoea: severe (up to 2 years follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 93/4354 102/2187 0.46 [ 0.35, 0.60 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 3.3. Comparison 3 Rotavac versus placebo, Outcome 3 All-cause diarrhoea: severe cases (up to 1
year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 3 All-cause diarrhoea: severe cases (up to 1 year follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 353/4532 211/2267 0.84 [ 0.71, 0.98 ]
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
Analysis 3.4. Comparison 3 Rotavac versus placebo, Outcome 4 All-cause death.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 4 All-cause death
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 30/4532 18/2267 97.0 % 0.83 [ 0.47, 1.49 ]
VAC Chandola 2017-IND 5/1017 0/339 3.0 % 3.67 [ 0.20, 66.27 ]
Total (95% CI) 5549 2606 100.0 % 0.92 [ 0.52, 1.62 ]
Total events: 35 (Rotavac), 18 (Placebo)
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Rotavac versus placebo, Outcome 5 All serious adverse events.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 5 All serious adverse events
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2006-IND (1) 1/30 2/28 0.3 % 0.47 [ 0.04, 4.87 ]
VAC Bhandari 2014-IND 947/4531 515/2265 95.7 % 0.92 [ 0.84, 1.01 ]
VAC Chandola 2017-IND 72/1017 19/339 4.0 % 1.26 [ 0.77, 2.06 ]
Total (95% CI) 5578 2632 100.0 % 0.93 [ 0.85, 1.02 ]
Total events: 1020 (Rotavac), 536 (Placebo)
Heterogeneity: Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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(1) intervention: 1 dose only
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Analysis 3.6. Comparison 3 Rotavac versus placebo, Outcome 6 Serious adverse events: intussusception.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 6 Serious adverse events: intussusception
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2006-IND (1) 0/30 0/28 Not estimable
VAC Bhandari 2009-IND (2) 0/185 0/184 Not estimable
VAC Bhandari 2014-IND 8/4532 3/2267 100.0 % 1.33 [ 0.35, 5.02 ]
VAC Chandola 2017-IND 0/1017 0/339 Not estimable
Total (95% CI) 5764 2818 100.0 % 1.33 [ 0.35, 5.02 ]
Total events: 8 (Rotavac), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Favours Rotavac Favours placebo
(1) intervention: 1 dose only
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
Analysis 3.7. Comparison 3 Rotavac versus placebo, Outcome 7 Rotavirus diarrhoea: of any severity (up to
1 year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 7 Rotavirus diarrhoea: of any severity (up to 1 year follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 313/4532 236/2267 0.66 [ 0.56, 0.78 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 3.8. Comparison 3 Rotavac versus placebo, Outcome 8 Rotavirus diarrhoea: of any severity (up to
2 years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 8 Rotavirus diarrhoea: of any severity (up to 2 years follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2014-IND 406/4354 310/2187 0.66 [ 0.57, 0.76 ]
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
Analysis 3.9. Comparison 3 Rotavac versus placebo, Outcome 9 Rotavirus diarrhoea: requiring medical
attention.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 9 Rotavirus diarrhoea: requiring medical attention
Study or subgroup Rotavac Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Up to 1 year follow-up (at least 1 rotavirus season)
VAC Bhandari 2014-IND 300/4532 218/2267 0.69 [ 0.58, 0.81 ]
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
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Analysis 3.10. Comparison 3 Rotavac versus placebo, Outcome 10 Reactogenicity: fever.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 10 Reactogenicity: fever
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
VAC Bhandari 2006-IND (1) 2/30 1/30 9.1 % 2.00 [ 0.19, 20.90 ]
VAC Bhandari 2009-IND (2) 7/183 10/184 90.9 % 0.70 [ 0.27, 1.81 ]
Subtotal (95% CI) 213 214 100.0 % 0.82 [ 0.35, 1.94 ]
Total events: 9 (Rotavac), 11 (Placebo)
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
2 After dose 2
VAC Bhandari 2009-IND (3) 9/176 12/180 100.0 % 0.77 [ 0.33, 1.77 ]
Subtotal (95% CI) 176 180 100.0 % 0.77 [ 0.33, 1.77 ]
Total events: 9 (Rotavac), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
3 After dose 3
VAC Bhandari 2009-IND (4) 13/177 12/181 100.0 % 1.11 [ 0.52, 2.36 ]
Subtotal (95% CI) 177 181 100.0 % 1.11 [ 0.52, 2.36 ]
Total events: 13 (Rotavac), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
0.01 0.1 1 10 100
Favours Rotavac Favours placebo
(1) intervention: 1 dose only
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(3) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(4) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
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Analysis 3.11. Comparison 3 Rotavac versus placebo, Outcome 11 Reactogenicity: diarrhoea.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 11 Reactogenicity: diarrhoea
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
VAC Bhandari 2006-IND (1) 5/30 5/30 10.9 % 1.00 [ 0.32, 3.10 ]
VAC Bhandari 2009-IND (2) 36/183 41/184 89.1 % 0.88 [ 0.59, 1.31 ]
Subtotal (95% CI) 213 214 100.0 % 0.90 [ 0.62, 1.30 ]
Total events: 41 (Rotavac), 46 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.57)
2 After dose 2
VAC Bhandari 2009-IND (3) 41/176 27/180 100.0 % 1.55 [ 1.00, 2.41 ]
Subtotal (95% CI) 176 180 100.0 % 1.55 [ 1.00, 2.41 ]
Total events: 41 (Rotavac), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.049)
3 After dose 3
VAC Bhandari 2009-IND (4) 40/177 10/181 100.0 % 4.09 [ 2.11, 7.92 ]
Subtotal (95% CI) 177 181 100.0 % 4.09 [ 2.11, 7.92 ]
Total events: 40 (Rotavac), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.18 (P = 0.000030)
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
(1) intervention: 1 dose only
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(3) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(4) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
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Analysis 3.12. Comparison 3 Rotavac versus placebo, Outcome 12 Reactogenicity: vomiting.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 12 Reactogenicity: vomiting
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
VAC Bhandari 2006-IND (1) 2/30 2/30 13.4 % 1.00 [ 0.15, 6.64 ]
VAC Bhandari 2009-IND (2) 18/183 13/184 86.6 % 1.39 [ 0.70, 2.76 ]
Subtotal (95% CI) 213 214 100.0 % 1.34 [ 0.71, 2.55 ]
Total events: 20 (Rotavac), 15 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 After dose 2
VAC Bhandari 2009-IND (3) 12/176 8/180 100.0 % 1.53 [ 0.64, 3.66 ]
Subtotal (95% CI) 176 180 100.0 % 1.53 [ 0.64, 3.66 ]
Total events: 12 (Rotavac), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
3 After dose 3
VAC Bhandari 2009-IND (4) 8/177 8/181 100.0 % 1.02 [ 0.39, 2.66 ]
Subtotal (95% CI) 177 181 100.0 % 1.02 [ 0.39, 2.66 ]
Total events: 8 (Rotavac), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
0.1 0.2 0.5 1 2 5 10
Favours Rotavac Favours placebo
(1) intervention: 1 dose only
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(3) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(4) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
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Analysis 3.13. Comparison 3 Rotavac versus placebo, Outcome 13 Immunogenicity: rotavirus vaccine
shedding (end of follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 13 Immunogenicity: rotavirus vaccine shedding (end of follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
VAC Bhandari 2006-IND (1) 12/30 2/30 62.9 % 6.00 [ 1.47, 24.55 ]
VAC Bhandari 2009-IND (2) 23/184 1/183 37.1 % 22.88 [ 3.12, 167.62 ]
Total (95% CI) 214 213 100.0 % 9.86 [ 2.58, 37.63 ]
Total events: 35 (Rotavac), 3 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours Rotavac
(1) intervention: 1 dose only
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
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Analysis 3.14. Comparison 3 Rotavac versus placebo, Outcome 14 Immunogenicity: seroconversion.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 14 Immunogenicity: seroconversion
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 After dose 1
VAC Bhandari 2009-IND (1) 40/61 11/60 100.0 % 3.58 [ 2.03, 6.29 ]
Subtotal (95% CI) 61 60 100.0 % 3.58 [ 2.03, 6.29 ]
Total events: 40 (Rotavac), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.43 (P < 0.00001)
2 After dose 2
VAC Bhandari 2009-IND (2) 38/58 13/59 100.0 % 2.97 [ 1.78, 4.98 ]
Subtotal (95% CI) 58 59 100.0 % 2.97 [ 1.78, 4.98 ]
Total events: 38 (Rotavac), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000034)
3 After dose 3
VAC Bhandari 2009-IND (3) 44/58 16/63 15.1 % 2.99 [ 1.91, 4.67 ]
VAC Bhandari 2014-IND 115/288 25/136 33.4 % 2.17 [ 1.48, 3.18 ]
VAC Chandola 2017-IND 335/866 35/288 51.6 % 3.18 [ 2.31, 4.39 ]
Subtotal (95% CI) 1212 487 100.0 % 2.82 [ 2.26, 3.51 ]
Total events: 494 (Rotavac), 76 (Placebo)
Heterogeneity: Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 9.22 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours Rotavac
(1) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(2) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
(3) vaccine: 3 doses of either 1x10ˆ4 or 1x10ˆ5 FFUs
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Analysis 3.15. Comparison 3 Rotavac versus placebo, Outcome 15 Dropouts before the end of the trial.
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 15 Dropouts before the end of the trial
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
VAC Bhandari 2006-IND (1) 2/30 2/30 1.8 % 1.00 [ 0.15, 6.64 ]
VAC Bhandari 2014-IND 113/4532 76/2267 91.4 % 0.74 [ 0.56, 0.99 ]
VAC Chandola 2017-IND 24/1017 5/339 6.8 % 1.60 [ 0.62, 4.16 ]
Total (95% CI) 5579 2636 100.0 % 0.81 [ 0.62, 1.06 ]
Total events: 139 (Rotavac), 83 (Placebo)
Heterogeneity: Chi2 = 2.33, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Rotavac Favours placebo
(1) intervention: 1 dose only
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Analysis 3.16. Comparison 3 Rotavac versus placebo, Outcome 16 Subgroup analysis: severe cases of
rotavirus diarrhoea by G and P types (up to 1 year follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 16 Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 1 year follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G1P[8]
VAC Bhandari 2014-IND 25/4354 19/2187 100.0 % 0.66 [ 0.36, 1.20 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.66 [ 0.36, 1.20 ]
Total events: 25 (Rotavac), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 G2P[4]
VAC Bhandari 2014-IND 21/4354 27/2187 100.0 % 0.39 [ 0.22, 0.69 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.39 [ 0.22, 0.69 ]
Total events: 21 (Rotavac), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
3 G12P[6]
VAC Bhandari 2014-IND 8/4354 13/2187 100.0 % 0.31 [ 0.13, 0.74 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.31 [ 0.13, 0.74 ]
Total events: 8 (Rotavac), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
4 G12P[8]
VAC Bhandari 2014-IND 3/4354 5/2187 100.0 % 0.30 [ 0.07, 1.26 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.30 [ 0.07, 1.26 ]
Total events: 3 (Rotavac), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
0.02 0.1 1 10 50
Favours Rotavac Favours placebo
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Analysis 3.17. Comparison 3 Rotavac versus placebo, Outcome 17 Subgroup analysis: severe cases of
rotavirus diarrhoea by G and P types (up to 2 years follow-up).
Review: Vaccines for preventing rotavirus diarrhoea: vaccines in use
Comparison: 3 Rotavac versus placebo
Outcome: 17 Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow-up)
Study or subgroup Rotavac Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G1P[8]
VAC Bhandari 2014-IND 40/4354 34/2187 100.0 % 0.59 [ 0.38, 0.93 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.59 [ 0.38, 0.93 ]
Total events: 40 (Rotavac), 34 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
2 G2P[4]
VAC Bhandari 2014-IND 26/4354 35/2187 100.0 % 0.37 [ 0.23, 0.62 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.37 [ 0.23, 0.62 ]
Total events: 26 (Rotavac), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.00013)
3 G9P[4]
VAC Bhandari 2014-IND 9/4354 1/2187 100.0 % 4.52 [ 0.57, 35.66 ]
Subtotal (95% CI) 4354 2187 100.0 % 4.52 [ 0.57, 35.66 ]
Total events: 9 (Rotavac), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
4 G12P[6]
VAC Bhandari 2014-IND 8/4354 13/2187 100.0 % 0.31 [ 0.13, 0.74 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.31 [ 0.13, 0.74 ]
Total events: 8 (Rotavac), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0089)
5 G12P[8]
VAC Bhandari 2014-IND 5/4354 8/2187 100.0 % 0.31 [ 0.10, 0.96 ]
Subtotal (95% CI) 4354 2187 100.0 % 0.31 [ 0.10, 0.96 ]
Total events: 5 (Rotavac), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
0.01 0.1 1 10 100
Favours Rotavac Favours placebo
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A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb Embaseb LILACSb BIOSIS
1 rotavirus rotavirus rotavirus rotavirus rotavirus rotavirus
2 diarrhoea diarrhoea ROTAVIRUS IN-
FECTIONS
ROTAVIRUS diarrhoea diarrhoea
3 diarrhoea diarrhoea 1 or 2 1 or 2 diarrhea diarrhoea
4 gastroenteritis gastroenteritis diarrhoea diarrhoea gastroenteritis gastroenteritis
5 2 or 3 or 4 2 or 3 or 4 gastroenteritis gastroenteritis 2 or 3 or 4 2 or 3 or 4
6 1 and 5 1 and 5 4 or 5 4 or 5 1 and 5 1 and 5
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011); upper case:
MeSH or EMTREE heading; lower case: free-text term.
Appendix 2. Trial type (efficacy or safety) and length of follow-up
Trial Type: efficacy or safety Follow-up time
RV1 Anh 2011-PHL Safety 1 month after last dose
RV1 Anh 2011-VNM Safety 1 month after last dose
RV1 Bernstein 1998-USA Safety 1 month
RV1 Bernstein 1999-USA Efficacy/Safety 2 years
RV1 Colgate 2016-BGD Efficacy 1 year
RV1 Dennehy 2005-NA Safety 10 to 12 months
RV1 GSK[021] 2007-PAN Safety 1 month after dose 3
RV1 GSK[033] 2007-LA Safety 1 month
RV1 GSK[041] 2007-KOR Safety 2 months
RV1 GSK[101555] 2008-PHL Safety 1 month
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(Continued)
RV1 Kawamura 2011-JPN Efficacy/Safety Up to the age of 2 years
RV1 Kerdpanich 2010-THA Safety 2 months after last dose
RV1 Kim 2012-KOR Safety 1 month after last dose
RV1 Li 2013a-CHN Safety 1 month
RV1 Li 2013b-CHN Safety 1 month
RV1 Li 2014-CHN Efficacy/Safety 2 years
RV1 Madhi 2010-AF Efficacy/Safety 2 years
RV1 Narang 2009-IND Safety 1 month
RV1 NCT00158756-RUS Safety 1 year
RV1 Omenaca 2012-EU Safety At least 1 month after dose 2
RV1 Phua 2005-SGP Efficacy/Safety Until infant aged 18 months (ie 13 to 15 months)
RV1 Phua 2009-AS Efficacy/Safety 3 years
RV1 Rivera 2011-DOM Safety 17 weeks after each dose
RV1 Ruiz-Palac 06-LA/EU Efficacy/Safety 9 to 10 months
RV1 Salinas 2005-LA Efficacy/Safety Up to 2 years
RV1 Steele 2008-ZAF Safety Up to 6 months
RV1 Steele 2010a-ZAF Safety 31 days after each dose, 42 days after the last dose
RV1 Steele 2010b-ZAF Safety Up to 6 months
RV1 Tregnaghi 2011-LA Efficacy/Safety Up to age 1 year
RV1 Vesikari 2004a-FIN Safety 8 to 30 days after each dose
RV1 Vesikari 2004b-FIN Efficacy/Safety 1 and 2 years (both reported)
RV1 Vesikari 2007a-EU Efficacy/Safety 1 and 2 years (plus 3 years in Finland)
RV1 Vesikari 2011-FIN Safety 2 months
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(Continued)
RV1 Ward 2006-USA Safety 7 days after each vaccination; 3 to 5 weeks after dose 2
RV1 Zaman 2009-BGD Safety 31 days
RV1 Zaman 2017-BGD Effectiveness 2 years
RV5 Armah 2010-AF Efficacy/Safety Up to 43 days for safety outcomes, up to 21 months for efficacy
outcomes
RV5 Block 2007-EU/USA Efficacy/Safety 42 days for safety/immunogenicity; 1 year for efficacy
RV5 Ciarlet 2009-EU Safety 42 days
RV5 Clark 2003-USA Efficacy/Safety 1 year
RV5 Clark 2004-USA Efficacy/Safety 1 year
RV5 Dhingra 2014-IND Safety 1 month
RV5 Iwata 2013-JPN Efficacy/Safety 25 months
RV5 Kim 2008-KOR Safety 42 days
RV5 Lawrence 2012-CHN Safety 2 weeks after last dose
RV5 Levin 2017-AF Safety 1 month
RV5 Merck[009] 2005-USA Safety 42 days
RV5 Mo 2017-CHN Efficacy/Safety 2 years
RV5 Vesikari 2006a-FIN Efficacy/Safety 1 to 3 years
RV5 Vesikari 2006b-INT Efficacy/Safety 43 days for safety; 2 years for efficacy
RV5 Zaman 2010-AS Efficacy/Safety Up to 43 days for safety outcomes, up to 2 years for efficacy outcomes
VAC Bhandari 2006-IND Safety 1 month
VAC Bhandari 2009-IND Safety 12 weeks
VAC Bhandari 2014-IND Efficacy/Safety up to 2 years of age
VAC Chandola 2017-IND Safety 1 year
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Appendix 3. Efficacy outcome measures by trial
Trial Rotavirus diarrhoea (any sever-
ity)
All-cause diarrhoea ED visit Hospitaliza-
tion (all-
cause)
All-cause
death
Dropouts
All Severe Hospital All Severe
RV1 Anh
2011-
PHL
X - - X - - - X X
RV1 Anh
2011-
VNM
X - - X - - - X X
RV1
Bernstein
1998-
USA
- - - - - - - - -
RV1
Bernstein
1999-
USA
X X X Xa - Xa - X -
RV1
Colgate
2016-
BGD
X X - X X - - X X
RV1
Dennehy
2005-NA
- - - - - - - - -
RV1
GSK[021]
2007-
PAN
- - - - - - - X X
RV1
GSK[033]
2007-LA
- - - - - - - X X
RV1
GSK[041]
2007-
KOR
X - - - - - - X X
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RV1
GSK[101555]
2008-
PHL
X - - - - - - X X
RV1
Kawa-
mura
2011-JPN
- X X - - - - X X
RV1
Kerd-
panich
2010-
THA
X - - X - - - X X
RV1 Kim
2012-
KOR
X - - X - - - X X
RV1
Li 2013a-
CHN
- - - - - - - X X
RV1
Li 2013b-
CHN
- - - - - - - - -
RV1 Li
2014-
CHN
X X X X X - - X X
RV1
Madhi
2010-AF
X X X - X - - X X
RV1
Narang
2009-
IND
X - - - - - - X X
RV1
NCT00158756-
RUS
- - - - - - - X X
RV1
Omenaca
2012-EU
X - - X - - - - X
295Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
RV1 Phua
2009-AS
Xa X X Xa X Xa X
RV1 Phua
2005-SGP
X X X X X X X X X
RV1
Rivera
2011-
DOM
X - - X - - - - X
RV1 Ruiz-
Palac 06-
LA/EU
Xa X X Xa X - Xa X Xa
RV1
Salinas
2005-LA
X X X X Xa - Xa X
RV1Steele
2008-ZAF
- - - - - - - X X
RV1Steele
2010a-
ZAF
X - - X - - - X X
RV1Steele
2010b-
ZAF
X X - - - - - X X
RV1
Tregnaghi
2011-LA
- X - - Xa - - X X
RV1
Vesikari
2004a-
FIN
- - - - - - - Xa X
RV1
Vesikari
2004b-
FIN
X X X X - - - X X
RV1
Vesikari
2007a-
EU
X X X Xa X Xa Xa - -
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RV1
Vesikari
2011-FIN
X - - X - - - X X
RV1 Ward
2006-
USA
- - - - - - - - -
RV1
Zaman
2009-
BGD
X - - - - - - X
RV1
Zaman
2017-
BGD
- X - - - - - - -
RV5
Armah
2010-AF
X X - X X - - X X
RV5
Block
2007-EU/
USA
X X - - - - - X X
RV5
Ciarlet
2009-EU
- - - - - - - X -
RV5Clark
2003-
USA
X Xa - - - - - - X
RV5Clark
2004-
USA
X X - - - - - - X
RV5
Dhingra
2014-
IND
- - - - - - - - X
RV5 Iwata
2013-JPN
X X - - - - - X X
RV5 Kim
2008-
KOR
- - - - - - - - -
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RV5
Lawrence
2012-
CHN
- - - - - - - X X
RV5 Levin
2017-AF
- - - - - - - X X
RV5
Merck[009]
2005-
USA
- - - - - - - X X
RV5
Mo 2017-
CHN
- - - - - - - X X
RV5
Vesikari
2006a-
FIN
X X - - - - - X X
RV5
Vesikari
2006b-
INT
X X X - - Xa Xa X X
RV5
Zaman
2010-AS
X X - - X - - X X
VAC
Bhandari
2006-
IND
- - - - - - - - X
VAC
Bhandari
2009-
IND
- - - - - - - - -
VAC
Bhandari
2014-
IND
X X X - X - - X X
VAC
Chandola
2017-
- - - - - - - X X
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IND
aReported as an outcome measure in trial, but no data available for analysis.
Appendix 4. Safety and immunogenicity outcomes measures by trial
Trial Safety Immunogenicity
Serious AE Reactogenicity AE to discontinuation Vaccine virus shedding Seroconversion
RV1 Anh 2011-
PHL
X X X - X
RV1 Anh 2011-
VNM
X X X - X
RV1 Bernstein
1998-USA
X X X X X
RV1 Bernstein
1999-USA
- X - X X
RV1Colgate 2016-
BGD
- - - - -
RV1 Dennehy
2005-NA
X X X X X
RV1 GSK[021]
2007-PAN
X X X X X
RV1 GSK[033]
2007-LA
X X X X X
RV1 GSK[041]
2007-KOR
X X X - X
RV1GSK[101555]
2008-PHL
X X X X X
RV1 Kawamura
2011-JPN
X X X - X
RV1 Kerdpanich
2010-THA
X X X X X
RV1 Kim 2012-
KOR
X X X - X
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(Continued)
RV1 Li
2013a-CHN
X X X X X
RV1 Li
2013b-CHN
- - - - -
RV1 Li 2014-CHN X X X - X
RV1 Madhi 2010-
AF
X - - - -
RV1 Narang 2009-
IND
X X X - X
RV1
NCT00158756-
RUS
X - X - X
RV1 Omenaca
2012-EU
X X - - X
RV1 Phua 2005-
SGP
X X Xa Xa X
RV1 Phua 2009-
AS
X - X - -
RV1 Rivera 2011-
DOM
X X - - X
RV1 Ruiz-Palac
06-LA/EU
X X X - Xa
RV1 Salinas 2005-
LA
X X - X X
RV1 Steele 2008-
ZAF
X X X X X
RV1 Steele 2010a-
ZAF
X Xa - X X
RV1 Steele 2010b-
ZAF
X X X X X
RV1 Tregnaghi
2011-LA
X - X - X
RV1 Vesikari
2004a-FIN
X X X X X
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RV1 Vesikari
2004b-FIN
X X X - X
RV1 Vesikari
2007a-EU
X X - - X
RV1 Vesikari
2011-FIN
X X X X X
RV1 Ward 2006-
USA
Xa - X Xa
RV1 Zaman 2009-
BGD
X X - X X
RV1 Zaman 2017-
BGD
X - - - -
RV5 Armah 2010-
AF
X Xa X - X
RV5 Block 2007-
EU/USA
X X X - X
RV5 Ciarlet 2009-
EU
X X - - X
RV5 Clark 2003-
USA
X X X X X
RV5 Clark 2004-
USA
Xa X X X X
RV5 Dhingra
2014-IND
X X X X X
RV5 Iwata 2013-
JPN
Xa X X - -
RV5 Kim 2008-
KOR
X Xa - - Xa
RV5 Lawrence
2012-CHN
X Xa X X -
RV5 Levin 2017-
AF
X X X X X
RV5 Merck[009]
2005-USA
X X X - -
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RV5 Mo
2017-CHN
X X X - -
RV5 Vesikari
2006a-FIN
X X X - X
RV5 Vesikari
2006b-INT
X X Xa - X
RV5 Zaman 2010-
AS
X Xa X - Xa
VAC Bhandari
2006-IND
X X - X -
VAC Bhandari
2009-IND
X X - X X
VAC Bhandari
2014-IND
X - - - X
VAC Chandola
2017-IND
X - - - X
AE: adverse events.
aReported as an outcome measure in trial, but no data available for analysis.
Appendix 5. Trial location
Trial Year Location Sites Country mortal-
ity rate
WHO mortality
strata
Region
RV1 Anh 2011-
PHL
2007 Philippines 1 Low-mortality B Asia
RV1 Anh 2011-
VNM
2007 Vietnam 11 Low-mortality B Asia
RV1 Bernstein
1998-USA
1998 USA 1 Low-mortality A North America
RV1 Bernstein
1999-USA
1999 USA 2 Low-mortality A North America
RV1 Colgate
2016-BGD
2014 Bangladesh 1 High-mortality D Asia
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RV1 Dennehy
2005-NA
2005 USA and Canada 41 Low-mortality A North America
RV1 GSK[021]
2007-PAN
2007 Panama 1 Low-mortality B Latin America
RV1 GSK[033]
2007-LA
2007 Colombia, Mex-
ico, and Peru
(2 in Colombia, 1
in Mexico, and 4
in Peru)
High-mortalitya B, D Latin America
RV1 GSK[041]
2007-KOR
2007 South Korea 6 Low-mortality B Asia
RV1
GSK[101555]
2008-PHL
2008 Philippines 1 Low-mortality B Asia
RV1 Kawamura
2011-JPN
2009 Japan 18 Low-mortality A Asia
RV1
Kerdpanich
2010-THA
2005 Thailand 2 Low-mortality B Asia
RV1 Kim 2012-
KOR
2010 Republic of Korea 19 Low-mortality B Asia
RV1 Li 2013a-
CHN
2010 China 1 Low-mortality B Asia
RV1 Li 2013b-
CHN
2010 China 1 Low-mortality B Asia
RV1 Li 2014-
CHN
2012 China 4 Low-mortality B Asia
RV1 Madhi
2010-AF
2010 South Africa and
Malawi
2 High-mortality E Africa
RV1 Narang
2009-IND
2009 India 4 High-mortality D Asia
RV1
NCT00158756-
RUS
2006 Russian
Federation
9 Low-mortality C Europe
RV1 Omenaca
2012-EU
2008 France,
Poland, Portugal,
Multiple sites in
each country
Low-mortality A, B Europe
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and Spain
RV1 Phua
2005-SGP
2005 Singapore 8 Low-mortality A Asia
RV1 Phua
2009-AS
2009 Hong Kong, Sin-
gapore, and Tai-
wan
3 Low-mortality A Asia
RV1 Rivera
2011-DOM
2008 Dominican
Republic
1 Low-mortality B Latin America
RV1 Ruiz-Palac
06-LA/EU
2006 Argentina, Brazil,
Chile, Colombia,
Dominican Re-
public, Finland,
Honduras, Mex-
ico, Nicaragua,
Panama, Peru, and
Venezuela
Multiple Low-mortalityb A, B, D Latin America/
Europe
RV1 Salinas
2005-LA
2005 Brazil, Mexico,
and Venezuela
3 Low-mortality B Latin America
RV1 Steele
2008-ZAF
2007 South Africa 1 High-mortality E Africa
RV1 Steele
2010a-ZAF
2008 South Africa 5 High-mortality E Africa
RV1 Steele
2010b-ZAF
2007 South Africa 7 High-mortality E Africa
RV1 Tregnaghi
2011-LA
2008 Argentina,
Brazil, Colombia,
Dominican Re-
public, Honduras,
and Panama
Multiple sites in
each country
Low-mortality B Latin America
RV1 Vesikari
2004a-FIN
2004 Finland 2 Low-mortality A Europe
RV1 Vesikari
2004b-FIN
2004 Finland 6 Low-mortality A Europe
RV1 Vesikari
2007a-EU
2007 Czech Republic,
Finland,
France, Germany,
Italy, and Spain
98 Low-mortality A Europe
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RV1 Vesikari
2011-FIN
2005 Finland 5 Low-mortality A Europe
RV1 Ward
2006-USA
2006 USA 2 Low mortality A North America
RV1 Zaman
2009-BGD
2005 Bangladesh 1 High-mortality D Asia
RV1 Zaman
2017-BGD
2011 Bangladesh 142 High-mortality D Asia
RV5 Armah
2010-AF
2009 Ghana, Kenya,
and Mali
3 High-mortality D, E Africa
RV5 Block
2007-EU/USA
2007 Finland and USA 30 Low-mortality A Europe and North
America
RV5 Ciarlet
2009-EU
2008 Austria, Belgium,
and Germany
26 Low-mortality A Europe
RV5 Clark
2003-USA
2003 USA 19 Low-mortality A North America
RV5 Clark
2004-USA
2004 USA 10 Low-mortality A North America
RV5 Dhingra
2014-IND
2012 India 2 High-mortality D Asia
RV5 Iwata
2013-JPN
2009 Japan 32 Low-mortality A Asia
RV5 Kim 2008-
KOR
2008 South Korea 8 Low-mortality B Asia
RV5 Lawrence
2012-CHN
2010 China Not reported Low-mortality B Asia
RV5
Merck[009]
2005-USA
2005 USA 10 Low-mortality A North America
RV5 Mo 2017-
CHN
2015 China 5 Low-mortality B Asia
RV5 Vesikari
2006a-FIN
2006 Finland 4 Low-mortality A Europe
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RV5 Vesikari
2006b-INT
2006 Belgium,
Costa Rica, Fin-
land, Germany,
Guatemala, Italy,
Jamaica, Mexico,
Puerto Rico, Swe-
den, Taiwan, and
USA
356 Low-mortalityb A, B, D Asia, Caribbean,
Eu-
rope, Latin Amer-
ica, North Amer-
ica
RV5 Zaman
2010-AS
2009 Bangladesh and
Vietnam
Multiple High-mortalitya B, D Asia
VAC Bhandari
2006-IND
2005 India 1 High-mortality D Asia
VAC Bhandari
2009-IND
2006-8 India 1 High-mortality D Asia
VAC Bhandari
2014-IND
2011-13 India 3 High-mortality D Asia
VAC Chandola
2017-IND
2014-15 India 1 High-mortality D Asia
aThis study was conducted mainly in high-mortality countries, but also in low-mortality countries.
bThis study was conducted mainly in low-mortality countries, but also in high-mortality countries.
Appendix 6. Vaccine schedules
Trial Number of doses Time between
doses (weeks)
Number of arms:
vaccine/placebo
Infant vaccination
status
Note
RV1 Anh 2011-
PHL
2 4 or 8 2/1 Commercially avail-
able
diphtheria, tetanus,
whole-cell pertussis
(DTPw), hepatitis B
(HBV) and oral po-
liovirus (OPV) vac-
cines were adminis-
tered concomitantly
with the study vac-
cine/placebo as part
of the routine Ex-
panded Programme
of
Compares different
schedules: (1) vac-
cine dose at month
1 and 2, and placebo
at day 0; and (2) vac-
cine dose at day 0
and month 2, and
placebo at month 1
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Immunization (EPI)
in the Philippines
RV1 Anh 2011-
VNM
2 4 or 8 2/1 Commercially avail-
able
diphtheria, tetanus,
whole-cell pertussis
(DTPw), hepatitis B
(HBV) and oral po-
liovirus (OPV) vac-
cines were adminis-
tered concomitantly
with the study vac-
cine/placebo as part
of the routine Ex-
panded Programme
of Immunization
(EPI) in Vietnam
Compares different
schedules: (1) vac-
cine dose at day 0
and month 1, and
placebo at month 2;
and (2) vaccine dose
at day 0 and month
2, and placebo at
month 1
RV1 Bernstein
1998-USA
2 6 to 10 1/1 Rotavirus vaccine
was separated from
all other infant vac-
cines by at least 2
weeks
-
RV1 Bernstein
1999-USA
2 6 to 10 1/1 Other vaccines sep-
arated from the trial
vaccines by at least 2
weeks
-
RV1Colgate 2016-
BGD
2 7 1/1 (no RV1) Alongside Rotarix at
10 and 17 weeks of
age the polio vaccine
intervention was the
administration of an
injected, inactivated
polio vaccine (IPV)
dose replacing the
4th dose of tOPV
at 39 weeks of age.
Study children also
received all standard
EPI vaccines (BCG
at birth; pentavalent
vac-
cine (DPT, HepB,
Hib) at 6, 10, and
14 weeks; bivalent
RV1 plus polio vacc-
cine (IPV), observa-
tional control group
only
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Measles-Rubella
at 40 weeks; and
monovalent Measles
at 65 weeks)
RV1 Dennehy
2005-NA
2 7 2/1 Vaccine or placebo
given concomitantly
with diphtheria-
tetanus-acel-
lular pertussis, inac-
tivated poliovirus,H
in-
fluenzae type b, and
S pneumoniae con-
jugate vaccines for
participants in USA
or with a diphtheria-
tetanus-acel-
lular pertussis/inac-
tivated poliovirus/H
influenza type
b combination vac-
cine for participants
in Canada
“Routine hepatitis B
vacci-
nations were admin-
istered according to
local practice.”
2 different PFUs
compared
RV1 GSK[021]
2007-PAN
3 8 2/2 Use of other vaccines
not mentioned
Licensed formula-
tion versus modified
formulation
RV1 GSK[033]
2007-LA
2 8 3/1 Use of other vaccines
not mentioned
3 ‘Lots’ of RV1 vac-
cine compared
RV1 GSK[041]
2007-KOR
2 8 1/1 H influenzae type
b vaccine adminis-
tered concomitantly
along with the
2 doses of vaccine/
placebo and at 2
months after dose 2;
other routine child-
hood vaccines were
to be given at least 14
days before trial vac-
cine/placebo
-
308Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
RV1GSK[101555]
2008-PHL
2 8 2/2 No men-
tion of whether in-
fants received other
vaccines
Data from
the lyophilized for-
mulation, which is
not yet approved or
marketed, are not re-
ported
RV1 Kawamura
2011-JPN
2 4 1/1 Combined diphthe-
ria and tetanus tox-
oids
and acellular pertus-
sis (DTPa) andHep-
atitis B (HBV) vac-
cineswere allowed to
be co-administered
along with RV1 vac-
cine/placebo
-
RV1 Kerdpanich
2010-THA
2 8 3/2 Diphtheria
toxoid, tetanus tox-
oid, acellular pertus-
sis, inactivated po-
lio and H influenzae
type b combination
vaccine (Infanrix™-
IPV/Hib) at 2 and 4
months of age and
diphtheria toxoid,
tetanus toxoid, acel-
lular pertussis, hep-
atitis B, inactivated
polio andH influen-
zae type b combi-
nation vaccine (In-
fanrix hexaT M ) at 6
months of age
Com-
pares: regular vac-
cine reconstituted in
buffer; vaccine re-
constituted in water;
vaccine stored above
recommended tem-
perature; placebo re-
constituted in wa-
ter; placebo recon-
stituted in buffer
RV1 Kim 2012-
KOR
2 4 1/1 Routine childhood
vaccines as recom-
mended by the local
vaccination schedule
were al-
lowed to be adminis-
tered concomitantly
with RIX4414/
placebo. These vac-
cines included the
combined diphthe-
-
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ria-tetanus-acel-
lular pertussis vac-
cine, Hemophilus in-
fluenzae type b vac-
cine, inactivated po-
liovirus vaccine and
pneumococcal vac-
cine.
The infants had re-
ceived the BCG vac-
cine and 2 doses of
hepatitis B vaccine
prior to study enrol-
ment
RV1 Li
2013a-CHN
1 - 1/1 Children were al-
lowed to receive rou-
tine childhood vac-
cinations according
to local immuniza-
tion practice dur-
ing the study period,
with a minimum in-
terval of at least 7
days between the ad-
ministration of rou-
tine vaccines and
the study vaccine or
placebo
Child arm (2 - 6
years of age) of the
same study as RV1
Li 2013b-CHN
RV1 Li
2013b-CHN
1 - 1/1 Infants were allowed
to receive routine
childhood vaccina-
tions according to
local immunization
practice during the
study period, with
a minimum inter-
val of at least 7
days between the ad-
ministration of rou-
tine vaccines and
the study vaccine or
placebo
Infant arm (6-16
weeks of age) of the
same study as RV1
Li 2013a-CHN
RV1 Li 2014-CHN 2 4 2/2 As part of the rou-
tine childhood vac-
cination
according to the EPI
-
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recommendations in
China, participants
also received 3 doses
of Infanrix™ vac-
cine and 3 doses of
the oral poliovirus
vaccine. The Infan-
rix™ and the OPV
vac-
cines were adminis-
tered independently
of (Sub-cohort 1) or
concomitantly with
(Sub-cohort 2) the
Rotarix™ vaccine.
When adminis-
tered concomitantly,
participants received
the 3 doses of In-
fanrix™ vaccine at
months 1, 2 and 3,
and the 3 doses of
the OPV vaccine at
Day 0, Month 1 and
Month 2
RV1 Madhi 2010-
AF
2 or 3 5 to 10 2/1 All participants re-
ceived routine infant
vaccinations accord-
ing to EPI recom-
mendations
-
RV1 Narang 2009-
IND
2 8 1/1 Routine vacci-
nations (diphtheria-
tetanus-
whole cell pertussis-
hepatitis b, H in-
fluenzae type b, and
oral poliovirus vac-
cine) were adminis-
tered at 6, 10, and14
weeks of age (given
with a 2-week sepa-
ration from the first
and subsequent dose
of the RV1 vaccine
or placebo)
-
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RV1
NCT00158756-
RUS
3 6 5 Glax-
oSmithKline (GSK)
Biologicals’ Tri-
tanrix™HepB and
GSK
BiologicalsKft’sDT-
PwHBV vaccines as
compared to con-
comitant adminis-
tration of Common-
wealth Serum Labo-
ratory’s (CSL’s)
DTPw (Triple Anti-
gen™) andGSKBi-
ologicals’ HBV (En-
gerix™B)
, when coadminis-
tered With GSK Bi-
ologicals’ Oral Live
Attenuated Human
Ro-
tavirus (HRV) vac-
cine, to healthy in-
fants at 3, 4½ and 6
months of age, after
a birth dose of Hep-
atitis B vaccine
Hep B and DTPw-
HBV vaccines in
combination
with other vaccines/
placebo were com-
pared in the study
arms
RV1 Omenaca
2012-EU
2 4 or 8 1/1 All participants re-
ceived routine infant
vaccinations
in accordance with
the local National
Plan of Immuniza-
tion schedule in each
of the respective par-
ticipating countries
-
RV1 Phua 2005-
SGP
2 4 3/1 Hepatitis B vaccine,
diphtheria-tetanus-
acellular
pertussis, poliovirus,
and H influenzae
type b co-adminis-
tered with interven-
tions
3 different PFUs
compared
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RV1 Phua 2009-
AS
2 6 to 10 1/1 Infants received
other routine paedi-
atric immunizations
(combined diphthe-
ria toxoid-tetanus
toxoid-acellular per-
tussis (DTPa) - in-
activated poliovirus
[IPV] andH influen-
zae type B (Hib)
vaccine and hepati-
tis B vaccine (HBV)
) during the study
period according to
local schedules. Al-
most all infants re-
ceived BCG dose at
birth. If oral po-
lio vaccine (OPV)
was given as part of
the routine sched-
ule in the partici-
pating countries, a
time interval of 2
weeks was observed
between the OPV
doses and RIX4414
vaccine/placebo
doses
-
RV1 Rivera 2011-
DOM
2 7 1/1 All infants received
3 doses of combined
diph-
theria, tetanus, acel-
lular pertussis, hep-
atitis B, inactivated
poliovirus and H in-
fluenzae vaccine.
1
complimentary dose
of RV1 was admin-
istered to all infants
enrolled in this study
(both study groups)
who were aged < 6
months at Visit 3
(Week 13) as a ben-
efit to the placebo
group for participa-
tion in the study
RV1 Ruiz-Palac
06-LA/EU
2 4 or 8 1/1 Routine im-
munizations accord-
ing to local regula-
tions; oral poliovirus
vaccination at least 2
weeks before or after
-
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rotavirus vaccine
RV1 Salinas 2005-
LA
2 8 3/1 Oral polio vaccine
given after 2 weeks,
not together with
RV1
3 different PFUs
compared
Main
publication did not
report that the trial
included 2 subsets:
2 doses of human
rotavirus or placebo
subset: these par-
ticipants received 2
oral doses of RV1
vaccine or placebo
according to a 0,
2 months schedule,
and routine vaccina-
tions (DTPw- Hep-
ati-
tis B vaccine (HBV)
+ Hib vaccine) at a
0, 2, and 4 months
schedule
3 doses of RV1 or
placebo subset: these
participants received
3 oral doses of RV1
vaccine or placebo,
and routine vaccina-
tions (DTPw-HBV
+ Hib vaccine) con-
comi-
tantlywith each dose
of human rotavirus
vaccine and placebo
at a 0, 2, and 4
months schedule
RV1 Steele 2008-
ZAF
2 4 3/1 RV1plus (1) oral po-
lio vaccine (OPV) +
diphtheria-tetanus-
acellular pertussis/H
influenzae
type b (DTPA/HIB)
vaccine; (2) OPV
placebo + diphthe-
ria-tetanus-acellular
pertussis inactivated
Compares different
co-ad-
ministration combi-
nations (see previous
column)
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polio-H influenzae
type b (DTPA-IPV/
HIB) vaccine; or (3)
OPV + DTPA/HIB
vaccine
RV1 Steele 2010a-
ZAF
3 4 1/1 RV1 vac-
cine was concomi-
tantly administered
with 3 doses of com-
bined diphtheria,
tetanus and whole-
cell pertussis, hepati-
tis B, and H influen-
zae type b vaccine
(TritanrixHepB-
Hib) and OPV (Po-
lioSabin)
For infants who de-
veloped clinical
symptoms of HIV
(WHO stages III or
IV disease) any time
after enrolment, ac-
cess to antiretrovi-
ral therapy (cotri-
moxazole) according
to the South African
national guidelines
was facilitated. In-
fants who needed
treatment were re-
ferred to antiretro-
viral therapy centres
by the investigators
RV1 Steele 2010b-
ZAF
2 or 3 4 2/1 Infants received rou-
tine vaccinations ac-
cording to the lo-
cal EPI schedule in
South Africa. BCG
and OPV vaccina-
tions were given at
birth; all other
routine vaccinations
(including diphthe-
ria-tetanus toxoids-
whole cell pertussis,
hepatitis B, H in-
fluenzae type b, and
OPV)were adminis-
tered concomitantly
with the study vac-
cine
Compares number
of doses (2 or 3)
RV1 Tregnaghi
2011-LA
2 4 or 8 1/1 All participants re-
ceived routine infant
vaccinations (Hep-
atitis B vaccine)
, diphtheria-tetanus-
acellular pertus-
-
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sis, poliovirus, and
H influenzae type
b) according to EPI
recommendations in
each country.
First 2 doses of
routine EPI vacci-
nations were co-ad-
min-
istered with the RV1
vaccine or placebo
doses; the 3ird rou-
tine EPI vaccination
was administered 1
to 2 months later ac-
cording to the na-
tional plan of im-
munization in each
country
RV1 Vesikari
2004a-FIN
2 8 3/1 Infant routine vac-
cinations were sepa-
rated from the study
vaccines by 2 weeks
3 different PFUs
compared
RV1 Vesikari
2004b-FIN
2 8 1/1 Infant routine vac-
cinations (diphthe-
ria tetanus toxoids-
pertussis, H influen-
zae type b, and in-
activated poliovirus
vaccines) were sepa-
rated from the study
vaccines by at least 2
weeks
-
RV1 Vesikari
2007a-EU
2 4 or 8 1/1 Concomitant vac-
cines included 7 va-
lent pneumococcal
polysaccharide con-
jugate vaccine (Pre-
venar)
and meningococcal
group c conjugate
vaccine (Menin-
gitec); Hepatitis B
vaccine, diphtheria-
tetanus-acel-
lular pertussis, po-
-
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lio virus, and H in-
fluenzae type b vac-
cines were co-ad-
ministered
RV1 Vesikari
2011-FIN
2 4 2/2 Routine childhood
vaccinations were al-
lowed according to
local practice, but at
least 14 days apart
from each dose of
study vaccine
Compares liquid
and lyophilized vac-
cine formulations
RV1 Ward 2006-
USA
2 4 2/1 Not specified 2 different PFUs
compared
RV1 Zaman 2009-
BGD
2 - 2/2 All chil-
dren in the study re-
ceived the standard
EPI vaccines starting
at 6 weeks of age.
Oral polio vaccine
(OPV) co-adminis-
tered in trial: either
concomitantly with
RV1 or 15 days be-
fore RV1
Compared RV1 plus
oral polio vaccine
with RV1 alone
RV1 Zaman 2017-
BGD
2 4 1/1 (no RV1 vac-
cine)
HRV was scheduled
to be given along
with other standard
infant vaccines in-
cluding OPV at the
DTP1 and DTP2
immunization visits,
recommended in
Bangladesh to occur
at 6 and 10 weeks of
age
Cluster randomised
trial
RV5 Armah 2010-
AF
3 4 1/1 All children in the
study received the
standard EPI vac-
cines (including oral
poliovirus vaccine)
starting at 6 weeks of
age
-
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RV5 Block 2007-
EU/USA
3 4 to 10 1/1 Use of oral po-
liovirus vaccine dur-
ing the course of the
study or within 42
days before first dose
of vaccine/placebo
was an exclusion cri-
terion; administra-
tion of other vac-
cines permitted
-
RV5 Ciarlet 2009-
EU
3 4 to 6 1/1 Hepatitis B vaccine,
diphtheria-tetanus-
acellular pertus-
sis, polio virus, and
H influenzae type b
co-administered
-
RV5 Clark 2003-
USA
3 6 to 8 1/1 Children
that had recently re-
ceived oral polio vac-
cine were excluded
from the study
Breastfed; infants in
the vaccine control
group (Group 1) re-
ceived the reassor-
tants as
administered in pre-
vious studies within
30 mins of feed-
ing Enfamil formula
(30 ml) or Mylanta
Double Strength (0.
5 ml/kg). Infants in
a correspond-
ing placebo group
(Group 2) were pre-
fed as in Group 1
RV5 Clark 2004-
USA
3 6 to 8 1/1 Receipt of any other
vaccines within 14
days was not allowed
-
RV5 Dhingra
2014-IND
3 4 4/1 Infants in Cohort
2 concomitantly re-
ceived a combined
DTPw-HB-Hib
pentavalent vaccine
and Trivalent Oral
Polio Vaccine
BRV-TV at 3 differ-
ent concentrations,
compared to RV5 or
placebo
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RV5 Iwata 2013-
JPN
3 4 to 10 1/1 No in-
formation about use
of other vaccines
-
RV5 Kim 2008-
KOR
3 4 to 10 1/1 Infants excluded if
they had or were to
re-
ceive oral poliovirus
vaccine at any time
during the study or
in the 42 days be-
fore the first dose;
concomitant admin-
istration of other li-
censed vaccines and
breastfeeding was
not restricted
-
RV5 Lawrence
2012-CHN
3 4-10 1/1 Other live vaccines
14 days before or
after study vaccine
were not allowed
-
RV5 Levin 2017-
AF
3 4-10 1/1 Enrol-
ment was closed in
participating coun-
tries when RV1 was
added to national
vaccine schedules
-
RV5 Merck[009]
2005-USA
3 4 to 10 1/1 Infants
were excluded if they
had or were to re-
ceive oral poliovirus
vaccine at any time
during the study or
in the 42 days be-
fore the first dose;
concomitant admin-
istration of other li-
censed vaccines and
breastfeeding was
not reported
-
RV5 Mo
2017-CHN
3 4 2/2 The routine
China EPI vaccines
(oral poliovirus vac-
cine and diphtheria,
tetanus, and acellu-
-
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lar pertussis vaccine)
either staggered or
concomitantly with
RV5 or placebo
RV5 Vesikari
2006a-FIN
3 4 to 8 3/1 Licensed
vaccines could be ad-
ministered through-
out the study, but
were not given on
the same day as
study vaccine; in-
activated poliovirus
vaccine was exclu-
sively used in Fin-
land at the time of
the study
Compares
different RV5 com-
ponents:G1-4, P1A;
G1-4; and P1A
RV5 Vesikari
2006b-INT
3 4 to 10 1/1 Admin-
istration of other
licensed childhood
vaccines and breast-
feeding were not re-
stricted; for a sub-
set of participants in
the USA (U.A. con-
comitant use cohort)
, Merck also pro-
vided the licensed
paediatric vaccines
that were adminis-
tered concomitantly
(same day)withRV5
or
placebo, which in-
cluded Comvax, In-
fanrix, Ipol, and Pre-
vnar
-
RV5 Zaman 2010-
AS
3 4 1/1 All children in the
study received the
standard EPI vac-
cines (including oral
poliovirus vaccine)
starting at 6 weeks of
age
-
VAC Bhandari
2006-IND
1 - 1/1 (/1) Infants were vac-
cinated with DPT,
In-
cluded an additional
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Hep B and OPV
separately from ro-
tavirus vaccine
vaccine arm for a ro-
tavirus vaccine can-
didate (I321) that
was not included for
anaysis in this review
VAC Bhandari
2009-IND
3 4 2/2 Infants received 3
doses of DTP; OPV;
and Hep B at 6, 10,
and 14 weeks of age;
Rotavac was admin-
istered at 8, 12, and
16 weeks of age
Randomized partic-
ipants to high- (1
x 105 ffu) and low-
dose (1 x 104 ffu)
vaccine arms which
were combined in
this review
VAC Bhandari
2014-IND
3 4 1/1 Other
childhood vaccines
(DTPw, Hib, Hep
B, and OPV) given
concurrently
-
VAC Chandola
2017-IND
3 4-8 3/1 Co-administered
with EPI vaccines:
OPV and combined
DPT,HepBandHib
Randomized partic-
ipants to 3 vaccine
production lots as
well as to placebo;
we combined the
different production
lot arms in our anal-
yses
BCG: Bacille Calmette Guérin; EPI: Extended Programme of Immunization; FFU: focus-forming unit;H influenzae: Haemophilus
influenzae; PFU: plaque-forming unit.
Appendix 7. Methods to collect adverse event data
Trial Passive or active
RV1 Anh 2011-PHL Not reported
RV1 Anh 2011-VNM Not reported
RV1 Bernstein 1998-USA Passive
RV1 Bernstein 1999-USA Passive and active
RV1 Colgate 2016-BGD Passive
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RV1 Dennehy 2005-NA Passive and active
RV1 GSK[021] 2007-PAN Not reported
RV1 GSK[033] 2007-LA Not reported
RV1 GSK[041] 2007-KOR Not reported
RV1 GSK[101555] 2008-PHL Not reported
RV1 Kawamura 2011-JPN Not reported
RV1 Kerdpanich 2010-THA Passive
RV1 Kim 2012-KOR Passive
RV1 Li 2013b-CHN Passive
RV1 Li 2014-CHN Not reported
RV1 Madhi 2010-AF Active
RV1 Narang 2009-IND Passive
RV1 NCT00158756-RUS Not reported
RV1 Omenaca 2012-EU Not reported
RV1 Phua 2005-SGP Passive
RV1 Phua 2009-AS Passive
RV1 Rivera 2011-DOM Passive
RV1 Ruiz-Palac 06-LA/EU Active
RV1 Salinas 2005-LA Passive
RV1 Steele 2008-ZAF Not reported
RV1 Steele 2010a-ZAF Active and passive
RV1 Steele 2010b-ZAF Not reported
RV1 Tregnaghi 2011-LA Not reported
RV1 Vesikari 2004a-FIN Passive
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RV1 Vesikari 2004b-FIN Passive
RV1 Vesikari 2007a-EU Passive and active
RV1 Vesikari 2011-FIN Passive
RV1 Ward 2006-USA Not reported
RV1 Zaman 2009-BGD Passive and active
RV1 Zaman 2017-BGD Not reported
RV5 Armah 2010-AF Active
RV5 Block 2007-EU/USA Passive and active
RV5 Ciarlet 2009-EU Passive and active
RV5 Clark 2003-USA Passive and active
RV5 Clark 2004-USA Passive and active
RV5 Dhingra 2014-IND Passive and active
RV5 Iwata 2013-JPN Passive
RV5 Kim 2008-KOR Passive
RV5 Lawrence 2012-CHN Not reported
RV5 Levin 2017-AF Active
RV5 Merck[009] 2005-USA Not reported
RV5 Mo 2017-CHN Passive
RV5 Vesikari 2006a-FIN Passive and active
RV5 Vesikari 2006b-INT Active
RV5 Zaman 2010-AS Active and passive
VAC Bhandari 2006-IND Passive and active
VAC Bhandari 2009-IND Passive and active
VAC Bhandari 2014-IND Passive and active
VAC Chandola 2017-IND Active
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Appendix 8. Ongoing studies: vaccine and location
Trial Rotavirus vaccine Location
Region Country
OTHER
ACTRN12610000525088
RV3-BB Oceania Australia
OTHER
CTRI/2015/07/006034
Rotasiil (Serum Institute of In-
dia Ltd.)
Asia India
OTHER
CTRI/2015/12/006428
RV1; Rotavac (Bharat) Asia India
OTHER NCT01061658 BRV-TV Asia India
OTHER NCT02153866 RV vaccine, type not reported Asia China
OTHER NCT02193061 RV1; RV5 America Mexico
OTHER NCT02542462 RV1; RV5 America USA
OTHER NCT02646891 Trivalent P2VP8 Africa South Africa
OTHER NCT02847026 RV1; RV5 Asia Bangladesh
OTHER NCT03462108 Rotavirus vaccine (Bio Farma) Asia Indonesia
OTHER NCT03483116 RV3-BB Africa Malawi
RV1 ISRCTN86632774 RV1 Africa South Africa
RV1 NCT02941107 RV1 Oceania Australia
RV1 Tatochenko 2008 RV1 Not reported Not reported
RV5 NCT02728869 RV5 Asia Bangladesh
Appendix 9. Deathsa: from published trials and from communication with trial authors
Vaccine Trial No. of deaths Cause of death
Vaccine Placebo Unclear Total
RV1 RV1 Anh 2011-
PHL
1 0 0 1 Salmonella gastroenteritis
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(Continued)
RV1 Anh 2011-
VNM
0 0 0 0 -
RV1 Bernstein
1998-USA
0 0 0 0 -
RV1 Bernstein
1999-USA
0 0 1 (1) 1 Pneumococcal sepsis
RV1 Colgate
2016-BGD
1 1 0 2 Reasons not reported
RV1 GSK[021]
2007-PAN
0 0 0 0 -
RV1 Tregnaghi
2011-LA
10 2 0 12 Meningitis bacterial (1 vaccine, 1 placebo), pneu-
monia (3 vaccine), aortic valve stenosis (1 vaccine)
, bronchiolitis (1 vaccine), dengue fever (1 vaccine),
endocarditis bacterial (1 vaccine), intussusception (1
vaccine), multi-organ failure (1 placebo), respiratory
failure (1 vaccine), sepsis (2 vaccine)
RV1 GSK[033]
2007-LA
3 0 0 3 Gastroenteritis (1 vaccine), bronchopneumonia (1
vaccine), aspiration (1 vaccine)
RV1 GSK[041]
2007-KOR
0 0 0 2 Not reported
RV1
GSK[101555]
2008-PHL
0 0 0 0 -
RV1 Kawamura
2011-JPN
0 0 0 0 -
RV1 Kerdpanich
2010-THA
0 0 0 0 -
RV1 Kim 2012-
KOR
0 0 0 0 -
RV1 Li 2013a-
CHN
0 0 0 0 -
RV1 Li 2013b-
CHN
0 0 0 0 -
RV1 Li
2014-CHN
6 7 0 13 Vaccine (6): Asphyxia, Drowning, Central nervous
system infection, Bronchopneumonia, Cortical dys-
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plasia, Intracranial Haemorrhage, Asphyxia, Menin-
gitis, Multi-organ failure, Hemotophagic histiocyto-
sis, Acute lymphocytic leukemia, Multi-organ failure
Placebo (7): Diarrhea, Multi-organ failure, Congen-
ital heart disease, Respiratory failure, brain contu-
sion, subarachnoid hemorrhage, skull fracture, cere-
bral hematoma, and brain herniation
RV1Madhi 2010-
AF
83 43 0 126 Reasons not stated
RV1 Narang
2009-IND
0 0 0 0 -
RV1
NCT00158756-
RUS
0 0 0 0 -
RV1 Phua 2005-
SGP
3 0 0 3 Leukaemia (1 vaccine); accident-induced subarach-
noid haemorrhage (1 vaccine); cardiorespiratory fail-
ure after acute viral pneumonitis (1 vaccine)
RV1 Phua 2009-
AS
1 3 0 4 Aspiration and metabolic disorder, adenoviral pneu-
monia, interstitial pneumonia, and sudden infant
death syndrome (not stated which group)
RV1 Rivera 2011-
DOM
0 0 0 0 -
RV1 Ruiz-Palac
06-LA/EU
56 43 0 99 Diarrhoea (4 vaccine, 2 placebo); pneumonia (16
vaccine, 6 placebo); other causes not mentioned
RV1 Salinas
2005-LA
2 1 0 3 Generalized visceral congestion (1 placebo); sepsis (1
vaccine); automobile accident (1 vaccine)
RV1 Steele 2008-
ZAF
3 5 0 8 Bronchopneumonia (1 placebo), pneumonia (2 vac-
cine, 2 placebo), hepatic steatosis (1 placebo), brain
oedema (1 vaccine, 1 placebo)
RV1Steele2010a-
ZAF
6 9 0 15 Bronchopneumonia, sepsis, and gastroenteritis were
the most common causes
RV1 Steele
2010b-ZAF
3 0 0 3 Bronchopneumonia and gastroenteritis (3 vaccines)
RV1 Vesikari
2004b-FIN
0 0 0 0 -
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RV1 Vesikari
2007a-EU
0 0 0 0 -
RV1 Vesikari
2011-FIN
0 0 0 0 -
RV1 Zaman
2009-BGD
1 0 0 1 -
RV5 RV5 Armah
2010-AF
76 82 0 158 Gastroenteritis (20 vaccine, 16 placebo); 11 deaths
occurred in identified HIV-infected participants in
Kenya; sudden infant death syndrome (1 placebo);
other causes not mentioned
RV5 Block 2007-
EU/USA
1 0 0 1 Sudden infant death syndrome (1 vaccine)
RV5 Ciarlet
2009-EU
0 0 0 0 -
RV5 Iwata 2013-
JPN
0 0 0 0 -
RV5 Lawrence
2012-CHN
0 0 0 0 -
RV5 Levin 2017-
AF
1 2 0 3 Pneumonia
RV5 Merck[009]
2005-USA
0 0 0 0 -
RV5 Mo 2017-
CHN
0 1 0 1 Reasons not reported
RV5 Vesikari
2006a-FIN
0 0 0 0 -
RV5 Vesikari
2006b-INT
24 20 0 44 Sudden infant death syndrome (7 vaccine and 7
placebo), other causes not mentioned
RV5 Zaman
2010-AS
3 4 0 7 Not all causes reported, most common causes were
drowning and sepsis
Rotavac VAC Bhandari
2014-IND
30 18 0 48 The most common causes of death were infection
and infestations followed by general disorders and
administration site conditions. Days after vaccina-
tion not reported. None were considered to be vac-
cine-related
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VAC Chandola
2017-IND
5 0 0 5 Cause of death: sepsis and aspiration (79 - 141
days after Rotavac vaccination), unexplained sudden
death (3 days after Rotavac vaccination). None were
considered to be vaccine-related
aNumbers in brackets are the number of deaths reported by the trial authors following personal communication with them, i.e. they
are not in the published trial reports.
Appendix 10. Other licensed rotavirus vaccines in use
Vaccine Vaccination schedule Vaccine antigens Manufacturer License information
Lanzhou lamb rotavirus
(LLR)
1 dose annually for chil-
dren 2 months to 3 years
and one booster dose at
3 to 5 years
Monovalent, live-atten-
uated lamb G10 P[12]
strain
Lanzhou Institute of Bi-
ological Products, China
2000 (China), nationally
licenced
Rotasiil, Bovine ro-
tavirus-pentavalent vac-
cine (BRV-PV)
3 doses
at 6, 10 and 14 weeks
Pentavalent, bovine-hu-
man reassortant vaccine
containing serotypesG1,
G2, G3, G4 and G9
Serum Institute of India
Ltd.
2017 (India), nationally
licenced
Rotavin-M1 2 doses
Minimum 6 weeks given
at least 30 days apart
Monovalent, live-atten-
uated human G1 P[8]
strain
Polyvac, Vietnam 2007 (Vietnam), nation-
ally licenced
WH A T ’ S N E W
Date Event Description
19 March 2019 New search has been performed We amended the protocol to include only vaccines pre-
qualified for use by the World Health Organization
(WHO). We included 14 new studies from the April
2018 search, including four studies on a new vaccine
(Rotavac). Nicholas Henschke joined the author team
19 March 2019 New citation required but conclusions have not changed This is the fourth update of the original rotavirus vac-
cines review (Soares-Weiser 2004). This review concerns
vaccines that have been prequalified for global use by the
WHO (WHO 2018). In the previous versions of this
review we included any rotavirus vaccine in use
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H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 5, 2010
Date Event Description
10 May 2012 New search has been performed No new trials were identified from the updated May
2012 search
10 May 2012 New citation required but conclusions have not
changed
Review updated to incorporate different country mor-
tality strata and outcomes changed to reflect the differ-
ent rotavirus vaccines’ efficacy and safety in countries
with different mortality rates
8 January 2012 New search has been performed Review updated to include nine trials identified in a
new literature search, whichwas conducted inOctober
2011 (MEDLINE via PubMed) and June 2011 (other
databases)
11 November 2011 New citation required but conclusions have not
changed
HannaBergman and SukkrtiNagpal joined the author
team.
10 May 2010 Amended Minor typographical errors corrected.
2 February 2010 New citation required and conclusions have changed A new search on 2 February 2010 identified 9 new
potentially relevant studies.We independently assessed
these studies and incorporated data from the eligible
trials into the review
21 July 2009 New search has been performed The original rotavirus vaccines review (Soares-Weiser
2004) was split into two reviews: rotavirus vaccines in
use (this review); and other rotavirus vaccines, includ-
ing those no longer in use or in development (Soares-
Weiser 2004).
This involved a new search, revised inclusion criteria,
updated reviewmethods. All data from those trials also
included in the original review were re-extracted. New
authors joined the review team for this review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is the fourth update of the original rotavirus vaccines review (Soares-Weiser 2004). This review concerns vaccines that have been
prequalified for global use by the WHO (WHO 2018). In the previous versions of this review we included any rotavirus vaccine in use
(Soares-Weiser 2004; Soares-Weiser 2010; Soares-Weiser 2012a; Soares-Weiser 2012b).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Diarrhea [∗prevention & control; virology]; Diarrhea, Infantile [∗prevention & control; virology]; Randomized Controlled Trials as
Topic; Rotavirus Infections [∗prevention & control]; Rotavirus Vaccines [∗therapeutic use]; Vaccines, Attenuated [therapeutic use]
MeSH check words
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